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EFFECT OF TOTAL BODY IRON ON METABOLIC DYSFUNCTION AMONG U.S. 
FEMALES IN THE NHANES 2003-2010 SURVEY, AGED 12-49 
                                             Joseph M. Carhart 
                                             December 05, 2017 
Experimental and epidemiological studies have reported positive associations 
between iron parameters and metabolic dysfunction including: Type 2 diabetes mellitus 
(T2DM) (1-6), metabolic syndrome (7-15), non-alcoholic fatty liver disease (NAFLD) 
(16-22) and insulin resistance (23,24) with a number of studies showing that reductions in 
total body iron via dietary modification (e.g., reducing red meat intake) or phlebotomy 
lead to increases in insulin sensitivity (25), decreases in insulin resistance (26), and 
reductions in the prevalence of complications associated with T2DM (5, 27), metabolic 
syndrome (28) and NAFLD (22, 29). Moreover, the risk associated with these outcomes 
and total body iron differ between males and females and it has been hypothesized that 
the divergence in risk of disease due to total body iron is related to the female 
reproductive lifespan (e.g., age at menarche, parity, oral contraceptive use and age at 
menopause). Regardless of study design, serum ferritin and transferrin saturation have 
consistently been used in these investigations to estimate total iron stores, which are 




The aim of the current study was to examine the clinical utility of an index of iron 
repletion developed by JD Cook et al. in 1993 (i.e. FeCOOK), which is unaltered by 
inflammation or liver function in a nationally-representative, community-dwelling, non-
institutionalized group of females participating in continuous NHANES from 2003 to 
2010 and to examine the association between the index and metabolic dysfunction. 
The current results highlight the clinical utility of FeCOOK in assessing the iron 
status in females of reproductive age. I did not observe a statistically significant 
association between metabolic dysfunction and continuously-scaled FeCOOK. However, 
when FeCOOK was modeled in accordance with common reporting patterns (i.e., 
categorically), significant, positive associations between increasing FeCOOK and metabolic 
dysfunction were observed among all females, and this pattern persisted after 
stratification by ethnicity and menopausal status. Further research is warranted to 
examine the clinical utility of FeCOOK among other cohorts. Moreover, additional research 
using FeCOOK is recommended in order to replicate these findings among a larger sample 
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CHAPTER 1: INTRODUCTION  
 
Experimental and epidemiological studies report positive associations between 
iron parameters and metabolic dysfunction including: Type 2 diabetes mellitus (T2DM) 
(1-6), metabolic syndrome (7-15), non-alcoholic fatty liver disease (NAFLD) (16-22) and 
insulin resistance (23, 24). While much consensus in the research community has been 
reached regarding the ascertainment of T2DM, metabolic syndrome and insulin 
resistance in population-based studies using World Health Organization (WHO) criteria, 
National Cholesterol Education Program-Adult Treatment Panel III (ATP III) criteria and 
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), respectively, no 
gold-standard method exists for the detection of hepatic steatosis that is both non-
invasive and cost-effective. Therefore, several algorithms which utilize markers found in 
serum have been developed to estimate the presence of fatty liver in large cohorts (Table 
7). Among these algorithms, the fatty liver index (FLI) has received the most attention in 
the epidemiological literature (30) and is the only algorithm that has been externally 
validated in four independent studies (31-34, Table 7) since its inception in 2006 (30). 
More recently, an index referred to as the U.S.-FLI has been developed to determine the 
presence of NAFLD among multi-ethnic cohorts. Unlike the FLI, the U.S.-FLI accounts 
for age and ethnicity and has been shown to outperform its predecessor (i.e., the FLI) (35) 
However, the U.S.-FLI has not been employed thus far to estimate the prevalence of 
NAFLD in U.S. females as a subgroup. 
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The magnitude of risk in the above reported associations between iron stores and 
metabolic dysfunction differ between males and females and it is thought that the 
divergence in risk of disease due to body iron status is related to the female reproductive 
lifespan. In his 1981 article entitled “Iron and the sex difference in heart disease risk” 
Jerome Sullivan was the first to hypothesize that blood loss during menstruation is the 
primary factor that protects premenopausal females from ischemic heart disease (36). In 
the years that followed, several publications have reported that parameters related to 
ovulation and menstruation (e.g., decreasing age at menarche, increasing parity, 
decreasing length of oral contraceptive use and increasing age at menopause) confer 
protection against chronic disease (37-40) and that this protection appears to be lost 
following the onset of menopause (38). Supporting these observations are clinical trials, 
cohort studies and case-control studies whose results consistently demonstrate that 
participants who reduce total body iron via dietary modification (e.g., reducing red meat 
intake) or blood donation/phlebotomy experience increases in insulin sensitivity (25), 
decreases in insulin resistance (26), and reductions in the prevalence of complications 
associated with T2DM (27), metabolic syndrome (42) and NAFLD (43). Regardless of 
study design, however, serum ferritin and transferrin saturation have consistently been 
used in these investigations to estimate iron stores. Despite its clinical utility, ferritin is 
adversely affected by inflammation, with levels of serum ferritin rising under 
inflammatory conditions (44). In addition, transferrin saturation (TSAT), which is the 
ratio of serum iron to total iron binding capacity (TIBC), demonstrates diurnal variation 
(45) and increases in the presence of health conditions such as inflammation, cirrhosis, 
hepatitis and microbial infection (46-49).   
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Predictive, non-invasive, and inexpensive analytes unaltered by inflammation or 
liver function would be of value in monitoring the iron status of females across the 
reproductive lifespan to distinguish the effects of iron stores on metabolic dysfunction. 
Moreover, reproductive parameters vary between females and this offers a natural setting 
in which to examine the effect of these parameters on iron stores and their association 
with metabolic dysfunction while controlling for the effect of covariates such as age, 
ethnicity, education, body mass index (BMI) and lifestyle factors (e.g., diet composition 
(i.e., foodstuffs and supplements which enhance and/or inhibit iron absorption), alcohol 
intake and smoking status (i.e., exposures which increase iron loading) and physical 
activity (i.e., an exposure which decreases iron loading). 
In this secondary analysis, my aim was to test the effect of reproductive 
parameters on iron stores and to evaluate body iron as a predictor of metabolic 
dysfunction in female participants of childbearing age (i.e., 12-49 years) participating in 
the continuous National Health and Nutrition Examination Survey (NHANES) from 
2003-2010. To estimate iron stores in the current sample, I employed a well-validated 
algorithm developed by JD Cook et al. in 2003 (50) which is a mathematically-derived 
ratio of soluble transferrin receptor and ferritin found in serum and appears to be a more 
stable index of iron stores than either analyte used independently (51-52).  
 
Aim 1:   To estimate iron stores in a nationally-representative, community-dwelling, 
non-institutionalized group of females participating in continuous NHANES from 




Aim 2:   To describe the relationships between age, ethnicity, education, BMI, alcohol 
consumption, smoking history, physical activity, dietary iron, foodstuffs which 
enhance/inhibit dietary iron absorption, reproductive parameters, and FeCOOK in the 
female cohort.  Specifically, it was hypothesized that: 
A. FeCOOK would be positively associated with  
1. Hispanic and Non-Hispanic Caucasian ethnicity  
2. Education 
3. BMI 
4. Alcohol consumption 
5. Smoking history 
6. Dietary iron intake 
7. Length of oral contraceptive use 
8. Decreasing age at menopause  
B. FeCOOK would be negatively associated with   
1. Non-Hispanic African American ethnicity  
2. Physical activity 
3. Decreasing age at menarche 
4. Parity  
Aim 3:   To estimate the prevalence of non-alcoholic fatty liver disease in the current 
sample using a validated algorithm developed by Ruhl et al. in 2015 (35), the U.S. 




Aim 4:   To describe the relationship between FeCOOK and risk of metabolic 
dysfunction in the female cohort. It is hypothesized that: 
A. FeCOOK would be positively associated with: 
1. Type 2 diabetes mellitus after controlling for age, BMI, alcohol 
consumption, smoking status physical activity and micronutrient 
status.  
2. Metabolic syndrome after controlling for age, BMI, alcohol 
consumption, smoking status physical activity and micronutrient 
status. 
3. Non-alcoholic fatty liver disease after controlling for age, BMI, 
alcohol consumption, smoking status physical activity and 
micronutrient status. 
4. Hepatic fibrosis, developed by Angulo et al. and defined by the Non-
alcoholic fatty liver disease Fibrosis Score (NFS) after controlling for 
age, BMI, alcohol consumption, smoking status physical activity and 
micronutrient status. 
5. Insulin resistance after controlling for age, BMI, alcohol consumption, 












CHAPTER 2: OVERVIEW OF IRON METABOLISM AND IRON STATUS IN 
HUMAN POPULATIONS 
 
As an essential micronutrient, humans require iron for cellular respiration, DNA 
synthesis, DNA repair, as a cofactor in biochemical reactions, oxygen transport, 
endocrine regulation, immunological regulation and bone health. Thus, iron is a major 
contributor to subcellular, intracellular, and systemic homeostasis due to the transition 
metal’s capacity for redox cycling (53), where labile iron can be oxidized from ferrous 
iron (Fe2+) to ferric iron (Fe3+) and reduced from ferric iron (Fe3+) to ferrous iron (Fe2+). 
Homeostasis of human iron metabolism is achieved at two levels: 1) systemic and 2) 
cellular. Each will be taken in turn, followed by a summary describing their interaction.  
Systemic iron metabolism   The regulation of systemic body iron occurs at the 
level of iron absorption (54). Humans acquire iron in two distinct forms: 1) heme iron 
contained in meats, poultry, seafood and fish and 2) non-heme iron contained in plant-
based foods such as vegetables, fruits, grains, nuts, beans and seeds. The heme iron 
content of meat varies considerably depending upon the source. Red meat contains 50% - 
80% heme iron while the heme iron content of chicken, pork or turkey varies between 
25% - 40% (55). Compared to non-heme iron, heme iron is absorbed with five to ten 
times greater efficiency (56) and its absorption is unaffected by current body iron stores 
(57). Moreover, absorption of heme iron is independent of duodenal pH (58) and is 
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relatively unaffected by common inhibitors of iron absorption such as phytate and 
polyphenols (59 Abbaspour et al.). In contrast, the bioavailability of non-heme iron is 
much less than that of heme iron (5-12%) (60) and its absorption is affected by current 
body iron stores (61) as well as dietary factors which can either promote or inhibit its 
absorption (62-64). Despite its lower bioavailability, however, non-heme iron appears to 
contribute more to human iron nutrition than does heme iron in developed nations (65).  
Heme iron is absorbed from the duodenum in the proximal intestine by heme-
carrier protein-1 (HCP1); also known as solute carrier family 48 member 1 (SLC48A1)) 
(66), whereupon it enters the cytosol of the enterocyte and is degraded by hemoxygenase 
1 (HOX1) to abstract the central ferrous iron ion from the heme group contained within 
the porphyrin moiety. In addition to heme iron intake, factors such as hypoxia and iron-
regulatory proteins (IRPs) serve to upregulate HCP1 mRNA expression (67). Cytosolic 
(soluble) ferrous iron in the enterocyte is oxidized to (insoluble) ferric iron by hephaestin, 
a multicopper oxidase localized mainly within the basolateral membrane of enterocytes 
(68) which loads oxidized iron onto transferrin, which serves as a siderophore. Briefly, a 
siderophore (e.g., Greek for “iron carrier”) is any small iron-chelating protein or 
compound which exhibits high-affinity for binding iron (69). Transferrin can bind up to 
two atoms of ferric iron (70) Hephaestin then works in concert with ferroportin to export 
transferrin into circulation (68,70) for utilization in the above mentioned physiological 
processes. The relationship between hepahestin and ferroportin is noteworthy in iron 
metabolism because under normal physiological conditions, hephaestin is down regulated 
when body iron is replete and if hepaestin activity is abolished, ferroportin is degraded 
(71).   
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In contrast to heme iron metabolism, non-heme iron metabolism is subject to 
tighter systemic regulation (e.g., non-heme iron metabolism requires an acidic duodenal 
pH for optimal absorption) (72). Following intake of non-heme iron, duodenal 
cytochrome B (DcytB), also known as cytochrome b reductase 1 (Cybrd1), a 
ferrireductase localized within the enterocyte apical membrane, reduces ferric iron to 
ferrous iron. Divalent metal transporter 1 (DMT1, also known as Nramp2) then transports 
ferrous iron into cell. DMT1 is expressed at the brush border of duodenal enterocytes and 
within intracellular endosomes of erythroid precursors (72) and is activated only in an 
acidic environment. In iron deficiency, DMT1 is upregulated and localizes at both the 
microvilli and cytoplasm. When body iron is replete, DMT1 is downregulated and 
localized to the cytoplasm. Similar to the above-mentioned step during heme iron 
metabolism, hephaestin then oxidizes ferrous iron to ferric iron and works in concert with 
ferroportin to regulate the efficiency of cellular iron efflux and loads oxidized (i.e., ferric) 
iron onto transferrin. In cells apart from enterocytes, ceruloplasmin (another multicopper 
oxidase enzyme synthesized and secreted by the liver with 50% homology to hephaestin) 
(73) regulates cellular iron export though the mechanism is not yet completely 
understood (74). Normally, transferrin in circulation is 25-35% saturated with ferric iron 
ions at a pH of 7.4 (75). Each transferrin siderophore then competitively binds transferrin 
receptors on target cells with HFE protein, which has been shown to function as an iron 
switch/sensor. In conditions such as hereditary hemochromatosis (HH), a mutation in the 
HFE gene (i.e., rs1800562: C282Y) leads to misfolded HFE proteins which aggregate in 
the Golgi complex and are thus not available to competitively bind transferrin receptors. 
Carriers of this mutation experience increased iron absorption due to a lack of this protein 
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sensor coupled with chronically suppressed hepcidin expression (discussed subsequently) 
(76). Under normal physiologic conditions, however, transferrin siderophores compete 
with HFE proteins and upon binding with transferrin receptor 1 (TFR1) or transferrin 
receptor 2 (TFR2) (and to a lesser extent glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)) (77-79), transferrin is endocytosed. It should be noted here that studies have 
reported that TFR1 has ~ 30-fold higher binding affinity for transferrin-bound iron and 
thus plays a larger role in receptor-mediated iron uptake into the cell (80, 81). Within the 
low pH of the endosomal compartment iron dissociates from transferrin and both the 
siderophore and receptor are recycled. However, if pH of arterial blood becomes acidic 
(i.e., pH < 6.5) transferrin loses it iron loading capacity (82).  
As labile (i.e., ferrous) iron accumulates within the cell or within systemic 
circulation, a soluble protein called ferritin is synthesized by nearly all cell types for iron 
storage. Each ferritin molecule is a nanocage that stores up to 4,500 atoms of iron and is 
composed of two heteropolymers, a heavy chain and light chain (83). Labile iron is 
imported through channels that are created between the bonds of the heavy and light 
chains (84). Ferritin heavy chain conducts ferroxidase activity that is necessary for iron 
deposition into the nanocage by converting ferrous iron to ferric iron (85). In addition to 
labile iron, expression of ferritin heavy chain is induced by NF-kB in response to TNF-α 
and is higher in tissues that require rapid/high utilization of iron (e.g., heart) (86). In 
contrast, ferritin light chain facilitates iron incorporation onto ferrihydrite (87), which 
binds iron to the inner wall of the nanocage and has been observed to participate in 
ferridoxase turnover. Ferritin light chain expression is higher in tissues that require long 
term storage (e.g., spleen, liver) (88). As ferritin becomes increasingly saturated, excess 
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iron precipitates around the protein and causes ferritin cages to aggregate. (89) The 
resulting insoluble protein is called hemosiderin. Once hemosiderin is formed, the 
protection provided by ferritin is lost and redox cycling begins (90). As such, some 
authors define iron deficiency and overload on the basis of the hemosiderin to ferritin 
ratio, where values less than 1 denote increasing iron deficiency and values greater than 1 
denote increasing iron overload (91). While appealing as an index of body iron burden, 
the quantification of hemosiderin is currently not cost-effective, as the only techniques 
available as of this writing for measuring hemosiderin are liver biopsy or MRI (92, 93). 
Regulating the above-mentioned mechanism is a recently discovered acute-phase 
protein called hepcidin. Hepcidin is expressed primarily in the liver, though some reports 
indicate that the protein is also expressed by macrophages and adipose tissue (94) and can 
be detected in urine, bile, ascitic, pleural, or cerebrospinal fluid (95). Hepcidin regulates 
body iron homeostasis at the level of duodenal cell absorption of dietary iron and 
macrophage release of iron from recycled erythrocytes, where the latter leukocytes 
increase ferritin synthesis with increasing hepcidin expression to sequester iron from 
invading pathogens. Hepcidin’s primary role in iron metabolism is in binding ferroportin, 
the only known cellular iron exporter. Increasing expression of hepcidin protein in serum 
results in the degradation, internalization, and eventual recycling of the ferroportin 
receptor on the cell membrane (96). In turn, this results in decreased export of iron from 
the cell into circulation.  
Several studies have demonstrated that hepcidin expression is regulated by 
systemic iron availability (i.e., transferrin saturation) (97), hepatic iron stores (i.e., 
feedback loops between iron sensing proteins such as hemojuvelin (HJV), HFE and 
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transferrin receptor) (98), erythropoietic activity (i.e., which increases in response to 
hepcidin suppression) (99), hypoxia (i.e., hepcidin expression is suppressed by hypoxia) 
and inflammatory/infectious states  and induced by IL6, IL1β, bone morphogenic protein-
2 (BMP-2) and LPS) (100, 101). 
Given that less than 10% of daily iron needs are met by intestinal absorption, the 
remaining iron requirements are fulfilled by macrophages that recycle intracellular iron 
(102). Macrophages phagocytose senescent or damaged erythrocytes and catabolize them 
via HOX1 which abstracts the central ferrous iron ion from the heme group contained 
within the porphyrin moiety after heme is broken down into biliverdin (103) Natural 
resistance-associated macrophage protein 1 (NRAMP1), a divalent metal transporter 
homologous to DMT1, is expressed within the phagolysosomal membrane of the 
macrophage and participates in iron export from phagocytic vesicles (104). Export of 
ferrous iron from macrophages then occurs via ferroportin, where it is oxidized to ferric 
iron by ceruloplasmin and bound to transferrin (105). Reflecting its crucial role in 
systemic iron balance, ferroportin expression in macrophages is regulated at the level of 
1) ferroportin transcription induced by erythophagocytosis and heme iron, 2) translation 
by the IRE/IRP system and 3) protein stability via hepcidin (106). 
Cellular iron metabolism   Iron homeostasis at this level of regulation is 
maintained by specific DNA binding proteins and sequence motifs called iron-regulatory 
proteins (IRPs) and iron-responsive elements (IREs), respectively. IREs are located in 
untranslated regions of genes which encode mRNAs that produce proteins involved in 
iron uptake, storage, utilization and export (70). The binding of IRPs to IREs suppresses 
the assembly and translation complex involved in ferritin and ferroportin mRNA 
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synthesis and increases transferrin receptor and DMT1 mRNA expression (70). When 
iron concentrations are high IRPs are degraded or inactivated causing a downregulation 
of serum transferrin receptor. IRP1 (also known as ACO1) is activated by iron deficiency 
(70) and loses affinity for IREs during iron replete status. IRP1 also exhibits aconitase 
activity. IRP2 (also known as IREB2) is activated by iron deficiency and degraded in 
conditions of iron excess and does not demonstrate aconitase activity (107, 108). 
Iron status in human populations   The following sections are an overview of the 
distribution of iron in the human body, the observed iron status and intake in human 
populations and a summary of trends and exposures (i.e., dietary and otherwise) which 
contribute to body iron stores. When data permits, iron status in males and females (i.e., 
pre-menopausal (nonpregnant), pre-menopausal (pregnant), post-menopausal) are 
presented separately and summaries are stratified by age and ethnicity. 
The total amount of body iron in free-living apparently healthy adults is 
maintained at a level of about four grams which is distributed in proteins and serum (109, 
110). One-to-two mg of iron per day is absorbed from the diet and is balanced by the 
excretion of 1-2 mg of iron per day via sloughing of intestinal epithelial cells, 
desquamation of skin and urinary cells, perspiration and fecal transit (109, 110). Total 
body iron in males typically ranges from 3.5 to 5 grams (109, 110) (~55 mg/kg) and in 
females ranges from 2 to 3.5 grams (109, 110) (~45 mg/kg). The distribution of body iron 
in both males and females is quite similar, where most of the metal is contained within 
hemoglobin (60%), myoglobin and enzymes (10%), ferritin and hemosiderin (20%), bone 
marrow (10%) and transferrin (~1%) (109, 110). In line with the reported distribution of 
hemoglobin, the average adult has 4 pints of blood and each pint (i.e., 1/2 liter) of blood 
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contains 250 mg of iron (109, 110). At ten pints (i.e., 5 liters), the human body therefore 
contains ~ 2.5 grams of iron in circulation (i.e., 62.5%).  
Several studies have shown that indices of iron status vary with gender, age, 
ethnicity and education (51, 111-114). Surveys of body iron status in populations have 
consistently demonstrated that males, regardless of ethnicity, begin to accumulate iron in 
their early 20s and by age 40 have approximately four-fold as much body iron as age-
matched females who have not yet proceeded through natural or surgical menopause 
(112). Thus, compared to males, iron status in females can be affected by factors such as 
age at menarche, parity, oral contraceptive use and/or age at menopause (115). However, 
once females reach menopause body iron stores tend to increase and eventually converge 
with those of males by the 7th decade of life (112). Table 5 contains common iron 
parameters with reference ranges.  
It is hypothesized that blood loss due to regular menstruation should decrease iron 
stores in females with each menstrual cycle and that an earlier age at menarche should 
equate to lower iron stores over time. Using data obtained from NHANES 1999-2006, 
however, Miller reported that self-reported age at menarche was not statistically 
associated with iron stores at the time of study participation (P = 0.31) (115). To my 
knowledge, this was the only survey to directly examine this hypothesis and replication is 
warranted before inferences can be made.  
Though the number of studies which have examined the association between 
parity and iron stores is small, two separate population-based studies have nonetheless 
thus far confirmed the hypothesis that increasing parity is associated with decreased body 
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iron (116, 117). Thus, these results need to be confirmed by more independent 
investigators.  
The effect of oral contraceptive (OC) use on body iron appears to be related to the 
formulation. Most OC formulations are composed of synthetic estrogen and progestin, 
hormones which inhibit the synthesis of follicle-stimulating hormone and leutinizing 
hormone. These hormones facilitate menstruation and ovum release from the ovaries. 
Thus, blocking their production via OC use should result in decreased iron loss (118). 
Frassinelli et al. assessed the effect of an oral formulation on iron parameters in a group 
of females (n = 46) over the course of two years and observed increased serum iron, 
transferrin, mean corpuscular volume (MCV), ferritin and decreased TIBC compared to 
another group of females (n = 71) who never self-administered oral contraceptives (119). 
The results suggest that OC use does indeed increase body iron. These observations were 
replicated in a separate investigation conducted by Milman et al. (117) and in a large, 
population-based study using data from NHANES 1999-2006 (115). 
In the U.S., pregnant females often develop transient anemia during the second 
and third trimesters due to hemodilution and iron loss to the developing fetus. Thus, the 
prevalence of iron-deficiency anemia in U.S. pregnant females during the second and 
third trimester has been estimated at 18% (120). Disparities in this estimate are evident, 
however, when stratifying by ethnicity. Hispanic and African American pregnant females 
are consistently observed to develop iron-deficiency anemia at higher rates than 
Caucasian females. Moreover, the disparity persists among nonpregnant African 
American and Caucasian females, where hemoglobin values among females in the latter 
ethnic group are higher compared to those of the former (112).    
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Compared to the adult reference ranges established by the CDC, both Caucasian 
and African American nonpregnant females have low mean hemoglobin values. 
According to Cook et al., however, “an estimated 2.6% of premenopausal and 1.9% of 
postmenopausal females (and 0.2% of males) are iron deficient in the U.S.” (121, p.729) 
If one extrapolates these data to the population-level, this estimate is quantitatively 
different than that reported by the CDC, where about 3 million rather than 5 million 
females would be considered iron-deficient (109). Results published by Cogswell et al. 
using females participating in NHANES 2003-2004 are congruent with these 
extrapolations. Cogswell and company estimated the prevalence of iron-deficiency 
among a sample of 3,742 nonpregnant females using an algorithm developed by Cook et 
al. for the quantification of body iron and compared these prevalence rates to those 
generated using a standard model for estimating iron-deficiency (51). Similar to the 
discrepancy in the prevalence estimates above, the equation developed by Cook et al. 
“produced lower estimates of iron-deficiency, better predicted anemia and was less 
affected by inflammation” than the standard model (51, p.1,334). Thus, the discrepancy 
between CDC estimates and those produced by the algorithm developed by Cook et al. 
most likely arise due to the difference in hemoglobin reference ranges utilized during the 
times when incidence was calculated and the fact that national surveys did not take into 
account the symptoms of iron-deficiency apart from hemoglobin values. In other words, 
the CDC appears to have used hemoglobin values alone in the determination of iron 
deficiency anemia. According to Moon, the presence of iron-deficiency anemia is not that 
common in developed nations (109). For instance, iron-deficiency due to menstruation is 
not the antecedent of iron deficiency anemia in most females (109). Although 
16 
 
hemoglobin levels and transferrin saturation may temporarily decrease during 
menstruation, dedicated compensatory mechanisms in the human body insure the 
absorption of more iron from the diet (109). Therefore, if iron-deficiency anemia does 
temporarily manifest during the menstrual cycle, it appears to be efficiently counteracted 
by increased iron absorption (109). This leads one to hypothesize that the iron status 
among females in developed nations has perhaps been estimated incorrectly.   
Using data obtained from participants in the Framingham Heart study and sex-
specific cutoffs for defining high iron stores (i.e., ferritin > 300 µ/L in males and > 200 
µ/L in females), Fleming et al. observed a high prevalence (12.9%) of elevated iron stores 
and a low prevalence of iron deficiency (122). Milman et al. observed a similar 
prevalence (i.e., 13%) of high iron stores in a small sample of 85-year old healthy Danes 
(123). In another healthy, free-living population of 1,332 Danish men aged 4-70 years, 
Milman et al. (124) observed a high prevalence of elevated iron stores in males 
comprising two of the oldest age groups (i.e., 20.8% in males in the 60-year old age 
group and 15.2% in males in the 70-year old age group). The results published by Garry 
et al. are congruent with these findings, where the authors report that the prevalence of 
elevated iron stores in free-living elderly males and females in Mexico were 35% and 
15%, respectively when defining elevated body iron stores on the basis of ferritin > 200 
µ/L (125). In a separate study conducted by Milman et al. which examined iron status 
among the Danes from 1994 to those who participated in the Dan-Monica survey ten 
years earlier the authors concluded that the prevalence of all-cause iron deficiency did not 
change, whereas the prevalence of iron overload increased (126). Moreover, the authors 
hypothesized that “the 1987 abolition of mandatory iron fortification of flour apparently 
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had no negative affect on iron status,” (126, p.612) stating that members of the 
population are ultimately accountable for their own primary prevention. Taken together 
these studies also appear to support the hypothesis that iron stores increase with age and 
that the prevalence of high iron stores is relatively common among both males and 
females in developed nations.   
As mentioned previously, body iron stores vary as a function of ethnicity. Using 
data obtained from NHANES III (1988-1994), Zacharski et al. reported that African 
American males have a higher body iron burden across the lifespan compared to 
Caucasian and Hispanic American males and that this disparity is amplified with 
increasing age (112). Gillum observed a similar trend for Hispanic American males using 
NHANES III data (113). Unfortunately, the latter author did not compare indices of body 
iron in these participants to those of other ethnic groups.  
Zacharski et al. also observed a similar trend among females following 
menopause. In other words, no difference in body iron stores among females of 
childbearing age was observed until after the 4th decade of life when body iron in black 
females rose more rapidly and exceeded those of Caucasian and Hispanic American 
females. However, as with most studies assessing body iron, the authors employed 
ferritin as a proxy for iron stores and did not control for inflammation. Thus, the observed 
differences in body iron burden across ethnicities by these authors could have been due to 
the anemia of chronic disease. The results from a more recent study using NHANES data 
from 2003-2006 are discordant with those of Zacharski et al. among females aged 20-49 
years. While the latter authors did not observe disparities in body iron burden among 
females of childbearing age, the results of Pfeiffer et al. demonstrate higher body iron 
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stores among Caucasian females followed by Hispanic American and African American 
females (114). The group used the algorithm developed by Cook et al. in the estimation 
of iron stores. More research is needed before inferences can be made on these results.  
In a follow-up study examining dietary factors associated with high iron stores in 
the Framingham cohort, Fleming et al. concluded that intakes of highly bioavailable 
forms of iron (e.g., supplemental iron and heme iron from red meat) and of fruit with 
vitamin C (i.e., an enhancer of iron absorption) promote high iron stores, whereas foods 
containing phytates (e.g., whole grains) decrease these stores (127). The results from 
another population-based study are congruent with these findings. In a study published 
using participants in NHANES III, the proportion of iron supplement users whose intake 
was at or below the recommended dietary allowance (RDA) was 18.1% in males aged 
19-30 years (n = 773), 21.7% in males aged > 31 years (n = 2,235), 59.3% in 
premenopausal females (n = 1,553) and 22.5% in postmenopausal females (n = 1,387). 
From these data, one can infer that over 81% of males aged 18-30 years, 78% of males 
aged 31 years and older, 40% of premenopausal females and 77% of postmenopausal 
females consume iron supplements in quantities greater than those recommended by the 
RDA. Among users with very high supplemental iron intakes, the authors report that 
males aged 19-30 years who consumed > 4 times the RDA was 12% and 12.7% in males 
> 31 years. The proportion of premenopausal and postmenopausal females who 
consumed > 4 times the RDA was 4.2% and 8.2%, respectively (128). The results 
published by Garry et al. are in alignment with these findings. In their study of free-living 
elderly males and females living in Mexico the authors reported that participants 
consuming > 18mg (i.e., roughly twice the RDA) had iron stores that were 65 mg higher 
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than participants who did not consume iron supplements (125). The current RDA for 
dietary iron and supplements combined in females of childbearing age is 18 mg/day. For 
pregnant females, the RDA is 27 mg/day and during lactation it is 10 mg/day. For all 
other adults, the RDA is 8 mg/day (129). Thus, it is not surprising that much of the 
population in developed nations is iron-replete, where the reported median dietary iron 
intake for men is 16-18 mg/day and 12 mg/day for postmenopausal females (109, 128). 
As mentioned previously, the rate of iron absorption depends on a variety of 
factors, such as body iron stores, rate of erythropoiesis, hemoglobin concentration and 
oxygen concentration. Several studies have demonstrated that the average rates of iron 
absorption in males and nonpregnant females is 15% of total dietary iron while pregnant 
females absorb approximately 17% of ingested iron. According to the Food and Nutrition 
Board, roughly half of the total amount of dietary iron ingested by the human population 
originates in fortified foods (i.e., flour, pastas, bread, cereals) (109). This is not 
surprising, given the mandatory fortification of the U.S. food supply with iron beginning 
in 1941 (109). It has been reported that some cereals contain up to 24 mg of iron per one-
cup serving (109) and Abbaspour et al. have demonstrated that the iron content in 
different varieties of wheat can vary from 25 mg to 56 mg/kg and iron in various strains 
of rice grains can vary from 7 mg to 23 mg/kg (59).   
In addition to fortified foods, body iron can be increased by means of other 
dietary exposures which increase its absorption. For instance, consumption of sugar has 
been shown to increase non-heme iron absorption by four-fold (62). Other dietary 
exposures which increase intestinal iron absorption are beta carotene, cauliflower, 
tomatoes, kiwifruit and oranges (130). Ascorbic acid (i.e., vitamin C) induces a change in 
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the redox potential of non-heme iron, shifting the valence from ferric iron to ferrous iron 
(109, 131). As mentioned earlier in the current chapter, the latter form is more soluble 
and 40-50% of iron ingested concomitantly with ascorbic acid is readily absorbed in the 
duodenum compared to the average rate of absorption of 15% or less (131). Moreover, 
concomitant consumption of red meat with non-heme iron can result in a significant 
increase in iron absorption and it has been reported that one gram of red meat intake has 
an enhancing effect on non-heme absorption equivalent to that of one milligram of 
ascorbic acid (110). Given that the heme iron content of the typical Western diet averages 
~10-15% (i.e., from red meats, processed meats, poultry and fish), it doesn’t appear as 
though heme iron is an independent contributor to total body iron stores. In other words, 
both heme iron as well as nonheme iron, in addition to exposures which increase and/or 
decrease iron absorption are all factors which must be accounted for when estimating 
total body iron stores. 
Exposures not typically found in the diet which nonetheless increase iron 
absorption include alcohol and smoking. Approximately 20-30% of heavy drinkers 
acquire up to twice the amount of dietary iron as do abstainers and light drinkers (132, 
133) because alcohol inhibits delta-amino-levulinic acid dehydratase, a key synthetase in 
porphyrin biogenesis and, ultimately, hemoglobin levels (134). Alcohol also increases 
non-heme iron absorption due to increasing gastric acid production, where the increased 
acidity precipitates iron ions in solution as they reach the duodenum where absorption 
into bloodstream occurs (134). In addition, alcohol decreases hepcidin synthesis and 
increases expression of DMT1 in the intestine, resulting in increased iron absorption 
(135). A typical cigarette contains approximately 84 micrograms of iron per gram of 
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tobacco (110, 136) Given that a cigarette contains approximately one gram of tobacco, a 
one-pack-a-day smoker can inhale up to 1.68 milligrams of iron per day. Moreover, some 
pipe tobaccos contain over 400 micrograms of iron per gram of tobacco (110, 136). 
Consistent with these statistics, alveolar macrophage iron content has been shown to be 
67% higher in smokers compared to nonsmokers (137) and is positively correlated with 
number of cigarettes smoked (138). 
Iron loss can occur through several routes, such as blood loss through donation 
and phlebotomy, menstruation and child birth. Blood donation and phlebotomy typically 
removes one pint (~ 475 cc) of blood and this equates to 0.25 grams (250 mg) of iron 
(109, 110). Blood is also lost during menstruation. The average period lasts anywhere 
from two to five days and blood loss during this time is estimated to range from 60 
milliliters (~ 4 tbs) for a light period to 250 milliliters (~ 1 cup; half of a pint; 125 mg of 
iron) for a heavy period (110). On average, however, about one pint of blood is lost 
annually during menstruation (110), which is equivalent to the amount of iron loss during 
blood donation/phlebotomy. Each child birth results in a loss of blood that is equivalent 
to the amount lost during a heavy period (110). Other factors which result in loss of iron 
include physical activity (i.e., iron is lost through perspiration and sloughing of the 
gastrointestinal tract), ulcers, trauma, hemodialysis, surgical procedures, colon cancer, 
uterine cancer, intestinal polyps, hemorrhoids and intravascular hemolysis (109). When 
hemolysis occurs, hemoglobin and heme iron are reported to be 1) scavenged by 
haptoglobin and hemopexin, respectively, 2) rapidly cleared from circulation and stored 
in ferritin, 3) recycled by macrophages or 4) lost by hemoglobinuria and hemosiderinuria, 
respectively (109, 110). 
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Notwithstanding the above-mentioned routes of blood loss, body iron stores can 
be reduced at the level of absorption. Dietary exposures which decrease iron absorption 
are fiber, soy protein, inositol phosphate-6 (IP6) (i.e., phytates/phytic acid) such as wheat 
bran, rice bran, whole wheat, corn, peas, rye, oats, brown rice, nuts and legumes (130, 
131) as well as oxalates such as spinach, bran flakes, rhubarb and beets (130). In 
addition, polyphenols such as flavonoids, phenolic acids, phenolic alcohols, stilbenes and 
lignans are ring structures that contain more than one hydroxyl group which bind non-
heme iron and render it unavailable for absorption (131). Calcium has been shown to 
inhibit non-heme iron absorption (and heme-iron, to a lesser extent) and ovotransferrin 
(i.e., ovalbumin) contained in eggs exhibits an iron-binding affinity similar to that of 
lactoferrin (110). Lactoferrin (found in bodily fluids such as perspiration, tears, seminal 
fluid, vaginal fluid, breast milk and to a lesser extent in saliva) (110) binds ferric iron 
with 240-times greater affinity than transferrin (110) and deprives microorganisms (e.g., 
bacteria, fungi) access to growth medium. In contrast to transferrin, however, iron that is 
sequestered by lactoferrin is not used by healthy cells (i.e., the sole function of lactoferrin 
is to bind excess iron) (109, 110). Consistent with these observations, it has been reported 
that one boiled egg can reduce absorption of iron in a meal by as much as 28%. (109). 
Finally, medications such as acid reducers (e.g., omeprazole (Prilosec), pantoprazole 
(Protonix)), Imipramine (i.e., an antidepressant) and aspirin have also been shown to 
reduce iron absorption. According to Weinberg, gastrointestinal microbleeding induced 







CHAPTER 3: IRON IN HUMAN HEALTH AND DISEASE 
 
Iron in human health   The importance of iron in human health was evident as 
early as the 17th century when iron was used to treat chlorosis, a condition which results 
from iron deficiency. However, it was not until 1932 when it was demonstrated that iron 
was required for hemoglobin synthesis that the metal began to become a fixture in the 
research community (109).   
Functional dependencies on iron   As mentioned in chapter 2, humans require 
iron for cellular respiration, DNA synthesis, DNA repair, as a cofactor in biochemical 
reactions, oxygen transport, endocrine regulation, thermoregulation and bone health. 
Three out of the four redox cofactors (i.e., complexes) in the electron transport chain and 
the electron carrier cytochrome c contain hemes and iron-sulfur clusters, respectively. All 
contain iron ions whose redox state serves to accept or donate electrons to keep the chain 
operational where ferrous iron acts as an electron donor and ferric iron acts as an electron 
acceptor (139). 
With respect to DNA synthesis and repair, the activity of ribonucleotide 
reductase, the rate limiting enzyme involved in the conversion of ribonucleotides to 
deoxyribonucleotides is iron dependent (140). Iron is also vital for the enzymatic activity 
in xenobiotic (e.g., plant alkaloids, fungal toxins) and medication metabolism. All 
cytochrome P450 (CYP450) enzymes contain iron in their active site where the redox 
potential of iron is used to catalyze the oxidation (i.e., activation) of most medications 
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(141-144). These enzymes are expressed in every tissue except skeletal muscle and 
erythrocytes (142). The reactions catalyzed by CYP450 enzymes begin with the 
abstraction of hydrogen from NADPH by cytochrome P450 reductase (142). The 
hydrogen is then used by CYP450s to reduce one of the two atoms of molecular oxygen 
to water. The other oxygen atom is retained in a highly reactive form, which in turn is 
used to force subsequent catalytic reactions upon the substrate (142-144).  
The enzymatic activities of aconitase (i.e., a regulatory protein), nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidoreductase and myeloperoxidase are 
dependent upon iron as a cofactor. In addition, catalase is an enzyme which uses iron as 
an electron donor and participates in the prevention of hydrogen peroxide (H2O2) induced 
cellular damage by converting the compound to water and molecular oxygen (145). 
Xanthine oxidase contains riboflavin (i.e., vitamin B2), molybdenum and ferrous iron in 
its active site (146). Finally, iron appears to be a negative regulator of nitric oxide (NO) 
synthase (147). Conversely, NO is a negative regulator of iron, whereby increased NO 
decreases labile iron by increasing ferritin mRNA expression and ferritin synthesis (148) 
and NO has been observed to be up-regulated in iron deficiency anemia (149).  
The genesis of oxygen transport occurs upstream within the bone marrow 
beginning with the synthesis of erythrocytes (i.e., erythropoiesis) and requires 25-30 mg 
of iron per day. The iron is obtained from reticuloendothelial macrophages which 
phagocytose and catabolize 20 mL of senescent erythrocytes each day resulting in the 25-
30 mg of required iron (150). Erythroid regulation of iron metabolism is controlled by 
erythroferrone (ERFE), a newly identified hormone produced by erythroblasts in 
response to erythropoietin which negatively mediates hepcidin expression during iron-
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deficient states. Briefly, the kidney acts as a sensor of oxygen levels in circulating 
erythrocytes. When oxygen levels decrease, erythropoietin is synthesized by interstitial 
fibroblasts within the renal medulla (151), which is released into circulation and 
upregulates erythroblast formation in the bone marrow. In turn, erythroblasts express 
ERFE, which lowers serum hepcidin and increases iron absorption (151). Thus, iron 
utilization for erythropoiesis increases after stimulation by erythropoietin or in response 
to hypoxemia (152). Conversely, inhibitors of erythropoiesis induce a rise in serum and 
tissue iron levels (153).  
Iron affects endocrine signaling in myriad ways. For example, increases in 
adipocyte ferritin synthesis has been shown to reduce adiponectin expression and 
increases insulin resistance (154, 155). In addition, iron and leptin appear to negatively 
regulate one another, as increases in leptin induce hepcidin expression (which decreases 
iron absorption) (156). Paradoxically, increases in iron are monotonically associated with 
decreases in leptin. For example, in a 2015 cross-sectional study conducted by Gao et al. 
using data from a cohort of 76 individuals, the authors sought to examine the relationship 
between serum ferritin and leptin and found a significant negative association between 
the two analytes (r = -0.53, P < 0.0001). Moreover, to extend these findings, the authors 
conducted an animal study using C57BL6/J mice, where the animals were fed one of two 
diets: 1) a high-iron diet (i.e., 2,000 mg/kg, N = 36) or 2) a low-normal iron diet (i.e., 35 
mg/kg, N = 36) for 2 months. At the end of the study, Gao et al. found that serum leptin 
decreased with increasing dietary iron (r = -0.26, P < 0.01) where mice in the high-iron 
group had 42% lower serum leptin concentrations compared to mice in the low-normal 
iron group  (157).  
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The relationships between sex hormones and body iron appear to be quite 
complex. For example, testosterone increases expression of erythropoietin, which 
decreases hepcidin expression to sequester iron for erythropoiesis (158). It has also been 
shown that testosterone directly suppresses hepcidin expression and increases iron 
absorption independent of erythropoietin signaling (159). Consistent with these results, 
Liu et al. reported that serum ferritin levels are inversely associated with total 
testosterone, sex-hormone binding globulin (SHBG) and free testosterone (160) and 
Winters et al. have demonstrated that SHBG is inversely related to insulin resistance 
(161) and metabolic syndrome (162). Yang et al. have recently shown that E2 contained 
in oral contraceptives suppresses hepcidin expression both in vitro and in vivo and 
increases iron absorption by binding to an estrogen response element in the hepcidin 
promoter gene. (163, 164). In an animal study using newly hatched White Leghorn 
chicks, E2 administration decreased total iron binding capacity (TIBC, i.e., the ratio of 
serum iron to transferrin saturation) in serum by ~ 20% from levels in a control of group 
of animals (n = 4) irrespective of iron content of diet and raised non-heme iron content of 
livers of animals in the experimental group (n = 4) by 40-50% over that of the control 
group irrespective of iron content of diet. (165). More alarming is that redox cycling of 
estrogen metabolites has been reported to release ferric iron from ferritin which in turn 
generates hydroxyl radicals via the Fenton reaction (discussed in greater detail below) 
(166).  
Human and animal studies have both reported links between excess body iron and 
decreased bone mineral density (BMD), lower serum osteocalcin, delays in bone 
mineralization, lower rates of bone formation and lower osteoblast numbers (167). 
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Individuals with beta-thalassemia, for example, consistently exhibit low levels of 
circulating osteocalcin (168) and osteoblast cells express transferrin receptor and ferritin 
throughout differentiation in vitro, suggesting that iron is important in osteoblast 
maturation and function (167). Iron suppresses osteoblast maturation and function in a 
dose-dependent and time-dependent manner (167) in cells isolated from primary fetal rat 
calvaria and it is hypothesized that that the effect is mediated by ferritin and its 
ferridoxase activity (169). As previously mentioned, ferritin light chain participates in 
ferridoxase turnover and studies have reported that ferritin light chain expression is 
normally high in osteoblasts (167). Thus, as intracellular concentrations of iron increase, 
ferridoxase turnover activity of ferritin light chain may diminish, leading to an increased 
number of immature osteoblasts. Moreover, cell line studies where DMT1 is mutated to 
increase iron absorption demonstrate that the ensuing iron overload leads to increased 
osteoblast autophagy and apoptosis (170). Taken together, it appears as though the effect 
of increased iron on bone health results in premature cell death and/or proliferation of 
immature osteoblasts. Finally, one group of authors have published data which indicates 
that serum ferritin is inversely correlated with osteocalcin and osteocalcin is associated 
with glucose and insulin metabolism by exerting a direct effect on beta cells via 
stimulating insulin production and enhancing adiponectin production from adipocytes 
(171). Thus, these researchers have recently developed a hypothesis which links high 
body iron to low osteocalcin, low adiponectin and increased insulin resistance (172).  
Iron has been implicated in the body’s ability to thermoregulate for quite some 
time. For example, several authors have reported that iron deficiency leads to impaired 
thermoregulation in response to acute cold exposure (173-176). Conversely, it has also 
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been hypothesized that ‘hot-flashes’ experienced by post-menopausal females are directly 
related to increases in body iron following the onset of menopause (177).  
Iron in human disease   An approach often employed by epidemiologists to 
implicate a given exposure in the development of disease is to demonstrate that the 
disease has a genetic or heritable component. Most diseases of iron overload result from 
loss of function mutations (e.g., hereditary hemochromatosis), resulting in suppressed 
hepcidin production. To this end, the following iron loading conditions have all been 
studied extensively and linked to adverse health outcomes: hereditary hemochromatosis, 
TFR2-related hemochromatosis, ferroportin disease, juvenile hemochromatosis (type 1 
and 2), beta thalassemia, sickle cell anemia, X-linked sideroblastic anemia, pyruvate-
kinase deficiency, hereditary spherocytosis, Fanconi anemia, Diamond-Blackfan anemia, 
chronic renal failure, Friedreich ataxia, hereditary atransferrinemia and hereditary 
aceruloplasminemia (178-181). Tables 6a-6e highlight each iron loading disorder, genetic 
mutation, genetic locus, mode of inheritance, mechanism, affected iron parameter and 
disease association(s)/clinical feature(s). For convenience, each disorder is categorized by 
subtype.  
Iron in infectious disease   Nearly all pathogenic microorganisms need iron for 
survival, growth and multiplication (110). Under normal physiologic conditions an 
immunological challenge results in an increased expression of interleukin-6 (IL6). In 
turn, hepcidin mRNA expression is reduced and interferon gamma (INF-γ) is induced. 
This results in the halt of export of iron from cells via degradation of ferroportin and a 
reduction of transferrin receptor expression, which enables invaded cells (e.g., 
macrophages) to starve invading pathogens. Several infectious microorganisms such as 
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Mycobacterium tuberculosis, Candida albicans, Borrelia burgdorferi, Staphylococcus 
aureus, Pseudomonas aeruginosa, Helicobacter pylori, Salmonella, Toxoplasma gondii 
directly induce hepcidin expression via pathogen associated molecular patterns (PAMPs), 
which also prompts the body to withhold iron and trigger the innate immune response via 
activation of toll-like receptors (182). Studies have shown that circulating hepcidin binds 
to TLR2, TLR3, TLR4, TLR7, TLR8, TLR9 and TLR10 (183). Pathogens, however, 
have evolved at least four strategies to acquire iron from hosts: 1) hemolysis (e.g., 
Streptococcus pneumoniae, Staphylococcus aureus), 2) transferrin or lactoferrin 
scavenging (e.g., Neisseria meningitis (i.e., transferrin scavenging), Helicobacter pylori 
(i.e., lactoferrin scavenging), Vibrio vulnificus (i.e., transferrin scavenging), 3) 
siderphores (e.g., Escherichia coli, Listeria monocytogenes, Haemophilus influenzae 
(183)), Neisseria meningitidis (183) or 4) target, infect and utilize intracellular 
macrophage iron (e.g., Coxiellaceae, Francisella tularensis, Legionnaires pneumoniae, 
Mycobacterium tuberculosis).  Moreover, hepatitis C virus has been shown to increase 
hepatic iron level in Huh7 and Huh7.5 cell lines by suppressing hepcidin expression 
(184) and five iron-dependent and iron-regulated steps are required for the replication of 
the human immunodeficiency virus (HIV) (185).  
Increases in body iron burden have been linked to the suppression of the 
complement system (186) and have been observed to have adverse effects on major 
aspects of macrophage/monocyte function such as decreasing immune and nonimmune 
phagocytosis, decreasing chemotaxis, altering cytokine production and release as well as 
decreasing antigen processing for subsequent presentation to B- and T- lymphocytes 
(186). Increased iron concentration in macrophages reduces their response to activation 
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by interferon-gamma (INF-γ) and diminishes their antimicrobial toxicity. Moreover, cell-
line studies have demonstrated that addition of iron to culture results in decreased 
antibody- (Ab) mediated and mitogen-stimulated phagocytosis by macrophages and 
monocytes (186). Conversely, orally-administered lactoferrin has been shown to restore 
humoral immunity in immunocompromised mice (187). It has been hypothesized that the 
above associations between iron and macrophage/monocyte function is due the ability of 
iron to negatively regulate NO synthesis. Given that NO is integral for macrophage 
cytotoxicity (188), this hypothesis warrants further investigation.  
Increases in body iron have also been implicated in alterations in T-lymphocyte 
subsets. For example, individuals with high iron stores demonstrate a reduction in 
circulating interleukin-2 (IL2) and subsequent impairment of the generation and activity 
of CD8+ cytotoxic T lymphocytes (CTLs) (186, 189) and natural killer cell (NKC) 
activation and proliferation. Moreover, these lymphocytes in individuals with increased 
body iron exhibit decreases in proliferative capacity, numbers and activity of helper 
(CD4) T cells (186) by increasing expression of IL-4, IL-10, and decreasing levels of IL-
12 and INF-γ. Thus, increases in iron appear to polarize helper T-cell subsets into Th2 
effector cell subtypes which are implicated in reduced immunological surveillance and 
anergy (183). This is thought to arise via the same mechanism implicated in macrophage 
anergy whereby iron antagonizes NO, which decreases Th1 proliferation (190) and 
polarizes the Th2 response. In turn, increased Th2 production of IL4 induces a 
suppression of INF-γ and this culminates in the activation of transferrin receptor mRNA 
synthesis which could lead to further increases in body iron. Clinical studies which 
support these in vitro results have shown that iron demonstrates an antagonistic effect for 
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individuals undergoing interferon therapy (191) and that treatment response is restored 
upon iron chelation therapy (191). In line with these observations, body iron also appears 
to have an effect on interferon therapy. The higher iron content of the liver, the less likely 
it is that a patient will respond to treatment (109). Related to this, Alexander et al. (192), 
performed weekly phlebotomies on 18 subjects with chronic hepatitis C infection who 
did not respond to initial interferon therapy. Phlebotomy continued until serum ferritin 
was < 50 ng/mL and the authors observed that “iron depletion was associated with a 
response rate of 22% in those who did not initially respond to monotherapy.” Taken 
together, it appears that the effects of iron on immunological regulation is related to 
immunological defense and surveillance. 
Iron in chronic disease   As a dietary exposure, iron appears to have a curvilinear 
relationship with human health and disease, as both severe iron-deficiency and varying 
degrees of iron excess have been implicated in the pathogenesis of several adverse health 
outcomes. As mentioned, the idea that excess iron could be potentially toxic to humans 
was first suggested by Jerome Sullivan in 1981 in his canonical article “Iron and the sex 
difference in heart disease risk” (36). In it, Sullivan hypothesized that blood loss via 
menstruation is the primary factor that protects premenopausal females from ischemic 
heart disease. A few years later in 1984, Halliwell and Gutteride demonstrated iron’s 
toxicity via oxygen radical generation in biological systems (193). Finally, in 1992 with 
Lauffer’s publication of Iron and Human Disease, iron became widely known as a bio-
metal that accumulates with increasing age (194) 
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Though iron is an essential micronutrient required for survival it is also a 
transition metal. Thus, iron can exert a detrimental effect on cellular, organ, and systemic 
homeostasis via the Fenton Haber-Weiss reaction, which can be summarized as follows: 
 
1):   Fe3+ + · O2
- → Fe2+ + O2 
2):   Fe2+ + H2O2 → Fe
3+ + OH- + · OH 
3):   · O2
- + H2O2 → OH
- + O2 + · OH 
High levels of insoluble iron can react with superoxide radicals and ferrous iron can react 
with H2O2, initiating the Fenton reaction (reactions 1 and 2). The end-product of these 
reactions includes the generation of unstable free radicals and oxidized ferric iron (195). 
Iron is also a key metal that catalyzes the Haber Weiss reaction, which is a secondary 
reaction to the Fenton reaction (196). A superoxide radical (· O2
-) generated from the 
Fenton reaction reacts with H2O2 which in turn generates a hydroxyl radical (196). Thus, 
iron is a pro-oxidant and is capable of generating reactive oxygen species (ROS). In turn, 
ROS contribute to oxidative stress (OS) and inevitably induce lipid peroxidation, 
endothelial dysfunction, and microsatellite mutations within regions of the genome (197). 
It is noteworthy to mention that the above reaction is an intracellular phenomenon. Thus, 
several authors have concluded that increased intracellular iron, in comparison to 
extracellular iron, has been shown to exhibit greater systemic toxicity and cellular 
damage. 
In developed nations including the Unites States, the seven leading causes of 
human mortality are cardiovascular disease (e.g., coronary heart disease), cancer, 
cerebrovascular disease (e.g., stroke), chronic obstructive pulmonary disease (COPD), 
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accidents, Alzheimer’s disease (AD), and diabetes (198). With the exclusion of accidents 
and diabetes, the ensuing review will examine the effect of iron deficiency and excess on 
the development of human chronic disease. A review of the effect of iron in the 
epidemiology of diabetes and other metabolic dysfunction appears in chapter 4. 
Iron and cardiovascular disease   Cardiovascular disease (CVD) is the leading 
cause of mortality in the U.S., accounting for 25.4% of total deaths (199). The postulation 
that iron influences the development of CVD originated with J.L. Sullivan in 1981 when 
the author published an article in the Lancet examining gender differences in the risk of 
heart disease (36). Sullivan proposed that the rate difference in incident CVD between 
men and females was likely due to iron loss through menstruation in premenopausal 
females. Thus, Sullivan’s hypothesis stated that iron excess was a risk factor for the 
development of CVD, while iron deficiency appeared to convey a protective effect.  
The iron-heart hypothesis has received support from in vitro models (200, 201), 
animal studies (200, 201) and epidemiological studies (202-211). For example, in a 
prospective study in a Finnish population (n = 1,931), Salonen et al (200) demonstrated 
that serum ferritin concentration was positively associated with risk of myocardial 
infarction (MI). Compared to men with serum ferritin levels < 200 ng/mL, men with 
serum ferritin concentrations ≥ 200 ng/mL exhibited more than a 2-fold increased risk of 
acute MI (200). In a study of 9,920 Canadian men and women, Morrison et al (201) have 
shown that the risk of fatal MI increases significantly in persons with serum iron 
concentrations ≥ 175 μg/dL combined with total cholesterol level ≥ 240 mg/dL. Tzonou 
and colleagues (202) examined the role of dietary iron in the development of coronary 
heart disease (CHD) in a case-control study in Greece. The study was comprised of 329 
34 
 
cases and 570 controls with no matching on age or gender. Cases were all recruited from 
the same hospital on the basis of CVD development. Hospital controls were selected on 
the basis of absence of CVD. The authors demonstrated a positive association between 
iron intake and CHD among cases > 60 years of age. The odds ratio that the authors 
reported for each monthly increment of 50 mg of iron was 1.47 (95% CI: 1.02-2.12). The 
effect of dietary iron was stronger for women (OR for each monthly increment of 50 mg 
dietary iron: 3.61; 95% CI: 1.45-9.01). Although slightly attenuated when adjusted for 
total cholesterol and blood pressure, the risk estimates remained significant for both men 
(OR = 1.36) and women (OR = 3.51). Thus, the results published by Tzonou et al support 
Sullivan’s hypothesis. Findings from van der A, et al (203) support the increased risk of 
CVD in females with diets high in heme iron. Participants were grouped into quartiles 
based upon increasing levels of dietary iron. In the study (n = 16,136), the authors found 
a 65% increase in CVD risk in middle-aged women who consume > 2.27 mg/day heme 
iron (Q4 vs Q1: HR = 1.65; 95% CI: 1.07-2.54). The significance of the risk estimates 
did not change when the authors adjusted for total energy intake or total cholesterol 
intake. Results from the Bruneck Study, however, have shown that serum ferritin is one 
of strongest predictors for progression of atherosclerosis in the presence of increasing 
concentrations of LDL cholesterol (204). The authors demonstrated that a 1-SD increase 
in ferritin concentration at LDL levels of 2.5 mmol, 3.6 mmol, and 4.9 mmol precipitated 
an increase in progression of atherosclerosis. The reported hazard ratios (HR) for each 
increasing concentration of LDL were 1.55 (95% CI: 1.30-1.85), 1.77 (95% CI: 1.40-
2.24), and 2.05 (95% CI: 1.50-2.80), respectively. These results suggest an interaction 
between iron and LDL cholesterol. A study conducted by Bazrgar et al (205) supports 
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this speculation. The authors examined the association between APOE status in patients 
with thalassemia major and the risk of left ventricular dysfunction. Participants (n = 202) 
were divided into three groups, based upon level of cardiac impairment (i.e., group 1= no 
cardiac impairment; group 2 = LV dilation with normal systolic function; group 3 = LV 
systolic dysfunction). Participants in group 3 were significantly more likely to carry the 
high risk APOEε4 allele, compared to participants in group 1 or group 2. Briefly, gene 
products of APOE function as lipid transporters and scavengers of free radicals (205). 
The locus itself is known to contain three variant alleles: APOEε2, APOEε3, and 
APOEε4. APOEε2 encodes greater concentrations of mRNA and displays high 
scavenging activity while APOEε4 encodes lower concentrations of mRNA and has 
exhibits decreased scavenging activity (205). The scavenging capacity of APOEε3 lies 
between APOEε2 and APOEε4.  Products of the APOE gene thus work to clear oxidized 
LDL (oxLDL) from systemic circulation (205, 206). It has been well established that ox-
LDL is one of the main contributors to atherosclerosis and that iron is a potent oxidizing 
agent (206). Hence, the synergistic relationship between iron and LDL cholesterol 
appears biologically plausible. Interestingly, cholesterol lowering medications (i.e., 
statins) have been shown to reduce serum ferritin levels, offering further support for iron 
in the iron-heart hypothesis (207).  
Genetic studies of CVD have contributed additional insights to risk susceptibility. 
For example, a prospective cohort study (n = 1,150) conducted by Tuomainen et al (208) 
demonstrated that heterozygous male carriers of the risk allele (i.e., C282Y) of the HFE 
gene, a mutation implicated with hereditary hemochromatosis, experience a 2.3-fold  
increased risk of acute MI (p = 0.03). These results were subsequently substantiated in a 
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study by Roest et al (209), who have shown that female HFE heterozygotes also have an 
increased risk of mortality from cardiovascular disease (OR = 1.6; 95% CI: 1.1-2.4)  
Further supporting the iron-heart hypothesis are studies which demonstrate a 
decreased risk of CVD among regular blood donors. Another prospective cohort study (n 
= 2,862) conducted by Salonen et al (210) demonstrated that blood donors experienced 
fewer CVD events (i.e., acute MI) compared to non-donors (0.7% vs 12.5%, respectively; 
p = 0.035).  Results from Ascherio et al (211), however, do not corroborate these 
findings. The authors argue that healthier individuals are more likely to donate blood and 
therefore do not constitute a random sample. It should also be noted that the literature 
offers further discordant support for the iron-heart hypothesis. For example, during a 14-
year follow-up study, Sempos et al (212) found no increased risk for CVD with 
increasing levels of transferrin saturation in a cohort of 4,518 men and women. These 
results have been confirmed in the Helsinki Heart Study (213) and the Health 
Professionals’ Follow-up Study (214). A retrospective cohort study published from data 
gathered during the NHANES I Follow-up Study demonstrated a negative association 
between serum iron concentration, transferrin saturation, and CVD (215). In a controlled-
feeding study Derstine and colleagues (216) reported no association between iron status 
and strong risk factors for cardiovascular disease (i.e., LDL oxidative susceptibility). It is 
interesting, however, that participants in the aforementioned study were administered 
food sources containing only non-heme iron (e.g., peanut butter). The literature clearly 
demonstrates that heme iron from animal sources (202, 203, 217), which is more readily 
absorbed in the gastrointestinal tract, is more closely linked to the association between 
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excess iron and cardiovascular disease risk. Derstine et al offered no reasoning for the 
exclusion of heme iron from each participant’s diet. 
Taken together, it appears that the iron-heart hypothesis finds support from human 
studies examining the relationship between excess iron stores (derived from heme-iron 
intake) and acute or ischemic cardiovascular-related phenomena. Thus, iron in excess 
appears to exert its effect in initiating or promoting CVD events (218). It should be noted 
that many markers of iron status (i.e., ferritin and transferrin) are acute-phase reactive 
proteins often present during infection and inflammation. Studies that have controlled for 
these related factors by concomitantly measuring serum C-reactive protein (CRP) (219, 
220) and α-1 acid glycoprotein (AGP) (220) nevertheless reveal significant associations 
between excess iron stores and risk of CVD. Given that the aforementioned relationship 
between iron and CVD appears to be significantly modified in persons with APOEε4 
status and/or abnormal lipid profiles (e.g., hyperlipidemia), further research is required to 
quantify iron’s unique contribution to the development of CVD.  
Iron and cancer   Malignant neoplasms (i.e., cancers) are the second leading 
cause of mortality in the U.S., accounting for approximately 23.2% of total deaths (198). 
The relationship between iron excess and cancer has been studied extensively. Multiple 
disciplines, ranging from genetics to epidemiology have reported upon the toxicity of 
iron in the human body. Emerging from these investigations is a seemingly coherent 
communiqué: iron in excess is positively associated with cancer mortality and the 
initiation or promotion of specific cancers. As mentioned previously, iron is capable of 
generating ROS, inducing lipid peroxidation, or endorsing microsatellite mutations. The 
culmination of the preceding events invariably leads to mutations within DNA as well as 
38 
 
organelle, cellular, and tissue damage (221-224). Moreover, forward propagation of these 
aberrant intracellular states often initiate irreversible mutations in essential DNA repair or 
tumor suppressor genes. In turn, an entire diabolical cascade of chemical events may 
ensue, leading to the dysfunction and destruction of mitochondria, organelles, and tissues. 
It remains unresolved, however, if iron conforms more suitably to the role of tumor 
initiator or promoter.  
Iron does not have carcinogenic properties, per se. Nevertheless, many studies 
have clearly linked iron to the development of malignancy. For example, using NHANES 
II data, Wu et al (225) demonstrated a dose-response effect of iron on cancer mortality. 
An investigation utilizing NHANES I data support the aforementioned results (226). 
Regarding cancer subtype, iron has been most strongly linked to the development of 
colorectal cancer (227-239) and breast cancer (240-255). These studies demonstrate that 
iron-specific parameters derived from study participants are often indicative of iron 
overload (as opposed to iron-deficiency) in these cancers. Furthering the association 
between iron excess and cancer are studies demonstrating an association between 
colorectal and breast cancer with the HFE C282Y mutation (256-262). Iron’s association 
with lung cancer is less clear, however. Four of six investigations establish a point 
estimate greater than one (263-266). However, only one of the six (263) estimates do not 
cross unity. Interestingly, iron appears to espouse a dual-role in prostate cancer (267-
275). Iron tends to be inversely associated incident prostate cancer (267-271) and 
positively associated with advanced, aggressive, and fatal prostate cancer (272). The 
subjects from each of the aforementioned studies were all middle aged and older, 
rendering it difficult to distinguish iron from other milieu as a tumor initiator. Given the 
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associations reported in the above investigations, however, regarding iron as a tumor 
promoter seems plausible. This speculation is further supported by human and animal 
studies demonstrating a clear association between primary iron overload (i.e., hereditary 
hemochromatosis) and secondary iron overload with digestive tract and liver cancer (276-
283). These sites are of particular interest, given their primary function in iron absorption, 
metabolism, and storage. Interestingly, tumor cells have been observed to express a high 
number of transferrin receptors (197), owing to their high rate of proliferation. Thus, it 
would be a formidable task to abrogate the role of iron in the promotion of malignancy in 
humans. Moreover, irrespective of initiating events, the alterations observed in iron status 
and metabolism in the above-mentioned cancers indicate that iron bolsters the 
aggressiveness and metastases of malignancy.  
Although iron is clearly implicated in the development and propagation of 
colorectal and breast cancer, investigations examining the role of iron in other types of 
cancer show no such associations. For example, inverse associations between iron status 
and renal cancer, pancreatic cancer, Barrett’s esophagus, and oral cancer have been 
reported in several studies (284-286). Nevertheless, these results do not diminish the 
significance of the role of iron in other tumor subtypes. For example, it is well known 
that iron chelators have been used in the treatment of certain types of cancer (287-290). 
Moreover, regular blood donation (291), phlebotomy (291), and anemia (292) are 
inversely associated with the subsequent development of malignancy.     
The association of iron with childhood malignancy has not yet been directly 
examined. However, one can speculate that iron does indeed appear to be indirectly 
involved in the development of childhood malignancy. For example, Dorak et al (293) 
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have noted that the HFE C282Y mutation is a male-specific risk factor for childhood 
acute lymphoblastic leukemia (ALL). In addition, other studies have teased apart an 
association between high birth weight (i.e., macrosomia) and childhood leukemia (294-
297). Lending support to this association are studies demonstrating a relationship 
between macrosomic infants of diabetic mothers and childhood cancer (298-301). 
Moreover, as indicated by Shetty et al in 2008, human and animal studies have shown a 
positive linear relationship between labile iron concentration and glycated hemoglobin 
(HbA1C) (302). In addition, macrosomic infants have also been shown to have increased 
numbers of hematopoietic stem cells (303), which has been correlated with increased 
cancer risk.  
Iron and cerebrovascular disease   Cerebrovascular disease is the third leading 
cause of mortality in the US, responsible for approximately 5.6% of total deaths (198). 
However, there is a paucity of literature specific to the association between iron and 
cerebrovascular disease (i.e., stroke). The available studies report that both iron 
deficiency and iron excess are risk factors for cerevrovasular disease. For example, a case 
report by Hartfield, et al (304) indicated that iron deficiency was the only common 
feature among six infant stroke patients. In a case-control study (15 cases:143 controls) 
examining the relationship between iron and childhood stroke, Maquire et al (305) have 
shown that cases were approximately twelve times more likely (OR = 12: 95% CI: 4-37) 
to have iron-deficiency anemia compared to controls. In another case-report by Munot 
and colleagues (306), the authors noted that dietary iron-deficiency was the only common 
factor among four children suffering from ischemic stroke. Conversely, Roest et al (209) 
demonstrated that adult female heterozygote carriers for the HFE mutation experienced 
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an increased risk of cerebrovascular disease (OR = 2.4; 95% CI: 1.3-3.5). Moreover, in 
an NHANES I follow-up study (n = 5,033), Gillum et al (307) found an increase risk of 
stroke incidence in white females aged 45-74 with both high and low transferrin 
saturations. Compared to females with transferrin saturation between 30-36%, those with 
levels > 44% experienced a RR of 1.96 (95% CI: 1.15-3.36), while those with transferrin 
saturation < 20% experienced a RR of 1.80 (95% CI: 1.20-2.71). The authors found no 
such associations in white men aged 45-74 or in African Americans (i.e., male or female). 
Iron and chronic obstructive pulmonary disease   In the US, COPD is the fourth 
leading cause of mortality, accounting for 5.3% of total deaths (196). Compared to 
cardiovascular disease and cancer, less is known about the relationship between iron and 
chronic obstructive pulmonary disease (COPD). A literature search revealed that lavage 
samples taken from patients (n = 44) with COPD exhibited elevated concentrations of 
iron and ferritin compared to healthy controls (n = 50) (308). A recent biomarker study 
demonstrated the identification of four sensitive and specific biological markers for 
COPD diagnosis and progression. Three out of four of these markers were iron-specific 
(i.e., haptoglobin, ceruloplasmin, and hemopexin) (309). The study demonstrated that 
each of these markers are elevated in patients with COPD, indicative of inflammation. In 
the presence of infection and inflammation, the iron-regulatory peptide hepcidin is 
synthesized by the liver. This hormone binds to and degrades the ferroportin receptor on 
basolateral membrane of enterocytes and outer membrane of macrophages, thereby 
prohibiting the release of stored iron. In addition, hepcidin sequesters the absorption of 
dietary iron by enterocytes. Thus, it is reasonable to speculate that patients with COPD 
may experience higher levels of stored iron compared to their abstaining counterparts. 
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Supporting this assertion is a recent study of European iron/steel foundry workers (n = 
459). In 2011, Bala & Tabaku discovered that iron workers experienced greater than a 2-
fold increase in risk of developing COPD compared to non-foundry workers (310). The 
authors controlled for other germane occupational exposures as well as smoking status. 
Given the dearth of available evidence, however, it can be concluded that the association 
between iron and COPD is tentative, at best. More research in this area is required prior 
to further extrapolation. 
Iron and Alzheimer’s disease   Alzheimer’s disease (AD) is the sixth leading 
cause of mortality in the US, accounting for up to 5.1% of total deaths (196). The 
relationship between iron and AD has recently been well-studied. Evidence indicates that 
transferrin receptors (TfRs) are fairly ubiquitous in the human brain (311). Interestingly, 
TfRs are more highly concentrated in the substania nigra, locus ceruleus, putamen, 
caudate nucleus, globus pallidus, and hippocampus (311) - regional sites commonly 
associated with neuronal dysfunction and degradation in Alzheimer’s disease (AD) (312-
314). Studies have supported this biochemical association by establishing that iron 
accumulates in regions of the brain of those affected by AD (315-317). In addition, field 
dependent relaxation rate increase (FDRI) (318, 319) and serial susceptibility weighted 
(SWI) (318, 320) magnetic resonance imaging (MRI) studies have revealed an age-
related increase in iron concentrations in the putamen, caudate, and globus pallidus.  
The iron-AD association is further supported by studies demonstrating that iron 
influences γ-secretase cleavage activity of amyloid precursor protein (APP) (321). Both 
human (322, 323) and animal studies (324) have confirmed that an increase in labile 
brain iron coincides with early Aβ plaque formation. Finally, carriers of the HFE C282Y 
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and H63D variants (mutations in the hereditary hemochromatosis) have been shown in 
epidemiological studies to display a small increased risk of AD as well as an earlier age 
of onset of the disease (325-328). However, it should be noted that not all studies 
examining this association have reported similar findings (329, 330). Similar to persons 
with high iron stores and abnormal lipid profiles in CVD, significant interactions between 
the APOEε4 variant and the C282Y and H63D variants have been established in the 
epidemiological literature for AD as well (331). Heterozygous carriers of both risk 
variants appear to experience an increased risk of AD compared to heterozygous carriers 
of either single risk variant alone (331). Thus, the above pathways seemingly converge to 
implicate a vascular pathway in the development of AD (332). Taken together, the 
aforementioned results support the hypothesis that iron contributes to the 
neurodegeneration exhibited in AD via the Fenton Haber-Weiss reaction. The role of iron 

















CHAPTER 4: LITERATURE REVIEW: IRON AND METABOLIC DYSFUNCTION 
 
Epidemiology of Type 2 Diabetes Mellitus (T2DM) 
History & Definition   Two decades ago T2DM was characterized by a triad, 
comprised of 1) pancreatic beta cell dysfunction, 2) excess glucose production by the 
liver and 3) insulin resistance, defined then as an impairment of insulin-mediated glucose 
uptake into target tissues (e.g., skeletal muscle) (333). This paradigm has more recently 
been abandoned by most groups in favor of a simpler model where the hallmarks of 
T2DM are now considered to be elevated fasting insulin concentrations and low insulin 
secretion by beta cells (334).  
Currently, the WHO and IDF define normoglycemia (i.e., normal glucose 
tolerance (NGT)) as two-hour postprandial (i.e., following a meal) plasma glucose 
concentrations less than 7 mmol/L (126 mg/dL), impaired glucose tolerance (IGT) as 
fasting plasma glucose (FPG) concentration less than 7 mmol/L (126 mg/dL) and two-
hour postprandial plasma glucose concentrations between 7.8 mmol/L and 11.1 mmol/L 
(140mg/dL and 200mg/dL), impaired fasting glucose (IFG) as FPG concentrations 
between 6.1 mmol/L and 6.9 mmol/L (110mg/dL and 125mg/dL) and two-hour 
postprandial plasma glucose concentrations less than 7.8 mmol/L (140mg/dL) and T2DM 
as the presence of FPG concentrations greater than or equal to 7 mmol/L (126 mg/dL) or 
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two-hour plasma glucose concentrations greater than or equal to 11.1 mmol/L 
(200mg/dL) (335) 
Descriptive Epidemiology   Given these criteria, the number of individuals 
affected with T2DM worldwide in 2010 was estimated to be 285 million (333). By the 
year 2030, this figure is projected to rise to 439 million individuals (336), representing a 
54% increase (395). This is not surprising, given the reported 11% conversion rate per 
year among those with IGT progressing to T2DM, accounting for an increase in the 
incidence of T2DM of 2 to 4 million new cases per year (333). The risk of T2DM appears 
to track across increasing levels of FPG concentrations. For example, higher incidence of 
T2DM is observed among individuals with FPG between 95 to 99 mg/dL compared with 
those with FPG < 85 mg/dL (HR = 2.33, 95% CI: 1.95-2.79) (337). When classified 
according to glycated hemoglobin A1C (HbA1c) concentrations, individuals 
demonstrating the highest risk of developing T2DM are those whose HbA1c level is 
between 5.7 and 6.4 % (39 to 46 mmol/L) (337).  
In 2001, the estimated number of individuals in the U.S. affected with T2DM was 
18.1 million, imposing a substantial burden on the healthcare system, with total 
healthcare costs exceeding $132 billion dollars (333). In 2008, this equated to a mean 
annual cost per T2DM diagnosis of $881, which was reported to be 21% of the gross 
domestic product per capita at that time (338).  
The National Health Interview Survey (NHIS) and data collected from NHANES 
have indicated that the prevalence of T2DM doubled from 1990 to 2008 in the U.S. and 
that there has been no significant change in prevalence from 2008 to 2012 (339). The 
prevalence of T2DM, however, increases with age from < 1% among those aged 20 years 
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and younger to 12.3% in those aged 21 to 65 years of age to 25% in those aged 65 years 
and older (337). Given that one of the largest segments of the population (i.e., Baby 
Boomers, ages 51-69) is ‘aging-in’ to the group with the highest prevalence of T2DM, 
the aforementioned stable pattern may soon be disrupted. 
Among U.S. adults, the current estimated prevalence of T2DM is reported to 
range from 11-14%, with males displaying a slight increase in prevalence compared to 
age-matched females (13.6% vs. 11.2%, respectively) (337). Moreover, the prevalence of 
T2DM in the U.S. varies across ethnicities, with Non-Hispanic whites demonstrating the 
lowest prevalence (7.6%), followed by Asian Americans (9%), Hispanic Americans 
(12.8%) and African Americans (13.2%) (334, 337). The ethnicities with the highest 
reported prevalence of T2DM are Native Americans and Alaska natives (15.9%) (333).  
The same trend appears when examining risks between ethnicities among 
females, with African American females showing an elevated risk (RR = 1.34, 95%CI: 
1.12-1.61) compared to their non-Hispanic white counterparts (340). Hispanic American 
females show a greater increased risk than both ethnicities (RR = 1.86, 95%CI: 1.40-
2.47) (340). Finally, Haffner et al. reported that the observed differences in insulin 
sensitivity between ethnic groups (i.e., African Americans and non-Hispanic whites) 
persist after adjustment for BMI, waist-to-hip ratio (WHR), level of physical activity and 
differences in diet (334). Moreover, the authors concluded that ethnic origin remained a 
powerful independent predictor of T2DM, accounting for an excess risk of approximately 
15% in the Hispanic American population (334). In line with these data, Hispanic 
Americans demonstrate a higher prevalence of T2DM than do Non-Hispanic whites 
residing within the same neighborhood (334).   
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The increased risk of complications among those who eventually progress to 
T2DM begins years (possibly decades) before diagnosis (341). At diagnosis, 
approximately 50% of those who have developed T2DM demonstrate overt hypertension 
or signs of macroangiopathy (341), which increases the risk for subsequent adverse 
health outcomes/complications such as cardiovascular disease, diabetic neuropathy, 
nephropathy and retinopathy (336). 
Pathophysiology   Periods of insulin resistance across the human lifespan are 
quite common. For instance, puberty, pregnancy and aging are all marked by increases in 
insulin resistance. However, insulin resistance appears to be a necessary, but not 
sufficient, condition which must manifest during the progression from normoglycemia to 
T2DM. Stated otherwise, as long as beta cells exhibit the capacity to compensate for 
varying degrees of insulin resistance, glucose tolerance remains within normal 
physiological limits (341).  
To develop a complete understanding of the etiology of T2DM, we must first 
examine the physiology of beta cells as individuals progress across the spectrum from 
insulin sensitive to insulin resistance. Following a meal, beta cells secrete insulin in a 
biphasic pattern and the amount of insulin secreted is positively related to systemic 
glucose concentration. In other words, any acute rise in plasma glucose concentration 
induces a burst of insulin secretion lasting 5 to 10 minutes (342) and this is referred to as 
first phase insulin secretion. The first phase typically occurs within 30 minutes of 
ingesting a meal, serves to prime target (i.e., metabolically active) tissues for forthcoming 
nutrients and is the main effector which quickly reduces blood glucose levels following a 
meal (343). The second phase of insulin secretion occurs approximately one- to two-
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hours following a meal (i.e., postprandially) and serves to further reduce systemic 
glycemia.  
As glucose tolerance moves from normal to impaired, first phase insulin secretion 
by beta cells is markedly attenuated (344). This results in an elevated postprandial rise in 
glycemia over the ensuing two hours. It is postulated that this postprandial rise in 
glycemia induces beta cells to secrete increasing amounts of insulin following the first 
phase. Thus, second phase insulin secretion, while less rapid (343), is higher than that of 
the first phase and functions as a compensatory response (333).  
To initially compensate for the perturbance in homeostasis, beta cells begin to 
hypertrophy, leading to increased beta cell mass (344) and increased insulin output, 
which results in hyperinsulinemia. The aforementioned compensation does not persist 
indefinitely, however. As insulin resistance worsens, the pulsatile pattern of first phase of 
insulin secretion is lost as beta cells begin to undergo apoptosis (333) due to oxidative 
stress. Eventually, the second phase of insulin secretion begins to decline as apoptosis 
continues until beta cells no longer secrete insulin (342) and the individual reaches a 
hyperglycemic state.  
Once present, insulin resistance persists (333). However, it appears that it is not a 
worsening of insulin resistance, per se, which leads to the observed increases in blood 
glucose concentrations. In other words, a change in the degree of insulin resistance does 
not appear to account for blood glucose concentrations progressing from NGT to IGT to 
T2DM (342), as it is common for individuals who develop insulin resistance to never 
progress to T2DM (344). As mentioned, it appears as if it is the worsening of beta cell 
compensation that is what is driving the individual across the spectrum from NGT to IGT 
49 
 
to T2DM and that this dysfunction occurs well before blood glucose values mark the 
presence of IGT (342).  
In terms of explaining the etiology and pathogenesis of T2DM, there are two 
leading hypotheses. One hypothesis states that FFAs and high triglycerides lead to the 
observed metabolic dysfunction and this is otherwise known as the “lipocentric” view of 
T2DM (333), which will be discussed in greater detail subsequently. Given that the 
oxidation of FFAs and glucose both contribute to the pool of metabolic fuel available for 
energy expenditure, their relative utilization is typically adjusted to match energy supply 
and demand. It has been postulated that glucose oxidation (i.e., glycolysis) is reduced in 
favor of FFA oxidation with increasing FFAs within the cytoplasm (345). Moreover, 
studies have also demonstrated that increased cytoplasmic concentrations of FFAs result 
in the skewing of the NAD/NADH ratio within the mitochondria, which leads to 
increased concentrations of acetyl-CoA and increased hepatic glucose production (346). 
Briefly, during beta oxidation NAD is the oxidizing agent which converts FFAs to acetyl-
CoA (346) As the concentration of FFAs increases, the rate of beta oxidation of FFAs to 
acetyl-CoA within the mitochondria also increases (345, 346). Over time, this is thought 
to increase the pool of acetyl-CoA with concomitant increases in hepatic glucose output. 
It must be noted, however, that if the concentration of FFAs does not decrease, the 
intracellular pool of NAD can become depleted and the NAD/NADH ratio can therefore 
become skewed, leading to mitochondrial dysfunction. This is thought to lead to the 
inhibition of FFA beta oxidation, increases in FFA storage as triglycerides, increased 
glucose output and, as mentioned, mitochondrial dysfunction and apoptosis. Stated 
differently, given that glycolysis is an energy-conversion pathway, one might hypothesize 
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that increased FFAs might concomitantly lead to increased intracellular glucose 
concentrations via competitive inhibition of glycolysis by FFAs as well as increased 
glucose output via the skewing of the NAD/NADH ratio within the mitochondria. 
Consistent with this hypothesis, Lam et al. have shown in an animal model that elevation 
of FFAs is linked to increased hepatic glucose production by increasing gluconeogenesis 
and this was attributed to an increased intracellular pool of acetyl-CoA (347).  
In addition to the above-mentioned metabolic dysregulation, the by-products of 
excess FFAs (i.e., ceramides) have also been shown to contribute to oxidative stress, 
which induces beta cell dysfunction and apoptosis (333). Studies which have shown 
increased triglyceride concentrations in muscle and liver to be a reliable (i.e., consistent) 
marker of insulin resistance lend further support to this hypothesis (348). Finally, it has 
been reported that in patients with overt T2DM that the deterioration of insulin sensitivity 
and secretion due to chronic hyperglycemia (i.e., glucotoxicity) is further aggravated by 
elevated FFAs (341). Given that elevated FFA concentrations appears to be a consistent 
feature of subjects with abdominal obesity as well as those diagnosed with T2DM, this 
hypothesis is plausible. 
A second hypothesis proposes that small intracellular amyloid fibrils of islet 
amyloid polypeptide (IAPP, amylin) leads to beta cell failure during the initial stages of 
the disease and that T2DM may be a manifestation of beta cell Alzheimer’s Disease 
(349). Amylin is co-secreted with insulin from beta cells and plays a role in glycemic 
regulation by slowing gastric emptying and promoting satiety (350). The net effect of 
amylin co-secretion with insulin is therefore to reduce postprandial glucose 
concentrations. According to this hypothesis, however, co-secretion of amylin is lost, 
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which leads to the accumulation of the amyloid fibrils through a process that has not been 
well-characterized. It is thought, however, that the accumulation of amyloid fibrils 
culminates in mitochondrial dysfunction via interaction with cyclophilin D (CypD), an 
integral protein of the mitochondrial permeability transition pore (mPTP) (351). Du et al. 
have shown that the interaction of amyloid fibrils with CypD promotes free radical 
production as well as the opening of the mPTP, which leads to mitochondrial apoptosis 
(352). 
This hypothesis is consistent with research related to other amyloid diseases, such 
as Alzheimer’s Disease, where the same process is thought to occur. A recent study by 
Perry et al. lends additional support to this hypothesis. The authors demonstrated that 
glucagon-like peptide (GLP-1) can modify IAPP processing and protect against oxidative 
injury (353). Briefly, GLP-1 is an endogenous insulinotropic gut hormone which appears 
to regulate plasma glucose levels by stimulating insulin secretion via the pancreas in a 
nutrient-dependent manner (347, 354). The signal transduction pathway of GLP-1 has 
been elucidated. Briefly, GLP-1 appears to act directly through the cAMP-PKA pathway 
to enhance and sensitize beta cells to glucose-stimulated insulin secretion (355). 
Following a meal, GLP-1 stimulates beta cells to increase the rate of glucose metabolism 
and the production of ATP, which increases the cytoplasmic ATP:ADP ratio. In turn, this 
leads to depolarization of the plasma membrane via closure of ATP-sensitive potassium 
channels, thereby permitting the opening of voltage-dependent calcium channels. The 
influx of cytosolic calcium then triggers the fusion of insulin containing secretory 
vesicles with the plasma membrane, followed by exocytosis of insulin into circulation. 
52 
 
Interestingly, studies have demonstrated that levels of GLP-1 are reduced among those 
with T2DM (355), which lends further support to this hypothesis.  
Analytic Epidemiology   Several studies support the hypothesis that a genetic 
predisposition for T2DM exists. For example, kinship studies demonstrate an increased 
(i.e., 2- to 3-fold) risk of developing T2DM among individuals with any first-degree 
relative diagnosed with the disease (334). Moreover, the risk is amplified (i.e., 5- to 6-
fold) among individuals whose parents have been diagnosed with T2DM (334). 
Investigators agree, however, that any genetic basis for T2DM is complex and that the 
inherited risk among those with a predisposition for the disease does not follow typical 
Mendelian patterns (333). In line with this conclusion, candidate gene studies have 
consistently shown small effect sizes (e.g., 20% - 30%) between single nucleotide 
polymorphisms (SNPs) in genes involved in beta cell function and T2DM (342, 356). 
Moreover, effect sizes for SNPs involved in insulin signaling or the glucose transport 
system are even smaller (356). Thus, environmental factors appear to mediate the 
development of the disease. For example, the prevalence of diabetes among the Pima 
Indians living in Mexico is less than 20%, while the risk for T2DM among Pima Indians 
living in the U.S. is twice that (~ 38%) (337). Given that individuals in each group are 
very closely related, the observed difference in prevalence rates among these two groups 
lends support to the role of environmental risk factors.  
Apart from a presumed increased risk of T2DM due to genetic predisposition, 
obesity is among the most highly publicized risk factors for the development of T2DM. 
Eckel et al. indicate that ~90% of obese patients progress to T2DM (357). Moreover, 
there appears to be a progressive decrease in insulin sensitivity with increasing degrees of 
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obesity, especially among those with a family history of T2DM (337). In addition, 
McColloch et al. have reported that increases in body mass index (BMI) over time appear 
to be the most important risk factor for progression to T2DM after adjusting for age and 
race/ethnicity (337). It should be noted here that visceral (i.e., intra-abdominal) fat, as 
opposed to subcutaneous or retroperitoneal fat, however, appears to confer the greatest 
risk (333).  
Other commonly reported risk factors for the development of T2DM are level of 
education, socioeconomic status (SES), developed environments, sedentary 
behavior/level of physical activity, smoking status, consumption of alcoholic beverages, 
disrupted sleep and diet. Each will briefly be summarized below.   
Level of education has consistently been shown to be inversely associated with 
risk of T2DM across age groups, genders and ethnicities (358-361, 338, 362, 363). In 
addition, studies have also indicated that there is an inverse relationship between 
socioeconomic status and the prevalence of T2DM (333, 364). Interestingly, 
investigations measuring both educational attainment and neighborhood SES indicate that 
the latter (i.e., low neighborhood SES) appears to confer a greater risk for the 
development of T2DM, even among those who have high educational achievement (359). 
In line with these data, Papier et al. have shown that residence in an urban area as a child 
is associated with the development of T2DM among both males and females (OR = 1.40, 
95%CI: 1.10-1.70 and OR = 1.40, 95%CI: 1.01-1.79, respectively), regardless of level of 
affluence reached as an adult (338).  
The association between developed environments and an increased risk of T2DM 
was highlighted several years ago when populations who rarely experienced T2DM 
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moved from an agrarian- and/or farming-existence to more developed economies (333). 
As already mentioned, the prevalence of T2DM among Pima Indians residing in Mexico 
compared to that of the Pima Indians residing in the southwest U.S. should closely 
parallel each other if no environmental component were involved in the etiology of 
T2DM. Moreover, Saharan nomadic tribes and Australian aborigines exhibit dramatic 
increases in the prevalence of T2DM when moving from an agrarian lifestyle to a 
developed environment (333). 
Physical inactivity (e.g., infrequent exercise, gardening, housework, prolonged 
television watching and/or computer usage) (338, 334) appears to increase the risk of 
T2DM (365) and the observed risk persists both in the presence and absence of weight 
gain (365). For example, low aerobic capacity and muscle strength among a Swedish 
cohort of males at 18 years of age was shown to be associated with an increased risk of 
T2DM after a twenty-five-year follow-up period (337). Of note, the same increased risk 
was noted for males with normal BMI, supporting the hypothesis that lack of physical 
exertion is a more reliable predictor of T2DM compared to caloric restriction to maintain 
a given BMI (334). In line with these observations, weight loss via caloric restriction 
coupled with increased physical activity has been shown to reduce FFAs and triglycerides 
in adipocytes (347) and reduce the risk of T2DM. 
Several studies have shown that current cigarette smoking and excessive alcohol 
intake increase the risk of T2DM (338). In a meta-analysis of 25 prospective cohort 
studies, current smokers had a 40% increased risk of developing T2DM (i.e., compared to 
nonsmokers) (pooled, adjusted RR = 1.40, 95%CI: 1.30-1.60). Moreover, the risk appears 
to be dose-dependent, with increasing risk with increasing number of cigarettes smoked 
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per day as well as with pack per year increases (344). Studies examining the effect of 
smoking cessation have indicated that the risk of developing T2DM reverted to that of 
never smokers after 20 years of smoking cessation (344) 
Sleep apnea, leading to a disrupted sleep cycle, has become a well-established risk 
factor in the development of T2DM (341, 336). Interestingly, McColloch et al. have 
shown that both lack of sleep as well as excessive sleep appears to confer sS an increased 
risk of developing T2DM. Compared with approximately 8 hours a day per night, short 
duration of sleep (defined as < 5 to 6 hours of sleep per night) and long duration of sleep 
(defined as > 8 to 9 hours of sleep per night) were significantly associated with an 
increased risk of T2DM (334). Thus, it appears that the association between sleep and 
risk of T2DM follows a U-shaped curve. Further research is warranted to understand the 
impact of sleep patterns on risk of developing T2DM. 
The literature indicates that several dietary exposures are associated with either 
decreasing or with increasing the risk of developing T2DM. Among the exposures which 
appear to reduce the risk of T2DM are nuts, brown rice, fiber, specific fruits (e.g., 
blueberries, grapes, apples, bananas, and pears), black coffee, green tea, vitamin D, 
vitamin E, magnesium and zinc (130, 131). Exposures which are associated with an 
increased risk of T2DM are sugar intake (e.g., sugar-sweetened soft drinks, sweets), 
white rice, red meat and processed meat (130, 131) independent of BMI, physical 
activity, age or family history (334). With regard to red meat and processed meat, iron 
has consistently been linked to an increased risk of T2DM. 
Iron and T2DM   The hypothesis that there is an association between iron and 
T2DM originally derives from studies demonstrating an increased prevalence of T2DM 
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among individuals with hereditary hemochromatosis (HH) (366), which, as mentioned in 
chapter 2, manifests due to two missense mutations (C282Y and H63D) in the 
hemochromatosis gene (HFE) located on the short arm (p) of chromosome 6 (366). 
As also mentioned, the HFE gene encodes for the HFE protein, which binds to TfR1 
and reduces its affinity for transferrin. Mutations of the HFE gene, however, result in 
a loss of this repressor function, which leads to increased iron sequestration in 
several tissues. Up to 60% of those affected with the condition eventually develop 
T2DM (Swaminathan), and several authors hypothesize that this is due to an increased 
accumulation of iron in the pancreas of those who go untreated.  
The hypothesis that increased body iron is implicated in the development of 
T2DM has received experimental support from cell line studies as well as from animal 
models. For instance, Bothwell et al. reported that the exocrine cells of the pancreas tend 
to accumulate a greater portion of the metal, yet remain functional (367). Interestingly, 
the authors report that while beta cells acquire less iron than exocrine cells, they appear to 
be more sensitive to the metal, which is most likely due to their low expression of 
antioxidants (e.g., catalase and superoxide dismutase 2 (SOD2)) (367). Ultimately, this 
sensitivity is thought to manifest as an impairment of insulin synthesis (368). In a mouse 
model of HH, iron excess and oxidative stress were shown to meditate apoptosis of 
pancreatic islets with a resultant decrease in insulin secretory capacity (369). Finally, 
several epidemiological investigations, including 10 cohort studies, 8 case-control studies 
and 8 cross-sectional studies have reported associations between iron stores and T2DM. 
Each study will be briefly summarized below.   
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During a 12-year prospective cohort study using data obtained from 33,541 
participants in the Health Professionals’ Follow-up Study, Jiang et al. grouped 
participants into quintiles of increasing intake of heme iron and heme iron from red meat, 
respectively. Compared to the lowest quintile of heme iron intake, participants in the 
highest quintile of heme iron intake had a RR of 1.28 (95% CI: 1.02-1.61, Ptrend = 0.05) 
for developing T2DM. Moreover, participants in the highest quintile of heme iron from 
red meat (compared to the lowest quintile of heme iron from red meat) had a RR of 1.63 
(95% CI: 1.26-2.10, Ptrend < 0.001) for developing T2DM (1). 
In another prospective nested case-control study (n = 698 cases, n = 716 controls) 
matched on age, race, fasting status and BMI, Jiang et al. followed 32,826 females 
participating in the Nurses’ Health Study over 10 years from 1989 through 1990. The 
authors observed a higher incidence of T2DM among cases as well as higher serum 
ferritin among cases compared to controls (109 ± 105 ng/mL (cases) vs 71.5 ± 69 ng/mL 
(controls), P < 0.001). Moreover, the authors reported that the risk of incident T2DM 
increased across increasing quintiles of ferritin among cases (RRQ2 = 1.09 (95%CI: 0.70-
1.70), RRQ3 = 1.26 (95%CI: 0.82-1.95), RRQ4 = 1.30 (95%CI: 0.83-2.04) and RRQ5 = 
2.68 (95%CI: 1.75-4.11, Ptrend < 0.001). The associations persisted after adjustment for 
menopausal status, alcohol consumption and C-reactive protein (370).  
Lee et al. followed 35,698 postmenopausal females aged 55 to 69 years for 11 
years to examine the effect of dietary exposures on incident T2DM. Over the follow-up 
period, baseline heme iron intake was associated with incident T2DM across increasing 
quintiles of intake (RRQ2 = 1.07 (95%CI not provided), RRQ3 = 1.12 (95%CI not 
provided), RRQ4 = 1.14 (95%CI not provided) and RRQ5 = 1.28 (95%CI: 1.04-1.58), Ptrend 
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= 0.02) after adjustment for non-dietary and dietary risk factors. The authors were also 
able to show an interaction between heme iron intake, alcohol consumption and T2DM. 
For example, the association between heme iron intake and T2DM was marginal among 
non-drinkers, but grew in magnitude among participants who consumed greater quantities 
of alcohol. In a model restricted to those who consumed at least 15 grams of alcohol per 
day, the RR across increasing quintiles of heme iron intake were RRQ2 = 2.26 (95%CI: 
0.79-6.44), RRQ3 = 3.22 (95%CI: 1.16-9.84), RRQ4 = 1.92 (95%CI: 0.63-5.87) and RRQ5 
= 4.42 (95%CI: 1.37-14.25), Ptrend = 0.05 (371). 
In 2004, Song et al. followed 37,309 participants aged 45 years and older in the 
Women’s Health Study for an average of 8.8 years who were free from cardiovascular 
disease, cancer, and T2DM at baseline to examine the association between red and 
processed meat intake and incident T2DM. During 326,876 person-years of follow-up, 
the authors reported positive associations between intakes of red meat and processed 
meat and risk of type 2 diabetes after adjustment for age, BMI, total energy intake, 
exercise, alcohol intake, cigarette smoking, and family history of diabetes. Compared to 
the females in the lowest quintile of red meat intake to females in the highest quintile of 
red meat intake, the RR for developing T2DM was 1.28 (95%CI: 1.07-1.53, Ptrend < 
0.001). Moreover, the RR for developing T2DM was 1.23 (95%CI: 1.05-1.45, Ptrend = 
0.001) among females in the highest quintile of processed meat intake compared to those 
in the lowest quintile of processed meat intake. The authors also reported an increased 
risk of developing T2DM among females who more frequently consumed processed 
meat, defined as consuming processed meat ≥ 5 days per week compared to consumption 
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less than once a month (RR 1.43, 95%CI: 1.17-1.75, P < 0.001) after adjustment for 
dietary fiber intake, magnesium, glycemic load and total fat intake (372). 
Fumeron et al. randomly selected 1,277 (i.e., 644 males and 633 females) 
participants from a pool of 4,501 individuals in the DESIR cohort to examine parameters 
of iron status at baseline with subsequent development of T2DM over a 3-year follow up 
period. The authors reported that baseline serum ferritin concentrations were positively 
correlated with fasting plasma insulin as well as fasting plasma glucose. Moreover, 
baseline serum ferritin concentration was reported to be an independent predictor of 
increases in plasma insulin concentrations over the 3-year follow-up period (P = 0.002). 
Finally, the authors noted that baseline serum ferritin and transferrin were independently 
associated with the onset of hyperglycemia over the 3-year follow-up period, regardless 
of gender (P < 0.001) (373). 
Rajpathak et al. conducted a prospective cohort study within the Nurses' Health 
Study, following 85,031 healthy females aged 34-59 years from 1980 to 2000 to examine 
the association between total iron intake, total dietary iron intake, supplemental iron 
intake and nonheme iron intake and the development of T2DM. Following the 20-year 
follow-up period, the authors reported no associations between total, dietary, 
supplemental or nonheme iron and the risk of T2DM. However, the authors did observe 
positive associations across increasing quintiles of heme iron intake and the risk of 
T2DM: RRQ2 = 1.08 (95%CI: 0.97-1.19), RRQ3 = 1.20 (95%CI: 1.09-1.33), RRQ4 = 1.27 
(95%CI: 1.14-1.41) and RRQ5 = 1.28 (95%CI: 1.14-1.45, Ptrend < 0.0001) after adjustment 
for age, BMI and other nondietary and dietary risk factors (374).  
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Using data obtained from 360 T2DM cases and 758 controls nested within the 
EPIC study, Fourouri et al. sought to examine the association between sex-specific 
baseline quintiles of serum ferritin concentration and T2DM. The authors reported that 
the baseline serum ferritin geometric mean was higher among cases than control 
participants in both males and females (males: 96.6 ng/mL (cases) vs 67.8 ng/mL 
(controls), P < 0.001; females 45.9 ng/mL (cases) vs 34.8 ng/ml (controls), P = 0.005). 
Moreover, the risk of incident T2DM was higher among those in the highest quartile of 
serum ferritin compared to those in the lowest quartile (OR = 7.4, 95%CI: 3.5-15.4, P < 
0.0001) after adjustment for age, BMI, sex, family history, physical activity, smoking, C-
reactive protein, IL-6 and fibrinogen (375). 
In 2007, Jehn et al. conducted a case-cohort study that was nested within the 
Atherosclerosis Risk in Communities (ARIC) Study (n = 599 cases, n = 690 controls 
obtained from a random sample of the cohort) to examine the association between serum 
ferritin and risk of T2DM after an 8-year follow-up period. Compared to cases in the 
lowest quintile of serum ferritin, cases in the highest quintile of serum ferritin had an 
increased risk of developing T2DM (HR = 1.74, 95%CI: 1.14-2.65, Ptrend < 0.001) after 
adjustment for age, gender, menopausal status, ethnicity, center, smoking status and 
alcohol intake (377). 
In a study published in 2008, Le et al. reported results from prospective cohort 
data from 5,512 male and female participants in the Aerobics Center Longitudinal Study 
(ACLS) between 1995 and 2001. Over the 5-year follow-up period, the authors reported 
that serum ferritin concentrations were significantly higher in males than in females 
(148.5 ± 104.7 ng/ml vs. 52.2 ± 45.9 ng/ml) and that male participants in the highest 
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quartile of serum ferritin had a greater risk of developing T2DM compared to those in the 
lowest quartile of serum ferritin (HR: 1.67, 95%CI: 1.05- 2.66, P = 0.027). While a 
similar trend was observed for females, the comparisons across quartiles of serum ferritin 
were not statistically significant (377). 
In contrast to the above positive associations between iron and the development of 
T2DM, in 2002 Mainous et al. reported that elevated serum transferrin saturation was not 
significantly associated with the development of T2DM in participants in NHANES. For 
example, the authors reported that the incidence of T2DM was 7.5% among individuals 
with serum transferrin saturation > 55% and 10.2% among individuals with serum 
transferrin saturation ≤ 45% (P = 0.38) and concluded that increased body iron was not 
associated with an increased risk of T2DM (378). It must be noted, however, that while 
Mainous et al. have published several studies using NHANES data, it is not clear as to 
how the authors accounted for the complex study design or sampling strategy. 
In 1988, Jones et al. were among the first groups to publish a case-control study 
evaluating the association between indices of body iron and T2DM (n = 25 cases, n = 37 
controls). The authors reported that serum ferritin concentration was increased in both 
males (124 ± 113 ng/mL (cases) vs 44 ± 38 ng/mL (controls), P < 0.001) and females 
(132 ± 118 ng/mL (cases) vs 25 ± 12 ng/mL (controls), P < 0.001) (379). 
Several years later in 2006, Adou-Shousha aimed to investigate the correlation 
between serum ferritin concentrations, sTfR and IL-8 concentrations among 20 females 
with T2DM who were matched on age to 10 healthy controls. The authors reported that 
serum ferritin was positively associated with IL-8 concentrations in those with T2DM (P 
= 0.0029) and not in controls. A similar positive association was observed between sTfR 
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and IL-8 concentrations across groups (P = 0.032) (380). Taken together, these results 
support the association between increased iron and T2DM.  
In 2008, Smotra conducted a case-control study (n = 50 cases, n = 50 controls) in 
a tertiary care hospital in North India to examine the relationship between serum ferritin 
concentrations and serum insulin concentrations among those with and without T2DM. 
The authors matched cases to controls on age, sex and BMI and reported a positive 
correlation between serum ferritin and serum insulin concentrations (r = 0.77, P = 0.01) 
and this corresponded to poor glycemic control (i.e., higher HbA1c concentrations) 
among those with T2DM (381) 
Waheed (2009) published a small case-control study (n = 30 cases, n = 30 
controls) using data collected from diabetic clinics of Rawalpindi in Pakistan. The 
authors reported that cases had higher fasting glucose concentrations, HbA1c, total 
cholesterol, LDL cholesterol, triglycerides and ferritin compared to controls (P < 0.001), 
while HDL cholesterol was lower in those with T2DM (P < 0.001) (382).  
Using controls obtained from two population-based studies (i.e., Copenhagen City 
Heart Study (CCHS, N = 9,121) and The Copenhagen General Population Study (CGPS, 
N = 24,195), Ellervik et al. 5:1 matched controls to 6,129 T2DM cases from the Steno 
Diabetes Centre on age and sex. Compared to cases with transferrin saturation < 50%, 
cases with transferrin saturation ≥50% had increased odds of developing T2DM: OR = 
1.7 (95%CI: 1.4-2.1; P = 0.001) (383). 
In contrast to the above positive associations between indices of body iron and 
prevalence of T2DM, some authors have reported no associations between indices of 
body iron and T2DM (i.e., the associations were not statistically significant). For 
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instance, Skomro et al. consecutively enrolled 58 T2DM cases and 48 controls into a 
sleep study in 2001, seeking to examine the association between sleep complaints and 
T2DM. However, the authors also collected data on biochemical parameters (including 
creatinine, urea, folate, vitamin B12 and serum ferritin) and reported that cases had 
higher serum ferritin compared to controls (154.7 ± 178.6 µg/L (cases) vs 107 ± 95 
(controls)) but this was not statistically significant (P = 0.14). While not statistically 
significant, the results appear support the aforementioned association between increased 
body iron and T2DM (384) 
A few years later, Elis et al. sought to evaluate the relationship between diabetic 
retinopathy and serum ferritin levels in a sample of T2DM cases and controls. The study 
sample was comprised of 3 groups: 1) individuals with T2DM and severe diabetic 
retinopathy (n = 22), 2) individuals with T2DM without retinopathy (n = 29) and 3) 
individual controls free from disease (n = 40). The groups were matched on age, gender 
and hemoglobin levels and comparisons between serum iron, transferrin and serum 
ferritin concentration were made across each of the three groups. While the authors 
reported higher concentrations of serum ferritin in the T2DM groups, the comparisons 
were not statistically significant compared to controls (P = 0.21). Moreover, the authors 
reported that there was no apparent correlation between serum iron or serum ferritin and 
HbA1c concentration between the groups comprised of individuals with T2DM. Thus, 
the authors concluded that iron does not appear to have a major role in the development 
of T2DM or diabetic retinopathy (385). Given the overall small sample size (n = 91), 
which was stratified into groups of 3, it appears that one cannot draw any valid 
conclusions based upon these data. 
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Finally, Rajpathak et al. conducted a nested case-control study (280 cases and 280 
age and sex matched controls) within the placebo arm of the Diabetes Prevention 
Program and reported that cases had higher sTfR levels compared to controls (3.50 ± 0.07 
mg/L vs. 3.30 ± 0.06 mg/L, P = 0.03) and that serum ferritin levels did not differ 
statistically between cases and controls. Cases in the highest quintile of sTfR 
concentrations were observed to have an increased risk of developing T2DM compared to 
those in the lowest quintile of sTfR concentrations (OR = 2.26 (95%CI: 1.37-4.01, P = 
0.008) (386). The results of this study allude to an increased requirement for iron as 
opposed to an increased storage of iron being associated with T2DM, which could be an 
artefact of the tendency of iron as a pro-oxidant to promote disease progression.  
Among the cross-sectional studies reporting associations between body iron and 
T2DM, Hughes et al. in 1998 were one of the first groups to show that serum ferritin 
concentrations were higher in individuals with T2DM than those unaffected with the 
condition. Using data obtained from participants in The National University of Singapore 
Heart Study (i.e., a cross-sectional study comprised of a random sample of individuals 
aged 30-69 years) the authors observed mean serum ferritin concentrations of 231 µg/L 
(range: 205-257 µg/L) in males affected with T2DM (n = 72), compared to 181 µg/L 
(range: 167-195 µg/L) in males who were unaffected (n = 248, P < 0.01). Moreover, the 
same trend was observed among females, where those affected with T2DM (n = 54) had 
higher mean serum ferritin concentrations than unaffected females (n = 282) (128 µg/L 
(range: 98-150 µg/L) vs 77 µg/L (range: 64-90 µg/L, P < 0.01)) after adjustment for age 
and ethnicity (387).  
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A year later Cogswell et al. examined the association between serum ferritin 
concentration, glucose tolerance status, insulin concentration, glucose concentration and 
glycosylated hemoglobin among 9,486 U.S. adults aged 20 years using data obtained 
from NHANES III (1988–1994). The authors created a dichotomous categorical variable 
from ferritin concentrations (i.e., < 300 µg/L vs. ≥ 300 µg/L in males and < 150 µg/L vs. 
≥ 150 µg/L in females) and reported an increased risk for T2DM for both males and 
females using these cutoffs (OR = 4.94 (95%CI: 3.05–8.01) for males and 3.61 (95%CI: 
2.01–6.48) for females) after adjustment for age, sex, ethnicity, education, BMI, alcohol 
consumption, alanine aminotransferase concentration, C-reactive protein concentration, 
and examination session attended (388).  
In 2006, Shi published the results from a cross-sectional household survey 
administered to 2,849 males and females aged 20 years and older in the Jiangsu Province 
of China and reported that both mean hemoglobin and serum ferritin concentrations 
increased with increasing FPG. Moreover, the authors observed an increased risk of 
T2DM for females in the highest quartile of hemoglobin concentration as well as those in 
the highest quartile of serum ferritin concentration compared to females in the lowest 
quartiles of hemoglobin and ferritin concentration, respectively (OR = 2.15 (95%CI: 
1.03-4.51), hemoglobin; OR = 3.79 (95%CI: 1.72-8.36, serum ferritin).  In addition, 
females in the highest quartile of dietary iron intake had an increased risk of T2DM 
compared to females in the lowest quartile of dietary iron intake (OR = 5.53 (95%CI: 
1.47-20.44). Similar trends were observed in males. However, none of the comparisons 
across quartiles were statistically significant (389) 
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In another cross-sectional study conducted a few years later, Kim et al. (2008) 
analyzed data obtained from 6,346 nonpregnant females participating in NHANES III 
(1988–1994). The authors categorized females into three groups: 1) those who self-
reported a history of gestational diabetes (n = 87), 2) those with diagnosed T2DM (n = 
244), or 3) those with neither condition (i.e., controls) (n = 6,015) and observed that 
serum ferritin was higher in females with T2DM compared to controls (120.3 ng/mL vs 
66.3 ng/mL, P < 0.05) (390). 
Luan (2008) examined the association between self-reported dietary iron intake 
(i.e., total iron intake and nonheme iron intake), serum ferritin and T2DM among 2,997 
individuals aged ≥ 18 years using data obtained from household surveys administered in 
the Liaoning Province in northern China. The authors reported that serum ferritin was 
positively associated with the risk of T2DM after adjustment for age, sex, non-dietary 
exposures and dietary exposures. No associations were observed between total iron 
intake, nonheme iron intake and risk of T2DM. However, higher self-reported heme iron 
intakes were significantly associated with an increased risk of T2DM after adjustment for 
age, sex, nondietary factors and dietary exposures (391).  
Sun (2008) et al. sought to examine the association between serum ferritin 
concentrations and T2DM in a sample of 3,289 participants aged 50-70 years of age from 
Beijing and Hanghai China during 2005. Not surprisingly, the authors noted that median 
ferritin concentrations were higher in males compared to females (155.7 ng/mL in males 
and 111.9 ng/mL in females). In addition, the authors reported an increased risk of T2DM 
among participants in the highest quartile of serum ferritin concentration compared to 
those in the lowest quartile of serum ferritin concentration (OR = 3.26, (95%CI: 2.36-
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4.51)) after adjustment for other dietary exposures, BMI, inflammatory markers, and 
adipokines (392). 
A few years later, Kim et al. analyzed clinical and laboratory data obtained from 
6,378 males and 5,712 females aged 20-89 years undergoing general medical checkups at 
the Health Promotion Center at Asan Medical Center in Seoul, Korea. The study sample 
included 1,054 subjects diagnosed with T2DM, 3,783 subjects with IFG and 7,253 
subjects with NGT. The authors observed that serum ferritin concentrations were the 
highest those with T2DM, followed by those in the IFG group and the NGT group, 
regardless of gender (186 ± 127 ng/mL (T2DM), 176 ± 108 ng/mL (IFG), and 156 ± 92 
ng/mL (NGT), respectively, in males; 85 ± 62 ng/mL (T2DM), 75 ± 55 ng/mL (IFG), and 
59 ± 47 ng/mL (NGT), respectively, in females)). In addition, the authors reported an 
increased risk for T2DM among those in the highest quartile of serum ferritin 
concentrations compared to those in the lowest quartile of serum ferritin concentrations 
(OR = 1.71 (95%CI: 1.38-2.12) in males and OR = 1.50 (95%CI: 1.05-2.13) in females) 
(393). 
Finally, Lee et al. (2011) examined the association between serum ferritin 
concentrations and T2DM among 6,311 individuals aged 20 years and older using data 
obtained from the 2008 Korean National Health and Nutrition Examination Survey. The 
authors reported that T2DM was more prevalent among individuals in the highest quartile 
of serum ferritin concentrations compared to those in the lowest quartile of serum ferritin 
concentrations in males (n = 2,684) (prevalence = 5.27% (95%CI: 3.13-7.41) vs. 1.42 
(95%CI: 0.40-2.44, P < 0.001), pre-menopausal females (n = 2,120) (prevalence = 7.34% 
(95%CI: 6.28-8.40) vs. 1.95 (95%CI: 0.95-2.95, P < 0.001), and post-menopausal 
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females (n = 1,507) (prevalence = 15.97% (95%CI: 10.91-21.02) vs. 8.68 (95%CI: 5.01-
12.34, P < 0.001) (394) 
More recently, two groups have each conducted separate meta-analyses 
examining the association between iron parameters (i.e., serum ferritin, heme iron intake) 
and T2DM with the above-mentioned studies. In 2013, Orban et al. included a total of 13 
studies in the calculation of pooled effect sizes for the association between the highest 
versus the lowest categories of serum ferritin concentration and risk of T2DM (Table 8). 
Overall, the pooled effect size across studies comparing the highest versus the lowest 
category of serum ferritin among study participants with T2DM was 1.67 (95%CI: 1.41-
1.99, P < 0.001, I-squared = 61%). A strength of the meta-analysis was that the authors 
were able to conduct subgroup analyses among studies adjusting for inflammation (e.g., 
C-reactive protein (CRP)) and reported a pooled effect size among studies controlling for 
CRP of 1.61 (95%CI: 1.18-2.20, P = 0.002) compared to 1.67 (95%CI: 1.23-2.27, P = 
0.001) for studies not controlling for CRP (395). 
In 2012, Zhao et al. published a meta-analysis which included a subset of the 
aforementioned studies (N = 12) which excluded a report that did not collect data on 
heme and non-heme iron intake (Table 8), and reported a pooled effect size of 1.31 
(95%CI: 1.20-1.43, I-squared = 0%) comparing individuals in the highest category of 
heme iron intake to those in the lowest category of heme iron intake. Moreover, when the 
authors stratified their analyses by study design (i.e., cohort vs cross-sectional) using the 
same studies as Oraban et al., they reported a similar pooled effect size for the association 
between serum ferritin and T2DM among cohort studies: RR = 1.66 (95%CI: 1.15-2.39, 
I-squared = 66.3%). The pooled effect size for the association between serum ferritin and 
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T2DM among cross-sectional studies was higher (RR = 2.29 (95%CI: 1.48-3.54, I-
squared = 88.7%)) (396). These results indicate that the pooled effect sizes obtained by 
Orban et al. may not be heavily influenced by study design, given that the pooled effect 
size for cohort studies calculated by Zhao et al. were of the same magnitude of as those 
calculated by Orban et al., who did not stratify effect size calculation by study design. 
Interventional Epidemiology   Additional support for a positive association 
between body iron and T2DM has been obtained interventional studies among HH 
patients whose body iron stores were reduced with phlebotomy and/or iron chelation 
therapy (397, 398). These investigators report that HH patients experienced 
improvements in glycemic control and 30-40% of patients in the study conducted by 
Facchini et al. were able to eliminate oral hypoglycemic therapy or were able to decrease 
their current dosage (398). 
Conclusion   Taken together, it appears as though iron stores are positively 
associated with the development of T2DM. It should be noted, however, that each of the 
above studies used serum ferritin and/or transferrin saturation as indices of iron stores. As 
already mentioned in Chapter 1, these parameters demonstrate diurnal variation and/or 
can be influenced by inflammation. Therefore, predictive, non-invasive, and inexpensive 
analytes unaltered by inflammation would be valuable for use in monitoring the iron 
status of those at risk for developing T2DM. To my knowledge, no study to date has 
employed the algorithm developed by JD Cook et al. in 2003 (50) as an index for iron 
repletion when examining the association between iron stores and T2DM. As mentioned, 
the index is a mathematically-derived ratio of soluble transferrin receptor and ferritin 
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found in serum and appears to be a more stable index of iron stores than either analyte 
used independently (51-52). 
 
Epidemiology of metabolic syndrome 
History & Definition   The modern concept of what is referred to as metabolic 
syndrome originated with Gerald Reaven in 1988 (399). Reaven postulated that insulin 
resistance was the driver of glucose intolerance, hyperinsulinaemia, increased very-low-
density lipoproteins (VLDLs), decreased high-density lipoproteins (HDLs) and 
hypertension (400.). Twenty years and a few different naming conventions later (e.g., 
Reaven’s syndrome, Syndrome X, CHAOS (i.e., coronary artery disease, hypertension, 
atherosclerosis, obesity and stroke), insulin resistance syndrome) the aforementioned 
cluster of metabolic abnormalities has become known as the metabolic syndrome (400, 
401). The benefit of utilizing the term metabolic syndrome is not so much in identifying 
patients with a general risk of cardiovascular disease and T2DM, but more so with the 
identification of specific subgroups of individuals with a shared pathophysiology (402). It 
should be noted here that the clinical utility of the term, however, has been criticized. It 
has been suggested that the ‘syndrome’ may not confer any greater risk than that 
explained independently by each of its components. Thus, it appears that the term 
metabolic syndrome should not be misused to refer to a disease unto itself (403), as there 
is a lack of treatment options available to ameliorate the cluster beyond those already 
employed to treat each individual component (404). 
The most frequently used definitions to determine the presence of metabolic 
syndrome include the National Cholesterol Education Program Adult Treatment Panel III 
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(NCEP-ATP III), criteria published in 2001 and updated in 2005, the International 
Diabetes Federation Criteria (IDF) proposed in 2004 and the WHO definition published 
in 1999 (405). The WHO definition requires that T2DM or impaired fasting glucose first 
be present in addition to any two of the following: obesity, dyslipidemia (i.e., increased 
triglycerides or decreased HDL), hypertension or microalbuminuria. The IDF criteria 
requires that obesity first be present in addition to any two of the following: impaired 
fasting glucose, increased triglycerides, decreased HDL or hypertension. The NCEP-ATP 
III criteria takes into account the same components as the IDF criteria. However, the 
NCEP-ATP III criteria treats all components equally and specifies that if at least three of 
the components are manifest, then metabolic syndrome is present. In 2009, several 
organizations (i.e., the IDF, the National Heart, Lung, and Blood Institute of the U.S., 
the American Heart Association, the World Heart Federation, the International 
Atherosclerosis Society and the International Association for the Study of Obesity) 
issued a joint statement on the definition of metabolic syndrome which included criteria 
upon which they have all agreed. These criteria are thus referred to as the “harmonized” 
criteria for metabolic syndrome. The updated criteria contained in the joint statement is 
essentially the NCEP-ATP III criteria with population- and country- specific definitions 
for obesity (i.e., waist circumference) (406.). 
Descriptive Epidemiology   Applying the NCEP-ATP III definition for metabolic 
syndrome, the age-adjusted prevalence in the U.S. using data obtained from 8,814 
participants in NHANES III has been estimated to be 23.7% (24.0% in males, 23.4% in 
females) (407, 408). However, more recent prevalence estimates of metabolic syndrome 
among U.S. adults demonstrate an increase in the prevalence of metabolic syndrome in 
72 
 
both males (30.3%) and females (35.6%), suggesting that the prevalence of metabolic 
syndrome in females has surpassed that among males (409). In line with these data, 
Ramos and Olden reported that approximately 50% (n = 643) of their study population of 
U.S. females of childbearing age either had metabolic syndrome or were at an increased 
risk for developing it (410). Based upon these estimates, it appears that metabolic 
syndrome in U.S. females is a growing public health concern. 
The prevalence of metabolic syndrome increases with age from 6.7% among 
those aged 20-29 years to 44% in those aged 60-69 years (408) to over 50% in those aged 
70 years and older (411). Given that the prevalence of each component of metabolic 
syndrome (i.e., obesity, hypertension, dyslipidemia and hyperglycemia) has also been 
observed to increase with age, it is not surprising that increasing age appears to be a 
determinant in the prevalence of metabolic syndrome.  
The prevalence of metabolic syndrome has also been observed to differ across 
ethnicities. For example, Hispanic Americans having a disproportionately higher 
prevalence of metabolic syndrome compared to other ethnicities (35.4%), followed by 
non-Hispanic whites (33.4%) and African Americans (32.7%) (409). This pattern holds 
when stratified by male gender and ethnicity, where the highest prevalence is found 
among Hispanic American males (37%), followed by non-Hispanic white males (25%) 
and the lowest prevalence is found among African American males (21%) (407, 411). 
The prevalence of metabolic syndrome among adult U.S. females is the highest among 
Hispanic American females (41%), followed by African American females (26%) and the 
lowest in non-Hispanic white females (21%) (407). The observed differences in the 
prevalence of metabolic syndrome across ethnicities has been postulated to be driven by 
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disparities in access to healthcare (412, 413), level of education (412), income (412) and 
level of urbanization (414). 
Pathophysiology   Although the etiology of metabolic syndrome is uncertain, 
several hypotheses implicate insulin resistance, visceral adiposity and low-grade 
inflammation as the drivers of each downstream component (400). As mentioned 
previously, insulin resistance has been defined as the inability of insulin to stimulate 
adequate glucose uptake in muscle and adipose tissue as well as the inability of insulin to 
suppress hepatic glucose output (415). Visceral adiposity (i.e., central obesity) commonly 
refers to increased visceral adipose tissue within the peritoneal cavity and inflammation 
in metabolic syndrome is defined by the presence of inflammatory cytokines/adipokines. 
While adipose tissue is an important source of chronic inflammation, it should be noted 
that other cell types within adipose tissue (e.g., macrophages) contribute substantially to 
the amount of inflammation present (405).  
Among these three factors, visceral adiposity appears to be the most salient in the 
etiology of metabolic syndrome (416), as visceral adipose tissue releases FFAs directly 
into portal circulation (416). Moreover, the literature indicates that FFAs accumulate in 
the liver, pancreas, heart and other organs with increasing adiposity (415). Eventually, 
this culminates in organ dysfunction, resulting in impaired insulin, glucose and 
cholesterol regulation, which is commonly referred to as “lipotoxicity.” In addition, there 
is a significant infiltration of macrophages in adipose tissue with increasing adiposity 
(415) and it has been shown that adipose tissue secretes monocyte chemotactic protein-1 
(MCP-1), which mediates macrophage recruitment to sites of inflammation. Briefly, 
MCP-1 is a chemokine whose production is primarily stimulated by inflammation and 
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oxidative stress, regulates migration and infiltration of reticuloendothelial cells (i.e., 
monocytes and macrophages) to tissues secreting the protein.  
Levels of systemic and adipose tissue MCP-1 are elevated in rodent models of 
obesity and targeted ablation of MCP-1 or its receptor reduces adipose tissue macrophage 
infiltration (417). This has been shown to improve insulin sensitivity. Conversely, insulin 
resistance and increased infiltration of macrophages within adipose tissue have been 
observed in models of MCP-1 overexpression (405). Finally, recruitment of macrophages 
via adipocyte secretion of MCP-1 leads to their subsequent activation and secretion of 
TNF-alpha and IL-6.  
In terms of other metabolic syndrome components, dyslipidemia appears to be 
secondary to increased visceral adiposity and the development of insulin resistance due to 
the effect of adipose tissue secretion of FFAs. In muscle, FFAs increase insulin resistance 
by inhibiting insulin-mediated glucose uptake via decreasing GLUT4 expression (418). 
The ensuing increase in circulating glucose thus induces beta cell insulin secretion, 
resulting in hyperinsulinemia. Moreover, FFAs directly increase the production of glucose, 
triglycerides and the secretion of VLDLs in the liver. For example, FFAs reduce the 
conversion of glucose to its storage form (i.e., glycogen) which leads to subsequent 
hyperglycemia with a concomitant increase in lipid accumulation in the form of 
triglycerides. The ensuing hypertriglyceridemia is the result of both an increase in VLDL 
production as well as a decrease in VLDL clearance. In other words, triglycerides stored 
in VLDLs are transferred to HDL by the cholesterol ester transport protein (CETP) in 
exchange for cholesteryl esters, resulting in triglyceride-enriched HDL and cholesteryl 
ester-enriched VLDL particles (419). It has been shown that the triglyceride-enriched 
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HDL particle is a more specific substrate for hepatic lipase (420). Thus, HDL is cleared 
more rapidly and VLDLs less rapidly from circulation, resulting in fewer HDL particles 
to participate in reverse cholesterol transport from the vasculature (419).  
Endothelial dysfunction (i.e., hypertension) also appears secondary to increased 
visceral adiposity and the development of insulin resistance, most likely due to the 
increase in FFAs that are released from visceral adipose tissue. In line with this 
hypothesis, 15% of normal-weight individuals in the U.S. have hypertension, whereas the 
prevalence of hypertension among obese individuals is 42% (421). Moreover, data from 
the Framingham Heart Study indicates that ~80% of essential hypertension in males and 
65% in females can be directly attributed to obesity (422). While the relationship between 
obesity, insulin resistance and hypertension has been well established, several different 
mechanisms have been proposed.  
One hypothesis is that FFAs are pressors and can themselves mediate 
vasoconstriction, as FFAs have been shown to increase angiotensinogen production by 
vascular smooth muscle cells (VSMCs) in culture (423). In line with these data, Egan et 
al. have also shown that increased adipocyte mass (i.e., hypertrophy) leads to increased 
angiotensinogen production in adipocytes (424). While the liver is the primary site of 
angiotensinogen production, it appears as though it is not the only site, and production of 
angiotensinogen in other tissues is thought to be affected by increasing concentration of 
FFAs (423).  
Another hypothesis involves insulin and nitric oxide (NO). Endothelin-1, a potent 
vasoconstrictor, is activated by insulin through the MAP kinase (MAPK) pathway (425). 
Thus, increasing concentrations of insulin within circulation appears to have a 
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vasocontricting effect (421, 426). Under normal physiologic conditions, NO inhibits the 
secretion of endothelin-1 (415). However, NO production decreases with increasing 
adiposity (427). Thus, in a hyperinsulinemic state the balance between endothelin-1 and 
NO is lost (421).  
Analytic Epidemiology   When considering risk factors associated with the 
development of metabolic syndrome, one must consider the risk factors associated with 
each component (i.e., obesity, hypertension, dyslipidemia and hyperglycemia) of 
metabolic syndrome. The literature indicates that the obesity component of metabolic 
syndrome (i.e., defined using WHO criteria as BMI > 29.9) is the single most important 
risk factor for the development of metabolic syndrome. Contributing to this trend is the 
fact that most parts of the world have moved from an era of persistent famine to one of 
nutrient excess comprised of high-fat and high-carbohydrate diets, concomitant 
decreases in physical activity and increased smoking and ethanol use. 
With respect to other components of metabolic syndrome, the risk factors 
implicated in the development of hypertension and hyperlipidemia also appear to overlap 
with those of the obesity component (e.g., unhealthy diet which is rich in sodium, lack of 
physical activity, smoking, alcohol use). Finally, while the risk factors for the 
development of hyperglycemia overlap somewhat with those of obesity, it should be 
noted that increased intake of sweets (e.g., sugar-sweetened beverages, candy) are 
additional risk factors associated with development of the hyperglycemia component of 
metabolic syndrome. Finally, several studies indicate that intake of red meat and indices 
of iron status are independently associated with an increased risk of metabolic syndrome.  
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Conclusion   The development of metabolic syndrome has been shown to increase 
the probability of progressing to T2DM up to fourfold (428) and the risk of progression 
increases with increasing number of metabolic syndrome components (429). Given that 
the prevalence of two or more metabolic syndrome components in the U.S. is 43.9%, 
public health officials are interested in determinants of the condition which are 
modifiable through primary prevention efforts. While several authors postulate that 
conversion from metabolic syndrome to T2DM appears to be primarily driven by the 
hyperglycemia component of metabolic syndrome, other groups postulate that dietary 
iron is a modifiable exposure that is directly involved in the initiation, promotion and 
progression of the condition (430). 
Iron and metabolic syndrome   Similar to T2DM, the hypothesis that there is an 
association between iron and metabolic syndrome derives from studies demonstrating an 
increased prevalence of metabolic syndrome among individuals with HH (366). Several 
epidemiological investigations, including 2 cohort studies, 2 case-control studies and 13 
cross-sectional studies have reported associations between iron stores and metabolic 
syndrome. Each study will be briefly summarized below.   
In 2007 Vari et al. followed a total of 944 individuals 30-65 years of age who 
were enrolled in the DESIR cohort (i.e., 469 males and 278 premenopausal and 197 
postmenopausal females) for a period of 6 years. At the end of the follow-up period, the 
authors reported increased odds of developing metabolic syndrome among those in the 
highest tertile of log(ferritin) concentrations compared to those in the lowest tertile of 
log(ferritin) concentrations: OR = 1.49 (95%CI: 1.14-1.94) for males, OR = 2.10 
(95%CI: 1.27-3.48) for premenopausal females and OR = 1.80 (95%CI: 1.21-2.68) for 
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postmenopausal females. In addition, the authors reported increased odds of developing 
metabolic syndrome among those in the highest tertile of transferrin concentrations 
compared to those in the lowest tertile of transferrin concentrations: OR = 1.94 (95%CI: 
1.53-2.47) for males, OR = 2.22 (95%CI: 1.32-3.75) for premenopausal females and OR 
= 2.14 (95%CI: 1.47-3.10) for postmenopausal females. At the end of the follow-up 
period, the authors observed that incident metabolic syndrome was associated with higher 
serum ferritin and transferrin at baseline across all three groups: OR = 1.46 (95%CI: 
1.13-1.89) for males, OR = 1.28 (95%CI: 0.85-1.94) for premenopausal females and OR 
= 1.62 (95%CI: 1.10-2.38) for postmenopausal females for serum ferritin. For transferrin, 
the OR = 1.41 (95%CI: 1.10-1.81) for males, OR = 1.63 (95%CI: 1.05-2.52) for 
premenopausal females and OR = 1.51 (95%CI: 1.02-2.22) for postmenopausal females. 
Baseline serum ferritin concentrations were strongly associated with hypertriglyceridemia 
component of metabolic syndrome at the end of the follow-up period (431) 
Park et al. conducted a prospective cohort study in 2012, following 18.022 
Korean men participating in a medical health check-up program who were free from 
metabolic syndrome at baseline for a period of 5 years. During 45,919.3 person-years of 
follow-up, the authors observed an increased risk of developing metabolic syndrome 
across serum ferritin quintiles: HRQ2 = 1.19 (95%CI: 0.98-1.45), HRQ3 = 1.17 (95%CI: 
0.96-1.43), HRQ4 = 1.36 (95%CI: 1.12-1.65), and HRQ5 = 1.66 (95%CI: 1.38-2.01, Ptrend 
< 0.001) (432). 
Xiao et al. were among the first groups to publish a case-control study examining 
the association between iron and metabolic syndrome. The group age matched 87 
individuals with metabolic syndrome to 102 healthy adults were recruited from the same 
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region in China. The authors grouped participants into dichotomous categories of dietary 
iron intake (i.e., < 15 mg/d vs. ≥ 15 mg/d) and reported an increased risk of metabolic 
syndrome in cases whose intake exceed 15 mg/d (OR = 7.12, no 95%CI provided). When 
stratified by type of iron intake (i.e., heme iron intake vs nonheme iron intake) the 
authors reported an increased risk of metabolic syndrome among those consuming > 7.5 
mg of heme iron per day (OR = 7.73, no 95%CI provided) (433) 
A year later, Hamalainen et al. conducted a population based cross-sectional study 
using data obtained from 766 Caucasian, middle-aged subjects (341 males and 425 
females) from Pieksämäki, Finland who were recruited for a free health check-up in 
2004. The authors reported that both hemoglobin and serum ferritin concentrations were 
higher in those with metabolic syndrome (P < 0.001 (hemoglobin), P = 0.018 (ferritin)), 
noting that hemoglobin concentration was higher in those with any metabolic syndrome 
component (P < 0.001) and that serum ferritin was higher in those with abdominal obesity 
(P < 0.001), high triglycerides (P = 0.002) or elevated glucose concentrations (P = 0.02) 
(434) 
Finally, several cross-sectional studies have highlighted an association between 
iron stores and metabolic syndrome. For example, in a population-based cross-sectional 
study using subjects participating in NHANES III between 1988 and 1994, Jehn et al. 
found that metabolic syndrome was more common in those in the highest quartile of 
serum ferritin concentration compared to those in the lowest quartile of serum ferritin 
concentration in males (27.3% vs. 13.8%; P < 0.001), pre-menopausal females (14.9% 
vs. 6.4%; P = 0.002), and post-menopausal females (47.5% vs. 28.2%; P < 0.001) (12). 
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In 2005, Bozzini et al. reported increased odds of developing metabolic syndrome 
among cases (n = 269) compared to age-matched counterparts who did not have 
metabolic syndrome (n = 210): OR = 1.53 (95%CI: 1.27-1.84) (15). During that same 
year Choi (2005) examined the association between serum ferritin, alanine 
aminotransferase (ALT) levels and cardiovascular risk factors of metabolic syndrome 
among 959 postmenopausal Korean females. The authors reported that cases 
demonstrated higher serum ferritin (74.7 ± 2.0 ng/mL vs 59.6 ± 2.0 ng/mL, P < 0.001) 
and ALT levels (21.3 ± 1.6 IU/L vs 18.7 ± 1.5 IU/L, P < 0.001). Moreover, increasing 
concentrations of serum ferritin corresponded to the presence of a greater the number of 
metabolic syndrome components (P < 0.001) (435). 
Similar to the results reported by Choi et al., in 2008 Shi et al. observed an 
increasing number of metabolic syndrome components with increasing serum ferritin 
concentrations in their study sample. Moreover, the authors reported that individuals with 
insulin resistance had increased serum ferritin concentrations compared to individuals 
without insulin resistance (124.5 ng/mL vs 80.1 ng/mL, P < 0.001). In addition, the 
authors noted that serum ferritin concentrations were higher among individuals with 
triglyceride concentrations ≥ 150 mg/dL compared to those whose triglyceride 
concentrations were < 150 mg/dL (76.8 ng/mL vs 40.1 ng/mL, P < 0.001) and higher 
among those with fasting plasma glucose concentrations ≥ 110 mg/dL compared to those 
whose fasting plasma glucose concentrations were < 110 mg/dL (75.7 ng/mL vs 41.7 
ng/mL, P = 0.005) (436).  
Later that year, Sun et al. conducted a cross-sectional survey using data obtained 
from 3,289 participants aged 50 to 70 years residing in Beijing and Shanghai China, 
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reporting an increased risk of metabolic syndrome for those in the highest quartile of 
serum ferritin concentrations compares to those in the lowest quartile of serum ferritin 
concentrations (OR 2.80 (95%CI: 2.24-3.49)) after adjustment for other dietary 
exposures, BMI, inflammatory markers, and adipokines (392). 
Ryu (2008) conducted a cross-sectional study of 1,444 adults between the ages of 
40 and 70 participating in a survey conducted as part of the Korean Rural Genomic 
Cohort Study (KRGCS), reporting that the prevalence of metabolic syndrome was higher 
among those in the highest quartile of serum ferritin concentration compared to those in 
the lowest quartile of serum ferritin concentration (37.1% vs. 22.4%, P = 0.006) in males 
and (58.8% vs. 34.8, P < 0.001) in females. Moreover, the authors observed an increased 
risk of metabolic syndrome among those in the highest quartile of serum ferritin 
concentration compared to those in the lowest quartile of serum ferritin concentration 
(OR = 2.21 (95%CI: 1.26-3.87, P = 0.024) in males and OR = 2.10 (95% CI: 1.40-3.17, P 
= 0.001) in females. In line with the observations of Choi et al. and Shi et al., the authors 
noted that increasing serum ferritin concentrations corresponded to a greater number of 
metabolic syndrome components (437). 
In a smaller cross-sectional study of 482 Tehrani females, subjects in the highest 
quintile of red meat intake (i.e., ≥ 63.7 g/d) had greater odds of metabolic syndrome (OR 
= 2.33; 95%CI: 1.24-4.38; Ptrend < 0.01) (14). The aforementioned group found a similar 
association using the same subjects classified according to dietary patterns, where 
females in the highest quintile of Western diets (i.e., characterized by high red-meat and 
refined grain intakes) had increased odds of metabolic syndrome (OR = 1.68; 95%CI: 
1.10-1.95; Ptrend < 0.01) (14). As previously mentioned, a limitation of a cross-sectional 
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study design is that one cannot decipher whether increases in body iron occurred before, 
during or after the development of metabolic syndrome. 
Kim (2011) investigated the association of serum ferritin concentrations with 
insulin resistance and impaired glucose metabolism among 12,090 subjects (6378 men 
and 5712 females between the ages of 20-89 years) undergoing general medical checkups 
at the Health Promotion Center at Asan Medical Center in Seoul, Korea. The study 
sample was comprised of 7,253 participants with NGT, 3,783 participants with IGT and 
1,054 participants with T2DM. The authors reported an increased risk of metabolic 
syndrome among those with NGT when in the highest quartile of serum ferritin 
concentrations compared to those in the lowest quartile of serum ferritin concentrations 
(OR = 2.85 (95%CI: 1.99-4.07)) in males and OR = 1.21 (95%CI: 0.82-1.79)) in females 
(393). 
Kang (2012) examined data obtained from 7,346 individuals (i.e., 3229 males, 
4,117 females) participating in the 2007-2008 Korean National Health and Nutrition 
Examination Survey (KNHANES). The authors reported an increasing risk of metabolic 
syndrome among those in the highest quartile of serum ferritin concentrations compared 
to those in the lowest quartile of serum ferritin concentrations (OR = 1.67, 95%CI: 1.24-
2.23 in males and OR = 1.41, 95%CI: 1.06-1.88) in females after adjusting for 
menopausal status. Moreover, the authors also observed that increasing serum ferritin 
concentrations were associated with components of metabolic syndrome, such as 
increased triglyceride concentrations in males and glucose intolerance in females (7). 
During the same year, Gabrielson et al. followed a group of 110 individuals to 
investigate the effect of iron intake on adiponectin, which is an insulin-sensitizing 
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adipokine that is commonly decreased among those with metabolic syndrome. The 
authors reported that serum ferritin concentrations were increased and adiponectin 
concentrations were decreased among those with metabolic syndrome compared to those 
without metabolic syndrome (260 ± 23 ng/mL vs 185 ± 21 ng/mL) (438). 
In another population-based cross-sectional study conducted in Taiwan, Chang et 
al. found that individuals in the highest tertile of serum ferritin concentrations had a 
higher risk of metabolic syndrome compared to those in the lowest tertile of serum 
ferritin concentrations (OR = 1.72, 95%CI: 1.21-2.45) (16). The authors further reported 
that serum ferritin concentrations demonstrated a linear relationship with individual 
components of metabolic syndrome. For instance, individuals in the highest tertile of 
serum ferritin had higher fasting serum glucose concentrations (OR = 2.16, 95%CI: 1.75-
2.65) and higher serum triglycerides (OR = 2.58, 95%CI: 1.07-3.22) (13). 
Li et al. (2013) sought to explore the relationship between serum ferritin and 
metabolic syndrome among 8,441 adults aged 18 and older participating in the China 
Health and Nutrition Survey. The authors observed that serum ferritin concentrations 
were significantly higher among those with metabolic syndrome (106.0 ng/mL vs 73.2 
ng/ml, P < 0.001) after adjustment for age, nationality, BMI, smoking status and alcohol 
consumption. Finally, the authors noted that the risk for metabolic syndrome increased 
across increasing quartiles of serum ferritin concentrations for both males and females 
(Ptrend < 0.001) (9).  
Tang et al examined data obtained from 3,274 males participating in the 2009–
2013 Fangchenggang Area Males Health and Examination Survey (FAMHES). The 
authors reported that those with metabolic syndrome had higher serum ferritin 
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concentrations compared to those without metabolic syndrome (median: 447.4 ng/mL 
(range: 294.1-612.4) vs. 302.4 ng/mL (range: 215.0-435.8), P < 0.01). Moreover, the 
authors observed positive correlations between serum ferritin concentrations and 
components of metabolic syndrome: blood pressure (BP) (Systolic BP: r = 0.11, Diastolic 
BP: r = 0.16), waist circumference (r = 0.33), fasting glucose concentration (r = 0.09), 
triglyceride concentration (r = 0.32) and low HDL cholesterol (r = 0.13) (P < 0.001 for all 
comparisons). Finally, the authors observed an increased risk of metabolic syndrome 
among those in the highest quartile of serum ferritin concentrations compared to those in 
the lowest quartile of serum ferritin concentrations (OR = 2.29, 95%CI: 1.47-3.54) (439). 
More recently, two groups have each conducted separate meta-analyses 
examining the association between iron parameters (i.e., serum ferritin) and metabolic 
syndrome with many of the above-mentioned studies. In 2014, Abril-Ulloa et al. included 
a total of fifteen studies in the calculation of pooled effect sizes (i.e., two prospective, one 
case-control and twelve cross-sectional studies, Table 9) and reported separate pooled 
effect sizes for both males and females. Overall, the pooled effect size across studies 
comparing the highest versus the lowest category of serum ferritin among study 
participants with metabolic syndrome was 1.73 (95%CI: 1.54-1.95, I-squared = 75.4%). 
For males, the pooled effect size for the association between the highest reported 
category of ferritin across studies to that of the lowest category of ferritin was 1.69 
(95%CI: 1.29-2.21). Among females, the pooled effect size was 1.65 (95%CI: 1.41-1.94). 
A strength of the meta-analysis was that thirteen of the fifteen studies included used the 
NCEP-ATP III definition to determine the presence of metabolic syndrome. Moreover, 
the authors were able to conduct subgroup analyses among studies adjusting for C-
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reactive protein (CRP) and reported a pooled effect size among studies controlling for 
CRP of 1.92 (95%CI: 1.61-2.30) compared to 1.52 (95%CI: 1.36-1.69) for studies not 
controlling for CRP. This finding is interesting, as one would expect the effect size to be 
attenuated by controlling for factors related to inflammation (11).  
Jin et al. published another meta-analysis reporting upon the association between 
serum ferritin and metabolic syndrome in 2015. In contrast to the former group, Jin and 
colleagues reported pooled effect sizes among studies examining the association between 
mean ferritin concentrations in study participants with metabolic syndrome compared to 
mean ferritin concentrations among study participants without metabolic syndrome. The 
authors included eight studies (four prospective, two case-control and two cross-sectional 
studies, Table 9), none of which overlapped with those analyzed by Abril-Uloa et al. in 
their meta-analysis, and reported a pooled effect size of 1.20 (95%CI: 0.69-1.71, I-
squared = 96%) (440) comparing the standardized mean difference in serum ferritin 
concentrations among study participants with metabolic syndrome to those without 
metabolic syndrome. It is plausible that the reported effect size was not statistically 
significant due to the high reported heterogeneity across studies, the inconsistent 
application of criteria to determine the presence of metabolic syndrome and the scaling of 
the dependent variable (i.e., continuous vs categorical) among the studies included in the 
meta-analysis. Despite these limitations, the reported effect size is in the same direction 
and of similar magnitude to those reported by Abril-Uloah.  
Interventional Epidemiology   Additional support for a positive association 
between body iron and metabolic syndrome has been obtained from an interventional 
study published by Houschyar et al. in 2012. The authors randomly allocated 64 
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individuals with metabolic syndrome to a treatment arm (i.e., iron reduction by 
phlebotomy, N = 33) or control arm (N = 31). Those in the treatment arm had 300 mL of 
blood removed at study entry and, depending upon baseline serum ferritin concentration, 
between 250 mL and 500 mL removed after four weeks. The primary outcomes of the 
study at the end of six weeks were 1) change in systolic blood pressure (SBP) and 2) 
change in HOMA-IR. Secondary outcomes measured by the group were 1) change in 
HbA1C, 2) change in plasma glucose concentration, 3) change in lipid profile and 4) 
change in heart rate beats per minute (bpm). The authors observed a significant reduction 
in SBP in the treatment group at the end of the study period (148.5 ± 12.3 mmHg to 
130.5 ± 11.8 mmHg, representing a difference of -16.6 mmHg (95%CI: -20.7 to -12.5, P 
< 0.001), which corresponded to a reduction in serum ferritin concentrations in the 
treatment group from 188.3 ± 212.4 to 104.6 ± 132.5. While those in the control group 
also experienced a reduction in serum ferritin concentrations from 173.2 ± 132.9 to 149.4 
± 124.9, this was not statistically significant. The average between-group reduction in 
serum ferritin concentration was 74.2 ng/mL (P < 0.001), favoring the treatment group. 
The change in SBP among those in the control arm was not significant (144.7 ± 14.4 
mmHg to 143.8 ± 11.9 mmHg). While HOMA-IR decreased in both arms (treatment 
HOMA-IR: 4.8 ± 7.2 to 3.6 ± 2.7; control HOMA-IR: 4.5 ± 3.8 to 4.1 ± 3.6), neither 
reduction was statistically significant. The greater reduction in HOMA-IR in the 
treatment arm, however, correlated with serum ferritin reduction (r = 0.39, P = 0.03). 
Finally, those in the treatment arm experienced significant reductions in all secondary 
outcomes (i.e., decreased HbA1C (from 5.56 ± 0.61 to 5.36 ± 0.58, P < 0.001)), blood 
glucose concentrations (from 110.7 ± 29.4 to 98.5 ± 24.0, P < 0.001), LDL/HDL ratio 
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(from 2.48 ± 0.88 to 2.21 ± 0.80, P < 0.01) and heart rate (from 72.1 ± 8.2 bpm to 70.0 ± 
5.8 bpm, P < 0.001) (28). 
Conclusion   Taken together, it appears as though iron stores are positively 
associated with the development of metabolic syndrome, including several individual 
components of metabolic syndrome (e.g., visceral adiposity, dyslipidemia, hypertension, 
as well as with increasing fasting insulin concentration and blood glucose levels). It 
should be noted, however, that each of the above studies used serum ferritin and/or 
transferrin saturation as indices of iron stores. As already mentioned, these parameters 
demonstrate diurnal variation and/or can be influenced by inflammation. Therefore, 
predictive, non-invasive, and inexpensive analytes unaltered by inflammation would be 
valuable for use in monitoring the iron status of those at risk for developing metabolic 
syndrome. To my knowledge, no study to date has employed the algorithm developed by 
JD Cook et al. in 2003 (50) as an index for iron repletion to examine the association of 
the former with metabolic syndrome. 
 
Epidemiology of non-alcoholic fatty liver disease (NAFLD) 
History & Definition   Non-alcoholic fatty liver disease is a chronic disease that 
spans a spectrum of hepatic pathology ranging from simple steatosis (i.e., defined as 
greater than 5% of total liver weight due to an accumulation of triglycerides inside 
hepatocytes, in the absence of hepatitis B and C virus or excessive ethanol intake) (441, 
442) to steatohepatitis, fibrosis and cirrhosis (443, 444). Studies whose aim has been to 
quantify the prevalence of NAFLD have been hindered by the fact that individuals at any 
stage of the disease are relatively asymptomatic (444) and techniques/tools (e.g., 
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ultrasonography, ALT assay, aspartate aminotransferase (AST) assay) which are 
commonly used in a clinical setting to diagnose the condition are neither sensitive nor 
specific (Table 7). Moreover, the gold standard for diagnosing and staging NAFLD is a 
liver biopsy (444), which is invasive and often cost-prohibitive at both the patient- and 
population-level.  
Descriptive Epidemiology   Before investigators in NHANES III (1988-1994) 
began performing gallbladder ultrasonography on all participants aged 20-74 years of 
age, there was no representative data in the U.S. available to study the epidemiology of 
NAFLD (442). These studies, however, revealed that the prevalence of NAFLD in the 
U.S. increased from 18% from 1988-1991 to 29% in 1999 (35). However, more recent 
and representative prevalence estimates of NAFLD using more sophisticated imaging 
techniques emerged from the Dallas Heart Study (DHS). The DHS was a multi-ethnic 
population-based cohort which collected data from July 2000 through January 2002 
(446). During this time period, 2,287 participants were screened using proton magnetic 
resonance spectroscopy to measure fat content of the liver. Based upon these data, the 
prevalence of NAFLD in the U.S. in 2002 was estimated to be 30%. Supporting these 
imaging data are observational studies which report that the prevalence of NAFLD tends 
to closely parallel the prevalence of obesity (442). Given that ~1/3 of the U.S. population 
is considered obese, the prevalence of NAFLD in the U.S. population is thus likely to be 
approximately 30% (446).  
Due to the asymptomatic presentation of NAFLD, most cases are diagnosed in the 
5th and 6th decades of life (443). NAFLD is rarely observed in individuals younger than 
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20 years (~1%), but increases to 18% in those aged 20-40 years and to 39% among those 
aged 60 and older (442).  
The prevalence of NAFLD varies across genders and ethnicities. Prior to the 
aforementioned population-based studies, NAFLD was traditionally thought to affect 
more females than males (442). However, authors have since demonstrated that males are 
twice as likely to develop NAFLD than females (441). For example, NHANES data 
indicate that the prevalence of NAFLD in U.S. males is estimated to be 53.1% versus 
29.1% in females (442). In addition, data from the Modena and Bologna/Turin study 
indicates that NAFLD exhibits a gender dimorphic pattern in which males tend to 
develop the disease approximately 10 years before their female counterparts (447). 
Interestingly, postmenopausal females are twice as likely as premenopausal females to 
develop NAFLD (444, 448). Moreover, the prevalence of NAFLD in females exceeds 
that in males following menopause (447).  
Data from the DHS indicates that the prevalence of NAFLD in Hispanic 
Americans is 45%, 33% in non-Hispanic whites and 24% in African Americans (443). 
Moreover, data from several other population-based studies are in alignment with the 
DHS, showing that Hispanic Americans demonstrate a higher prevalence of NAFLD 
compared to non-Hispanic whites and African Americans across all age categories and 
genders (442, 446). Explanations for the observed differences in the prevalence of 
NAFLD are hypothetical and relatively vague. Moreover, some authors posit that the 
observed differences may be related to the ethnic differences in body fat distribution 
and/or fat metabolism, with African Americans having more subcutaneous fat but less 
visceral fat. It has also recently been suggested that African Americans have different 
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lipoprotein metabolism (i.e., lower serum concentrations of triglycerides than age and 
gender-matched counterparts) compared to other ethnicities (449). Lastly, the higher 
observed prevalence of NAFLD in Hispanic Americans has also been attributed to 
intrinsic factors such as a genetic predisposition for greater adiposity and insulin 
resistance compared to other ethnicities (442). 
Pathophysiology   Several studies have reported that NAFLD is highly correlated 
with obesity, T2DM (442, 444), biomarkers of dyslipidemia (e.g., high triglyceride 
concentrations and low HDL concentrations) and insulin resistance. However, insulin 
resistance appears to be considered the pathophysiological hallmark of NAFLD (442), as 
mild insulin resistance/hyperinsulinemia is commonly observed at the earliest stages of 
NAFLD in the absence of obesity (450) and more severe insulin resistance (e.g., such as 
that observed in metabolic syndrome and T2DM) correlates with more advanced stages 
of NAFLD (442).  
To my knowledge, a single hypothesis has been put forward to explain the 
etiology of NAFLD, which highlights the role of increased concentrations of FFAs 
leading to insulin resistance and subsequent hepatic steatosis. In the normal hepatocyte, 
energy received from circulating glucose, fructose and lipids is stored as glycogen and 
triglycerides, respectively. Under normal physiologic conditions, any increase in lipid 
concentration within the hepatocyte results in 1) the redistribution of the lipids to 
peripheral storage within adipose tissue or 2) the lipids are directly converted to 
metabolic fuel through oxidation. In other words, it appears that hepatocytes have very 
little capacity for the storage of triglycerides (i.e., the storage form of FFAs) and do so 
only when all other mechanisms for lipid utilization, trafficking or storage have been 
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exhausted. In NAFLD, lipid trafficking appears to be dysregulated, which culminates in 
increased intrahepatocellular lipids, particularly as saturated FFAs (e.g., palmitic acid, 
stearic acid) (451).  
Within the hepatocyte, these excess FFAs appear to directly contribute to 
organelle dysfunction and failure. As mentioned previously, FFAs contribute to 
mitochondrial dysfunction by skewing the NAD/NADH ratio which leads to increased 
concentrations of acetyl-CoA and hepatic glucose production. Over time, this culminates 
in elevated triglyceride storage within the hepatocyte, organelle failure and apoptosis. 
Moreover, FFAs can induce endoplasmic reticulum stress by increasing ceramide 
concentration (452) as well as by other poorly understood mechanisms (452).  
There is also substantial evidence which demonstrates that FFAs can directly 
induce cellular toxicity by increasing oxidative stress and activation of pro-inflammatory 
pathways (457). For example, FFA accumulation within the hepatocyte is associated with 
Kupffer cell activation (452). Kupffer cells are resident macrophages within the liver 
parenchyma in close physical proximity to hepatocytes, endothelial cells, sinusoids and 
stellate cells (452). It is worth noting that stellate cells reside between hepatocytes and 
the small blood vessels of the liver and are normally quiescent. It appears that their main 
function is to store vitamin A and maintain the basement membrane matrix. Activation of 
stellate cells leads to collagen secretion and formation of scar tissue and appears to be a 
central step in the initiation of hepatic fibrosis. Interestingly, not only is the activation of 
Kupffer cells thought to play a central role in the pathogenesis and progression of liver 
disease by contributing to parenchymal inflammation, hepatocyte ballooning and injury 
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and initiation of fibrosis via TNF-alpha secretion (452), Kupffer cells have also been 
shown to modulate stellate cell activation (454) 
In terms of linking FFAs to inflammation and NAFLD, TNF-alpha secretion by 
macrophages promotes lipolysis and increases FFA concentration (455) and has been 
observed to increase in a stepwise-fashion from obesity to simple steatosis (452). 
Interestingly, TNF-alpha both promotes and is activated by insulin resistance via 
activation of IKK-B (inhibitor of nuclear factor kappa B kinase subunit beta (NF-kB)) 
(456), which mediates the activity of NF-kB (i.e., a proinflammatory protein complex). 
This complex regulates inflammatory mediators including C-reactive protein (CRP), 
plasminogen activator inhibitor (PAI-1), TNF-alpha and IL-1B (456).  
As mentioned previously, TNF-alpha has been shown to antagonize adiponectin 
(452) and vice versa (457). Thus, it has been postulated that adiponectin may protect the 
liver from inflammation via this antagonistic effect on TNF-alpha. Lending support to 
this line of reasoning, recombinant adiponectin has been shown to inhibit TNF-alpha 
concentration, improve insulin sensitivity and reduce steatohepatitis in two mouse models 
of hepatic steatosis (452). Taken together, these results support the hypothesis of FFAs 
leading to insulin resistance and subsequent NAFLD, where FFA accumulation leads to 
insulin resistance and subsequent hepatic steatosis, which is amplified by increasing 
insulin resistance.  
Analytic Epidemiology   The risk for developing NAFLD correlates positively 
with BMI, as prevalence of the disease ranges from 30% in normal weight individual of 
the general population to 57% among overweight individuals (446) to 80%-90% among 
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obese individuals (449). Given that 66% of U.S. population is estimated to be overweight 
(i.e., as indexed by BMI), this is obviously a growing public health concern. 
Suzuki et al. have speculated that FFA oxidation in the liver may decrease 
following menopause while lipogenesis may be enhanced (447). Thus, it appears that 
menopausal status (i.e., pre- vs. post-menopause) be considered a risk factor. In line with 
this observation, other authors report that postmenopausal females receiving hormone 
replacement therapy are significantly less likely to develop NAFLD compared to females 
who do not (442, 447) and Carulli et al. have postulated that circulating levels of 
estrogens within the physiological range might be responsible for a protective effect on 
the development of hepatic steatosis (458). In support of the latter hypothesis, NAFLD in 
animal models has been reversed by the administration of estradiol (459). Interestingly, it 
appears that no connection has been made between the development of NAFLD among 
pre- and post-menopausal females and the cessation of menstruation among 
postmenopausal females. 
Given that much of the research community concurs that NAFLD is the ‘hepatic 
manifestation of metabolic syndrome,’ additional risk factors independent from those 
already associated with the development of metabolic syndrome are not commonly 
reported in the NAFLD literature. Similar to T2DM and Metabolic syndrome, however, 
several small case studies have indicated that parameters of iron status may be involved 
in the initiation, promotion and progression of NAFLD.  
Iron and non-alcoholic fatty liver disease    Given that parameters of iron status 
and their association with NAFLD have received little attention in the epidemiological 
literature, it follows that presenting the results of investigations relating the risk of 
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developing NAFLD to iron stores in a systematic manner is a challenge. Among the 
studies examining the relationship between iron and NAFLD, dysmetabolic iron overload 
syndrome (DIOS) appears to be a common feature of NAFLD, with a prevalence of 
~33% (460) among those diagnosed with the condition. In subjects with DIOS, serum 
ferritin is elevated, while transferrin saturation is within the normal reference range (461).  
As mentioned, associations between iron stores and NAFLD have been most often 
reported in case-studies. For example, in 2004, Younossi et al. obtained biopsies from 65 
patients with NASH, noting that 31% of patients were either heterozygous or 
homozygous for the C282Y polymorphism at the HFE locus rs1800562, and the presence 
of this mutation resulted in a higher histological grade of iron, increased hepatic iron 
content and an increase in histological fibrosis (462). Gene expression data published by 
Mitsuyoshi et al. in 2009 support the results of Younossi et al. The former group obtained 
biopsy specimens from 74 patients with NAFLD and observed an increase in hepatic iron 
score (HIS) as the stage of fibrosis progressed. Moreover, sTfR1 expression significantly 
increased with progressing stage of fibrosis (463). In addition, Nelson et al. published a 
study in 2011 with data obtained from 849 patients enrolled in the Nonalcoholic 
Steatohepatitis Clinical Research Network demonstrating that participants whose 
reticuloendothelial system (RES) cells (i.e., monocytes and macrophages) contained 
stainable iron were also more likely to have advanced pathohistological features such as 
fibrosis, portal inflammation, hepatocellular ballooning and biopsy-confirmed NASH 
compared to participants without stainable hepatocellular iron. In this study, the presence 
of stainable RES iron was independently associated with advanced hepatic fibrosis 
following multiple regression analysis controlling for age, gender, diabetes status, and 
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BMI (OR = 1.60, 95%CI: 1.10 – 2.33, P = 0.015) (464). In 2012, Shim published a study 
showing that elevated serum ferritin was an independent predictor of histologic severity 
and advanced fibrosis in subjects with NAFLD (465). Later that year another group (466) 
conducted a genetic association study examining the effects of the C282Y (rs1800562) 
and H63D (rs1799945) polymorphisms on serum hepcidin, hepatic iron deposition, and 
histology of NAFLD. The authors observed that subjects with NAFLD and C282Y (but 
not H63D) mutations had lower median serum hepcidin levels and higher mean 
hepatocellular iron grades compared to wild-type subjects. Nelson et al. also observed an 
inverse relationship between hepatic iron stores and serum hepcidin concentration across 
all HFE genotypes, indicating that elevated iron stores are associated with NAFLD 
independent of HFE genotype (466). The latter observation is supported by a study 
conducted in 1999 by Mendler et al. who reported that patients with no HFE mutations 
had similar degrees of iron overload as those with mutations in the HFE gene, apart from 
compound heterozygotes (i.e., individuals heterozygous for both HFE mutations), who 
presented with significantly more iron burden (467). A meta-analysis published in 2012, 
which includes the study conducted by Mendler et al., lends support to these individual 
investigations, as the authors concluded that elevated iron in NAFLD is independent of 
HFE genotype (468). It thus appears that insulin resistance in NAFLD is associated with 
more subtle degrees of iron overload than is observed in iron-loading disorders, such as 
HH and beta-thalassemia (469).  
Mechanistically, iron appears to have a direct role in the activation of hepatic 
Kupffer cells and hepatic stellate cells. For example, iron has been shown to activate 
inflammatory signaling via hepatic macrophages in vitro and ferritin treatment of isolated 
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rat hepatic stellate cells has been shown to increase NF-kB signaling. As mentioned, the 
activation of stellate cells appears to be a central step in the initiation of hepatic fibrosis. 
Animal studies have also shown that hepatic sTfR-1 is upregulated due to a high-fat diet, 
which may lead to increased hepatocellular uptake of dietary iron despite an already 
increased hepatocellular iron load. In alignment with these studies, Otogawa et al have 
observed an increase in red cell fragility in response to a high-fat diet in rabbits and this 
fragility leads to increased erythrophagocytosis by Kupffer cells (470). From a 
pathophysiological perspective, Kupffer cells can also accumulate iron via phagocytosis 
of necrotic hepatocytes (471). These latter findings may, in part, explain the observed 
increases in hepatic reticuloendothelial iron that has been observed in some NASH 
cohorts (154). 
Serum hepcidin levels also appear to increase as individuals transition from 
NAFLD to NASH, and DMT-1 is upregulated in patients with NASH, despite the 
observed increased serum hepcidin concentrations (472), indicating a perturbation in iron 
metabolism where the requirement for iron is increased along with iron storage.  
Finally, dietary iron loading in leptin-receptor deficient mice has been recently 
reported to lead to inflammasome and immune cell activation, which directly corresponds 
to hepatocellular ballooning. In other words, mice who lack satiety signals and have high 
intakes of dietary iron appear to have Kupffer cell activation and increased oxidative 
stress, which leads to liver dysfunction.  
Interventional Epidemiology   Valenti et al. demonstrated in a case-control study 
that iron depletion by phlebotomy improves insulin resistance in patients diagnosed with 
NAFLD (473). More recently, a meta-analysis of studies examining the effect of 
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phlebotomy on insulin resistance lends further support to the initial results of Valenti et 
al. The primary outcome analyzed across all studies in the meta-analysis conducted by 
Jaruvongvanich et al. (Table 10) was the pooled mean difference (MD) of the 
homeostasis model assessment of insulin resistance (HOMA-IR) (468). The authors 
found that study subjects with NAFLD who underwent phlebotomy had lower HOMA-IR 
indices with an MD of 0.84 (95%CI: 0.01 to 1.67, I-squared = 34%), lower triglyceride 
levels (MD = 9.89, 95%CI: 4.96-14.83, I-squared = 22%) levels and increased high 
density cholesterol level (MD = 3.48, 95%CI: 2.03-4.92, I-squared = 18%) compared to 
controls (i.e., subjects with NAFLD who did not receive phlebotomy) and concluded that 
phlebotomy decreased insulin resistance and liver transaminase levels in patients with 
NAFLD.  
Conclusion   Taken together, it appears as though iron stores are positively 
associated with NAFLD. Compared to T2DM and metabolic syndrome and a lack of 
several population-based studies, however, the strength of the associations between iron 
stores and NAFLD are unclear. Moreover, each of the above studies employed invasive 
and costly methods to assay iron status. Predictive, non-invasive, and inexpensive 
analytes unaltered by inflammation would be valuable for use in monitoring the iron 
status of those at risk for developing NAFLD. To my knowledge, no study to date has 
employed the algorithm developed by JD Cook et al. in 2003 (50) as an index for iron 
repletion to examine the association of the former with NAFLD. 
Given that the prevalence of NAFLD is increasing and that quantification of the 
presence of the condition often involves cost-prohibitive and/or invasive methods, an 
index with high sensitivity and specificity which utilizes biochemical parameters would 
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be of significant value. To this end, several indices and algorithms have been developed. 
However, the sensitivity and specificity of each index varies (Table 7) in terms of 
accurate classification across populations. Thus, an index referred to as the U.S.-FLI has 
was recently developed to determine the presence of NAFLD among multi-ethnic 
cohorts. As mentioned, the index accounts for age and ethnicity and has been shown to 
outperform its predecessor, the FLI (35).  
The U.S.-FLI has not been employed thus far to estimate the prevalence of 
NAFLD in U.S. females as a subgroup. Moreover, no investigations to date have 
examined the association between body iron as indexed by Cook’s equation and NAFLD 
as indexed by the U.S.-FLI. 
 
Epidemiology of insulin resistance 
History & Definition   It is well-established in the literature that insulin resistance 
is involved in the development of T2DM (366-398), metabolic syndrome (7,9,12-15, 392, 
393, 431-440) and NAFLD (460-473), often decades before glucose intolerance occurs or 
any of the above conditions are diagnosed. Insulin resistance has traditionally been 
framed in terms of the effects of insulin on glucose metabolism, otherwise known as the 
“glucocentric” view of insulin resistance. The traditional “glucocentric” view of insulin 
resistance has shifted over the past decade, however, to a “lipocentric” view of insulin 
resistance due to advances in our understanding of the etiology of insulin resistance. The 
“lipocentric” view of insulin resistance will be discussed subsequently.  
Descriptive Epidemiology   In the U.S. population, the prevalence of insulin 
resistance has been estimated at 45% (9.6% in normal weight adults aged 40-79 years, 
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and ~ 50% in overweight adults aged 40-79 years) (474). Prevalence estimates for insulin 
resistance may be underreported, however, as the gold-standard for diagnosis of insulin 
resistance is the hyperinsulinemia-euglycemic clamp, which is both invasive as well as 
cost-prohibitive at the patient-level as well as in population-based studies. In addition, the 
prevalence of insulin resistance alone has rarely been quantified in the absence of T2DM, 
metabolic syndrome or NAFLD.  
Pathophysiology   As previously mentioned, however, the traditional 
“glucocentric” view of insulin resistance has shifted over the past decade to a 
“lipocentric” view of insulin resistance due to results emerging from recent 
investigations. For example, in vivo research conducted using 13C-MRS (13C-Magnetic 
Resonance Spectroscopy) to examine the cellular mechanisms of insulin resistance in 
humans is a technique which allows for the real-time, non-invasive measurement of the 
concentration of intracellular metabolites containing naturally occurring isotopes of 1H, 
13C, and 31P (475, 476). Using this approach with sets of age- and weight-matched 
subjects with and without T2DM, Peterson and colleagues have demonstrated that the 
rate of insulin-stimulated muscle glycogen synthesis (i.e., assessed via the incorporation 
of 13C-glucose into gastrocnemius/soleus muscle glycogen) is decreased by ~50% in 
T2DM subjects (475, 476). Extrapolating these data to the whole-body, the group 
concluded that almost all the insulin resistance observed in these subjects could be 
attributed to defects in insulin-stimulated muscle glycogen synthesis. Further analysis of 
the glycogen synthesis pathway revealed that the rate-limiting step leading to insulin 
resistance was reduced insulin-stimulated glucose transport activity. Finally, through 
additional 13C and 31P MRS studies, the group determined that the accumulation of 
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FFAs within the myocyte induces insulin resistance (i.e., via reducing insulin action) by 
directly inhibiting activation of glucose transport activity by reducing transcription of 
GLUT4 (476), the insulin-regulated glucose transporter primarily involved in regulating 
whole-body glucose homeostasis.  
To appreciate the impact of FFAs on GLUT4 transcription, we must examine the 
tissue distribution and mechanism of action of GLUT4. The tissues which remove 
glucose from circulation for utilization via GLUT4 are skeletal muscle, liver and adipose 
tissue. Under normal physiologic conditions, insulin secretion 1) stimulates glucose 
uptake in skeletal muscle and adipocytes by translocation of GLUT4 to the cell surface, 
2) stimulates the synthesis of glycogen from glucose and inhibits glycogenolysis in 
skeletal muscle and hepatocytes and 3) decreases hepatic gluconeogenesis (i.e., the 
generation of glucose from non-carbohydrate substrates such as amino acids, 
triglycerides, pyruvate and lactate) (477), in order to prevent an influx of additional 
glucose into the bloodstream. Moreover, insulin secretion inhibits lipolysis (i.e., fat 
breakdown) in adipocytes and stimulates glucose uptake in adipose tissue (478). Thus, 
the net effect of insulin secretion by beta cells is to increase glucose uptake via GLUT4, 
reduce circulating glucose levels by suppressing hepatic glucose production and to 
increase the conversion of glucose to glycogen or fat (477).  
Experimental models have demonstrated that altering GLUT4 activity directly 
impacts insulin action. For example, mice with targeted downregulation of GLUT4 in 
skeletal muscle and adipose tissue have been shown to develop insulin resistance in each 
tissue (478). Moreover, it has also been shown in mouse models that overexpression of 
GLUT4 in adipose tissues is associated with improved insulin sensitivity (480). Taken 
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together, it appears that the “lipocentric” view of insulin resistance usurps the previous 
“glucocentric” view of insulin resistance, as the former view places FFAs at the 
beginning of the pathway which leads to beta cell dysfunction by decreasing GLUT4 
expression and this is thought to result in hyperglycemia with subsequent 
hyperinsulinemia as a compensatory response. 
It is worth noting that with increasing FFAs, it has been postulated that glucose 
oxidation (as well as glycolysis) is reduced in favor of FFA oxidation. As a consequence, 
the metabolic by-products of excess FFA oxidation (i.e., ceramides) (452) contribute to 
oxidative stress, which is thought to lead to further increases beta cell dysfunction and 
apoptosis (333). For instance, studies have shown that ceramide directly impairs insulin-
stimulated glucose uptake and GLUT4 translocation when added to cultured adipocytes 
and myocytes (481). These effects appear to be mediated by the effects of ceramide to 
inhibit tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1, which transmits 
signals from insulin to downstream intracellular pathways such as PI3K/Akt and MAP 
kinase) (478). Moreover, FFAs are endocytosed and metabolized directly by beta cells 
(477), which has been hypothesized to lead directly to beta cell dysfunction (477). 
Moreover, FFAs can be re-esterified to triglycerides by several tissues including muscle, 
fat and liver (341), which leads to the increased storage of these lipids.  
As mentioned in the section covering T2DM, studies have demonstrated that 
FFAs contribute to mitochondrial dysfunction by skewing the NAD/NADH ratio and this 
is thought to lead to inhibition of FFA beta oxidation, increases in FFA storage as 
triglycerides, mitochondrial dysfunction and eventual mitochondrial apoptosis. Thus, the 
manifestation of diminished GLUT4 activity via increased FFA concentrations, coupled 
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with increasing hyperinsulinemia and hyperglycemia, results in a variety of metabolic 
abnormalities including several perturbations downstream of insulin resistance. These 
perturbations manifest in hepatic steatosis (previously discussed in the NAFLD section), 
elevated triglycerides, low levels of high-density lipoproteins (HDL) and increased 
secretion of very low-density lipoproteins (VLDL) (previously discussed in the metabolic 
syndrome section).  
Iron & insulin resistance   In a three-year prospective study among 1,277 
French adults, Fumeron et al. reported that baseline serum ferritin level was an 
independent predictor of increases in serum insulin concentrations at the end of the 
follow-up period. The authors reported that each 1 ng/mL increase in ferritin was 
associated with an 0.05 ± 0.02 µU/mL increase in serum insulin concentration (P = 
0.002) (373). Two other cross-sectional studies have indicated that increased body 
iron is associated with insulin resistance.  
The first cross-sectional study examined the effect of dietary patterns (i.e., 
healthy, Western, traditional) on iron status and insulin resistance in 486 Tehrani females. 
In these subjects, a Western dietary pattern classification scheme was developed using 
factor analysis, where red meats and refined grains had the highest factor loadings of 0.56 
and 0.66, respectively (14). The authors observed that females who were in the highest 
quintile of Western dietary pattern scores (i.e., the highest red meat and refined grain 
intake) had greater odds of insulin resistance, as measured by the homeostasis model 
assessment-insulin resistance (HOMA-IR) (OR = 1.26; 95%CI: 1.00-1.78; Ptrend < 0.01). 
Given the cross-sectional study design, however, it is not possible to conclude whether 
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increased body iron preceded increases in HOMA-IR, accompanied increases in HOMA-
IR or followed increases in HOMA-IR.  
In another population-based cross-sectional study involving 1,013 Finnish men, 
subjects in the highest quintile of serum ferritin concentrations had 21.6% higher fasting 
serum insulin concentrations (95%CI: 7.3%-37.9%; P < 0.001) (24). In these subjects, 
fasting blood glucose was also higher in those in the highest quintile of serum ferritin 
concentrations (6.1%; 95%CI: 2.3%-9.9%; P < 0.001).  
Conclusion   Taken together, these three investigations suggest that iron is 
associated with insulin resistance and may be involved in the etiology of insulin 
resistance. Additional prospective studies are needed, however, to confirm this 
hypothesis.   
 In terms of linking iron to the etiology of insulin resistance by way of a testable 
hypothesis, we must first examine several lines of evidence demonstrating the effects of 
insulin administration on iron parameters, as well as the effects of iron on factors 
reported in the literature to be associated with insulin resistance, such as chemokines, 
cytokines, adipokines and insulin-sensitizing agents. Most importantly, an association 
between iron and the purported driver of insulin resistance, FFAs, must be demonstrated. 
 Effects of insulin administration on iron parameters   Two groups thus far have 
shown that administration of insulin to cultured adipocytes increases iron uptake in these 
cells by increasing the expression of sTfR1 (482, 483) and decreased insulin-stimulated 
glucose transport (484). Another group have replicated these findings using the HepG2 
hepatic cell line and the HL-7702 hepatic cell line (485). Moreover, these results garner 
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additional support from a rodent model demonstrating that insulin injections lead to 
subsequent increases in sTfR1 in vivo (486).  
Related to these observations, studies have also shown that serum transferrin 
receptor 2 (sTfR2) can be regulated by insulin-like growth factor 1 (IGF1, a hormone 
produced in the liver that shares structural similarity to insulin), where IGF1 expression 
increased sTfR2 cycling (167). Finally, several authors have reported that 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can also act as a transferrin 
receptor and is a preferred receptor for transferrin in some cell lines (CHO-TRVb, J774 
cell lines) (77, 78, 487, 488). This is an interesting finding, as GAPDH is the same 
enzyme involved in the breakdown of glucose to pyruvate during glycolysis (487).  
It is also worth mentioning here that the finding from Davis et al. and Tanner 
et al. is notable, especially when considering other studies which have suggested that 
iron within the adipocyte might interfere with cellular insulin sensitivity and contribute to 
increased lipolysis (16). This leads to one to hypothesize that increased lipolysis by iron 
within the adipocyte could increase the pool of FFAs. Moreover, one can hypothesize 
that insulin resistance might amplify these effects, as insulin appears to enhance iron 
uptake by increasing serum transferrin receptor expression with increasing concentrations 
of insulin. 
 Iron and chemokines   Zager et al. have shown that both iron sucrose as well as 
iron gluconate increase plasma and renal MCP-1 concentration (489). Given that iron is a 
pro-oxidant it is feasible that iron could also contribute to increased MCP-1 expression.  
Iron and cytokines   The effects of iron on the immune system was reviewed 
previously in chapter 3. However, no special attention was given to the cytokines 
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associated with the development of insulin resistance nor was any attention given to how 
iron is associated with insulin resistance or conditions associated with insulin resistance. 
Several studies have been published which report elevated levels of ferritin and TNF-
alpha, IL-6, IL-8 and C-reactive protein (CRP) (380, 382, 490). For instance, in an age- 
and sex- matched case-control study, Elsammak et al. have reported that both serum 
ferritin and TNF-alpha increase among individuals with NGT (N = 18), T2DM (N = 22), 
Hep C infection with T2DM (N = 23) and Hep C infection (TNF-alpha: 0.32 (0-5.8) 
pg/mL, 0.85 (0-10.5) pg/mL, 19.8 (0.51-139) pg/mL, 25.5 (0.43-124.0) pg/mL, 
respectively; serum ferritin: 159 ± 76.9 ng/mL, 86.9 ± 41.8 ng/mL, 285.8 ± 124.3 ng/mL, 
258.1 ± 116.2 ng/mL, respectively). Moreover, the authors reported that the degree of 
insulin resistance decreased among those with both HepC infection and T2DM, T2DM, 
Hep C infection and NGT (HOMA-IR: 6.1 ± 2.36, 4.53 ± 2.84, 3.69 ± 2.2, 1.32 ± 0.49, 
respectively). In addition, Abou-Shousha et al. have shown that serum ferritin, sTfR and 
IL-8 are all elevated in states of insulin resistance. Taken together, these results indicate 
that iron, cytokines and insulin resistance are positively associated and emphasize the 
importance of excluding and/or controlling for Hep C infection and adjusting for CRP 
concentrations during the analysis of the effect of iron on any outcome in which insulin 
resistance plays a role.   
Iron and adipokines   Leptin and adiponectin are two-well characterized 
adipokines produced and secreted by adipose. Briefly, leptin was identified in 1994 by 
Halaas et al. as a 16kDa protein encoded by the obese (ob) gene. The group discovered 
the protein to be directly involved in body weight, where its secretion from adipose tissue 
is activated by the ventromedial hypothalamus of the brain via gastric stretching 
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following a meal and provides a feedback signal of satiety to the brain so that food intake 
be halted (491). 
Adiponectin was first identified in 1995 by Scherer as 30kDa protein secreted by 
adipose tissue and is now recognized for its insulin-sensitizing, anti-inflammatory, 
antiatherogenic and cardioprotective properties (492). Adiponectin secretion is quite 
distinct from that of leptin. Adiponectin is less dependent on state of satiety compared 
to leptin. Rather, adiponectin exhibits an ultradian pulsatility (i.e., a pattern 
characterized by periods of secretion longer than an hour and shorter than a day) and 
diurnal variation (i.e., adiponectin secretion declines up to 30% during sleep) (493).  
Collectively, these adipokines have been shown to decrease triglycerides 
synthesis, promote FFA degradation (i.e., leptin, adiponectin) (334) and enhance insulin 
action in both skeletal muscle and liver (i.e., adiponectin) (478). In line with these data, 
studies which show that leptin concentrations are increased and levels of adiponectin are 
decreased in obese individuals with insulin resistance as well as in animal models of 
obesity with insulin resistance (494, 495), suggest that obesity leads to a state of leptin 
resistance and adiponectin deficiency. 
Interestingly, TNF-alpha, whose expression is reported to increase in insulin-
resistant conditions, appears to have an antagonistic relationship with adiponectin. 
Studies have shown that TNF-alpha expression dose-dependently reduces adiponectin 
expression in adipocytes by suppressing its promoter activity (496). Conversely, 
adiponectin attenuates the secretion of TNF-alpha from monocytes and macrophages 
(496). Moreover, increased adiponectin levels appear to reduce TNF-alpha-induced 
expression of adhesion molecules in vascular smooth muscle cells (VSMCs) (497). 
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Data published by Green et al. suggests that dietary iron overload induces insulin 
resistance in mice (484). In their study, the authors concluded that iron accumulation 
within adipose tissue may result in decreased expression of adiponectin (484). In line 
with this data, other studies have shown that serum ferritin concentrations are inversely 
related to adiponectin concentrations (498). 
Iron and insulin-sensitizing agents   Thiazolidinediones (TZs) are a class of 
medications also known as the glitazones, which are commonly used to treat 
T2DM. Administration of TZ has been shown to improve insulin sensitivity (i.e. via 
lowering circulating glucose and insulin concentrations) by increasing adiponectin gene 
expression (411) as well as increasing the rate of mitochondrial beta oxidation of FFAs, 
which decreases FFA concentrations and reduces FFA turnover (411). It has also been 
suggested that TZs increase mitoNEET expression, a putative direct mitochondrial target for 
TZs (499). mitoNEET is an iron-sulfur protein residing within the outer mitochondrial 
membrane (499) and increases in mitoNEET expression have been shown to increase the rate 
beta oxidation (500), which, as mentioned above, decreases FFA concentrations (411). This 
leads one to hypothesize that TZs may be involved in balancing the NAD/NADH ratio, as 
previously discussed. 
Iron and FFAs   The observation that FFAs are siderophores is based upon a 
serendipitous discovery in 1991 which began with publications demonstrating that 
alveolar macrophages in smokers accumulate large amounts of iron (501). Given that 
macrophages phagocytose senescent erythrocytes, the authors hypothesized that the 
erythrocytes in smokers were somehow accumulating iron. Although organic extracts 
of cigarette smoke do not contain significant amounts of iron, previous work by Qian and 
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Eaton had shown that particulate matter from cigarette smoke contained significant 
amounts of FFAs. This lead the authors to hypothesize that FFAs bind iron and transfer it 
to erythrocyte membranes. The authors then used mass spectroscopy to identify the 
purported iron-binding FFAs in cigarette smoke as strearic and palmitic acid. While 
Qian and Eaton did not provide data on the definitive structure of the presumed iron:FFA 
complex, they did hypothesize that the complex forms as a result of the interaction 
between iron and the carboxylic esters of FFAs (e.g., RCOO:Fe), where the hydrocarbon 
tails of FFAs are capable of forming a metal chelate, which readily binds iron through an 
ionic interaction. It therefore became plausible that once erythrocytes had reached the end 
of their lifespan, they were then phagocytosed by macrophages and this accounted for the 
observation that alveolar macrophages in smokers had increased amounts of iron. 
Nalini and Balasubramanian were the next group to demonstrate that FFAs 
bind iron, showing that 3 to 4 moles of FFAs are required to bind 1 mole of iron 
(502). More recently, Boiteau et al. have shown that marine microbes employ the 
same mechanism to bind iron in conditions of iron scarcity (503). Other authors (504) 
have gone so far to suggest that iron absorption in the GI tract may also involve FFAs in 
addition to more widely-known mechanisms of iron absorption, discussed in chapter 2.  
Conclusion   It appears biologically plausible that iron stores are associated with 
the initiation, promotion and progression of insulin resistance. Lending support to this 
hypothesis are studies showing that FFAs are siderophores for iron and that iron activates 
Kuppfer cells, increases both inflammation and the expression of inflammatory mediators 
and, as mentioned in Chapter 2, is a pro-oxidant capable of generating ROS and the 
propagation of lipid peroxidation.  Much more population-based research is needed to 
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tease apart the magnitude of the associations between iron stores and insulin resistance. 
To this end, predictive, non-invasive, and inexpensive analytes unaltered by 
inflammation would be valuable for use in monitoring the iron status of those at risk for 
developing insulin resistance. To my knowledge, no study to date has employed the 
algorithm developed by JD Cook et al. in 2003 (50) as an index for iron repletion for use 
in examining the association between the former and insulin resistance.  
Summary    
The relationships between T2DM, metabolic syndrome, NAFLD and insulin 
resistance and increased body iron warrants further investigation. Given the iron-replete 
status of much of the U.S. population, in particular post-menopausal females, it is 
necessary to increase the sensitivity and specificity of existing estimates of body iron 
status or to develop novel, non-invasive, and cost-effective procedures to assay individual 
iron status across the reproductive lifespan.  
Predictive biomarkers obtained from serum which correlate with the above 
mentioned etiological and pathological hallmarks of metabolic dysfunction are of interest 
in epidemiology and public health due to their value in disease screening, prevention, and 
treatment. Thus, assays apart from hemoglobin, hematocrit, serum iron, transferrin 
saturation, total iron binding capacity, or serum ferritin, unaltered by inflammation or 
liver function would provide increased value in monitoring the iron status of females 
across the reproductive lifespan.  
To my knowledge, the index of iron repletion developed by Cook et al. in 1993 
(50), has received no attention in the epidemiological literature with regard to its 
association with metabolic dysfunction (i.e., Type 2 diabetes mellitus (T2DM) defined by 
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the World Health Organization (WHO); metabolic syndrome defined by the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III); non-alcoholic 
fatty liver disease (NAFLD) defined by the U.S. Fatty Liver Index (U.S.-FLI); insulin 



























CHAPTER 5: RESEARCH METHODS 
Study population 
The study population was comprised of nonpregnant, community-dwelling 
females aged 12-49 participating in the continuous NHANES 2003-2010 survey with 
complete data for all parameters of interest. Since 1999, the National Health and 
Nutrition Examination Survey (NHANES) has collected cross-sectional data every two 
years on the health and nutritional status of the community-dwelling U.S. population. 
NHANES data were not obtained using a simple random sample. Rather, the survey 
obtains a stratified, multistage (i.e., four stages) probability sample designed to represent 
the U.S. population on the basis of age, sex, and race-ethnicity. The NHANES sampling 
procedure consisted of four stages. Stage one consisted of primary sampling units 
(PSUs), which were selected from strata defined by geography and proportions of 
minority populations. Primary sampling units were mostly single counties or, in a few 
cases, groups of contiguous counties selected with probability proportional to a measure 
of size (PPS). Most strata contained two PSUs. Additional stages of sampling were 
performed to select various types of secondary sampling units (SSUs), namely the 
segments, households, and individuals that were selected in Stages 2, 3, and 4. In stage 
two, the PSUs were divided into segments (generally, city blocks or their equivalent). As 
with each PSU, sample segments were selected with PPS. During stage three, households 
within each segment were listed, and a sample was randomly drawn. In geographic areas 
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where the proportion of age, ethnic, or income groups selected for over-sampling is high, 
the probability of selection for those groups was greater than in other areas. Finally, in 
stage four, individuals were chosen to participate in NHANES from a list of all persons 
residing in selected households. Individuals were selected at random within designated 
age-sex-race/ethnicity screening sub-domains.  On average, 1.6 persons were selected per 
household (505). Because of the differential probabilities of selection, sampling weights 
were created that reflected the base probabilities of selection, adjustment for non-
response, and post-stratification. All subjects have hitherto provided written informed 
consent and the study was approved by the National Center for Health Statistics 
Institutional/Ethics Review Board.  
Data collection procedures    
The current work was a secondary analysis of an ongoing population-based 
cross-sectional study. Briefly, NHANES data were released for public consumption in 
2-year cycles. Just as each year's sample was representative of the resident, community-
dwelling U.S. population, the same was true for each 2-year cycle of data. In order to 
have sufficient sample sizes to obtain stable estimates for population subgroups of 
interest, however, data cycles spanning the years 2003-2010 were pooled to increase 
statistical power. Baseline data for continuous NHANES were collected during an in-
home interview and a subsequent visit to a mobile examination center. During the in-
home interview, a standardized questionnaire was used to collect demographic and 
health-related information including age, race-ethnicity, sex, level of education, alcohol 
consumption, reproductive health, and use vitamin supplementation. The response rate 
for all females during the interview for 2003-2004, 2005-2006, 2007-2008 and 2009-
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2010 were 80%, 80.9%, 78.6% and 79.7%, respectively (506-509). During the mobile 
examination, biochemical parameters were collected along with anthropometric 
measurements. The response rate during the examination for 2003-2004, 2005-2006, 
2007-2008 and 2009-2010 were 76%, 77.8%, 75.5% and 77.4%, respectively (506-509). 
Subjects with probable hemochromatosis (N = 304) based upon abnormal values of 
several iron markers (i.e., serum iron > 175 μg/dL, serum ferritin > 200 μg/L, and 
transferrin saturation > 60%), with reported hepatitis C infection (N = 328) or who 
reported being pregnant (N = 695) were excluded. 
Variable ascertainment and Instrumentation 
Predictor Variables   In 2003, Cook et al. (50) developed an algorithm to calculate an 
index of iron repletion, which is given by the equation FeCOOK (mg/kg) = (−[log10⁡(𝑅 ∗
1000/𝐹) − 2.8229])/0.1207, where R = serum transferrin receptor (mg/L) and F = 
serum ferritin (mcg/L). When the index was developed, serum transferrin receptor 
concentrations were input into the equation in micrograms per liter. I thus converted 
milligrams per liter to the required unit by multiplying by 1,000. Serum transferrin 
receptor is primarily derived from developing red blood cells, reflects the magnitude of 
erythropoiesis and the body’s demand for iron. Ferritin is an intracellular protein whose 
primary function is iron storage. When measured independently, levels of serum 
transferrin receptor decrease and levels of ferritin increase with increasing iron 
intake/absorption. When employing the equation developed by Cook et al., however, the 
derived value scales proportionately with increasing/decreasing iron repletion, where 
positive values indicate storage of iron and negative values indicate tissue iron 
deficiency. In order to develop a more complete understanding of the index, the reader is 
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encouraged to visit Appendix 1 for a thorough treatment of FeCOOK and a demonstration 
of the mechanics of the index via eight simulations.  
Contributing to the practical value of the equation, iron repletion can be assessed 
using serum alone, obviating the need for the collection of whole blood. Furthermore, 
since the function is a ratio of two analytes in serum, it is not adversely affected by 
hemoconcentration or hemodilution, as hemoglobin or hematocrit would be. Finally, 
unlike ferritin, the derived value of the function is less altered by chronic inflammation. 
During NHANES data collection, serum ferritin was measured using two 
methods. In 2003, a single-incubation two-site immunoradiometric assay (BioRad 
Laboratories, Hercules, CA) was used. The assay was discontinued by the manufacturer 
in early 2004, so ferritin was measured in 2004– 2010 by the Roche Tina-quant ferritin 
immunoturbidimetric assay on the Hitachi 912 clinical analyzer (Roche Diagnostics, 
Indianapolis, IN) (510), where latex-bound ferritin antibodies react with the antigen in the 
same to form an antigen-antibody complex and this was measured turbidimetrically. 
Because of methodological differences between the BioRad and Roche ferritin assays, 
concentrations obtained for 2003 samples with the BioRad assay were statistically 
adjusted in order to be comparable with those obtained for 2004-2010 samples with the 
Roche assay. This was accomplished before the data release by the National Center for 
Health Statistics NCHS by applying 3 piecewise linear-regression equations described in 
detail elsewhere (510).  
In accordance with the methods of Cogswell et al. (511), I converted the Roche 
sTfR concentrations to those equivalent to the Flowers assay used in the development of 
the body iron model in the original studies. I then applied the same conversion equation 
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in the current study derived from a previous comparison of the 2 assays used by Cogswell 
et al. (511): Flowers sTfR = [1.5(Roche sTfR) + 0.35 mg/L]. I used the original Roche 
ferritin concentrations for the body iron calculation because a previous comparison of the 
Roche assay with the enzyme-linked immunosorbent assay method used by Skikne et al. 
(512) and Cook et al. (50) in the calculation of body iron showed no difference between 
these 2 methods. 
From 2003–2010, hemoglobin and hematocrit were measured as part of a 
complete blood count in the NHANES mobile examination centers with the Beckman 
CoulterMAXM hematology flow cytometer (Beckman Coulter Inc, Fullerton, CA), where 
the lytic reagent used for the complete blood count (CBC) parameters prepares blood so 
that the system can count leukocytes and sense the amount of hemoglobin. The lytic 
reagent rapidly and simultaneously destroys the erythrocytes and converts a substantial 
proportion of the hemoglobin to a stable pigment while it leaves leukocyte nuclei intact. 
The absorbance of the pigment is directly proportional to the hemoglobin concentration 
of the sample. The accuracy of this method equals that of the hemiglobincyanide method, 
the reference method of choice for hemoglobinometry recommended by the International 
Committee for Standardization in Hematology (ICSH). 
Hematocrit was computed as the product of red blood cell count (RBC) and mean 
corpuscular volume (MCV) / 10. Serum iron and unsaturated iron-binding capacity were 
measured at Collaborative Laboratory Services in Ottumwa, Iowa, by the automated 
Beckman LX20 (Beckman Coulter, Fullerton, CA). Total iron-binding capacity (TIBC) 
was calculated indirectly from serum iron and unsaturated iron-binding capacity plus the 
iron concentration. Transferrin saturation (%) was calculated by dividing the 
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concentration of serum iron (μmol/L) by the total iron-binding capacity (μmol/L). Dietary 
and supplemental iron intake was assessed during the in-home interview using a 
standardized 24-hour dietary recall questionnaire.  
Outcome Variables   Insulin resistance in the current work was determined among 
subjects using the homeostasis model assessment (HOMA-IR) developed by Matthews et 
al. in 1985 to describe glucose and insulin homeostasis via a set of mathematically-
derived nonlinear equations (513). The physiological basis for HOMA-IR is encapsulated 
by the relationship between basal concentrations of glucose and insulin which reflect the 
action of a negative feedback-loop between hepatic glucose release and pancreatic beta 
cell activity (513). In this feedback loop, hepatic insulin resistance can be estimated 
based on reduced insulin secretion by beta cells, which leads to increased hepatic glucose 
efflux. The resulting increase in plasma glucose stimulates increased secretion of insulin 
within the portal vein until glucose levels return to normal, thereby completing the 
feedback loop. The basal plasma insulin levels necessary to maintain normal glucose 
levels are directly proportional to the degree of insulin resistance (513). Based upon the 
aforementioned interactions between liver and pancreatic beta cells, Matthews et al. 
developed an approximating equation for insulin resistance, which is derived from the 
use of the insulin-glucose product, divided by a constant, and was calculated as  
𝐻𝑂𝑀𝐴 − 𝐼𝑅 = ⁡⁡ ((𝐹𝑃𝐼⁡𝑥⁡𝐹𝑃𝐺))/22.5 
where FPI fasting plasma insulin concentration (mU/L) and FPG = fasting plasma 
glucose (mmol/L). The product of FPG × FPI provides an index of hepatic insulin 
resistance. The constant of 22.5 is a normalizing factor (i.e., the product of fasting plasma 
insulin of 5 µU/mL and fasting plasma glucose of 4.5 mmol/L is assumed to be typical of 
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a typical healthy individual). HOMA-IR has been validated in several study populations 
to be an accurate, reliable, and non-invasive means with which to determine the presence 
of insulin resistance in humans.  
           In the 2003-2004 NHANES sample, fasting plasma insulin concentration 
(uIU/mL) was measured using the Tosoh AIA-PACK IRI assay (Tosoh Bioscience, 
Prussia, PA), which is a two-site immunoenzymometric assay performed entirely within 
the AIA-PACK. For this assay, insulin present in the test sample was bound with a 
monoclonal antibody which was immobilized on a magnetic solid phase and enzyme-
labeled monoclonal antibody within the AIA-PACK. The magnetic beads were washed to 
remove unbound enzyme-labeled monoclonal antibodies and were then incubated with 
the fluorogenic substrate, 4-methylumbelliferyl phosphate (4MUP). The amount of 
enzyme-labeled monoclonal antibody bound to the beads was directly proportional to the 
IRI concentration in the test sample. For the years spanning 2005-2010, the Merocodia 
Insulin ELISA assay (Mercodia Inc, Winston Salem, NC) was used to measure fasting 
plasma insulin. This assay is a two-site enzyme immunoassay which utilizes the direct 
sandwich technique where two monoclonal antibodies are directed against separate 
antigenic determinants of the insulin molecule. Specimen, control, or standard were 
pipetted into the sample well followed by the addition of peroxidase-conjugated anti-
insulin antibodies. Insulin present in the sample binds to anti-insulin antibodies bound to 
the sample well, while the peroxidase-conjugated anti-insulin antibodies also bind to the 
insulin at the same time. After washing to remove unbound enzyme-labelled antibodies, a 
labelled substrate was added which binds to the conjugated antibodies. Acid was then 
added to the sample well to stop the reaction and the colorimetric endpoint was read on a 
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microplate spectrophotometer set to the appropriate light wavelength. No conversion was 
necessary for entry of insulin into the HOMA-insulin resistance equation, as uIU/mL is 
equivalent to mU/L. 
           Fasting plasma glucose concentration (mmol/L) was determined by a standard 
hexokinase method using the Roche Cobas Mira platform for years 2003-2004, the 
Roche/Hitachi 911 platform for years 2005-2006 and the Roche Modular P chemistry 
analyzer (Roche Diagnostics, Indianapolis, IN) for years 2007-2010, where the enzyme 
catalyzes the reaction between glucose and adenosine triphosphate (ATP) to form 
glucose-6-phosphate (G6P) and adenosine diphosphate (ADP). In the presence of 
nicotinamide adenine dinucleotide (NAD), G-6-P is oxidized by the enzyme glucose-6-
phosphate dehydrogenase (G6PD) to 6-phosphogluconate and reduced nicotinamide 
adenine dinucleotide (NADH). The increase in NADH concentration is directly 
proportional to the glucose concentration and can be measured spectrophotometrically at 
340 nm.  
To determine the presence of non-alcoholic fatty liver disease (NAFLD) among 
subjects, I used the U.S.-Fatty Liver Index (U.S.-FLI) developed by Ruhl et al. in 2015 
which was calculated as 
U.S.-FLI = 𝑒^(−0.8073(𝑁𝐻𝐵) + 0.3458(𝐻) + 0.0093(𝑎𝑔𝑒) + 0.6151(ln(𝐺𝐺𝑇)) +
⁡⁡⁡⁡0.0249(𝑤𝑐) + ⁡1.1792(ln(𝑖𝑛𝑠)) + 0.8242(ln⁡(𝑔𝑙𝑢)) − 14.7812)/(1 + ⁡𝑒^(−0.8073(𝑁𝐻𝐵) +
0.3458(𝐻) + ⁡0.0093(𝑎𝑔𝑒) + 0.6151(ln⁡(𝐺𝐺𝑇)⁡) + 0.0249(𝑤𝑐) + 1.1792(ln(𝑖𝑛𝑠)) +
0.8242(ln⁡(𝑔𝑙𝑢)) − 14.7812)⁡) * 100, 
where NHB = non-Hispanic black ethnicity (i.e., scored as ‘1’ if the participant is of that 
ethnicity, ‘0’ otherwise), H = Hispanic ethnicity (i.e., scored as ‘1’ if the participant is of 
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that ethnicity, ‘0’ otherwise), GGT = gamma-glutamyl transferase (U/L), wc = waist 
circumference (cm), ins = insulin (uIU/mL), glu = glucose (mg/dL). As is evident in the 
equation, the U.S.-FLI is an algorithm based upon demographic measures (i.e., ethnicity, 
age) an anthropomorphic measure (i.e., waist circumference) and analytes obtained from 
serum (i.e., GGT, insulin, glucose). The U.S.-FLI ranges from 0 to 100 (35) and has been 
validated with a sensitivity of 62% and specificity of 88% (PPV = 5.2, NPV = 0.43) when 
using a cut-off of ≥ 30 to define the presence of fatty liver (35). 
Ruhl et al. derived the U.S.-FLI using stepwise regression with backward 
elimination after noting that the development of the fatty liver index (FLI) by Bedogni et 
al. (30) 1) assumed that insulin was not a widely available measurement in population-
based studies, 2) was based upon a homogeneous sample (i.e., the FLI did not account for 
ethnicity) and 3) did not account for age. As previously mentioned, the prevalence of 
NAFLD is associated with insulin resistance, varies across ethnicities and increases with 
age. Thus, an index of fatty liver which incorporates these three factors might be 
considered more reliable in risk stratification. Moreover, the U.S.-FLI incorporates GGT, 
which has been shown in previous research (e.g., used alone or with ALT and AST) to be 
a reliable marker of liver injury. Levels of GGT increase due to excessive alcohol intake, 
hyperlipidemia, obesity, diabetes or when using certain medications (e.g., aspirin, 
phenobarbital, phenytoin, steroids, tamoxifen, tetracycline). GGT is expressed within the 
blood-brain barrier, astrocytes, white blood cells, participates in receptor-ligand 
interactions at cell membranes and concentration of GGT appears to better differentiate 
between alcoholic fatty liver disease and non-alcoholic fatty liver disease compared to 
ALT or AST (514). GGT functions to maintain the available pool of intracellular cysteine 
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by breaking down extracellular glutathione (GSH). Thus, as levels of intracellular 
cysteine diminish due to hepatic injury, concentration of GGT increases to convert 
circulating GSH to its amino acid constituents (i.e., cysteine, glycine, glutamic acid) in 
order to restore the pool of available cysteine. 
From 2003-2006, GGT (U/L) was measured using the Beckman Synchron LX20 
(Beckman Coulter, Fullerton, CA). The LX uses an enzymatic rate method to determine 
the GGT activity in serum or plasma. In the reaction, the GGT catalyzes the transfer of a 
gamma-glutamyl group from the colorless substrate, gamma-glutamyl- p-nitroaniline, to 
an acceptor, glycylglycine where the production of a colored product, p-nitroaniline, 
occurs. The system monitors the rate of change in absorbance at 410 nm over a fixed-
time interval. The rate of change in absorbance is directly proportional to the activity of 
GGT in the sample. From 2007-2010, GGT was measured using the Beckman Synchron 
LX20 and the Beckman Unicel DxC800 Synchron platform (Beckman Coulter, Fullerton, 
CA). The DxC800 uses the same chemistry as the LX20 and measurements appear to 
have been used to cross-validate those obtained from the LX20. 
 In the current work, the presence of hepatic fibrosis was determined using the 
method developed by Angulo et al. in 2007, called the NALFD fibrosis score (NFS). The 
NFS was derived as follows: 
NFS = −1.675⁡ + ⁡0.037(age) + 0.094(BMI) + 1.13(IFG or T2DM) + 0.99(𝐴𝑆𝑇/𝐴𝐿𝑇) – 
0.013(platelets) −0.66(albumin), 
where BMI = body mass index, IFG = impaired fasting glucose (defined as having a 
fasting plasma glucose concentration of ≥ 110 mg/dL and T2DM = type 2 diabetes 
mellitus (i.e., scored as ‘1’ if either condition is present, ‘0’ otherwise)). AST = aspartate 
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aminotransferase (U/L) and ALT = alanine aminotransferase (U/L). Platelets are entered 
into the equation in units of cells per liter (i.e., 1000 cells/uL) and albumin is entered into 
equation as g/dL. According to Augulo et al., advanced fibrosis is defined as having an 
NFS > 0.676 (515). 
During the NHANES mobile examination, unassisted standing height was 
measured in meters as the maximum value recorded by a fixed stadiometer whose inputs 
were sent to a computer for reading and storage. Weight (kg) was measured in a standing 
position by a digital weight scale. Waist circumference was measured in a standing 
position, above the uppermost lateral border of the right ilium to the nearest 0.1 cm using 
a soft tape measure. BMI was calculated after obtaining a subject’s height and weight via 
the following standard equation: (𝑤𝑒𝑖𝑔ℎ𝑡⁡(𝑘𝑔))/(⁡ℎ𝑒𝑖𝑔ℎ𝑡⁡(𝑚)^2) and categorized in 
accordance with the WHO BMI classification scheme (i.e., < 18.5 underweight, 18.5 – 
24.9 normal weight, 25.0 – 29.9 overweight or > 29.9 obese). After resting quietly in a 
sitting position for 5 minutes and determining the maximum inflation level after cuff 
adjustment, three to four systolic and diastolic blood pressure measurements were 
obtained using a mercury sphygmomanometer in accordance with the protocol of the 
American Heart Association. 
From 2003–2010, platelets were measured as part of a complete blood count in 
the mobile examination centers with the Beckman CoulterMAXM hematology flow 
cytometer (Beckman Coulter Inc, Fullerton, CA), where the lytic reagent used for the 
complete blood count (CBC) parameters modifies the blood in a reaction so that the 
system can count platelets based upon the principles of light scattering. Platelets were 
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identified by their size (< 30 FL, low angle light scatter) and refractive index (N = 1.35 to 
N = 1.40 or high angle light scatter. 
The concentration of serum albumin was determined by the Beckman Synchron 
LX20 using a bichromatic digital endpoint method. Briefly, using this method albumin 
combines with Bromcresol Purple (BCP) reagent in a reaction to form a complex which 
absorbs light at 600nm. The system thus monitors the change in absorbance at 600 nm, 
which is directly proportional to the concentration of albumin in the sample. 
From 2003-2006, triglycerides (mg/dL) were measured with the Beckman 
Synchron LX20 (Beckman Coulter, Fullerton, CA), where a timed-endpoint method was 
used to determine the concentration of these esters in serum or plasma. Triglycerides in 
the sample are hydrolyzed to glycerol and free fatty acids by the action of lipase. A 
sequence of three coupled enzymatic steps using glycerol kinase (GK), glycerophosphate 
oxidase (GPO), and horseradish peroxidase (HPO) causes the oxidative coupling of 3,5-
dichloro-2-hydroxybenzenesulfonic acid (DHBS) with 4-aminoantipyrine to form a red 
quinoneimine dye. The system monitors the change in absorbance at 520 nm for a fixed- 
time interval. The change in absorbance is directly proportional to the concentration of 
triglycerides in the sample. From 2007-2010, trigylcerides were also measured using the 
Backman Synchron LX20 and the Beckman Unicel DxC800 Synchron platform 
(Beckman Coulter, Fullerton, CA). The Unicel DxC800 Synchron uses the same 
chemistry as the LX20 and measurements appear to have been used to cross-validate 
those obtained from the LX20. 
HDL cholesterol (mg/dL) was measured using the direct HDL method, where the 
lipoprotein is obtained from serum and quantified via an enzymatic reaction on the 
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Hitachi 912 Analyzer (Roche Diagnostics, Indianapolis, IN). During the assay reaction, 
apolipoprotein B (apoB) containing lipoproteins in the specimen are reacted against a 
blocking reagent which renders them non-reactive with a separate enzymatic cholesterol 
reagent. The apoB containing lipoproteins are thus effectively excluded from the assay 
and only HDL cholesterol is detected at an absorbance of 600nm. 
 From 2003-2010, there were three HbA1c laboratory platforms and two 
laboratories used in NHANES. HbA1c measurement (%) was performed in the first 
laboratory on the Primus CLC330 platform (Primus Diagnostics, Kansas City, MO) 
platform from 2003-2004 and in the second laboratory on the Tosoh A1C 2.2 Plus 
platform (Tosoh Bioscience, Prussia, PA) platform from 2005-2006. From 2007-2010, 
HbA1c measurements were performed in the second laboratory on the Tosoh A1C G7 
platform (Tosoh Bioscience, Prussia, PA). Laboratory method cross-over studies were 
conducted at the time of each of the laboratory instrument changes. Both laboratories 
analyzing NHANES HbA1c data from 2003-2010 were standardized by participating in 
the National Glycohemoglobin Standardization Program (NGSP). 
Covariates   Age (defined continuously and categorically defined as 12-21 years 
of age, 22-31 years of age, 32-41 years of age and > 41 years of age), ethnicity (defined 
as non-Hispanic white, Hispanic and non-Hispanic African American), and education 
(defined as (1) less than high school diploma, (2) high school diploma/GED, (3) some 
college or (4) college degree/post-graduate degree) were obtained during the structured 
in-home interview questionnaire. As mentioned above, anthropomorphic measurements 
were obtained during the mobile examination and body mass index was calculated using 
these measurements. Alcohol intake (defined as the number of drinks per day and 
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categorically defined as 0 drinks/d, 1-3 drinks/d or > 3 drinks/d), smoking status (defined 
as the number of cigarettes smoked per day and categorically defined as 0 cigarettes/d, 1-
5 cigarettes/d or > 5 cigarettes/d) and physical activity (defined as the sum of metabolic 
equivalent scores (METS) and categorically grouped by METS tertiles) were obtained 
using the structured in-home interview questionnaire. Data on dietary recall and food 
frequency was obtained during each participant’s mobile examination and again three to 
ten days later via telephone interview. Age at menarche (defined continuously and 
categorized as < 12 years of age, 12 years of age or > 12 years of age), oral contraceptive 
use (dichotomously defined as YES/NO) and parity (defined as the number of children 
each female has given birth to and categorically defined as 0 children, 1 child, 2-3 
children or > 3 children) was obtained during the in-home interview using a structured 
reproductive history questionnaire. Menopause was defined to align with previous 
literature (Taylor et al. 2014). Briefly, females aged 18 years of age and older were asked 
“Have you had at least one menstrual period in the past 12 months? (Please do not 
include bleedings caused by medical conditions, hormone therapy, or surgeries).” 
Females who answered “no” to this question were subsequently asked “What is the 
reason that you have not had a period in the past 12 months?” Females were classified as 
premenopausal if they answered “yes” to the first question or answered “no” to the first 
question but indicated the reason as pregnancy, breastfeeding, irregular periods or 
medical conditions/treatments. Females were classified as postmenopausal if they 
answered “no” to the first question and indicated the reason to be natural menopause or 
hysterectomy (516).   
125 
 
Summary   In the current analysis, I have examined the effect of age, ethnicity, 
education, body composition, alcohol consumption, smoking history, level of physical 
activity, dietary and supplemental iron intake, promoters and inhibitors of iron 
absorption, age at menarche, oral contraceptive use, parity, menopausal status, length of 
reproductive lifespan and FeCOOK to evaluate their respective impact on metabolic 
dysfunction. 
Variable coding and data analyses 
Descriptive Statistics   Continuous variables (e.g., age, age at menarche, age at 
menopause, length of reproductive lifespan, hemoglobin, hematocrit, serum iron, total 
iron binding capacity, transferrin saturation, dietary iron intake, FeCOOK, fasting plasma 
insulin, fasting plasma glucose, gamma-glutamyl transferase, triglycerides, waist 
circumference, systolic blood pressure, diastolic blood pressure, HDL cholesterol, HbA1c) 
were summarized with standard descriptive statistics including means, medians, standard 
deviations, and ranges. Categorical variables (e.g., ethnicity, education, BMI, alcohol 
consumption, smoking history, oral contraceptive use, parity, menopausal status, FeCOOK 
category, presence/absence of T2DM, presence/absence of metabolic syndrome, U.S.-FLI 
category, HOMA-IR category) were summarized as frequencies and percentages. Ninety-








Categorical Outcomes    
The presence of Type 2 diabetes mellitus (T2DM) was determined using WHO 
guidelines and scored as present (i.e., NO = 0, YES = 1) if any of the following criteria 
are met: fasting glucose ≥ 126 (mg/dL), HbA1c ≥ 6.5 (DCCT%), self-reported diagnosis 
of T2DM, or self-reported use of medications used to treat T2DM. The presence of 
metabolic syndrome (metabolic syndrome) was defined according to the definition set 
forth by ATP III as follows: waist circumference > 35 inches in females, elevated blood 
pressure (diastolic > 85 mmHg & / systolic > 130 mm Hg in females), HDL cholesterol < 
50 mg/dL in females, fasting plasma glucose > 100 mg / dL, and triglycerides > 150 
mg/dL and scored as present (i.e., NO = 0, YES = 1) if three or more of the above criteria 
are met. NAFLD was scored as present (i.e., NO = 0, YES = 1) using the cutoffs 
developed by Ruhl et al. for the U.S.-FLI, where a score ≥30 denotes the presence of 
NAFLD (35). NFS was scored as present (i.e., NO = 0, YES = 1) using the cutoff 
developed by Angulo et al., where a score > 0.676 denotes the presence of advanced 
fibrosis (515). HOMA-IR was modeled by creating the following categories: < 3: normal 
insulin resistance, 3-5: moderate insulin resistance, > 5: severe insulin resistance and 
collapsed into a binary variable and modeled as follows: 0 – 5 normal to moderate insulin 
resistance, > 5 severe insulin resistance. 
 If data for the primary predictor variable (i.e., FeCOOK) or any outcome variables 
with > 2 categories (i.e., NAFLD using U.S.-FLI, insulin resistance using HOMA-IR) 
were too sparse, data from the first two tertiles/categories was collapsed in order to create 
a dichotomous variable (e.g., 1st and 2nd vs. 3rd tertile/category for a given variable). Odds 
of T2DM, metabolic syndrome, NAFLD and/or insulin resistance was determined 
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between FeCOOK groups using the standard formula 𝑂𝑅 =⁡ (𝑎𝑖 ∗ 𝑑𝑖))/(𝑏𝑖 + 𝑑𝑖)), where 
ai is the number of events for subject i in the highest FeCOOK tertile, bi is the number of 
non-events for subject i in the highest FeCOOK tertile, ci is the number of events for 
subject i in the lowest two FeCOOK tertiles, and di is the number of non-events for subject i 
in the lowest two FeCOOK tertiles. 
 Categorical outcomes were analyzed using chi-square tests (e.g., one categorical 
predictor and categorical outcome variable), logistic regression (e.g., one continuous 
predictor variable and one dichotomous outcome variable), or loglinear models (e.g., > 1 
categorical predictor variable and one categorical outcome variable), where appropriate, 
by applying PROC SURVEY procedures to account for the NHANES study design. Point 
estimates (i.e., odds ratios) and ninety-five percent confidence intervals have been 
provided.  
 
Continuous Outcomes    
 U.S.-FLI and HOMA-IR were also modeled as continuous outcomes to examine 
the effect of FeCOOK when the latter is treated as both a continuous and categorical 
predictor. Diagnostics were performed on the data to determine appropriate statistical 
modeling prior to all analyses. When standard modeling assumptions were upheld for 
continuous outcomes and when FeCOOK was treated as a continuous predictor, statistically 
significant associations were determined using linear regression and/or Pearson 
correlation. When standard modeling assumptions were met for continuous outcomes and 
when FeCOOK was treated as a categorical predictor, statistically significant differences in 
outcomes as a function of FeCOOK tertile were evaluated using independent t-tests. 
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Wilcoxon Rank-Sum tests were applied when standard modeling assumptions were not 
met.  
 Power & Sample Size   Given the cross-sectional study design of the current 
secondary analysis, total sample size during continuous NHANES from 2003 to 2010 is 
immutable. Therefore, I calculated the statistical power to detect each outcome, given the 
observed sample size. Power estimates were calculated across varying effect sizes, while 
assuming equal alpha allocation across each of the four metabolic conditions (i.e., p = 
0.05 / 4 = 0.0125) in accordance with the method proposed by Wittes (517).  
Decision Rule   The above experiment-wise alpha allocation does not account for 
multiple testing, thus the Sidak correction (518) was employed using the formula 1 – (1-
α)1/n where n is the number of independent tests (e.g., in the current proposed study, 10 
tests were conducted for each of the four primary hypotheses) and α is the nominal level 
of statistical significance established in the above power and sample size calculations 
(i.e., 0.0125) to control for false positive findings. Thus, the level of statistical 
significance for any finding must fall below p = 0.00125. All data management and data 










Statistical Models (in order of each hypothesis listed in the aims section) 
 
Aims 2A1 – 2A6 & Aims 2B1-2B3 
 
a) 2A1 & 2B1: FeCOOKi = αi + β1iethnicityX1i + εi  
b) 2A2: FeCOOKi = αi + β1ieducationX1i + εi 
c) 2A3: FeCOOKi = αi + β1iBMIX1i + εi 
d) 2A4: FeCOOKi = αi + β1ioral contraceptive useX1i + εi 
e) 2A5: FeCOOKi = αi + β1iage at menopauseX1i + εi 
f) 2B2: FeCOOKi = αi + β1iage at menarcheX1i + εi 
g) 2B3: FeCOOKi = αi + β1iparityX1i + εi    
where α is the model intercept, β1 is the beta coefficient associated with predictor 
variable 1 through n, modeled independently, for subject i and ε is the associated 












Aim 3A.1 insulin resistance: 
 
a) insulin resistancei = αi + β1iFeCOOKX1i + εi   (Basic Model)  
b) insulin resistancei = αi + β1iFeCOOKX1i + β2iageX2i + εi 
c) insulin resistancei = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi 
d) insulin resistancei = αi + β1iFeCOOKX1i + β2educationX2i + εi 
e) insulin resistancei = αi + β1iFeCOOKX1i + β2BMIX2i + εi 
f) insulin resistancei = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi 
g) insulin resistancei = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi 
h) insulin resistancei = αi + β1iFeCOOKX1i + β2parityX2i + εi 
i) insulin resistancei = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi 
j) insulin resistancei = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi 
k) insulin resistancei = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi 
l) insulin resistancei = αi + β1iFeCOOKX1i + β2physical activityX2i + εi 
m) insulin resistancei = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi 
n) insulin resistancei = αi + FeCOOK + age + ethnicity + BMI + alcohol 
consumption + smoking history + physical activity level + eFe + iFe + C-
reactive protein + εi, where eFe = enhancers of iron absorption and iFe = 







Aim 3A.2 non-alcoholic fatty liver disease: 
 
a) logit(NAFLD)i = αi + β1iFeCOOKX1i + εi    (Basic Model)  
b) logit(NAFLD)i = αi+ β1iFeCOOKX1i + β2iageX2i + εi 
c) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi 
d) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2educationX2i + εi 
e) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2BMIX2i + εi 
f) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi 
g) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi 
h) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2parityX2i + εi 
i) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi 
j) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi 
k) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi 
l) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2physical activityX2i + εi 
m) logit(NAFLD)i = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi 
n) logit(NAFLD)i = αi + FeCOOK + age + ethnicity + BMI + alcohol consumption + 
smoking history + physical activity level + eFe + iFe + C-reactive protein + εi, 
where eFe = enhancers of iron absorption and iFe = inhibitors of iron absorption.  







Aim 3A.3 metabolic syndrome: 
 
a) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + εi   (Basic Model)  
b) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2iageX2i + εi 
c) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi 
d) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2educationX2i + εi 
e) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2BMIX2i + εi 
f) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi 
g) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi 
h) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2parityX2i + εi 
i) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi 
j) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi 
k) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi\ 
l) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2physical activityX2i + εi 
m) logit(metabolic syndrome)i = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi 
n) logit(metabolic syndrome)i = αi + FeCOOK + age + ethnicity + BMI + alcohol 
consumption + smoking history + physical activity level + eFe + iFe + C-reactive 
protein + εi, where eFe = enhancers of iron absorption and iFe = inhibitors of iron 







Aim 3A.4 Type 2 diabetes mellitus: 
 
a) logit(T2DM)i  = αi + β1iFeCOOKX1i + εi    (Basic Model)  
b) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2iageX2i + εi 
c) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2ethnicity X2i + εi 
d) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2educationX2i + εi 
e) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2BMIX2i + εi 
f) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2age at menarcheX2i + εi 
g) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2oral contraceptive useX2i + εi 
h) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2parityX2i + εi 
i) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2age at menopauseX2i + εi 
j) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2alcohol consumptionX2i + εi 
k) logit(T2DM)i  = αi + β1iFeCOOKX1i + β2smoking historyX2i + εi 
l) logit(T2DM)i   = αi + β1iFeCOOKX1i + β2physical activityX2i + εi 
m) logit(T2DM)i   = αi + β1iFeCOOKX1i + β2C-reactive proteinX2i + εi 
n) logit(T2DM)i   = αi + FeCOOK + age + ethnicity + BMI + alcohol consumption + 
smoking history + physical activity level + eFe + iFe + C-reactive protein + εi, 
where eFe = enhancers of iron absorption and iFe = inhibitors of iron absorption.  





















Dashed arrow indicates hypothesized mediation. Bolded arrows identify hypotheses tested in proposed statistical models.
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Age at menarche (+) 
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CHAPTER 6: RESULTS  
 
Data from 14,895 females aged 12 years and older during the years 2003-2010 
were available for analysis in current study. After excluding females on the basis of 
probable hemochromatosis (i.e., serum iron > 175 μg/dL, serum ferritin > 200 μg/L, and 
transferrin saturation > 60%) (N = 304), who reported hepatitis C infection (N = 328) or 
who reported being pregnant (N = 695), a total of 13,568 remained eligible for inclusion 
from the initial pool of participants. Of these eligible females, 7,461 had complete data 
that could be used for the calculation of iron repletion (i.e., FeCOOK) (Figure 1).     
Demographics   The mean age of females in this sample was 27.21 years (sd = 
11.64, range: 12 – 49). White females comprised the largest proportion of the sample 
population (42.65%, N = 3182), followed by Hispanic (32.30%, N = 2,432) and black 
females (24.76%, N = 1,846) (Table 1). Roughly half of the sample population (52.97%) 
reported having less than a high school education, 13.22% reported having a high school 
diploma/GED equivalent, and 13.34% reported having a college or post-graduate degree. 
Four females refused to provide information regarding education (Table 1). When 
education was stratified by ethnicity, a greater percentage of white females reported 
having a college or post-graduate degree compared to black or Hispanic females (68.1% 




The average height in the sample population was 161.48 cm (sd = 7.03 cm, range: 
132.9 – 194.2 cm). White females tended to be slightly taller than Hispanic and black 
females (ẍ = 163.48 cm, sd = 6.68 cm vs 158.03 cm, sd = 6.37 cm and 162.60 cm, sd = 
6.75 cm, respectively). The average weight for females in the current sample was 71.01 
kg (sd = 20.97 kg: range 24.0-211.7 kg). Black females tended to weigh more than white 
or Hispanic females (ẍ = 76.37 kg, sd = 24.19 kg vs 70.57 kg, sd = 20.42 kg and 67.53 
kg, sd; = 18.05 kg, respectively). The average waist circumference for participants was 
89.33 cm (sd = 16.85, range: 55.0 - 176.7 cm). Black females tended to have larger waist 
circumferences than white or Hispanic females (ẍ = 90.74 cm, sd = 19.20 cm vs 88.67 
cm, sd = 16.67 cm and 88.14 cm, sd = 15.05 cm, respectively. The mean BMI for females 
in the sample population was 27.14 (sd = 7.47, range: 13.59 – 84.87). Most females had a 
BMI between 18.5 and 24.9 (41.21%), followed by 29.45% having a BMI > 29.9, 
23.88% having a BMI between 25.0 and 29.9 and 5.46% having a BMI < 18.5 (Table 1). 
On average, white females had a lower BMI (ẍ = 26.34, sd = 7.20) than Hispanic females 
(ẍ = 26.97, sd = 6.70) and black females (ẍ = 28.77, sd = 8.56). Moreover, when 
collapsing the lowest two WHO BMI categories and collapsing the highest two WHO 
BMI categories to create a dichotomous BMI variable (e.g., underweight to normal 
weight vs. overweight to obese), a greater proportion of white females were categorized 
in the former group compared to the latter (53.12% vs. 46.88%). This pattern reversed for 
Hispanic females (44.02% vs. 55.98%) and was more pronounced for black females 
(39.04% vs. 60.96%). When BMI was further stratified by ethnicity, more white females 
had a BMI < 18.5 or between 18.5 and 24.9 than Hispanic or black females (47.64% vs. 




females had similar proportions of BMIs between 25.0 and 29.9 (38.84% and 37.25%, 
respectively), while the proportion of black females in this BMI range was smaller 
(23.91%). More white females than Hispanic or black females had a BMI > 29.9 (36.42% 
vs. 31.86% and 31.72%, respectively). As mentioned, however, white females tended to 
have lower BMIs than Hispanic or black females. 
Among females who reported drinking alcoholic beverages, the average number 
of drinks consumed per day was 0.97 (sd = 1.75). The greatest proportion of females 
(62.14%) reported that they did not drink alcoholic beverages, while 30.29% reporting 
consuming between 1 to 3 drinks per day and 7.57% reported consuming greater than 3 
alcoholic beverages a day (Table 1). When alcohol consumption was stratified by 
ethnicity, a greater proportion of white and Hispanic than black females (35.47% and 
36.07% vs. 28.46%), reported abstinence from drinking among those in this respondent 
category. Among those who did report consuming alcohol, a greater proportion of white 
females (54.46%) reported drinking than Hispanic (26.84%) or black females (18.70%). 
When categorized further (i.e., 1 – 3 drinks/d vs > 3 drinks/d), a greater proportion of 
white females (54.09%) than Hispanic (25.23%) or black females (20.67%) reported 
alcohol consumption in this respondent category. Similar patterns were observed for 
females reporting to drink greater than 3 alcoholic beverages a day, where a greater 
proportion of white females than Hispanic or black females reported alcohol consumption 
in this respondent category (55.93% vs 33.27% and 10.80%, respectively).  
Among females who reported smoking cigarettes, the average number of 
cigarettes smoked per day was 1.92 (sd = 5.87). Similar to the overall pattern observed 




remaining 6.78% of females reported smoking 1 – 5 cigarettes per day and 10.93% of 
females reported smoking > 5 cigarettes per day. When smoking was stratified by 
ethnicity, a greater proportion of white and Hispanic than black females (38.51% and 
35.39% vs. 26.10%), reported not smoking among respondents in this category. Among 
those who smoked, a greater proportion of white females (61.92%) reported smoking 
than Hispanic (19.53%) or black females (18.55%). When categorized further (i.e., 1 – 5 
vs > 5 cigarettes/d), a greater proportion of white females reported smoking 1 – 5 
cigarettes per day compared to Hispanic or black females (41.70% compared to 36.56% 
and 21.74%, respectively). Similar patterns were observed for females in the highest 
smoking category, where a greater proportion of white females (74.48%) reported 
smoking > 5 cigarettes per day compared to Hispanic females (8.96%) and black females 
(16.56%).   
The average METS score in the current sample was 9.97 (sd = 9.24). On average, 
white females were more active than black and Hispanic females: ẍ = 10.17 (sd = 9.15) 
for white females, ẍ = 9.73 (sd = 8.48) for black females and ẍ = 9.29 (sd = 8.49) for 
Hispanic females. When METS scores were grouped into tertiles, a greater proportion of 
white females were in the highest tertile of METS scores compared to black and Hispanic 
females (38.30%, compared to 30.40% and 26.69%, respectively, P < 0.0001). 
Females in the current sample reported a mean dietary intake of 13.93 mg/day (sd 
= 11.69 mg/day). When stratified by ethnicity, white females reported higher intakes of 
dietary iron than Hispanic and black females: ẍ = 14.06 (sd = 10.35), ẍ = 13.88 (sd = 
13.51) and ẍ = 13.28 (sd = 10.03), respectively), which was not statistically significant (P 




supplements (35.74% (95%CI: 32.23-39.25). When iron supplement use was stratified by 
ethnicity, a greater proportion of black females compared to Hispanic and white females 
reported using iron supplements (40.46% compared to 38.09% and 34.42%, P = 0.17).  In 
terms of dietary composition (i.e., USDA food groups), most of the total iron intake 
among all females was obtained from grains and meats: 57.16% and 16.98%, respectively 
for white females, 58.03% and 17.87% for Hispanic females and 52.66% and 22.98% for 
black females. Taken together, black females obtained more of their total daily iron 
intake from grains and meats compared to their white and Hispanic counterparts (Figure 
2).  
For convenience, dietary intakes, supplement intakes and dietary composition of 
foodstuffs considered as covariates in the current work are summarized below in terms of 
their effect on iron absorption (i.e., enhancers and inhibitors of iron absorption).  
Promoters of iron absorption   The average intake of saturated fats among 
females in the current sample was 22.56 g/d (sd = 19.06 g/d). White females reported 
higher intakes of saturated fats than black and Hispanic females: 23.09 g/d (sd = 16.06 
g/d), 22.63 g/d (sd = 16.09 g/d) and 20.11 g/d (sd = 17.12 g/d), respectively, a small 
fraction of which was obtained from supplements containing saturated fats. Only 3.04% 
of white females reported taking supplements containing saturated fats, followed by 
Hispanic females and black females (2.39% and 1.54%, respectively, P = 0.20). Overall, 
most saturated fats were obtained from milk and milk products, meat, poultry and fish 
and grains. The distribution across ethnicities, however, differed. For instance, among 
white females, the dietary composition of saturated fats obtained from each of the 




females, the dietary composition of saturated fats obtained from each food group was 
25.88%, 23.18% and 29.49%. Among black females, the dietary composition of saturated 
fats obtained from each food group was 18.76%, 31.06% and 27.76%. Taken together, 
black females obtained less saturated fats from milk and milk products and more 
saturated fats from meats compared to their white and Hispanic counterparts (Figure 3). 
The average intake of carbohydrates/sugars among females in the current sample 
was 228.42 g/day (sd = 124.63). Overall, black females reported higher intakes of 
carbohydrates/sugars than Hispanic and white females: 234.11 g/d (sd = 143.04 g/d), 
229.99 g/d (sd = 154.44 g/d) and 227.01 g/d (sd = 106.70 g/d), respectively, a small 
fraction of which was obtained from supplements containing carbohydrates/sugars. 
Stratified by ethnicity, 16.67% of white females reported taking supplements containing 
carbohydrates/sugars, followed by black females and Hispanic females (10.25% and 
8.82%, respectively, P = 0.002). Overall, most carbohydrates/sugars were obtained from 
grains and sugar/sweeteners/beverages. As with saturated fats, the dietary 
composition/distribution of carbohydrates/sugar dietary differed across ethnicities. For 
instance, among white females, the dietary composition of carbohydrates/sugars obtained 
from each of the aforementioned USDA food groups was 42.94% and 24.78%. Among 
Hispanic females, the dietary composition of carbohydrates/sugars obtained from each 
food group was 44.14% and 24.20%. Among black females, the dietary composition of 
carbohydrates/sugars obtained from each food group was 37.50% and 31.59%. Taken 
together, black females obtained fewer carbohydrates/sugars from grains and more 
carbohydrates/sugars from sugar/sweeteners/beverages compared to their white and 




The average vitamin C intake among females in the current sample was 79.07 
mg/day (sd = 126.84 mg/d). Hispanic females reported higher intakes of vitamin C than 
black and white females: 95.99 mg/d (sd = 118.23 mg/d), 91.20 mg/d (sd = 124.62 mg/d) 
and 73.07 mg/d (sd = 102.58 mg/d), respectively, a substantial fraction of which was 
obtained from supplements containing vitamin C. When stratified by ethnicity, 48.43% of 
Hispanic females reported taking supplements containing vitamin C, followed by black 
and white females (46.17% and 44.42%, respectively, P = 0.39). Overall, most vitamin C 
was obtained from fruits, vegetables and sugar/sweeteners/beverages. The 
composition/distribution across ethnicities differed for vitamin C as well. For instance, 
among white females, the dietary composition of vitamin C obtained from each of the 
aforementioned USDA food groups was 39.82%, 26.06% and 15.95%. Among Hispanic 
females, the dietary composition of saturated fats obtained from each food group was 
45.80%, 19.11% and 19.96%. Among black females, the dietary composition of vitamin 
C obtained from each food group was 43.23%, 15.36% and 32.43%. Taken together, 
black females obtained more vitamin C from sugar/sweeteners/beverages than their white 
and Hispanic counterparts and white females obtained less vitamin C from fruits and 
more vitamin C from vegetables from their Hispanic and black counterparts (Figure 5).  
Inhibitors of iron absorption   The average intake of fiber among females in the 
current sample was 14 g/d (sd = 13.74 g/d). Hispanic females reported higher intakes of 
fiber than white and black females: 15.04 g/d (sd = 12.69 g/d), 14.18 g/d (sd = 13.09 g/d) 
and 11.79 g/d (sd = 9.75 g/d), respectively, a small fraction of which was obtained from 
supplements containing fiber. Only 3.09% of white females reported taking supplements 




respectively, P = 0.45). Overall, most fiber was obtained from grains, fruits and 
vegetables. The distribution across ethnicities, however, differed. For instance, among 
white females, the dietary composition of fiber obtained from each of the aforementioned 
USDA food groups was 46.28%, 11.45% and 20.92%. Among Hispanic females, the 
dietary composition of fiber obtained from each food group was 46.81%, 15.18% and 
15.96%. Among black females, the dietary composition of fiber obtained from each food 
group was 43.95%, 10.76% and 23.75%. Taken together, black females obtained less 
fiber from grains and more fiber from vegetables compared to their white and Hispanic 
counterparts (Figure 6). 
The average intake of calcium among females in the current sample was 860.46 
mg/d (sd = 778.17 mg/d). White females reported higher intakes of calcium than 
Hispanic and black females: 890.88 mg/d (sd = 675.16 mg/d), 832.74 mg/d (sd = 767.09 
mg/d) and 729.08 mg/d (sd = 497.14 mg/d), respectively, a substantial fraction of which 
was obtained from supplements containing calcium. When stratified by ethnicity, 57.04% 
of Hispanic females reported taking supplements containing calcium, followed by white 
females and black females (52.53% and 49.18%, respectively, P = 0.32). Overall, most 
calcium was obtained from milk and milk products, grains, sugar/sweeteners/beverages, 
meat and fruits. The composition/distribution of calcium differed across ethnicities as 
well. For instance, among white females, the dietary composition of calcium obtained 
from each of the aforementioned USDA food groups was 41.76%, 27.73%, 11.42%, 
6.48% and 3.61%. Among Hispanic females, the dietary composition of calcium obtained 
from each food group was 37.21%, 28.30%, 12.13%, 6.48% and 7.13%. Among black 




30.65%, 12.81%, 10.84% and 7.07%. Taken together, black females obtained less 
calcium from milk and milk products and more calcium from meats compared to their 
white and Hispanic counterparts (Figure 7). 
The average intake of magnesium among females in the current sample was 
247.79 mg/d (sd = 216.12 mg/d). White females reported higher intakes of magnesium 
than Hispanic and black females: 254.67 mg/d (sd = 203.46 mg/d), 246.08 mg/d (sd = 
165.71 mg/d) and 212.61 mg/d (sd = 117.10 mg/d), respectively, a moderate fraction of 
which was obtained from supplements containing magnesium. When stratified by 
ethnicity, 38.92% of Hispanic females reported taking supplements containing 
magnesium, followed by white and black females (37.35% and 34.37%, respectively, P = 
0.71). Overall, most magnesium was obtained from grains, meats and milk/milk products. 
The distribution across ethnicities, however, differed. For instance, among white females, 
the dietary composition of magnesium obtained from each of the aforementioned USDA 
food groups was 30.27%, 13.18% and 13.18%. Among Hispanic females, the dietary 
composition of magnesium obtained from each food group was 34.35%, 15.15% and 
10.57%. Among black females, the dietary composition of magnesium obtained from 
each food group was 29.54%, 18.86% and 8.11%. Taken together, white females 
obtained most of their magnesium from milk/milk products, Hispanic females obtained 
most of their magnesium from grains and black females obtained most of their 
magnesium from meat (Figure 8). 
The average vitamin D intake among females in the current sample was 4.35 µg/d 
(sd = 5.59 µg/d). White females reported higher intakes of vitamin D than Hispanic and 




2.89 µg/d), respectively, a moderate fraction of which was obtained from supplements 
containing vitamin D. When stratified by ethnicity, 48.92% of black females reported 
taking supplements containing vitamin D, followed by Hispanic and white females 
(48.13% and 43.18%, respectively, P = 0.09). Overall, most vitamin D was obtained from 
milk/milk products, meat, grains and eggs. As with the above patterns, the 
composition/distribution of vitamin D in the diet differed across ethnicities as well. For 
instance, among white females, the dietary composition of vitamin D obtained from each 
of the aforementioned USDA food groups was 51.52%, 17.98%, 14.18% and 6.16%. 
Among Hispanic females, the dietary composition of vitamin D obtained from each food 
group was 47.43%, 18.46%, 11.95% and 9.39%. Among black females, the dietary 
composition of vitamin D obtained from each food group was 37.48%, 26.19%, 16.23% 
and 8.31%. Taken together, white females obtained most of their vitamin D from 
milk/milk products, Hispanic females obtained most of their vitamin D from eggs and 
black females obtained most of their vitamin D from meat and grains (Figure 9). 
The average vitamin E intake among females in the current sample was 6.51 mg/d 
(sd = 8.96 mg/d). White females reported higher intakes of vitamin E than black and 
Hispanic females: 6.74 mg/d (sd = 8.27 mg/d), 5.99 mg/d (sd = 4.05 mg/d) and 5.89 mg/d 
(sd = 5.97 mg/d). Overall, most vitamin E was obtained from grains, vegetables, meat, 
legumes/seeds and milk/milk products. The distribution across ethnicities, however, 
differed. For instance, among white females, the dietary composition of vitamin E 
obtained from each of the aforementioned USDA food groups was 32.67%, 15.97%, 
11.97%, 12.82% and 6.19%. Among Hispanic females, the dietary composition of 




3.43%. Among black females, the dietary composition of vitamin E obtained from each 
food group was 31.10%, 20.69%, 16.81%, 8.13% and 3.05%. Taken together, white 
females obtained most of their vitamin E from milk/milk products, legumes, nuts and 
seeds, Hispanic females obtained most of their vitamin E from grains and black females 
obtained most of their vitamin E from meat and vegetables (Figure 10). 
The average zinc intake among females in the current sample was 10.17 mg/d (sd 
= 8.74 mg/d). White females reported higher intakes of zinc than Hispanic and black 
females: 10.32 mg/d (sd = 6.17 mg/d), 9.96 mg/d (sd = 12.41 mg/d) and 9.62 mg/d (sd = 
8.84 mg/d), respectively, a moderate fraction of which was obtained from supplements 
containing zinc. When stratified by ethnicity, 40.12% of Hispanic and black females 
reported taking supplements containing zinc, followed by white females (37.56%, P = 
0.59).  Overall, most zinc was obtained from meat, grains and milk/milk products. The 
distribution/composition of zinc, however, differed across ethnicities. For instance, 
among white females, the dietary composition of zinc obtained from each of the 
aforementioned USDA food groups was 32.14%, 33.87%, and 15.90%. Among Hispanic 
females, the dietary composition of zinc obtained from each food group was 36.14%, 
33.75% and 13.07%. Among black females, the dietary composition of zinc obtained 
from each food group was 43.53%, 29.16% and 8.81%. Taken together, white females 
obtained most of their zinc from milk/milk products and grains compared to their 
Hispanic and black counterparts who obtained most of their zinc from meat (Figure 11).  
Reproductive Lifespan   The mean age of menarche among the current sample 
population was 12.36 years (sd = 1.61, range: 7 – 19) (Table 1). Menarche occurred 




= 12.62). When age at menarche was categorized as < 12 years of age, 12 years old, or > 
12 years of age, 27.75% of the sample population reported experiencing menarche at < 12 
years of age, 28.33% reported experiencing menarche at age 12 and 43.92% reported 
experiencing menarche > 12 years of age (Table 1). When stratified by ethnicity, 35.08% 
of white females, 34.91% of Hispanic females and 30.01% of black females reported 
experiencing menarche at < 12 years of age in this respondent category. Among those 
who reported experiencing menarche at 12 years of age, a greater proportion of white 
females (42.36%) than Hispanic or black females (33.17% and 24.47%, respectively) 
reported experiencing menarche in this respondent category. Similar patterns were 
observed among those reporting experiencing menarche > 12 years of age, where a 
greater proportion of white females than Hispanic or black females (48.99% vs. 30.42% 
and 20.59%, respectively) reported experiencing menarche in this group of respondents. 
Roughly half of the sample population reported having ever used oral 
contraceptives (53.11%) (Table 2) and the mean age of oral contraceptive users was 
33.07 (sd = 9.94). When stratified by ethnicity, more white females than Hispanic or 
black females reported ever having used oral contraceptive (53.50% vs. 25.14% and 
21.36%, respectively). Most of the females in the current sample were nulliparous 
(49.51%). Among those females reporting being pregnant at least one time, the average 
number of pregnancies was 2.98 (sd = 1.93, range: 1 – 34). When the response was 
categorized as 1 child, 2 to 3 children, or > 3 children, 10.02% of females reported having 
a single child, 24.92% reported having between 2 to 3 children, and 15.55% reported 
having > 3 children. When this variable was stratified by ethnicity, a greater proportion of 




respondent category (48.85% vs. 30.53% and 20.61%, respectively). Similarly, a greater 
proportion of white females than Hispanic or black females reported having 2 to 3 
children in this respondent category (47.05% vs. 31.51% and 21.44%, respectively). A 
similar pattern was observed in the final respondent category, where a greater proportion 
of white females reported having > 3 children than Hispanic or black females (39.67% vs. 
34.94% and 25.39%, respectively). The mean age of menopause in the sample population 
was 43.94 (sd = 4.80, range: 20 – 49) (Table 2). This variable was then categorized in 
accordance with common definitions for premature menopause (i.e., < 40 years of age), 
early menopause (i.e., between 40 and 45 years of age) and natural menopause (> 45 
years of age) (Shuster et al.). Grouped in this manner, 16.99%, 35.38% and 47.63% of 
females in the sample experienced premature menopause, early menopause and natural 
menopause, respectively (Table 2). When stratified by ethnicity, a greater proportion of 
white females than Hispanic or black females reported experiencing premature 
menopause (68.85% compared to 16.39% and 14.75%, respectively). Similarly, a greater 
proportion of white females than Hispanic or black females reported experiencing early 
menopause (51.97% compared to 22.05 and 25.98%, respectively). The same pattern held 
for natural menopause, where a greater proportion of white females reported experiencing 
menopause naturally (53.80%), followed by black females (25.15%) and Hispanic 
females (21.05%). The average length of the reproductive lifespan among females in this 
sample was 27.55 years (sd=51.10). When stratified by ethnicity, black females had the 
longest reproductive lifespan (36.94 years, sd = 10.17), followed by Hispanic females 




Iron parameters   Mean hemoglobin (Hb) concentration among the sample 
population was 13.44 g/dL (sd = 2.96 g/dL) (Table 3). When stratified by ethnicity, white 
females had the highest Hb concentration (ẍ = 13.64 g/dL, sd = 2.19 g/dL), followed by 
Hispanic females (ẍ = 13.26 g/dL, sd = 1.90 g/dL) and black females (ẍ = 12.61 g/dL, sd 
= 1.23 g/dL). Ethnicity explained ~ 10% of the variation in Hb concentration in the 
current sample (r-squared = 0.09, P < 0.0001). Mean hematocrit (Hct) among the sample 
population was 39.39% (sd = 9.09%) (Table 2). When stratified by ethnicity, white 
females had the highest Hct (ẍ = 39.83%, sd = 7.36%), followed by Hispanic females (ẍ 
= 38.89%, sd = 5.99%) and black females (ẍ = 37.62%, sd = 4.35%). Ethnicity explained 
~ 6% of the variation in Hct concentration in the current sample (r-squared = 0.06, P < 
0.0001). Mean serum iron concentration (μg/dL) among the sample population was 77.42 
μg/dL (sd = 48.74 μg/dL) (Table 2). When stratified by ethnicity, white females had the 
highest serum iron concentration (ẍ = 80.32 μg/dL, sd = 45.25 μg/dL), followed by 
Hispanic females (ẍ = 73.58 μg/dL, sd = 42.65 μg/dL) and black females (ẍ = 66.61 
μg/dL, sd = 25.65 μg/dL). Ethnicity explained ~ 2% of the variation in serum iron 
concentration in the current sample (r-squared = 0.02, P < 0.0001). Mean total iron 
binding capacity (TIBC) among the sample population was 365.02 μg/dL (sd = 102.28 
μg/dL) (Table 2). When stratified by ethnicity, Hispanic females had the highest TIBC 
concentration (ẍ = 371.13 μg/dL, sd = 76.10 μg/dL), followed by white females (ẍ = 
364.26 μg/dL, sd = 83.02 μg/dL) and black females (ẍ = 362.60 μg/dL, sd = 58.86 
μg/dL). Ethnicity explained < 1% of the variation in TIBC concentration in the current 
sample (r-squared = 0.002, P = 0.52). Mean transferrin saturation (TSAT) among the 




white females had the highest TSAT (ẍ = 22.64%, sd = 13.29%) followed by Hispanic 
females (ẍ = 20.45%, sd = 13.63%) and black females (ẍ = 19.13%, sd = 8.73%). 
Ethnicity explained ~ 1% of the variation in TSAT concentration in the current sample (r-
squared = 0.01, P = 0.0007). Mean serum transferrin receptor (sTfR) concentration 
(mg/L) among the sample population was 3.59 mg/L (sd = 2.47 mg/L) (Table 2). When 
stratified by ethnicity, black females had the highest sTfR concentration (ẍ = 4.48 mg/L, 
sd = 3.23 mg/L), followed by Hispanic females (ẍ = 3.63 mg/L, sd = 2.37 mg/L) and 
white females (ẍ = 3.41 mg/L, sd = 1.97 mg/L). Ethnicity explained ~ 4% of the variation 
in sTfR concentration in the current sample (r-squared = 0.04, P = 0.002). Mean ferritin 
concentration (μg/L) among the sample population was 47.94 μg/L (sd = 47.47 μg/L) 
(Table 2). When stratified by ethnicity, white females had the highest ferritin 
concentration (ẍ = 49.22 μg/L, sd = 39.03 μg/L), followed by black females (ẍ = 46.95 
μg/L, sd = 41.81 μg/L) and Hispanic females (ẍ = 43.07 μg/L, sd = 59.51 μg/L). Ethnicity 
explained < 1% of the variation in serum ferritin concentration in the current sample (r-
squared = 0.004, P = 0.08). 
Total Body Iron and Demographics   Mean iron stores via Cook’s iron repletion 
index (i.e., FeCOOK) in the sample were 6.98 mg/kg (sd = 4.82 mg/kg) (Table 3). White 
females were more iron replete (FeCOOK ẍ = 7.27 mg/kg, sd = 4.28 mg/kg), followed by 
Hispanic females (FeCOOK ẍ = 6.52 mg/kg, sd = 6.81 mg/kg), and black females (FeCOOK 
ẍ = 5.95 mg/kg, sd = 4.24 mg/kg) (P < 0.0001, Figure 12). Ethnicity explained ~ 2% of 
the variation in FeCOOK concentration in the current sample (r-squared = 0.02, P < 
0.0001). FeCOOK was linearly related to age, where FeCOOK increased 0.03 mg/kg with 




by ethnicity, where FeCOOK increased 0.03 mg/kg in white females (P < 0.0001), 0.02 
mg/kg for Hispanic females (P = 0.03) and 0.02 mg/kg in black females (P = 0.06) with 
each increasing year of age. Similar patterns were observed when age was treated as a 
categorical variable, where FeCOOK increased across age categories. FeCOOK increased 
from 6.32 mg/kg among those in the 12-21 year-old age group to 7.21 mg/kg among 
those in the 22-31 year-old age group, decreased slightly among those in the 32-41 year-
old age group to 7.10 mg/kg and increased again among those in the > 41 year-old age 
group (FeCOOK ẍ = 7.32 mg/kg) (P < 0.0001, Figure 13). The same trend appeared when 
stratified by ethnicity, where FeCOOK increased across the first two age categories (i.e., 
12-21y and 22-31y), decreased in the third age category (i.e., 32-41y) and increased again 
in the highest age category (> 41 years of age) for white and Hispanic females and 
increased monotonically across age groups in black females (Figure 14).  
Mean FeCOOK increased with increasing education, where females in the highest 
category of education had higher FeCOOK (ẍ = 6.48 among those with less than a high 
school education, ẍ = 7.08 among those with a high school education/GED, ẍ = 7.21 
among those with some college and ẍ = 7.38 among those with a college degree/post-
graduate education) (P < 0.0001, Figure 15). This trend diverged slightly when stratifying 
by ethnicity (Figure 16). FeCOOK increased across the lowest two categories of education, 
decreased slightly in the third category of educational attainment and increased again in 
the highest category for white females (ẍ = 6.73, ẍ = 7.48, ẍ = 7.43, ẍ = 7.57, P < 
0.0001). For Hispanic females FeCOOK increased across the first three categories of 
educational attainment and decreased in the highest category (ẍ = 6.23, ẍ = 6.72, ẍ = 




decreased from the lowest category of educational attainment to the second category, 
increased significantly among females in the third category and decreased again among 
females in the highest category of educational attainment (ẍ = 5.88, ẍ = 5.45, ẍ = 6.35, ẍ 
= 5.86, P = 0.05). 
FeCOOK was inversely associated with height (b1 = -0.03, t = -1.23, P = 0.22). 
When stratified by ethnicity, this effect was more pronounced in white and black females 
compared to Hispanic females (b1 = -0.06 mg/kg, t = -2.16, P = 0.03 for white females, 
b1 = -0.05 mg/kg, t = -1.06, P = 0.29 for black females and b1 = -0.03, t = -0.86, P = 0.39 
for Hispanic females). When height and FeCOOK were categorized according to tertiles, 
the same pattern emerged where increasing height was associated with decreasing FeCOOK 
(Ptrend = 0.01) and the trend persisted after stratifying by ethnicity, where taller females 
within each ethnicity had lower FeCOOK than shorter females. 
FeCOOK was linearly associated with weight and waist circumference, where 
FeCOOK increased 0.009 mg/kg in with each increasing kilogram of weight (P < 0.0001) 
and 0.01 mg/kg for each increasing centimeter of waist circumference (P < 0.0001). 
FeCOOK was linearly related to BMI, where FeCOOK increased 0.01 mg/kg with each 
increasing unit of BMI (P = 0.05). When BMI was categorized in accordance with the 
risk-based strata developed by the WHO, a similar pattern was observed. However, the 
linear trend was no longer statistically significant (P = 0.19, Figure 17).  
FeCOOK was linearly related to alcohol consumption, where FeCOOK increased 0.23 
mg/kg with each increasing unit of self-reported daily alcohol intake (P < 0.0001). The 
same trend was observed after stratifying by ethnicity, though the magnitude of the 




0.23 mg/kg, P < 0.0001) vs 0.20 mg/kg (P = 0.01) and 0.13mg/kg (P = 0.02), 
respectively, for each unit of increasing alcohol intake. When alcohol intake was 
categorized into three groups (i.e., 0 drinks/d, 1-3 drinks/d or > 3 drinks/d), a similar 
pattern emerged where FeCOOK increased 0.68 mg/kg with each increasing category (P < 
0.0001, Figure 18).  Again, the same trend was observed after stratifying by ethnicity, 
where the magnitude of the association was greater for white females compared to black 
and Hispanic females (b1 = 0.68 mg/kg, P < 0.0001) vs 0.37 mg/kg (P = 0.08) and 0.40 
mg/kg (P = 0.01), respectively, for each increasing category of alcohol intake (Figure 
19).  
FeCOOK was positively associated with smoking, where FeCOOK increased 0.05 
mg/kg with each increasing cigarette (P < 0.0001). The same trend was observed after 
stratifying by ethnicity, though the magnitude of the association was greater for white 
females compared to black and Hispanic females (b1 = 0.04 mg/kg, P < 0.0001) vs 0.01 
mg/kg (P = 0.76) and 0.02 mg/kg (P = 0.63), respectively, for each cigarette smoked. 
When cigarette smoking was categorized into two groups (i.e., non-smokers vs smokers), 
a similar pattern emerged where FeCOOK was 0.86 mg/kg higher among smokers 
compared to non-smokers (P < 0.0001, Figure 20).  Again, the same trend was observed 
after stratifying by ethnicity, where the magnitude of the association was greater for 
white females compared to black and Hispanic females (b1 = 0.81 mg/kg, P < 0.0001) vs 
0.79 mg/kg (P = 0.02) and 0.49 mg/kg (P = 0.13), respectively, comparing FeCOOK of 
smokers to that of non-smokers (Figure 21). When cigarette smoking was categorized 
into three groups (i.e., 0 cigarettes/d, 1-5 cigarettes/d or > 5 cigarettes/d), the same 




smoking (P < 0.0001, Figure 22).  Moreover, the same trend was observed after 
stratifying by ethnicity, where the magnitude of the association was greater for white 
females compared to black and Hispanic females (b1 = 0.50 mg/kg, P < 0.0001) vs 0.54 
mg/kg (P = 0.008) and 0.42 mg/kg (P = 0.07), respectively, with each increasing category 
of smoking (Figure 23).  
FeCOOK was inversely associated with physical activity (i.e., METS score), though 
the correlation was not statistically significant (r = -0.02, P = 0.11). The same pattern was 
observed among white and black females when stratifying by ethnicity (b1 = -0.006 
mg/kg for each increasing unit of METS, P = 0.71 for white females; b1 = -0.005 mg/kg 
for each increasing unit of METS, P = 0.86 for black females). The pattern was opposite 
for Hispanic females (b1 = 0.07 mg/kg for each increasing unit of METS, P = 0.05). 
Though dietary iron was positively associated with FeCOOK, the correlation was 
weak and not statistically significant (r = 0.01, P = 0.28). In addition, increasing amounts 
of dietary iron did not have a substantial impact on FeCOOK (b1 = 0.007 mg/kg, P = 0.35). 
Overall, the use of dietary supplements was inversely (but not significantly) associated 
with FeCOOK (b1 = -0.03 mg/kg, P = 0.87), which was magnified when stratifying by 
ethnicity. Compared to white females, FeCOOK was significantly inversely associated with 
iron supplementation among both Hispanic and black females (b1 = -1.03 mg/kg, P = 
0.04 and b1 = -1.79 mg/kg, P = 0.0004). Taken together, iron, whether obtained from 
dietary or supplemental sources did not appear to be independently associated with iron 




As above, the association between FeCOOK and dietary/supplement intakes from 
foodstuffs considered as covariates in the current work are summarized below in terms of 
their effect on iron absorption (i.e., enhancers and inhibitors of iron absorption).  
Promoters of iron absorption   Overall, increased intakes of total saturated fats (in 
grams) obtained from the diet was positively associated with FeCOOK (b1 = 0.004 mg/kg, 
P = 0.41). Given that the mean dietary intake of saturated fats was 22.56 grams per day, 
this corresponds to an increase in FeCOOK of 0.09 mg/kg per day among those consuming 
the average amount of saturated fats in the sample. Increased intakes of palmitic and 
stearic saturated fatty acids were also positively associated with FeCOOK (b1 = 0.006, P = 
0.56 and b1 = 0.009 mg/kg, P = 0.62, respectively). In addition, the use of dietary 
supplements containing saturated fats was positively associated with FeCOOK (b1 = 0.28 
mg/kg, P = 0.63). Increasing intakes of dietary carbohydrates and sugars were inversely 
associated with FeCOOK (b1 = -0.0006 mg/kg, P = 0.09 and b1 = -0.002, P = 0.03, 
respectively). In addition, use of supplements containing carbohydrates/sugars was 
inversely associated with FeCOOK (b1 = -0.13, P = 0.71). Finally, increasing intakes of 
vitamin C was inversely associated with FeCOOK (b1 = -0.0008 mg/kg, P = 0.25). 
Conversely, use of supplements containing vitamin C was positively associated with 
FeCOOK (b1 = 0.16 mg/kg, P = 0.51). Taken together, promoters of iron absorption did not 
appear to be strongly associated with iron stores in this sample of females. 
Inhibitors of iron absorption   Intakes of dietary fiber were positively associated 
with FeCOOK (b1 = 0.004 mg/kg, P = 0.51). Conversely, use of supplements containing 
fiber was inversely associated with FeCOOK (b1 = -1.10 mg/kg, P = 0.01). Dietary and 




0.07 and b1 = 0.31, P = 0.13, respectively). Magnesium from dietary sources and 
supplements were both positively associated with FeCOOK (b1 = 0.001 mg/kg, P = 0.03 
and b1 = 0.17 mg/kg, P = 0.47, respectively). Intakes of vitamin D from dietary and 
supplemental sources were positively associated with FeCOOK (b1 = 0.04 mg/kg, P = 0.01 
and b1 = 0.25 mg/kg, P = 0.28, respectively). Dietary vitamin E intake was positively 
associated with FeCOOK (b1 = 0.003 mg/kg, P = 0.83). Dietary and supplemental zinc 
intake was positively associated with FeCOOK (b1 = 0.02, P = 0.02 and b1 = 0.20 mg/kg, P 
= 0.42). Taken together, the only inhibitor of iron absorption in the current sample of 
females which was associated with decreased iron stores was fiber obtained from 
supplements. 
Total Body Iron and Reproductive Lifespan    Mean FeCOOK increased with self-
reported age at menarche (b1 = 0.009 mg/kg, P = 0.83). When age at menarche was 
categorized as < 12 years of age, 12 years old or > 12 years of age, FeCOOK increased with 
increasing age category: FeCOOK ẍ = 6.93 (sd = 5.63), ẍ = 6.94 (sd = 3.90) and ẍ = 7.03 
(sd = 5.50), respectively, for each increasing age category (P = 0.76, Figure 24). A 
similar pattern emerged when stratified by ethnicity (Figure 25). While FeCOOK increased 
across increasing categories for each ethnicity, no differences in FeCOOK between 
ethnicities were detected (P = 0.89). 
FeCOOK increased with self-reported oral contraceptive use (FeCOOK ẍ = 7.29 (sd = 
3.95) vs 6.32 (sd = 5.78), yes vs no) (P < 0.0001, Figure 26), decreased with increasing 
parity: 1 child, FeCOOK ẍ = 7.59, (sd = 4.45); 2-3 children, FeCOOK ẍ = 7.04 (sd = 4.81); > 




post-menopausal females (FeCOOK ẍ  = 9.98 (sd = 3.34) vs FeCOOK ẍ  = 6.74 (sd = 4.87, P 
< 0.0001, Figure 28).  
Metabolic dysfunction   When defined using the criteria developed by the WHO, 
T2DM was present in 3.34% of the sample population (Table 3) and the mean age of 
females affected with T2DM was 38.52 (sd = 9.45). When stratified by ethnicity, T2DM 
was present in 2.64% of white, 3.79% of Hispanic and 3.95% of black females. When 
females were grouped into categories according to menopausal status, T2DM was present 
in 2.96% of premenopausal females and 10.58% of postmenopausal females (Table 3). 
When defined using the criteria developed by ATP III, metabolic syndrome was present 
in 15.71% of the sample (Table 3) and the mean age of those affected with metabolic 
syndrome was 35.78 (sd = 10.36). When stratified by ethnicity, metabolic syndrome was 
present in 13.83% of white, 14.82% of Hispanic and 14.08% of black females. When 
females were grouped into categories according to menopausal status, metabolic 
syndrome was present in 13.07% of premenopausal females and 34.01% of 
postmenopausal females (Table 3). When defined by the U.S.-FLI, the prevalence of 
NAFLD was 7.38% (Table 3) and the mean age of those affected with NAFLD was 31.49 
(sd = 11.46). When stratified by ethnicity, the prevalence of NAFLD was 6.12% of white, 
11.27% of Hispanic and 4.50% of black females. When females were grouped into 
categories according to menopausal status, 7.06% of premenopausal females had NAFLD 
and 11.58% of postmenopausal females had NAFLD (Table 3). When defined by 
HOMA-IR, the distribution of insulin resistance in the sample population was 64.06% - 
normal insulin resistance, 24.96% - moderate insulin resistance and 10.98% - severe 




resistance was 27.74 (sd = 11.69). When stratified by ethnicity, the distribution of insulin 
resistance for white females was 73.23% - normal insulin resistance, 18.72% - moderate 
insulin resistance and 8.04% severe insulin resistance. For Hispanic females, the 
distribution of insulin resistance was 57.49% - normal insulin resistance, 29.35% - 
moderate insulin resistance and 13.16% - severe insulin resistance. The distribution of 
insulin resistance among black females was similar to that of Hispanic females, where 
57.52% of females experienced normal insulin resistance, 29.51% experienced moderate 
insulin resistance and 12.96% experienced severe insulin resistance. When females were 
grouped into categories according to menopausal status (i.e., pre- vs. post-menopausal), 
64.98% of premenopausal females experienced normal insulin resistance, 24.64% 
experienced moderate insulin resistance and 10.38% experienced severe insulin 
resistance (Table 3). Approximately sixty-three percent (i.e., 63.37%) of postmenopausal 
females experienced normal insulin resistance, 22.09% experienced moderate insulin 
resistance and 14.53% experienced severe insulin resistance (Table 3). Taken together, 
Hispanic and black females were disproportionately affected by T2DM, metabolic 
syndrome and insulin resistance. In addition, the prevalence of NAFLD was nearly two-
fold higher in Hispanic females compared to their white counterparts and nearly three-
fold higher compared to black females. Regardless of ethnicity, metabolic dysfunction 
was more prevalent among postmenopausal females compared to premenopausal females. 
Total Body Iron and Metabolic Dysfunction    The odds of T2DM increased with 
increasing FeCOOK (OR = 1.03, 95%CI: 0.99-1.08, P = 0.15 for each unit increase in 
FeCOOK. The effect was slightly attenuated after adjusting for covariates. When 




menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10) 
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of 
T2DM were 1) 1.01 (95%CI: 0.98-1.05, P = 0.43), 2) 1.05 (95%CI: 1.00-1.09, P  = 0.05), 
3) 1.03 (95%CI: 0.99-1.08, P  = 0.16), 4) 1.03 (95%CI: 0.98-1.07, P  = 0.24), 5) 1.03 
(95%CI: 0.98-1.08, P  = 0.25), 6) 1.02 (95%CI: 0.97-1.07, P  = 0.40), 7) 1.03 (95%CI: 
0.98-1.08, P  = 0.21), 8) 1.00 (95%CI: 0.95-1.05, P  = 0.94), 9) 1.04 (95%CI: 0.99-1.09, 
P  = 0.12), 10) 1.03 (95%CI: 0.99-1.08, P  = 0.17), 11) 1.03 (95%CI: 0.99-1.08, P  = 
0.16) and 12) 1.02 (95%CI: 0.98-1.07, P = 0.37) (Table x), respectively. In a full model 
which adjusted for all covariates, the odds of T2DM increased with increasing FeCOOK, 
though the effect size was slightly attenuated (OR = 1.02, 95%CI: 0.97-1.06, P = 0.53) 
(Table x). Given that ethnicity and menopausal status appeared to have the largest 
impacts as covariates, separate models were built to examine the interaction of each on 
the association between FeCOOK and odds of T2DM. Compared to white females, the odds 
of T2DM among Hispanic and black females were 2.28 (95%CI: 1.65-3.14, P < 0.0001) 
and 2.42 (95%CI: 1.77-3.30, P < 0.001), respectively, for each unit increase in FeCOOK. 
Taken together, it appears that non-white ethnicity is an effect modifier of FeCOOK on the 
risk of T2DM, since ethnicity is more strongly associated with the outcome rather than 
the exposure. Compared to premenopausal females, the odds of T2DM among 
postmenopausal females were nearly 3-fold higher (OR = 2.96, 95%CI: 1.78-4.94, P < 
0.0001).  
When FeCOOK was categorized according to tertiles, the odds of T2DM among 
those in the highest tertile of FeCOOK compared to those in the lowest tertile were 1.30 




ethnicity. Among white females, the odds of T2DM among those in the highest tertile of 
FeCOOK compared to those in the lowest tertile were 1.11 (95%CI: 0.57-2.19, P = 0.75). 
The odds of T2DM were higher among Hispanic and black females in the highest tertile 
of FeCOOK compared to those in the lowest tertile: OR = 1.52 (95%CI: 0.87-2.64, P = 
0.14) and OR = 2.52 (95%CI: 1.39-4.57, P = 0.002. Finally, I examined the components 
of T2DM (i.e., fasting glucose concentration and HbA1C).  FeCOOK was linearly 
associated with fasting glucose concentration. For each unit increase in glucose 
concentration (md/dL), FeCOOK increased 0.01 mg/kg (P = 0.01). Similarly, for each unit 
increase in FeCOOK, fasting glucose concentration increased 0.22 mg/dL (P = 0.01). 
FeCOOK was inversely associated with HbA1C.For each unit (%) increase in HbA1C, 
FeCOOK decreased 0.22 mg/kg (P = 0.02). Similarly, for each unit increase in FeCOOK, 
HbA1C decreased 0.005% (P = 0.02).    
The odds of metabolic syndrome increased with increasing FeCOOK (OR = 1.01, 
95%CI: 0.99-1.04, P = 0.23 for each unit increase in FeCOOK. The effect was attenuated 
after adjusting for individual covariates and inverted in the full model. For example, 
when independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at 
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10) 
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of 
metabolic syndrome were 1) 1.00 (95%CI: 0.98-1.02, P = 0.92), 2) 1.02 (95%CI: 1.00-
1.04, P  = 0.13), 3) 1.01 (95%CI: 0.99-1.03, P  = 0.36), 4) 1.01 (95%CI: 0.99-1.03, P  = 
0.53), 5) 1.01 (95%CI: 0.98-1.03, P  = 0.65), 6) 1.00 (95%CI: 0.97-1.02, P  = 0.86), 7) 
1.01 (95%CI: 0.98-1.03, P  = 0.54), 8) 0.99 (95%CI: 0.96-1.01, P  = 0.37), 9) 1.01 




0.99-1.04, P  = 0.25) and 12) 1.00 (95%CI: 0.98-1.02, P  = 0.73) (Table x), respectively. 
In a full model which adjusted for all covariates, the effect size inverted to mirror the 
odds associated with FeCOOK and metabolic syndrome when menopausal status was 
entered into the model (OR = 0.99, 95%CI: 0.96-1.01, P = 0.28) (Table x). Thus, a 
separate model was built to examine the interaction of menopausal status on the 
association between FeCOOK and odds of metabolic syndrome. Compared to 
premenopausal females, the odds of metabolic syndrome among postmenopausal females 
was 2.7-fold higher (OR = 2.65, 95%CI: 2.02-3.47, P < 0.0001). Thus, menopausal status 
is an effect modifier of FeCOOK on the risk of metabolic syndrome, since menopausal 
status is more strongly associated with the outcome rather than the exposure. 
When FeCOOK was categorized according to tertiles, the odds of metabolic 
syndrome among those in the highest tertile of FeCOOK compared to those in the lowest 
tertile were 1.14 (95%CI: 0.94-1.39, P = 0.18). A similar pattern was observed after 
stratifying by ethnicity. Among white females, the odds of metabolic syndrome among 
those in the highest tertile of FeCOOK compared to those in the lowest tertile were 1.08 
(95%CI: 0.82-1.41, P = 0.61). The odds of metabolic syndrome were higher among 
Hispanic and black females in the highest tertile of FeCOOK compared to those in the 
lowest tertile: OR = 1.28 (95%CI: 0.90-1.81, P = 0.16) and OR = 1.57 (95%CI: 1.15-
2.16, P = 0.005). Finally, I examined the components of metabolic syndrome (i.e., fasting 
glucose concentration, triglycerides, HDL cholesterol, waist circumference and blood 
pressure).  Among those with metabolic syndrome, FeCOOK was linearly associated with 
fasting glucose concentration (b1 = 0.005 mg/kg, P = 0.39 for each mg/dL increase in 




increase in triglycerides), HDL cholesterol (b1 = 0.06 mg/kg, P = 0.52 for each mg/dL 
increase in HDL cholesterol) and waist circumference (b1 = 0.009 mg/kg, P = 0.44 for 
each cm increase in waist circumference). Among those with metabolic syndrome, 
FeCOOK was inversely associated with systolic BP (b1 = -0.04 mg/kg, P = 0.002 for each 
unit increase in systolic BP (mmHg) and diastolic BP (b1 = 0.01 mg/kg, P = 0.41 for 
each unit increase in diastolic BP (mmHg). 
FeCOOK was linearly associated with U.S.-FLI. For each unit increase in U.S.-FLI, 
FeCOOK increased 0.02 mg/kg (P = 0.001). Similarly, for each unit increase in FeCOOK, 
U.S.-FLI increased 0.34 units (P = 0.003). The odds of NAFLD increased with increasing 
FeCOOK (OR = 1.04, 95%CI: 1.00-1.08, P = 0.04 for each unit increase in FeCOOK. The 
effect was attenuated when adjusting for covariates and abrogated in the full model. For 
instance, when independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) 
age at menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10) 
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of 
NAFLD were 1) 1.02 (95%CI: 0.99-1.06, P = 0.11), 2) 1.04 (95%CI: 1.00-1.08, P  = 
0.02), 3) 1.04 (95%CI: 1.00-1.08, P  = 0.03), 4) 1.01 (95%CI: 0.98-1.05, P  = 0.48), 5) 
1.04 (95%CI: 0.99-1.08, P  = 0.09), 6) 1.03 (95%CI: 0.99-1.08, P  = 0.12), 7) 1.03 
(95%CI: 0.99-1.08, P  = 0.09), 8) 1.03 (95%CI: 0.99-1.07, P  = 0.22), 9) 1.02 (95%CI: 
0.98-1.06, P  = 0.31), 10) 1.02 (95%CI: 0.98-1.06, P  = 0.35), 11) 1.02 (95%CI: 0.98-
1.06, P  = 0.31) and 12) 1.02 (95%CI: 0.99-1.06, P  = 0.22) (Table x), respectively. In a 
full model which adjusted for all covariates, no increased odds of NAFLD as a function 




When FeCOOK was categorized according to tertiles, the odds of NAFLD increased 
across increasing tertiles (Ptrend = 0.04). Compared to those in the lowest tertile of FeCOOK 
the odds of NAFLD were 1.05 (95%CI: 0.77-1.44, P = 0.74) for those in the middle 
tertile of FeCOOK. Compared to those in the lowest tertile of FeCOOK, the odds of NAFLD 
were 1.35 (95%CI: 1.00-1.81, P = 0.05). A similar pattern was observed after stratifying 
by ethnicity. Among white females, the odds of NAFLD among those in the highest 
tertile of FeCOOK compared to those in the lowest tertile were 1.52 (95%CI: 1.00-2.31, P = 
0.05). The odds of NAFLD were higher among Hispanic females in the highest tertile of 
FeCOOK compared to those in the lowest tertile: OR = 1.10 (95%CI: 0.69-1.75, P = 0.69). 
Compared to their white and Hispanic counterparts, the odds of NAFLD were higher 
among black females in the highest tertile of FeCOOK compared to those in the lowest 
tertile: OR = 1.62 (95%CI: 0.88-3.01, P = 0.12). FeCOOK was also linearly associated with 
liver fibrosis (i.e., NFS). For each unit increase in NFS, FeCOOK increased 0.42 mg/kg (P 
< 0.0001). Similarly, for each unit increase in FeCOOK, NFS increased 0.05 units (P < 
0.0001).  
FeCOOK was linearly associated with insulin resistance. For each unit increase in 
HOMA-IR, FeCOOK increased 0.02 mg/kg (P = 0.41). Similarly, for each unit increase in 
FeCOOK, HOMA-IR increased 0.01 units (P = 0.43). The odds of insulin resistance 
increased with increasing FeCOOK (OR = 1.04, 95%CI: 1.00-1.08, P = 0.05 for each unit 
increase in FeCOOK. The effect was not attenuated after adjusting for covariates. When 
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at 
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10) 




insulin resistance were 1) 1.04 (95%CI: 1.00-1.08, P = 0.04), 2) 1.05 (95%CI: 1.01-1.09, 
P  = 0.01), 3) 1.04 (95%CI: 1.00-1.08, P  = 0.02), 4) 1.03 (95%CI: 0.99-1.06, P  = 0.20), 
5) 1.04 (95%CI: 1.00-1.08, P  = 0.04), 6) 1.04 (95%CI: 1.00-1.08, P  = 0.03), 7) 1.04 
(95%CI: 1.00-1.08, P  = 0.04), 8) 1.04 (95%CI: 0.99-1.07, P  = 0.07), 9) 1.03 (95%CI: 
0.99-1.08, P  = 0.12), 10) 1.03 (95%CI: 0.99-1.07, P  = 0.17), 11) 1.03 (95%CI: 0.99-
1.07, P  = 0.22) and 12) 1.02 (95%CI: 0.98-1.06, P  = 0.27) (Table x), respectively. In a 
full model which adjusted for all covariates, the effect size persisted. However, the effect 
was no longer statistically significant (OR = 1.04, 95%CI: 1.00-1.08, P = 0.07) (Table x). 
When FeCOOK was categorized according to tertiles, the odds of insulin resistance 
increased across increasing tertiles (Ptrend = 0.10). Compared to those in the lowest tertile 
of FeCOOK the odds of insulin resistance were 1.23 (95%CI: 0.86-1.78, P = 0.26) for those 
in the middle tertile of FeCOOK. Compared to those in the lowest tertile of FeCOOK, the odds 
of insulin resistance were 1.46 (95%CI: 1.03-2.06, P = 0.03) among those in the highest 
tertile of FeCOOK. A similar pattern was observed after stratifying by ethnicity, especially 
among white females. Among white females, the odds of insulin resistance among those 
in the highest tertile of FeCOOK compared to those in the lowest tertile were 2.59 (95%CI: 
1.45-4.65, P = 0.005). The odds of insulin resistance were also higher among Hispanic 
and black females in the highest tertile of FeCOOK compared to those in the lowest tertile: 













CHAPTER 7: DISCUSSION, LIMITATIONS AND CONCLUSIONS 
 
     The aim of the current dissertation was to evaluate iron stores in a nationally-
representative, community-dwelling, non-institutionalized group of females participating 
in continuous NHANES from 2003 to 2010 using an index of iron repletion developed by 
JD Cook et al. in 1993 (i.e., FeCOOK) (50). I first sought to describe the relationships 
between FeCOOK and age, ethnicity, education, BMI, physical activity, alcohol intake and 
smoking status in the female cohort.  I hypothesized that FeCOOK would be positively 
associated with Hispanic and Non-Hispanic Caucasian ethnicity, education, BMI, alcohol 
consumption, smoking and negatively associated with Non-Hispanic African American 
ethnicity and physical activity. The results confirm that mean FeCOOK in all females in the 
current sample was higher than the reference mean for the index (i.e., ẍ = 5.5 ± 3.4 
mg/kg) (50), indicating that these females were iron-replete. This finding aligns with 
several recent large prospective studies which indicate that most of the U.S. population is 
iron-replete. In the current sample, Hispanic and white females had higher FeCOOK than 
black females, with white females having higher body iron than other ethnicities. 
Moreover, FeCOOK increased with increasing age, education, BMI, alcohol consumption 
and smoking history among females in the sample and decreased with increasing physical 
activity among white and black females. Therefore, it appears that FeCOOK as an index of 




and demographic variables in the current sample of U.S. females. An unexpected finding 
was that FeCOOK increased with increasing physical activity among Hispanic females.  
 Next, my aim was to examine the distribution of FeCOOK in the total sample after 
stratifying participants on several variables related to the female reproductive lifespan. 
Specifically, I hypothesized that FeCOOK would be positively associated with use of oral 
contraceptives and decreasing age at menopause and negatively associated with age at 
menarche and parity. The results confirm that FeCOOK increased with oral contraceptive 
use, decreased with decreasing age at menarche and decreased with increasing parity, 
highlighting again the practical use (i.e., clinical utility) of the index in assessing the 
association between iron stores and reproductive parameters among U.S. females. 
 It should be noted, however, that the current results do not support the hypothesis 
that FeCOOK increases with an earlier age at menopause. This could be due to several 
factors, including the age distribution among females in the sample. As mentioned, 
approximately 43% (i.e., 42.9%) of the sample were between the ages of 12 and 21 
compared to 17% who were aged 42 years or older. Moreover, while the mean age of 
females in the current sample was 27.21 years, the mode was 14 years of age. In addition, 
NHANES did not collect data on the actual self-reported age at menopause among 
females. Rather, the survey inquired as to what age each participant experienced her last 
menstrual cycle. Given that this question was not age-restricted, nor was it associated 
with any obvious any skip-pattern, one must infer that this question applied to all females 
in the sample. In other words, the age at which a given participant experienced her ‘last’ 
menstrual cycle could have very well been the same age at which she was interviewed. 




obviously lead to biased results. Thus, menopausal status was ascertained in the current 
sample by utilizing two additional survey questions (i.e., one which inquired as to 
whether the participant had at least one period in the past twelve months and another 
which inquired as to the reason why the participant had not had a period in the past 
twelve months). When the age distribution of females who answered ‘no’ to the former 
question and ‘menopause/hysterectomy’ to the latter question was examined, FeCOOK was 
positively associated with age. This is not surprising, given that this particular finding 
was derived from the self-reported age during the time of interview among females who 
were subsequently scored as postmenopausal.   
I then sought to estimate the prevalence of NAFLD among females in the current 
sample using a validated algorithm developed by Ruhl et al. in 2015, the U.S. fatty liver 
index (U.S.-FLI). Overall, the prevalence of NAFLD among females in the sample was 
low (i.e., 7.38% in all females, 6.12% in white females, 11.27% in Hispanic females and 
4.50% in black females). As mentioned, NAFLD is rarely observed in individuals 
younger than 20 years (~1%), but increases with age (~18% in those aged 20-40 years to 
39% among adults aged 60 and older) (442). Given the age distribution among females in 
the current sample, these data are in agreement with the epidemiological literature. 
Moreover, the prevalence of NAFLD observed across ethnicities in the current sample is 
in accord with previous reports. For example, investigators from the Dallas Heart Study 
have reported that the prevalence of NAFLD was higher in Hispanic Americans 
compared to other ethnicities. Moreover, the same study demonstrated that African 
Americans had the lowest prevalence of NAFLD (443). Taken together, these results are 




 Next, my aim was to confirm and extend associations between iron stores, in 
particular FeCOOK, and metabolic dysfunction reported in the epidemiological literature. I 
hypothesized that FeCOOK would be positively associated with T2DM, metabolic 
syndrome, NAFLD and insulin resistance after controlling for age, BMI, alcohol 
consumption, smoking status, physical activity and micronutrient status. When metabolic 
dysfunction was modeled as a function of continuously-scaled FeCOOK, the current work 
confirms a positive association between FeCOOK and T2DM and insulin resistance but not 
for metabolic syndrome or NAFLD after adjustment for covariates. All effect sizes were 
small and not statistically significant. However, while the magnitude of associations 
between continuously-scaled FeCOOK and metabolic dysfunction was small, the direction 
of the observed associations supports previous work (395,396). It is worth noting that 
T2DM, metabolic syndrome and NAFLD are all diseases which develop over several 
decades. As mentioned, the prevalence of T2DM, metabolic syndrome and NAFLD 
among individuals < 20 years of age is < 1%, ~7% and < 1%, respectively. Therefore, it 
should be expected that the magnitude of association between continuously-scaled 
FeCOOK and metabolic dysfunction in the current sample be small.  
 The current results also support previous work demonstrating independent 
associations between ethnicity and menopausal status and risk of metabolic dysfunction. 
In other words, when continuously-scaled FeCOOK was used to model metabolic 
dysfunction, it appears that ethnicity and menopausal status modified the effect of FeCOOK 
on the risk of T2DM and metabolic syndrome among females in this sample, indicating 





 Finally, and most importantly, the results between continuously-scaled FeCOOK and 
metabolic dysfunction are not surprising based upon trends in reporting commonly found 
in the literature, where nearly all associations between iron stores (i.e., serum ferritin, 
TSAT) and metabolic dysfunction have modeled iron stores categorically (e.g., tertiles, 
quartiles, quintiles). Thus, the current results align more closely with what has been 
published when FeCOOK was also modeled categorically. For example, females in the 
highest tertile of FeCOOK compared to those in the lowest tertile of FeCOOK had 
significantly increased odds of T2DM, metabolic syndrome, NAFLD and insulin 
resistance (OR = 1.30, 95%CI:0.90-1.89, Ptrend = 0.17 for T2DM, OR = 1.14, 95%CI: 
0.94-1.39, Ptrend = 0.18 for metabolic syndrome, OR = 1.35, 95%CI: 1.00-1.81, Ptrend = 
0.05 for NAFLD and OR = 1.46, 95%CI: 1.03-2.06, Ptrend = 0.03). Differential risk 
patterns for each outcome emerged across ethnicities when categorizing FeCOOK in this 
manner. Black females in the highest tertile of FeCOOK compared to those in the lowest 
tertile of FeCOOK had significantly increased odds of T2DM compared to their Hispanic 
and white counterparts. This does not align with prevalence estimates reported in the 
literature, which indicate that Hispanic females have the highest risk of T2DM and 
metabolic syndrome, followed by black females and white females. One might speculate 
that the discordance between the current results and what has been reported in the 
literature is due to Hispanic females in the current sample consuming 3.25 g/d more 
dietary fiber (i.e., an inhibitor of iron absorption) than black females. Moreover, given 
that all females were iron-replete, the decreased risk of T2DM, metabolic syndrome and 
NAFLD among white females could have been moderated by increased physical activity 




NAFLD among black females could have been moderated by increased intake of dietary 
sugars and saturated fat in this group, where the former has been shown to increase iron 
absorption and the latter increases siderophores. 
 A strength of the current work is that I used a large, ethnically-diverse and 
nationally-representative sample of U.S. females. Therefore, the current findings should 
be generalizable at the population level. Moreover, the standardized methodology 
employed in the quantification of FeCOOK and outcomes of the study permits replication 
of each finding, as NHANES data is available for public use. Another strength of the 
study is that the clinical validity of the index developed by Cook et al. was highlighted 
compared to TSAT when examining the associations between each index and metabolic 
dysfunction (Appendix 2). While TSAT is widely used in the clinical setting to assess 
iron stores, it was previously highlighted that it is unreliable due to diurnal variation in 
serum iron concentrations (i.e., the numerator of TSAT). Moreover, only a small 
percentage of total body iron is accounted for by TSAT (~1%, compared to 20% with 
ferritin) (109,110). As also mentioned, inflammation and the use of oral contraceptives 
decreases total iron binding capacity (i.e., the denominator of TSAT) which would 
ultimately lead to lower TSAT among females who use them. To this end, most of the 
females in the current sample reported using oral contraceptives (53.11%) and white 
females had the highest self-reported usage of oral contraceptives compared to Hispanic 
and black females (53.50% vs. 25.14% and 21.36%, respectively). It is important to 
mention these proportions for several reasons. First, if one assumes that the use of oral 
contraceptives influences TSAT, then it appears that the odds associated with each 




(Table 13). Second, if one also considers the mean age of females in the sample with 
T2DM (38.52, sd = 9.45), metabolic syndrome (35.78, sd = 10.36), NAFLD (31.49, sd = 
11.46) and insulin resistance (27.74, sd = 11.69) with the mean age of oral contraceptive 
users (i.e., 33.07 (sd = 9.94)), it is tempting to hypothesize that the reduced odds of each 
outcome with increasing tertile of TSAT is also related to the use of oral contraceptives. 
An alternative explanation is that increasing iron deficiency accounts for the increased 
risk of metabolic dysfunction among those in the lowest tertile of TSAT. Otherwise, 
females in the highest tertile of TSAT would not have had a decreased risk of metabolic 
dysfunction compared to those in the lowest tertile of TSAT. Given the average TSAT 
among females in the current sample was 21.84% and that a TSAT < 20% is typically the 
threshold used in the clinical setting to distinguish iron deficiency, it doesn’t appear that 
females in the current sample were iron deficient. Therefore, it doesn’t appear that 
increasing iron deficiency was associated with an increased risk of metabolic 
dysfunction, which is what the observed effect sizes indicate. A simpler explanation is 
that TSAT among females in the current sample was adversely affected by the 
aforementioned limitations of the index, particularly oral contraceptive use. 
Theoretically, oral contraceptive use should increase iron stores (i.e., serum ferritin 
concentrations) due to the cessation of menstruation. The results obtained in the current 
work using the index developed by Cook et al supports this theory, where FeCOOK 
increased with increasing OC use. Given that FeCOOK is unaffected by diurnal variation, 
accounts for a larger fraction of body iron stores and is unaffected by inflammation or use 
of oral contraceptives, it is reasonable to conclude that the clinical utility and clinical 




 There are several limitations in the current work which must be noted. First, given 
the cross-sectional study design of NHANES, one cannot infer causal relationships based 
upon the current results. Second, a key variable used in the derivation of FeCOOK (i.e., 
serum transferrin receptor) was not collected among male participants or females aged 
greater than 49 years of age. This is discouraging, as much of the current research 
supporting an association between iron stores and metabolic dysfunction has been 
obtained from studies using males and/or older (i.e., postmenopausal) females. As most 
of the females in the sample were young (mode = 14), it is possible that no significant 
associations between iron stores and metabolic dysfunction were observed due to regular 
menstruation. Moreover, the development of each outcome can take decades to manifest. 
In line with the latter association, I was able to detect a positive association between 
increasing tertiles of FeCOOK and all outcomes among postmenopausal females when 
FeCOOK was modeled in accordance with common reporting patterns in the current 
literature (Table 14), though no comparison was statistically significant due to such a 
small number of postmenopausal females in the current study.  
Another limitation of the current work is that many females did not have complete 
data for biochemical parameters required in the derivation of each outcome. Thus, the 
sample size for each outcome differed from the number of females in the full sample and 
it is therefore possible that 1) the low prevalence of metabolic dysfunction might have 
been an artefact of missing data and 2) the original power calculations were 
overestimates. The latter is a limitation, as post hoc power analyses were not conducted 
in the current work. Moreover, the reduced and variable sample sizes for each outcome 




that could generalize to the population. It would have been interesting to model the data 
using standard SAS procedures. While one could not generalize to the population, 
different patterns may have been observed among females in the current sample.  
In conclusion, the current results highlight the clinical utility of FeCOOK in assessing 
the iron status in females of reproductive age. I did not observe a statistically significant 
association between metabolic dysfunction and continuously-scaled FeCOOK. However, 
when FeCOOK was modeled in accordance with common reporting patterns (i.e., where 
iron stores are modeled categorically), significant, positive associations between 
increasing FeCOOK and metabolic dysfunction were observed among all females, and this 
pattern persisted after stratification by ethnicity and menopausal status. Further research 
is warranted to examine the clinical utility of FeCOOK among other cohorts. Moreover, 
additional research using FeCOOK is recommended in order to replicate these findings 
















1. Jiang R, Ma J, Ascherio A, et al. Dietary iron intake and blood donations in 
relation to risk of type 2 diabetes in men: a prospective cohort study. Am J Clin 
Nutr, 2004;79: 70-75. 
2. Witte DL, Crosby WH, Edwards CQ, et al. Practice guideline development task 
force of the college of American pathologists: hereditary hemochromatosis. Clin 
Chim Acta, 1996;245: 139-200. 
3. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload 
screening in a racially diverse population. N Engl J Med, 2005;352: 1769-1778. 
4. Cooksey RC, Jouihan HA, Ajioka RS, et al. Oxidative stress, beta-cell apoptosis, 
and decreased insulin secretory capacity in mouse models of hemochromatosis. 
Endocrinology, 2004;145: 5305-5312. 
5. Minamiyama Y, Takemura S, Kodai S, et al. Iron restriction improves type 2 
diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol 
Endocrinol Metab, 2010;298: E1140-E1149. 
6. Shah SV, Fonseca VA. Iron and diabetes revisited. Diabetes Care, 2011;34: 1676. 
7. Kang H.T., Linton J.A., Shim J.Y. Serum ferritin level is associated with the 
prevalence of metabolic syndrome in Korean adults: The 2007-2008 Korean 





8. Hämäläinen P., Saltevo J., Kautiainen H. Erythropoietin, ferritin, haptoglobin, 
hemoglobin and transferrin receptor in metabolic syndrome: a case control 
study. Cardiovasc Diabetol, 2012;11: 116–123.  
9. Li J., Wang R., Luo D. Association between serum ferritin levels and risk of the 
metabolic syndrome in Chinese adults: a population study. PLoS One, 2013;8(9): 
e74168.  
10. Freixenet N., Remacha Á., Berlanga E. Serum soluble transferrin receptor 
concentrations are increased in central obesity. Results from a screening 
programme for hereditary hemochromatosis in men with hyperferritinemia. Clin 
Chim Acta, 2009;400(1–2):111–116. 
11. Abril-Ulloa V, Flores-Mateo G, Sola-Alberich R, et al. Ferritin levels and risk of 
metabolic syndrome: meta-analysis of observational studies. BMC Public Health, 
2014;14: 483-90. 
12. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome 
in US adults. Diabetes Care, 2004;27: 2422-28. 
13. Chang JS, Lin SM, Huang Tc, et al. Serum ferritin and risk of the metabolic 
syndrome: a population-based study. Asia Pac J Clin Nutr, 2013;22(3): 400-7. 
14. Azadbakht L, Esmaillzadeh A. Red meat intake is associated with metabolic 
syndrome and the plasma C-reactive protein concentration in women. J Nutr, 
2009;139: 335-9. 
15. Bozzini C, Tenuti I, Girelli D, et al. Prevalence of body iron excess in the 




16. Dongiovanni P, Fracanzani AL, Fargion L. Iron in fatty liver and in the metabolic 
syndrome: a promising therapeutic target. J Hepatol, 2011;55: 920-32. 
17. Jézéquel C, Lainé F, Laviolle B, Kiani A, Bardou-Jacquet E, et al. (2015) Both 
hepatic and body iron stores are increased in dysmetabolic iron overload 
syndrome: a case-control study. PLoS ONE 10(6): 1-4. 
18. Shim JJ. Body iron, serum ferritin, and non-alcoholic fatty liver disease. Korean J 
Hepatol, 2012;18: 105-7. 
19. Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater 
parenchymal iron in non-alcoholic fatty liver disease patients with C282Y HFE 
mutations. Hepatology, 2012; 56: 1730-40. 
20. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic 
iron overload. Gastroenterology, 1999;117: 1155-63. 
21. Hernaez R, Yeung E, Clark JM, et al. Hemochromatosis gene and nonalcoholic 
fatty liver disease: a systematic review and meta-analysis. J Hepatol, 2011;55(5): 
1079-85. 
22. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy 
improves insulin resistance in patients with NAFLD and hyperferritinemia: 
evidence from a case control study. Am J Gastroenterol, 2007;102: 1251-58. 
23. Esmaillzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L et al. Dietary patterns, 
insulin resistance, and the prevalence of the metabolic syndrome in women. Am J 




24. Tuomainen TP, Nyyssonen K, Salonen R, et al. Body iron stores are associated 
with serum insulin and blood glucose concentrations: population study in 1,013 
eastern Finnish men. Diabetes Care, 1997;20(3): 426-8. 
25. Hua NW, Stoohs RA, Facchini FS. Low iron status and enhanced insulin 
sensitivity in lacto-ovo vegetarians. British J Nutr, 2001;86: 515-19. 
26. Equitani F, Calvani M, Fernandez-Real JM, et al. Bloodletting ameliorates insulin 
sensitivity and secretion in parallel to reducing iron in carriers of HFE gene 
mutations. Diabetes Care, 2008;31: 3-8. 
27. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and 
insulin sensitivity and secretion. Clin Chem, 2005;52(7): 1201-05. 
28. Houschyar KS, Ludtke R, Dobos GJ, et al. Effects of phlebotomy-induced 
reduction of body iron stores on metabolic syndrome: results from a randomized 
clinical trial. BMC Medicine, 2012;10: 54-61. 
29. Penkova M, Dragneva S, Marinova C. Phlebotomy in the treatment of iron 
overload in patients with nonalcoholic and alcoholic fatty liver diseases. Int J 
Busin, Hum, and Technol, 2012;2(6): 48-51. 
30. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and 
accurate predictor of hepatic steatosis in the general population. BMC 
Gastroenterology, 2006;33(6): 1-7. 
31. Koehler EM, Schouten JNL, Hansen BE, et al. External validation of the fatty 
liver index for identifying nonalcoholic fatty liver disease in a population-based 




32. Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for 
identifying ultrasonographic fatty liver in a large scale cross-sectional study in 
Taiwan. PLOS One, 2015;DOI:10.1371/journal.pone.0120443. 
33. Huang X,  Xu M, Chen Y, et al. Validation of the fatty liver index for 
nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine, 
2015;94(40): 1-7. 
34. Jager S, Jacobs S, Kroger J, et al. Association between the fatty liver index and 
risk of type 2 diabetes in the EPIC-Potsdam study. PLOS One, 
2015;DOI:10.1371/journal.pone.0124749. 
35. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States national 
health and nutrition examination survery. Aliment Pharmacol Ther, 2015;41: 65-
76. 
36. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet, 
1981;1(8233): 1293-4. 
37. LaVecchia C, Decarli A, Franceschi S, et al. Menstrual and reproductive factors 
and the risk of myocardial infarction in women under fifty-five years of age. Am J 
Obstet Gynecol, 1987;157(5): 1108-12. 
38. Canoy D, Beral V, Balkwill A, et al. Age at menarche and risks of coronary heart 
and other vascular diseases in a large UK cohort. Circulation, 2014; 
https://doi.org/10.1161/CIRCULATIONAHA.114.010070  
39. Soloman CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for 




40. Parikh NI, Jeppson RP, Berger JS, et al. Reproductive risk factors and coronary 
heart disease in the women’s health initiative observational study. Circulation, 
2016; https://doi.org/10.1161/CIRCULATIONAHA.115.017854.  
41. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of 
cardiovascular disease: the Framingham study. Ann Int Med, 1976;85(4): 447-
452. 
42. Beaton MD, Chakrabarti S, Levstik, et al. Phase II clinical trial of phlebotomy for 
non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2013;37(7): 720-729. 
43. Jaruvongvanich V, Riangwiwat T, Sanguankeo A, Upala S. Outcome of 
phlebotomy for treating nonalcoholic fatty liver disease: A systematic review and 
meta-analysis. Saudi J Gastroenterol, 2016;22:407-14. 
44. Suchdev PS, Williams AM, Mei Z, et al. Assessment of iron status in settings of 
inflammation: challenges and potential approaches. Am J Clin Nutr, 
2017;106Suppl 6): 1626S-1633S. 
45. Guillygomarc’h A, Christian J, Romain M, et al. Circadian variations of 
transferrin saturation levels in iron-overloaded patients: implications for the 
screening of C282Y-linked haemochromatosis. Brit J Haematol, 2003;120: 359-
363. 
46. Chiari MM, Bagnoli R, DeLuca PD, et al. Influence of acute inflammation on iron 
and nutritional status indexes in older patients. J Am Geriatr Soc, 1995;43(7): 
767-71. 
47. Buyukasik NS, Nadir I, Akin FE, et al. Serum iron parameters in cirrhosis and 




48. Shan Y, Lambrecht RW, Bonkovsky HL. Association of hepatitis C virus 
infection with serum iron status: analysis of data from the third national health 
and nutrition examination survey. Clin Infect Dis, 2005;40(6): 834-841. 
49. Neves JV, Wilson JM, Rodrigues PNS. Transferrin and ferritin response to 
bacterial infection: the role of the liver and brain in fish. Dev & Compar Immunol, 
2009;33(7): 848-857. 
50. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. 
Blood, 2003;101(9): 3359-64. 
51. Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in 
US preschool children and nonpregnant females of childbearing age: national 
health and nutrition examination survey 2003-2006. Am J Clin Nutr, 2009;89: 
1334-42. 
52. Gallagher CM, Chen JJ, Kovach JS. The relationship between body iron stores 
and blood and urine cadmium concentrations in US never-smoking, non-pregnant 
women aged 20-49 years. Env Res, 2011;111(5): 702-707. 
53. Buchner JR, Tien M, Morehouse LA, Aust SD. Redox cycling and lipid 
peroxidation: the central role of iron chelates. Fundam Appl Toxicol, 1983;3(4): 
222-6. 
54. Steele TM, Frazer DM, Anderson GJ. Systemic regulation of intestinal iron 
absorption. IUBMB Life, 2005;57: 499-503. 
55. Cross AJ, Harnly JM, Ferrucci LM, et al. Developing a heme iron database for 





56. Hurrell R, Egli I. Iron bioavailability and dietary reference values. Am J Clin 
Nutr, 2010;91(suppl): 1461S-7S. 
57. Waldvogel-Abramowski S, Waeber G, Gassner C, et al. Physiology of iron 
metabolism. Transfus Med Hemother, 2014;41: 213-221. 
58. Kappas A, Drummond GS, Galbraith RA. Prolonged clinical use of a heme 
oxygenase inhibitor: hematological evidence for an inducible but reversible iron-
deficiency state. Pediatrics, 1993;91: 537-539. 
59. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for 
human health. J Res Med Sci, 2014;19(2): 164-174. 
60. Yang L, Zhang Y, Wang J et al. Non-heme iron absorption and utilization from 
typical whole Chinese diets in young Chinese urban men measured by a double-
labeled stable isotope technique. PLoS One, 2016;11(4); e0153885. 
61. Roughead ZKF, Zito CA, Hunt JR. Initial uptake and absorption of nonheme iron 
and heme iron in humans are unaffected by the addition of calcium as cheese to a 
meal with high iron bioavailability. Am J Clin Nutr, 2002;76(2): 419-25. 
62. Christides T. Sugars increase non-heme iron bioavailability in human epithelial 
intestinal and liver cells. PLoS One, 2013;8(12): e83031. 
63. Beck KL, Conlon CA, Kruger R, et al. Dietary determinants of and possible 
solutions to iron deficiency for young women living in industrialized countries: a 
review. Nutrients, 2014;6(9): 3747-3776. 
64. Reddy MB, Hurrell RF, Cook JD. Estimation of nonheme-iron bioavailability 




65. Monsen ER, Hallberg L, Layrisse M, et al. Estimation of available dietary iron. 
Am J Clin Nutr, 1978;31: 134-41. 
66. Shayeghi M, Latunde-dada GO, Oakhill JS, et al. Identification of an intestinal 
heme transporter. Cell, 2005;122(5): 789-801.  
67. Simpson RJ, McKie AT. Regulation of intestinal iron absorption: the mucosa 
takes control? Cell Metab, 2009;10(2): 84-87. 
68. Vaschenko G, MacGillivray. Multi-copper oxidases and human iron metabolism. 
Nutrients, 2013;5(7): 2289-2313. 
69. Neilands JB. Siderophores: Structure and function of microbial iron transport 
compounds. J Biol Chem, 1995;270(45): 26723–26726. 
70. Hentze MW, Muckenthaler MU, Galy B. et al. Two to tango: regulation of 
mammalian iron metabolism. Cell, 2010;142: 24-38. 
71. HuijunC, Trent S, Zouhair KA, et al. Systemic regulation of hephaestin and Ireg1 
revealed in studies of genetic and nutritional iron deficiency. Blood, 2003;102(5): 
1893–1899. doi:10.1182/blood-2003-02-0347. 
72. West AR, Oates PS. Mechanisms of heme iron absorption: current questions and 
controversies. W Gastroenterol, 2008;16(26): 4101-4110. 
73. Anderson GJ, Frazer DM, McKie AT, et al. The ceruloplasmin homolog 
hepaestin and the control of intestinal iron absorption. Blood Cells Mol Dis, 
2002;29(3): 367-375.  
74. Iacopetta BJ, Morgan EH. The kinetrics of transferrin endocytosis and iron uptake 




75. Weinberg ED. Iron availability and infection. Biochem Biophys Acta, 
2009;1790(7): 600-605. 
76. Van Dijk BAC, Laarakkers CMM, Klaver SM, et al. Serum hepcidin levels are 
innately low in HFE-related haemochromatosis but differ between C282Y-
homozygotes with elevated and normal ferritin levels. Brit J Haematol, 2008;142: 
979-985. 
77. Kumar S, Sheokand N, Mhadeshwar ME, et al. Characterization of 
glyceraldehyde-3-phosphate dehydrogenase as a novel transferrin receptor. Int J 
Biochem & Cell Biol, 2012;44: 189-199. 
78. Sheokand N, Kumar S, Malhotra H, et al. Secreted glyceraldehyde-3-phosphate 
dehydrogenase is a multifunctional autocrine transferrin receptor for cellular iron 
acquisition. Biochem Biophys Act, 2013;1830: 3816-3827. 
79. Boradia VM, Raje M, Raje CI. Protein moonlighting in iron metabolism: 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Biochem Soc Transact, 
2014;42(6): 1796-1801. 
80. Kawabata H, Tong X, Kawanami T, et al. Analyses for binding of the transferrin 
family of proteins to the transferrin receptor 2. Brit J Haematol, 2004;127(4): 
464-73. 
81. West AP Jr, Giannetti AM, Herr AB, et al. Mutational analysis of the transferrin 
receptor reveals overlapping HFE and transferrin binding sites. J Mol Biol, 
2001;312(2): 385-97. 





83. Harrison PM and Arosio P. The ferritins: molecular properties, iron storage 
function and cellular regulation. Biochim Biophys Acta, 1996;1275: 161–203. 
84. Worwood M, Brook JD, Cragg SJ, Hellkuhl B, Jones BM, Per- era P, Roberts SH, 
and Shaw DJ. Assignment of human ferritin genes to chromosomes 11 and 
19q13.319qter. Hum Genet, 1985;69: 371–374. 
85. Lawson DM, Treffry A, Artymiuk PJ, Harrison PM, Yewdall SJ, Luzzago A, 
Cesareni G, Levi S, and Arosio P. Identification of the ferroxidase centre in 
ferritin. FEBS Lett 254: 207–210, 1989. 
86. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De 
Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, and Franzoso G. Ferritin 
heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by 
suppressing reactive oxygen species. Cell 119: 529–542, 2004. 
87. Toussaint L, Bertrand L, Hue L, Crichton RR, and Declercq JP. High-resolution 
X-ray structures of human apoferritin H-chain mutants correlated with their 
activity and metal-binding sites. J Mol Biol 365: 440–452, 2007. 
88. Lawson DM, Artymiuk PJ, Yewdall SJ, Smith JM, Livingstone JC, Treffry A, 
Luzzago A, Levi S, Arosio P, Cesareni G, Thomas CD, Shaw WV, and Harrison 
PM. Solving the structure of human H ferritin by genetically engineering 
intermolecular crystal con- tacts. Nature 349: 541–544, 1991. 
89. De Domenico I, Vaughn MB, Li L, Bagley D, Musci G, Ward DM, and Kaplan J. 
Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by 




90. Fleming RE, Migas MC, Holden CC, Waheed A, Britton RS, Tomatsu S, Bacon 
BR, and Sly WS. Transferrin receptor 2: con- tinued expression in mouse liver in 
the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci 
U S A 97: 2214–2219, 2000. 
91. Saito H. Metabolism of iron stores. Nagoya J Med Sci, 2014;76: 235-254. 
92. Jensen JH, Tang H, Tosti CL, et al. Separate MRI quantification of dispersed 
(ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med, 
2010;63(5): 1201-1209. 
93. Hernando D, Levin YS, Sirlin CB, et al. Quantification of liver iron with MRI: 
state of the art and remaining challeneges. J Magn Reson Imaging, 2015;40(5): 
1003-1021. 
94. Tsuji Y. JunD activates transcription of the human ferritin H gene through an 
antioxidant response element during oxidative stress. Oncogene 24: 7567–7578, 
2005. 
95. Tsuji Y, Akebi N, Lam TK, Nakabeppu Y, Torti SV, and Torti FM. FER-1, an 
enhancer of the ferritin H gene and a target of E1A-mediated transcriptional 
repression. Mol Cell Biol 15: 5152–5164, 1995. 
96. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, and Torti FM. Coordinate 
transcriptional and translational regulation of fer- ritin in response to oxidative 
stress. Mol Cell Biol 20: 5818–5827, 2000. 
97. Tsuji Y, Kwak E, Saika T, Torti SV, and Torti FM. Preferential repression of the 
H subunit of ferritin by adenovirus E1A in NIH- 3T3 mouse fibroblasts. J Biol 




98. Tsuji Y, Miller LL, Miller SC, Torti SV, and Torti FM. Tumor necrosis factor-
alpha and interleukin 1-alpha regulate transfer-  rin receptor in human diploid 
fibroblasts: relationship to the in- duction of ferritin heavy chain. J Biol Chem 
266: 7257–7261, 1991. 
99. Tsuji Y, Moran E, Torti SV, and Torti FM. Transcriptional reg- ulation of the 
mouse ferritin H gene: involvement of p300/CBP adaptor proteins in FER-1 
enhancer activity. J Biol Chem 274: 7501–7507, 1999. 
100. Tsuji Y, Torti SV, and Torti FM. Activation of the ferritin H en- hancer, FER-1, 
by the cooperative action of members of the AP1 and Sp1 transcription factor 
families. J Biol Chem 273: 2984–2992, 1998. 
101. Turano M, Tammaro A, De Biase I, Lo Casale MS, Ruggiero G, Monticelli A, 
Cocozza S, and Pianese L. 3-Nitropropionic acid increases frataxin expression in 
human lymphoblasts and in trans- genic rat PC12 cells. Neurosci Lett 350: 184–
186, 2003. 
102. Vahdat Shariatpanaahi M, Vahdat Shariatpanaahi Z, Moshtaaghi M, Shahbaazi 
SH, and Abadi A. The relationship between de- pression and serum ferritin level. 
Eur J Clin Nutr 61: 532–535, 2007. 
103. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, and 
Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its 
inflammatory stimulation. Blood 109: 353–358, 2007. 
104. Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS, Siani 
V, Benson MD, Calvas P, Miravalle L, Rascol O, and Delisle MB. Intracellular 




neurodegenerative disease associated with a mutation in the ferritin light 
polypeptide gene.  J Neuropathol Exp Neurol 63: 363–380, 2004. 
105. Voisine C, Schilke B, Ohlson M, Beinert H, Marszalek J, and Craig EA. Role of 
the mitochondrial Hsp70s, Ssc1 and Ssq1, in the maturation of Yfh1. Mol Cell 
Biol 20: 3677–3684, 2000. 
106. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J 
and Anderson GJ. Hephaestin, a ceruloplasmin ho- mologue implicated in 
intestinal iron transport, is defective in the sla mouse. Nat Genet 21: 195–199, 
1999. 
107. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi ME, Britton 
RS, Bacon BR, and Sly WS. Regulation of transferrin-mediated iron uptake by 
HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U 
S A 99: 3117–3122, 2002. 
108. Anderson CP, Shen M, Eisenstein RS, et al. Mammalian iron metabolism and its 
control by iron regulatory proteins. Biochem Biophys Acta, 2012;1823(9): 1468-
1483. 
109. Moon J. Iron: the most toxic metal. Chico, CA: George Ohsawa Macrobiotic 
Foundation; 2008.  
110. Weinberg ED, Garrison CD. Exposing the hidden dangers of iron: what every 
medical professional should know about the impact of iron on the disease 




111. Mei Z, Cogswell ME, Looker AC, et al. Assessment of iron status in US pregnant 
women from the national health and nutrition examination survey (NHANES), 
1999-2006. Am J Clin Nutr, 2011;93: 1312-20. 
112. Zacharski LR, Ornstein DL, Woloshin S, et al. Association of age, sex, and race 
with body iron stores in adults: analysis of NHANES III data. Am Heart J, 
2000;140: 98-104. 
113. Gillum RF. Association of serum ferritin and indices of body fat distribution and 
obesity in Mexican American men: the third national health and nutrition 
examination survey. Int J Obesity, 2001;25: 639-645. 
114. Pfeiffer CM, Sternberg MR, Caldwell KL, et al. Race-ethnicity is related to 
biomarkers of iron and iodine status after adjusting for sociodemographic and 
lifestyle variables in NHANES 2003-2006. J Nutr, 2013;143: 977S-985S. 
115. Miller EM. Iron status and reproduction in US women: national health and 
nutrition examination survey, 1999-2006. PLoS One, 2014;9(11): e112216. 
116. Farooq A, Rauf S, Hassan U, et al. Impact of multiparity on iron content in 
multiparous women. J Ayub Med Coll Abbottabad, 2011;23(2): 32-35. 
117. Milman N, Kirchoff M, Jorgensen T. Iron status markers, serum ferritin and 
hemoglobin in 1359 Danish women in relation to menstruation, hormonal 
contraception, parity and postmenopausal hormone treatment. Ann Hematol, 
1992;65(2): 96-102. 
118. Friedman J, Cremer M, Jelani Q, et al. Oral contraceptive use, iron stores, and 





119. Frassinelli-Gunderson EP, Margen S, Brown JR. Iron stores in users of oral 
contraceptive agents. Am J Clin Nutr, 1985;41(4): 703-12. 
120. Gupta PM, Hamner HC, Suchdev PS, et al. Iron status of toddlers, nonpregnant 
females and pregnant females in the United States. Am J Clin Nutr, 2017; 
acjn155978. 
121. Cook JD, Skikne BS, Lynch SR, et al. Estimates of iron sufficiency in the US 
population. Blood, 1986;68(3): 726-31. 
122. Fleming DJ, Jacques PF, Tucker KL, et al. Iron status of the free-living elderly 
Framingham Heart cohort: an iron-replete population with a high prevalence of 
elevated iron stores. Am J Clin Nutr, 2001;73: 638-46. 
123. Milman N, Ingerslev J, Graudal N. Serum ferritin and iron status in a population 
of ‘healthy’ 85-year old individuals. Scand J Clin Lab Invest, 1990;50: 77-83. 
124. Milman N. Ovesen L, Byg K, et al. Iron status in Danes update I: prevalence of 
iron deficiency and iron overload in 1332 men aged 40-70 years. Influence of 
blood donation, alcohol intake and iron supplementation. Ann Hematol, 1999;78: 
393-400. 
125. Garry PJ, Hunt WC, Baumgartner RN. Effects of iron intake on iron stores in 
elderly men and women: longitudinal and cross-sectional results. J Am Col Nutr, 
2000;19(2): 262-69. 
126. Milman N, Byg KE, Ovesen L. Iron status in Danes 1994 II: prevalence of iron 
deficiency and iron over,load in 1319 Danish women aged 40-70 years: influence 
of blood donation, alcohol intake and iron supplementation. Ann Hematol, 




127. Fleming DJ, Tucker KL, Jacques PF, et al. Dietary factors associated with the risk 
of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr, 
2002;76: 1375-84. 
128. Blanck HM, Cogswell ME, Gillespie C, et al. Iron supplement use and iron status 
among US adults: results from the third national health and nutrition examination 
survey. Am J Clin Nutr, 2005;82(5): 1024-1031. 
129. Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for 
Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, 
Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington 
(DC): National Academies Press (US); 2001. 9, Iron. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK222309/.  
130. Gibson RS. The role of diet- and host-related factors in nutrient bioavailability 
and thus in nutrient-based dietary requirement estimates. Food Nutr Bulletin, 
2007;28(1): S77-S100. 
131. Cook JD. Determinants of nonheme iron absorption in man. Food Technol, 1983: 
124-126. 
132. Ioannou GN, Dominitz JA, Weiss NS, et al. The effect of alcohol consumption on 
the prevalence of iron overload, iron deficiency and iron deficiency anemia. 
Gastroenterol, 2004;126: 1293-1301. 
133. Whitfield JB, Zhu G, Heath AC, et al. Effects of alcohol consumption on indices 





134. Doss MO, Kuhnel A, Gross U. Alcohol and porphyrin metabolism. Alcohol & 
Alcoholism, 2000;35(2): 109-125. 
135. Dostalikova-Cimburova M, Balusikova K, Kratka K, et al. Role of duodenal iron 
transporters and hepcidin in patients with alcoholic liver disease. J Cell Mol Med, 
2014;18(9): 1840-1850. 
136. Weinberg ED. Tobacco smoke iron: an initiator/promoter of multiple diseases. 
Biometals, 2009;22: 207-210. 
137. Corhay JL, Weber G, Bury T, et al. Iron content in human alveolar macrophages. 
Eur Respir J, 1992;5: 804-809. 
138. McGowan SE, Henley SA. Iron and ferritin contents and distribution in human 
alveolar macrophages. J Lan Clin Med, 1988;111: 611-7. 
139. Karp G. Cell and molecular biology: concepts and experiments. Chichester: John 
Wiley; 2008. 
140. Singh S, Hider RC. Therapeutic iron-chelating agents: Free radical damage and its 
control. Rice CA, Burdon RH (Eds); 1994. 
141. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of 
xenobiotics. CMLS Cell Mol Life Sci, 2001;58: 737-47. 
142. Furge LL, Guengerich FP. Cytochrome P450 enzymes in drug metabolism and 
chemical toxicology. Biochem Mol Biol Edu, 2006;34(2): 66-74. 
143. Cedarbaum AI. Molecular mechanisms of the microsomal mixed function 




144. Johnson EF, Connick JP, Reed JR, et al. Correlating structure and function of 
drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab 
Dispos, 2014;42: 9-22. 
145. Vlasits J, Jakopitsch C, Schwanniger M, et al. Hydrogen peroxide oxidation by 
catalase-peroxidase follows a non-scrambling mechanism. FEBS Letters, 
2007;581(2): 320-324. 
146. Fridovich I, Handler P. Xanthine oxidase: IV, participation of iron in internal 
electron transfer. J Biol Chem, 1958;233(6): 1581-85. 
147. Weiss G, Werner-Felmayer G, Werner E, et al Iron regulates nitric oxide synthase 
activity by controlling nuclear transcription factor. J Exp Med, 1994;180: 969-76. 
148. Cooper CE. Nitric oxide and iron proteins. Biochimica et Biophysica Acta, 
1999;1411: 290-309. 
149. Ni Z, Morcos S, Vaziri ND. Up-regulation of renal vascular nitric oxide synthase 
in iron-deficiency anemia. Kidney Int, 1997;52: 195-201. 
150. Gottlieb Y, Topz O, Cohen LA, et al. Physiologically aged red blood cells 
undergo erythrophagocytosis in vivo but not in vitro. Haematologica, 2012;97(7): 
994-1002. 
151. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid 
regulator of iron metabolism. Nat Genet, 2014;46(7): 678-84. 
152. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J 
Physiol Rena Physiol, 2010;299(1): F1-F13. 
153. Pak M, Lopez MA, Gabayan V, et al. Suppression of hepcidin during anemia 




154. Gabrielsen JS, Gao Y, Simcox JA, et al. Adipcyte iron regulates adiponectin and 
insulin sensitivity. J Clin Inv, 2012;122(10): 3529-40. 
155. Dongiovanni P, Ruscica M, Rametta R, et al. Dietary iron overload induces 
visceral adipose tissue insulin resistance. Am J Pathol, 2013;182(6): 2254-63. 
156. Chung B, Matak P, McKie AT, et al. Leptin increases the expression of the iron 
regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr, 2007;137: 
2366-2370. 
157. Gao Y, Li Z, Gabrielsen JS, et al. Adipocyte iron regulates leptin and food intake. 
J Clin Inv, 2015;125(9): 3681-91 
158. Malgor LA, Barrios L, Blanc CC. Effects of testosterone on bone marrow 
erythroid cells of normal and nephrectomized rats. Acta Physiol Lat Am, 
1975;25(3): 179-87. 
159. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a 
potential mechanism for testosterone-induced erthrocytosis. J Clin Endocrinol 
Metab, 2010;95(10): 4743-4747. 
160. Liu Z, Ye F, Zhang H, et al. The association between the levels of serum ferritin 
and sex hormones in a large scale Chinese male population. PLoS One, 
2013;8(10): e75908. 
161. Winters SJ, Gogineni J, Karegar M, et al. Sex hormone-binding globulin gene 





162. Krishnasamy SS, Chang CC, Wang C, et al. Sex hormone-binding globulin and 
the risk for metabolic syndrome in children of south Asian indian origin. Endocr 
Pract, 2012;18: 668-675. 
163. Yang Q, Jian J, Katz S, et al. 17-beta-estradiol inhibits iron hormone hepcidin 
through an estrogen responsive element half-site. Endocrinol, 2012;153: 3170-
3178. 
164. Hou Y, Zhang S, Wang L, et al. Estrogen regulates iron homeostasis through 
governing hepatic hepcidin expression via an estrogen response element. Gene, 
2012;511: 398-403. 
165. McKnight GS, Lee DC, Palmiter RD. Transferrin gene expression: regulation of 
mRNA transcription in chick liver by steroid hormones and iron deficiency. J Biol 
Chem, 1980;255(1): 148-153. 
166. Wyllie S, Liehr JG. Release of iron from ferritin storage by redox cycling of 
stilbene and steroid estrogen metabolites: a mechanism of induction of free 
radical damage by estrogen. Arch Biochem Biophys, 1997;346(2): 180-86. 
167. Kilbarger A. The effect of iron overload on osteoblast function in cell culture 
[master’s thesis]. Greensboro, NC: The University of North Carolina at 
Greensboro; 2007. 
168. Persiano C, Marzetti E, Spinelli MS, et al. Physiopathology of bone modifications 
in beta-thalassemia. Anemia, 2012;2012, 5p. 
169. Zarjou A, Jeney V, Arosio P, et al. Ferritin ferroxidase activity: a potent inhibitor 




170. Liu F, Zhang WL, Meng HZ, et al. Regulation of DMT1 on autophagy and 
apoptosis in obestoblast. Int J Med Sci, 2017;14(3): 275-283. 
171. Patti A, Gennari L, Merlotti D, et al. Endocrine actions on osteocalcin. Int J 
Endocrinol, 2013;2013: 10p. 
172. Juanola-Falgarona M, Candido-Fernandez J, Salas-Salvado J, et al. Association 
between serum ferritin and osteocalcin as a potential mechanism explaining the 
iron-induced insulin resistance. PLoS One, 2013;8(10): e76433. 
173. Lukaski HC, Hall CB, Nielsen FH. Thermogenesis and thermoregulatory function 
of iron-deficient women without anemia. Aviat, Space, and Environ Med, 
1990;61: 913-20. 
174. Beard JL, Borel MJ, Derr J. Impaired thermoregulation and thyroid function in 
iron-deficiency anemia. Am J Clin Nutr, 1990;52: 813-9. 
175. Brigham D, Beard J, Tobin B. Iron and thermoregulation: a review. Crit Rev Food 
Sci Nut, 1996;36(8): 747-63. 
176. Rosenzweig PH, Volpe SL. Iron, thermoregulation and metabolic rate. Crit Rev 
Food Sci Nut, 1999;39(2): 131-48. 
177. Jian J, Pelle E, Huang X. Iron and menopause: does increased iron affect the 
health of postmenopausal women? Antiox Redox Signal, 2009;11(12): 2939-2943. 
178. Darshan D, Frazer DM, Anderson GJ. Molecular basis of iron-loading disorders. 
Exp Rev Mol Med, 2010;12: e36 22p. 
179. Siddique A, Kowdley KV. Review article: the iron overload syndromes. Ailment 




180. Makker J, Hanif A, Bajantri B, et al. Dysmetabolic hyperferritinemia: all iron 
overload is not hemochromatosis. Case Rep Gastroenterol, 2015;9: 7-14. 
181. Sebastiani G, Pantopoulos K. Disorders associated with systemic or local iron 
overload: from pathophysiology to clinical practice. Metallomics, 2011;3: 971-86. 
182. Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity. IMAJ, 
2008;10: 83-84. 
183. Ashrafian H. Hepcidin: the missing link between hemochromatosis and 
infections. Infect Immun, 2003;71(12): 6693-6700. 
184. Miura K, Taura K, Schnabl B, et al. Hepatitis C virus-induced stress suppresses 
hepcidin expression through increased histone deacetylase activity. Hepatol, 
2008;48: 1420-29. 
185. Nekhai S, Kumari N, Dhawan S. Role of cellular iron and oxygen in the 
regulation of HIV-1 infection. Future Virol, 2013;8(3): 301-11. 
186. Walker EM Jr., Walker SM. Review: effects of iron overload on the immune 
system. Ann Clin Lab Sci, 2000;30(4): 354-65. 
187. Artym J, Zimecki M, Paprocka M, et al. Orally administered lactoferrin restores 
humoral immune response in immunocompromised mice. Immunol Letters, 
2003;89(1): 9-15. 
188. Lok HC, Sahni S, Jansson PJ, et al. A nitric oxide storage and transport system 
that protects activated macrophages from endogenous nitric oxide cytotoxicity. J 
Biol Chem, 2016;291: 27042-61. 





190. Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell 
functions. Ann Rheum Dis, 2006;65(Suppl 3): iii37-40. 
191. Fontana RJ, Israel J, LeClair P, et al. Iron reduction before and during interferon 
therapy of chronic hepatitis C: results of a multicenter, randomized, controlled 
trial. Hepatol, 2000;31(3): 730-6. 
192. Alexander J, Tung, BY, Croghan A, et al. Effect of iron depletion on serum 
markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic 
hepatitis C: results of a pilot study. Liver Int, 2007;27(2): 268-73. 
193. Halliwell B Gutteridge JMC. Oxygen toxicity, oxygen radicals, transition metals 
and disease. Biochem J, 1984;219: 1. 
194. Lauffer RB, ed. Iron and Human Disease. Boca Raton, Ann Arbor; London, 
Tokyo: CRC Press; 1992. 
195. Himmelfarb, J. Iron regulation. J Am Soc Nephrol, 2007;18: 379-81. 
196. Evststiev R, Gasche C. Iron sensing and signaling. Gut, 2011;online: 1-20. 
197. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: a key role 
in iron overload and iron toxicity. Biochimica et Biophysica Acta, 2011;(in press): 
8p. 
198. "FASTSTATS - Leading Causes of Death." Centers for Disease Control and 
Prevention. Web. 27 Dec. 2011. http://www.cdc.gov/nchs/fastats/lcod.htm.  
199. "National Vital Statistics Reports." Centers for Disease Control and Prevention. 




200. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated 
with excess risk of myocardial infarction in eastern Finnish men. Circulation, 
1992;86: 803-811. 
201. Morrison HI, Semenciw RM, Mao Y, et al. Serum iron and risk of fatal acute 
myocardial infarction. Epidemiology, 1994;5: 243-246. 
202. Tzonou A, Lagiou P, Trichopoulou et al. Dietary iron and coronary heart disease 
risk: a study from Greece. Am J Epidemiol, 1998;147: 161-166. 
203. van der A DL, Peeters PH, Grobbee DE, et al. Dietary haem iron and coronary 
heart disease in women. Eur Heart J, 2004;26(3): 257-262. 
204. Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid 
atherosclerosis: prospective results from the Bruneck Study. Circulation, 
1997;96(10): 3300-3307. 
205. Bazrgar M, Karimi M, Peiravian F, et al. Apolipoprotein E4 allele and the risk of 
left ventricular dysfunction in thalassemia major. Iranian Cardiovasc Res J, 
2007;1(1): 13-19. 
206. Martins IJ, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, 
diabetes, and the convergence of risk factors for Alzheimer’s disease and 
cardiovascular disease. Molecular Psychiatry, 2006;11: 721-36. 
207. DePalma RG, Hayes VW, Chow BK, et al. Iron stores, inflammation and 
biomarkers: how do they influence atherosclerosis: do statins help? Notes from 
the Annual Society for Vascular Surgery Meeting, June 12, 2009: Denver, CO.  
208. Tuomainen TP, Kontula K, Nyyssonen K, et al. Increased risk of acute 




mutation: a prospective cohort study in men in eastern Finland. Circulation, 
1999;100(12): 1274-1279. 
209. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary 
hemochromatosis gene is associated with cardiovascular death in women. 
Circulation, 1999;100: 1268-1273. 
210. Salonen JT, Tuomainen TP, Salonen R, et al. Donation of blood is associated with 
reduced risk of myocardial infarction. Am J Epidemiol, 1998;148: 445-451. 
211. Ascherio A, Rimm EB, Giovannucci E, et al. Blood donations and risk of 
coronary heart disease in men. Circulation, 2001;103: 52-57. 
212. Sempos CT, Locker AC, Gillum RF, et al. Body iron stores and the risk of 
coronary heart disease. N Eng J Med, 1994;330: 1119-1124. 
213. Manttai M, Manninen V, Huttunen JK, et al. Serum ferritin and ceruloplasmin as 
coronary risk factors: a nested case control study in Helsinki Heart Study 
population. Circulation, 1993;83: 70. 
214. Ascherio A, Willett WC, Rimm EB, et al. Dietary iron intake and risk of coronary 
heart disease among men. Circulation, 1994;89: 969-974. 
215. Lia Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative 
findings from the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol, 
1994;139: 704-712. 
216. Derstine JL, Murray-Kolb LE, Yu-Poth S, et al. Iron status in association with 





217. Corti MC, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular 
disease. Ann Epidemiol, 1997;7: 62-68. 
218. Sullivan JL. Iron and the genetics of cardiovascular disease. Circulation, 
1999;100: 1260-1263. 
219. Kervinen H, Tenkanen L, Palosuo T, et al. Serum iron, infection and 
inflammation; effects on coronary risk. Scand Cardiovasc J, 2004;38: 345-348. 
220. Bozzini C, Girelli D, Tinazzi E, et al. Biochemical and genetic markers of iron 
status and the risk of coronary artery disease: an angiography-based study. 
Clinical Chem, 2002;48(4): 622-628. 
221. Richter C, Suter M, Walter PB. Mitochondrial free radical damage and DNA 
repair. Biofactors, 1998;7(3): 207-209. 
222. Chitambar CR. Cellular iron metabolism: mitochondria in the spotlight. Blood, 
2005;105(2): 1844-1845. 
223. Walter PB, Knutson MD, Paler-Martinez A, et al. Iron deficiency and iron excess 
damage mitochondria and mitochondrial DNA in rats. PNAS, 2002;99(4): 2264-
2269. 
224. Solaini G, Sgarbi G, Baracca A. Oxidative phosphorylation in cancer cells. 
Biochimica et Biophysica Acta, 2011;1807: 534-542. 
225. Wu T, Sempos CT, Freudenheim JL, et al. Serum iron, copper and zinc 
concentrations and risk of cancer mortality in US adults. Ann Epidemiol, 2004;14: 
195-201. 
226. Wells BJ, Mainous III AG, Everett CJ, et al. Iron, cholesterol, and the risk of 




227. Wurzelman JI, Silver A, Schreinemachers, et al. Iron intake and the risk of 
colorectal cancer. Cancer Epidemiol Biomarker Prev, 1996;5: 503-507. 
228. Lee DH, Anderson KE, Harnack LJ, et al. Heme iron, zinc, alcohol consumption, 
and colon cancer: Iowa Women’s Health Study. JNCI, 2004;5(3): 403-407. 
229. Cross AJ, Sinha R, Wood RJ, et al. Iron homeostatis and distal colorectal 
adenoma risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
Trial. Cancer Prec Res, 2011;4: 1465-1475. 
230. Balder HF, Vogel J, Margje CJF, et al. Heme and chlorophyll intake and risk of 
colorectal cancer in the Netherlands Cohort Study. Cancer Epidemiol Biomarker 
Prev, 2006;15: 717-725. 
231. Larsson SC, Adami HO, Giovannucci, E, et al. Re: heme iron, zinc, alcohol 
consumption, and risk of colon cancer. JNCI, 2005;97(3): 232-234. 
232. Cross AJ, Ferrucci LM, Risch A, et al. A large prospective study of meat 
consumption and colorectal cancer risk: an investigation of potential mechanisms 
underlying this association. Cancer Res, 2010;70: 2406-2414. 
233. Kabat GC, Miller AB, Jain M, et al. A cohort of dietary iron and heme iron intake 
and risk of colorectal cancer in women. British J Cancer, 2007;97: 118-122. 
234. Cross AJ, Gunter MJ, Wood RJ, et al. Iron and colorectal risk in the α-tocopherol, 
β-carotene cancer prevention study. Int J Cancer, 2006;118: 3147-3152. 
235. Chua A, Klopcic B, Lawrance IC, et al. Iron: an emerging factor in colorectal 
carcinogenesis. WJG, 2010;16(6): 663-672. 
236. Butterworth JR. Another important function for an old friend! The role of iron in 




237. Brookes MJ, Hughes S, Turner FE, et al. Modulation of iron transport proteins in 
human colorectal carcinogenesis. Gut, 2006;55: 1449-1460. 
238. Ward DG, Roberts K, Brookes MJ, et al. Increased hepcidin expression in 
colorectal carcinogenesis. World J Gastroenterol, 2008;14(9): 1339-1345. 
239. Weizer-Stern O, Adamsky K, Margalit O, et al. Hepcidin, a key regulator of iron 
metabolism, is transcriptionally activated by p53. British J Haematology, 138: 
253-262. 
240. Cui Y, Vogt S, Olson N, et al. Levels of zinc, selenium, calcium, and iron in 
benign breast tissue and risk of subsequent breast cancer. Cancer Epidemiol 
Biomarker Prev, 2007;16: 1682-1685. 
241. Lee DH, Anderson KE, Harnark LJ, et al. Dietary iron intake and breast cancer: 
The Iowa Women’s Health Study. Proc Amer Assoc Cancer Res, 2004;45. 
242. Mainous III AG, Wells BJ, Koopman RJ, et al. Iron, lipids, and risk of cancer in 
the Framingham Offspring Cohort. Am J Epidemiol, 2005;161: 1115-1122. 
243. Moore AB, Shannon J, Chen C, et al. Dietary and stored iron as predictors of 
breast cancer risk: a nested case-control study. Int J Cancer, 2009;125(5): 1110-
1117. 
244. Levi F, Pasche C, Lucchini F, et al. Dietary intake of selected micronutrients and 
breast cancer risk. Int J Cancer, 2001;91: 260-263. 
245. Kabat GC, Miller AB, Jain M, et al. Dietary iron and heme iron intake and risk of 





246. Kabat GC, Rohan TE. Does excess iron play a role in breast carcinogenesis? 
Cancer Causes Control, 2007;18: 1047-1053. 
247. Huang X. Does iron have a role in breast cancer? Lancet Oncol, 2008;9(8): 803-
807. 
248. Jian J, Yang Q, Dai J, et al. Effects of iron deficiency and iron overload on 
angiogenesis and oxidative stress: a potential dual role for iron in breast cancer. 
Free Radical Biol Med, 2011;50: 841-847. 
249. Silva MP, Tomal A, Perez CA, et al. Determination of Ca, Fe, Cu, and Zn and 
their correlations in breast cancer and normal adjacent tissues. X-Ray Spectrom, 
2009;38: 103-111. 
250. Thompson HJ, Kennedy K, Witt M, et al. Effect of dietary iron deficiency or 
excess on the induction of mammary carcinogenesis by 1-methyl-nitrosurea. 
Carcinogenesis, 1991;12(1): 111-114. 
251. Shpyleva SI, Tryndyak VP, Kovalchuk O, et al. Role of ferritin alterations in 
human breast cancer cells. Breast Cancer Res Treat, 2011;126: 63-71. 
252. Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regulation in breast 
cancer progression and prognosis. Sci Transl Med;43(2): 1-10. 
253. Kabat GC, Cross AJ, Park Y, et al. Intakes of dietary iron and heme-iron and risk 
of postmenopausal breast cancer in the National Institutes of Health-AARP Diet 
and Health Study. Am J Clin Nutr, 2010;92: 1478-1483. 
254. Cade J, Thomas E, Vail A. Case-control study of breast cancer in south east 




255. Majore S, Pennese A, DeSantis A, et al. HAMP gene mutation c.208T>C 
(p.C70R) identified in an Italian patient with severe hereditary hemochromatosis. 
Human Mutation, 2004:DOI: 10.1002/humu.9232. 
256. Fergelot P, Orhant M, Thenie A, et al. Over-expression of wild type and mutant 
HFE in a human melanocyte cell line reveals an intracellular bridge between 
MCH class I pathway and transferring iron uptake. Biology of the Cell, 2003;95: 
243-255. 
257. Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis: 
current concepts and progress. Am J Med, 2006;119: 391-399. 
258. Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new 
insights into the relationship between iron overload and chronic liver diseases. 
Digestive and Liver Disease, 2011;43: 89-95. 
259. Chan AT, Ma J, Tranah GJ, et al. Hemochromatosis gene mutations, body iron 
stores, dietary iron, and risk of colorectal adenoma in women. JNCI, 2005;97(12): 
917-926. 
260. Abraham BK, Justenhoven C, Pesch B, et al. Investigation of genetic variants of 
genes of the hemochomatosis pathway and their role in breast cancer. Cancer 
Epidemiol Biomarker Prev, 2005;14: 1102-1107. 
261. Kallianpur AR, Hall LD, Yadav M, et al. Increased prevalence of the HFE C282Y 
hemochromatosis allele in women with breast cancer. Cancer Epidemiol 
Biomarker Prev, 2004;13: 205-212. 
262. Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at 




263. Mahabir S, Forman MR, Dong YQ, et al. Mineral intake and lung cancer risk in 
the NIH-AARP Diet and Health Study. Cancer Epidemiol Biomarker Prev, 
2010;19(8): 14p. 
264. Tasevska N, Cross AJ, Dodd KW, et al. No effect of meat, meat cooking 
preferences, meat mutagens or heme iron on lung cancer risk in the Prostate, 
Lung, Colotectal and Ovarian Cancer Screening Trial. IJC, 2011;128: 402-411. 
265. Zhou W, Park S, Liu G, et al. Dietary iron, zinc, and calcium and the risk of lung 
cancer. Epidemiology, 2005;16(6): 772-779. 
266. Tasevska N, Sinha R, Kipnis V, et al. A prospective study of meat, cooking 
methods, meat mutagens, heme iron, and lung cancer risks. Am J Clin Nutr, 
2009;89: 1884-1894. 
267. Sinha R, Park Y, Graubard BI, et al. Meat and meat-related compounds and risk 
of prostate cancer in a large prospective cohort study in the United States. Am J 
Epidemiol, 2009;170: 1164-1177. 
268. Tzonou A, Signorello LB, Lagiou P, et al. Diet and cancer of the prostate: a case-
control study in Greece. Int J Cancer, 1999;80: 704-708. 
269. Kristal AR, Stanford JL, Cohen JH, et al. Vitamin and mineral supplement use is 
associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarker 
Prev, 1999;8: 887-892. 
270. Vlajinac HD, Marinkovic JM, Kocev NI. Diet and prostate cancer: a case-control 
study. Eur J Can, 1997;33(1): 101-107. 
271. Key TJA, Silcocks PB, Davey GK, et al. A case-control study of diet and prostate 




272. Choi JY, Neuhouser ML, Barnett MJ, et al. Iron intake, oxidative stress-related 
genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. 
Carcinogenesis, 2008;29(5): 964-970. 
273. Kuvibidila SR, Gauthier T, Rayford W. Serum ferritin levels and transferring 
saturation in men with prostate cancer. J Nat Med Assoc, 2004;96(5): 641-649. 
274. Ohno Y, Yoshida O, Oishi K, et al. Dietary β-carotene and cancer of the prostate: 
a case-control study in Kyoto, Japan. Cancer Res, 1988;48: 1331-1336. 
275. Lee MM, Wang RT, Hsing AW, et al. Case-control study of diet and prostate 
cancer in China. Cancer Cases Control, 1998;9: 545-552. 
276. Lee DH, Anderson KE, Folsom AR, et al. Heme iron, zinc and upper digestive 
tract cancer: The Iowa Women’s Health Study. Int J Cancer, 2005;117: 643-647. 
277. Deugnier Y. Iron and liver cancer. Alcohol, 2003;145: 145-150. 
278. Deugnier Y, Turlin B. Iron and hepatocellular carcinoma. J Gastroent Hepatol, 
2001;16: 491-494. 
279. Asare GA, Mossanda KS, Kew MC, et al. Hepatocellular carcinoma caused by 
iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology, 
2006;219: 41-52. 
280. Gangaidzo IT, Gordeuk VR. Hepatocellular carcinoma and African iron overload. 
Gut, 1995;37: 727-730. 
281. Sorrentino P, D’Angelo S, Ferbo U, et al. Liver iron excess in patients with 





282. Chen J, Chloupkova M. Abnormal iron uptake and liver cancer. Cancer Biol 
Therapy, 2009;8(18): 1699-1708. 
283. Viatte L, Nicholas G Lou DQ, et al. Chronic hepcidin induction causes 
hyposideremia and alters pattern of iron accumulation in hemochromatotic mice. 
Blood, 2006;107: 2952-2958. 
284. Aktar M, Akhmedkhanov A, Zeleniuch-Jaquotte A, et al. Relaibility of serum 
iron, ferritin, nitrite, and association with risk of renal cancer in women. Cancer 
Detect Prev, 2003;27(2): 116-121. 
285. Michaud DS, Giovannucci E, Willett WC, et al. Dietary meat, dairy products, fat, 
and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol, 
2003;157: 1115-1125. 
286. Kesavan Y, Giovannucci E, Fuchs CS, et al. A prospective study of magnesium 
and iron intake and pancreatic cancer in men. Am J Epidemiol, 2010;171: 223-
241. 
287. Richardson, DR. Molecular mechanisms of iron uptake by cells and the use of 
iron chelators for the treatment of cancer. Current Medicinal Chem, 2008;12: 
2711-2729. 
288. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment 
of iron overload disease and cancer. Pharm Rev, 2005;57(4): 547-583. 
289. Woo KJ, Lee TJ, Park JW, et al. Desferrioxamine, an iron chelator, enhances 





290. Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, reduces 
inflammation and atherosclerotic lesion development in experimental mice. Exp 
Biol Med, 2010;235(5): 633-641. 
291. Edgren G, Reilly M, Tran TN, et al. Donation frequency, iron loss, and risk of 
cancer among blood donors. JNCI, 2008;100(8): 572-578. 
292. Garry PJ, Wayne SJ, Koehler KM, et al. Prediction of iron absorption based on 
iron status of female blood donors. Am J Clin Nutr, 1992;56: 691-698. 
293. Dorak MT, Burnett AK, Worwood M. Hemochromatosis gene in leukemia and 
lymphoma. Leukemia & Lymphoma, 2002;43(3): 467-477. 
294. Okcu MF, Goodman KJ, Carozza SE, et al. Birth weight, ethnicity, and 
occurrence of cancer in children: a population-based, incident case-control study 
in the State of Texas, USA. Cancer Causes Control, 2002;13: 595-602. 
295. Ross JA. High birthweight and cancer: evidence and implications. Cancer 
Epidemiol Biomarkers Prev, 2006;15(1): 1-2. 
296. McLaughlin CC, Baptiste MS, Schymura MJ, et al. Birth weight, maternal weight 
and childhood leukemia. British J Can, 2006;94: 1738-1744. 
297. Milne E, Laurvick CL, Blair E, et al. Fetal growth and cute childhood leukemia: 
looking beyond birth weight. Am J Epidemiol, 2007;166: 151-159. 
298. Celebreeze J, Catalano PM. The infant of the woman with gestational diabetes 
mellitus. Clin Obstet Gynecol, 2000;43(1): 127-139. 
299. Persuad OD. Maternal diabetes and the consequences for her offspring. J 




300. Nold JL, Georgieff MK. Infants of diabetic mothers. Pediatr Clin N Am, 2004;51: 
619-637. 
301. Berglund G, Zetterson R. Infants of diabetic mothers: foetal hypoxia in maternal 
diabetes. Acta Pediatr, 1954;43:368-373. 
302. Shetty JK, Prakash M, Ibrahim MS. Relationship between free iron and glycated   
hemoglobin in uncontrolled type 2 diabetes patients associated with 
complications. Ind J Clin Biochem, 2008:23(1): 67-70. 
303. Strohsnitter WC, Savarese TM, Low HP, et al. Correlation of umbilical cord 
blood hematopoietic stem and progenitor cell levels with birth weight: 
implications for a prenatal influence on cancer risk. BJM, 2008;98: 660-663. 
304. Hartfield DS, Lowry NJ, Keene DL, et al. Iron defiency: a cause of stroke in 
infants and children. Pediatric Neurology, 1997;16(1): 50-53. 
305. Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia 
and stroke in young children. Pediatrics, 2007;120(5): 1053-1057. 
306. Munot P, DeVile C, Hemingway C, et al. Severe iron deficiency anaemia and 
ischaemic stroke in children. Arch Dis Child, 2011;96: 276-279. 
307. Gillum RF, Sempos CT, Makuc DM, et al. Serum transferring saturation, stroke 
incidence, and morality in women and men. Am J Epidemiol, 1996;144: 59-68. 
308. Ghio AJ, Hilborn ED, Stonehuerner JG, et al. Particulate matter in cigarette 
smoke alters iron homeostasis to produce a biological effect. Am J Respir Crit 




309. Verrills NM, Irwin JA, He XY, et al. Identification of novel diagnostic 
biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med, 2011;183: 1633-1643. 
310. Bala S, Tabaku A. COPD rates high among eastern European iron/steel workers. 
Central Eur J Publ Health, 2010; online. 
311. Pelizzoni I, Macco R, Francesco M, et al. Iron handling in hippocampal neurons: 
activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging 
Cell, 2011;10: 172-83. 
312. Yaari R, Corey-Bloom J. Alzheimer’s disease. Semin Neurol, 2007;27: 32-41. 
313. Belzil C. Alzheimer’s dementia. Lethbridge Undergrad Res J, 2007;1(2): 1-8. 
314. Hendrie H. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr 
Psychiatr, 1998;(suppl 6): S3-S18. 
315. Farlow MR. Etiology and pathogenesis of Alzheimer’s disease. Am J Health-Syst 
Pharm, 1998;55(suppl 2): S5-S10. 
316. Fallin MD, Matteini A. Genetic epidemiology in aging research. J Geront, 
2009;64A(1): 47-60. 
317. Kuller LH. Dementia epidemiology research: it is time to modify the focus of 
research. J Geront, 2006;61A(12): 1314-18. 
318. Mihai G. Methods for brain iron evaluation in normal aging: t2 and phase 
measurements at 3 tesla and 7 tesla. Dissertation, 2007. 1-157. 
319. Kirsch W, McAuley G, Holshouser B, et al. Serial susceptibility weighted MRI 





320. Bartzokis G, Lu PH, Tishler TA, et al. Prevalent iron metabolism gene variants 
associated with increased brain ferritin iron in healthy older men. J Alzheim Dis, 
2010;20(1): 333-41. 
321. Zecca L, Moussa B, Youdim H, et al. Iron, brain ageing and neurodegenerative 
disorders. Nature Reviews, 2004;5: 863-73. 
322. Umur EE, Oktenli C, Celik S, et al. Increased iron and oxidative stress are 
separately related to cognitive decline in elderly. Geriatr Gerontol Int, 2011;11: 
504-509. 
323. Pelizzoni I, Macco R, Zacchetti D, et al. Iron and calcium in the central nervous 
system: a close relationship in health and sickness. Biochm Soc Trans, 2008;36: 
1309-12. 
324. Weiss G, Werner-Felmayer G, Werner ER, et al. Iron regulates nitric oxide 
synthase activity by controlling nuclear transcription. J Exp Med, 1994;180: 969-
76. 
325. Bartzokis G, Lu PH, Tishler TA, et al. Prevalent iron metabolism gene variants 
associated with increased brain ferritin iron in healthy older men. J Alzheim Dis, 
2010;20(1): 333-41. 
326. Moalem S, Percy ME, Andrews DF, et al. Are hereditary hemochomatosis 
mutations involved in Alzheimer disease? Am J Med Genet, 2000;93: 58-66. 
327. Lehmann DJ, Worwood M, Ellis R, et al. Iron genes, iron load and risk of 




328. Berlin D, Chong G, Chertkow, H, et al. Evaluation of HFE (hemochromatosis) 
mutations as genetic modifiers in sporadic AD and MCI. Neurobiol of Aging, 
2004;25: 465-474. 
329. Alizadeh BZ, Njajou OT, Millan MR, et al. HFE variants, APOE and Alzheimer’s 
disease: findings from the population-based Rotterdam Study. Neurobiol of 
Aging, 2009;30:330-32. 
330. Guerreiro RJ, Bras JM, Santana I, et al. Association of HFE common mutations 
with Parkinson’s disease, Alzheimer’s disease and mild cognitive impairment in a 
Portuguese cohort. BMC Neurology, 2006;24(6): 1-8. 
331. Percy M, Moalem S, Garcia A, et al. Involvement of APOE E4 and H63D in 
sporadic Alzheimer’s disease in a folate-supplemented Ontario population. J 
Alzheim Dis, 2008;14: 69-84. 
332. de la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? 
Data, dogma, and dialectics. Lancet, 2004;3: 184-190. 
333. Leahy JL (Ed). Contemporary endocrinology: type 2 diabetes mellitus: an 
evidence-based approach to practical management. Epidemiology of type 2 
diabetes. Feinglos MN, Bethel MA (Eds): Humana Press, Totowa, NJ; 2008. 
334. Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care, 
1998;21(3): C3-C6. 
335. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. A 






336. Whiting DR, Guariguata L, Weil C, et al.IDF diabetes atlas: global estimates of 
the prevalence of diabtes for 2011 and 2030. Diabet Res Clin Prac, 2011;94: 311-
321. 
337. McCulloch DK, Nathan DM, Mulder JE. Risk factors for type 2 diabetes. In: Post 
T, ed. UpToDate. Waltham, Mass.: UpToDate; 2017. www.uptodate.com. 
338. Papier K, Jordan S, D’Este C, et al. Incidence and risk factors for type 2 diabetes 
mellitus in transitional Thailand: results from the Thai cohort study. BMJ Open, 
2016;6: e014102. 
339. Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed 
diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA, 
2014;312(12): 1218-26. 
340. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity and risk of type 2 diabetes in 
women: a 20-year follow-up study. Diabets Care, 2006;29(7): 1585-90. 
341. Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin 
resistance and impaired insulin secretion. IJCP, 2000;(Suppl 11): 3-13. 
342. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res, 2005;36: 197-
209. 
343. Jenssen T, Hartmann A. Emerging treatments for post-transplantation diabetes 
mellitus. Nat Rev Nephrol, 2015;11(8): 465-77. 
344. McCulloch DK, Nathan DM, Mulder JE. Pathogenesis of type 2 diabetes mellitus. 




345. Lodish H, Berk A, Zipursky SL, et al. Molecular Cell Biology. 4th edition. New 
York: W. H. Freeman; 2000. Section 16.1, Oxidation of Glucose and Fatty Acids 
to CO2. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21624/. 
346. Pietrocola F, Galluzi L, Bravo-San Pedro JM. Acetyl coenzyme A: a central 
metabolite and second messenger. Cell Metab, 2015;21(6): 805-21. 
347. Lam TK, van de Werve G Giacca A. Free fatty acids increase basal hepatic 
glucose production and induce hepatic insulin resistance at different sites. Am J 
Physiol Endocrinol Metab, 2003;284(2): E281-90. 
348. Corcoran MP, Lamon-Fava S, Fielding RA. Skeletal muscle lipid deposition and 
insulin resistance: effect of dietary fatty acids and exercise. Am J Clin Nutr, 
2007;85(3): 662-677. 
349. Marzban L, Park K, Verchere CB. Islet amyloid polypeptide and type 2 diabetes. 
Exp Gerontol, 2003;38(4): 347-51. 
350. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the 
treatment of diabetes. Diabetes, 2004;53(suppl 3): S233-38. 
351. Pagani L, Eckert A. Amyloid-beta interaction with mitochondria. Int J 
Alzheimer’s Dis, 2011; Published online 2011 Mar 15. doi:  10.4061/2011/925050 
352. Du H, Guo L, Fang F, et al. Cyclophilin D deficiency attenuates mitochondrial 
and neuronal perturbation and ameliorates learning and memory in Alzheimer’s 
disease. Nat Med, 2008;14(10): 1097-1105. 
353. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases 
endogenous amyloid-beta peptide (AB) levels and protects hippocampal neurons 




354. Patel SK, Goyal RK, Anand IS, et al. Glucagon like peptide-1: a new therapeutic 
target for diabetes mellitus. Indian J Pharmacol, 2006;38(4): 231-237. 
355. Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-
1. Prog Mol Biol Transl Sci, 2014;121: S23-65. 
356. Bogardus C. Missing heritability and GWAS utility. Obesity (Silver Spring), 
2009;17(2): 209-210. 
357. Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be 
unified and what needs to be individualized? J Clin Endocrinol Metab, 
2011;96(6): 1654-63. 
358. Sacerdote C. Ricceri F, Rolandsson O, et al. Lower educational level is a 
predictor of incident type 2 diabetes in European countries: the EPIC-InterAct 
study. Int J Epidem, 2012;41: 1162-73. 
359. Krishnan S, Cozier YC, Rosenberg L, et al. Socioeconomic status and incidence 
of type 2 diabetes: results from the black women’s health study. Am J Epidemiol, 
2010;171: 564-570. 
360. Steele CJ, Schottker B, Marshall AH, et al. Education achievement and type 2 
diabetes-what mediates the relationship in older adults? Data from the ESTHER 
study: a population-based cohort study. BMJ Open, 2017;7: e013569. 
361. Papier K, Jordan S, D’Este, et al. Incidence and risk factors for type 2 diabetes 
mellitus in transitional Thailand: results from the Thai cohort study. BMJ Open, 
2016;6: e014102. 
362. Agardh EE, Sidor A, Hallqvist J, et al. Burden of type 2 diabetes attributed to 




363. Shang X, Li J, Tao Q, et al. Educational level, obesity and incidence of diabetes 
among Chinese adult men and women aged 18-59 years old: an 11-year follow-up 
study. PLoS One, 2013;8(6): e66479. 
364. Dalsgaard, EM. Socio-economic position and risk of T2DM. Diapedia, 2015;10: 
published online at https://doi.org/10.14496/dia.3104466190.10. 
365. Joseph JJ, Echouffo-Tcheugui JB, Golden SH, et al. Physical activity, sedentary 
behaviors and the incidence of type 2 diabetes mellitus: the multi-ethnic study of 
atherosclerosis (MESA). Diabetes Res Care, 2016;4: e000185. 
366. Rajpathak SN, Crandall JP, Wylie-Rosett J, et al. The role of iron in type 2 
diabetes. Biochimica et Biophysica Acta, 2009;1790: 671-681 
367. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic 
and clinical aspects. Semin Hematol, 1998;35(1): 55-71. 
368. Conniff ME, James FD, Huang TT, et al. Reduction in Mn-superoxide dismutase 
(SOD2) corrects insulin resistance due to high fat feeding in oxidative tissues of 
mice. FASEB, 2008;22(Meeting Abstract Supplement): 1226.44. 
369. Cooksey RC, Jouihan HA, Ajioka RS, et al. Oxidative stress, beta-cell apoptosis, 
and decreased insulin secretory capacity in mouse models of hemochromatosis. 
Endocrinology, 2004;145: 5305-5312. 
370. Jiang R, Manson JE, Meigs JB, et al.Body iron stores in relation to risk of 
type 2 diabetes in apparently healthy women. JAMA 2004;291(6): 711–717. 
371. Lee DH, Folsom AR, Jacobs DR Jr., et al. Dietary iron intake and Type 2 diabetes 
incidence in postmenopausal women: the Iowa Women’s Health Study. 




372. Song Y, Manson JE, Buring JE, Liu S. A prospective study of red meat 
consumption and type 2 diabetes in middle-aged and elderly women: the 
women’s health study. Diabetes Care, 2004;27(9): 2108–15. 
373. Fumeron F, Pean F, Driss F, et al. Ferritin and transferrin are both predictive of 
the onset of hyperglycemia in men and women over 3 years:  the data from an 
epidemiological study on the Insulin Resistance Syndrome (DESIR) study. 
Diabetes Care, 2006;29(9): 2090–2094. 
374. Rajpathak S, Ma J, Manson J, et al. Iron intake and the risk of type 2 diabetes 
in women a prospective cohort study. Diabetes Care, 2006;29(6): 1370–6. 
375. Fourouri NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict 
new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. 
Diabetologia, 2007;50(5): 949-56. 
376. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, et al. A prospective 
study of plasma ferritin level and incident diabetes the Atherosclerosis Risk in 
Communities (ARIC) Study. Am J Epidemiol, 2007;165(9): 1047–54. 
377. Le TD, Bae S, Ed Hsu C, Singh KP, Blair SN, et al. Effects of 
Cardiorespiratory Fitness on Serum Ferritin Concentration and Incidence of 
Type 2 Diabetes: Evidence from the Aerobics Center Longitudinal Study 
(ACLS). Rev Diabet Stud, 2008;5(4): 245–52. 
378. Mainous AG 3rd, King DE, Pearson WS, Garr DR. Is an elevated serum 
transferrin saturation associated with the development of diabetes? J Fam 




379. Jones AF, Winkles JW, Jennings PE, Florkowski CM, Lunec J, Barnett AH. 
Serum antioxidant activity in diabetes mellitus. Diabetes Res 1988; 7(2): 89–92. 
380. Abou-Shousha S, Abd El-Megeed MH, Sultan HK. Interleukin-8, ferritin and 
soluble transferrin receptors in type II diabetes mellitus. Egypt J Immunol, 
2006;13(1): 19–25. 
381. Smotra S, Kudyar RP. Relationship between serum ferritin and type-2 diabetes 
mellitus. JK Science, 2008;10(4): 170-174. 
382. Waheed P, Naveed AK, Farooq F. Levels of inflammatory markers and their 
correlation with dyslipidemia in diabetics. J Coll Physicians Surg Pak, 
2009;19(4): 207–210. 
383. Ellervik C, Mandrup-Poulsen T, Andersen HU, et al. Elevated transferrin 
saturation and risk of diabetes: three population-based studies. Diabetes Care, 
2011; 34(10): 2256–2258. 
384. Skomro RP, Ludwig S, Salamon E, Kryger MH. Sleep complaints and restless legs 
syndrome in adult type 2 diabetics. Sleep Med, 2001;2(5): 417–422. 
385. Elis 2004 Elis A, Ferencz JR, Gilady G, Livne A, Assia EI, Lishner M. Is serum 
ferritin high in patients with diabetic retinopathy? A controlled study.  Endocr 
Res, 2004; 30(2): 141–147. 
386. Rajpathak SN, Wylie-Rosett J, Gunter MJ, et al. Biomarkers of body iron stores 





387. Hughes K, Choo M, Kuperan P, Ong CN, Aw TC. Cardiovascular risk factors in 
non-insulin-dependent diabetics compared to non-diabetic controls: a population-
based survey among Asians in Singapore. Atherosclerosis, 1998; 136(1): 25–31. 
388. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. 
adults. Diabetes Care, 1999; 22(12): 1978–1983. 
389. Shi Z, Hu X, Yuan B, Pan X, Meyer HE, Holmboe-Ottesen G. Association 
between serum ferritin, hemoglobin, iron intake, and diabetes in adults in Jiangsu, 
China. Diabetes Care, 2006; 29(8): 1878–1883. 
390. Kim C, Cheng YJ, Beckles GL. Inflammation among women with a history of 
gestational diabetes mellitus and diagnosed diabetes in the Third National Health and 
Nutrition Examination Survey. Diabetes Care, 2008; 31(7): 1386–1388. 
391. Luan DC, Li H, Li SJ, Zhao Z, Li X, Liu ZM. Body iron stores and dietary 
iron intake in relation to diabetes in adults in North China. Diabetes Care 
2008; 31 (2): 285–286. 
392. Sun L, Franco OH, Hu FB, et al. Ferritin concentrations, metabolic syndrome, and 
type 2 diabetes in middle-aged and elderly Chinese. J Clin Endocrinol Metab, 
2008;93(12): 4690–4696. 
393. Kim CH, Kim HK, Bae SJ, Park JY, Lee KU. Association of elevated serum 
ferritin concentration with insulin resistance and impaired glucose metabolism in 
Korean men and women. Metabolism, 2011;60(3):  414–420. 
394. Lee BK, Kim Y, Kim YI. Association of serum ferritin with metabolic syndrome 




Korean National Health and Nutrition Examination Survey 2008. Metabolism, 
2011; 60(10): 1416–1424. 
395. Orban E, Schwab S, Thorand B, et al. Association of iron indices and type 2 
diabetes: a meta-analysis of observational studies. Diab Metab Res Rev, 2014;30: 
372-94. 
396. Zhao Z, Li S, Liu G, et al. Body iron stores and heme-iron intake in relation to 
risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One, 
2012;7(7): e41641. 
397. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron 
metabolism and diabetes. Diabetes, 2002; 51(8): 2348–2354. 
398. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-
intolerant patients with clinical evidence of nonalcoholic fatty liver diease. 
Gastroenterol, 2002;122(4): 931-9. 
399. Reaven GM. Role of insulin resistance in human disease. Diabetes, 1988;37(12): 
1595-1607. 
400. Thaman RG, Arora GP. Metabolic syndrome: definition and pathophysiology-the 
discussion goes on! J Phys Pharm Adv, 2013;3(3): 48-56 
401. Shankar P, Sundarka M. Metabolic syndrome: its pathogenesis and management. 
JIACM, 2003;4(4): 275-81. 
402. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech, 
2009;2(5-6): 231-37. 
403. Handselman Y. Metabolic syndrome pathophysiology and clinical presentation. 




404. Laclaustra M, Corella D. Ordovas JM. Metabolic syndrome pathophysiology of 
adipose tissue. Nut Met Cardio Dis, 2007;17: 125-139. 
405. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic 
syndrome. Curr Hypertens Rep, 2008;10: 156-64. 
406. Alberi KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic 
syndrome: a joint interim statement of the international diabetes federation task 
force on epidemiology and prevention; national heart, lung and blood institute, 
American heart association, world heart federation, international atherosclerosis 
society and international association for the study of obesity. Circulation, 
2009;120: 1640-1645. 
407. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US 
adults. JAMA, 2002;287: 356-359. 
408. Kolovou GD, Anagnostpoulou KK, Cokkinos DV. Pathophysiology of 
dyslipidaemia in the metabolic syndrome. Poastgrad Med J, 2005;81: 358-366. 
409. Aguilar M, Bhuket T, Torres S, et al Prevalence of the metabolic syndrome in the 
United States. JAMA, 2015;313(19): 1973-4. 
410. Ramos RG, Olden K. The prevalence of metabolic syndrome among US women 
of childbearing age. AJPH, 2008;98: 1122-27. 
411. Miranda PJ, DeFronzo RA, Califf RM, et al. Metabolic syndrome: definition, 
pathophysiology and mechanisms. Am Heart J, 2005;149: 33-45. 
412. Beltran-Sanchez H, Harhay MO, Harhay MM, et al. Prevalence and trends of 





413. Moore JX, Chaudhary N, Akinyemiju T. Metabolic syndrome prevalence by 
race/ethnicity and sex in the United States, national health and nutrition 
examination survey, 1988-2012. Pub Health Res Prac, 2017;14(E24): 16p. 
414. Assah FK, Ekelund U, Brage S, et al. Urbanization, physical activity and 
metabolic health in sub-saharan Africa. Diabetes Care, 2011;34(2): 491-96. 
415. Leroith D. Pathophysiology of the metabolic syndrome: implications for the 
cardiometabolic risks associated with type 2 diabetes. Am J Med Sci, 2012;343(1): 
13-16. 
416. Mikhail N. The metabolic syndrome: insulin resistance. Curr Hypertens Rep, 
2009;11: 156-58. 
417. Kanda H, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, 
insulin resistance, and hepatic steatosis in obesity. J Clin. Invest, 2006;116:1494–
1505. 
418. Aganovic I, Dusek T. Pathophysiology of metabolic syndrome. Published online 
at: 
http://www.ifcc.org/ifccfiles/docs/Pathophysiology_of_Metabolic_Syndrome.pdf 
419. McPherson R, Marcel Y. Role of cholesterol ester transfer protein in reverse 
cholesterol transport. Clin Cardiol, 1991;14: 31-34. 
420. DeVries R, Borggreve SE, Dullaart RP. Role of lipases, lechithin: cholesterol 
acyltransferase and cholesteryl ester transfer protein in abnormal high-density 
lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin 




421. Mendizabal Y, Llorens S, Nava E. Hypertension in metabolic syndrome: vascular 
pathology. Int J Hypertens, 2013;230868: 15p. 
422. Prase S, Jusupovic F, Ramic E, et al. Obesity is a risk factor for artherial 
hypertension. Mater Sociomed, 2012;24(2): 87-90. 
423. Sun J, Luo J, Ruan Y, et al. Free datty acids activate renin-angiotensin system in 
3T3-L1 adipocytes through nuclear factor-kapp B pathway. J Diabetes Res, 2016; 
Published online 2015 Dec 31. doi:  10.1155/2016/1587594. 
424. Egan BM, Greene EL, Goodfriend TL. Insulin and cardiovascular disease. Am J 
Hypertens, 2001;14(6 Pt 2): 116S-25S. 
425. Chen QW, Edvinsson L, Xu CB. Role of ERK/MAPK in endothelin receptor 
signaling in human aortic smooth muscle cells. BMC Cell Biol, 2009;10(52): 13p. 
426. Yanai H, Tomono Y, Ito K, et al. The underlying mechanisms for development of 
hypertension in the metabolic syndrome. Nutritional J, 2008;7:10: 6p. 
427. Sansbury BE, Bhatnagar A, Hill B. Impact of nutrient excess and endothelial 
nitric oxide synthase on the plasma metabolite profile in mice. Front Phisiol, 
2014, 5:43: 12p. 
428. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor 
for type 2 diabetes: The San Antonio Heart Stud. Diabetes Care, 2003;26(11): 
3153-59. 
429. Dragsbaeck K, Neergaard JS, Laursen JM, et al. Metabolic syndrome and 
subsequent risk of type 2 diabetes and cardiovascular disease in elderly women. 




430. Wilson PW, D’Agostino RB, Parise H, et al. Metabolic syndrome as a precursor 
of cardiovascular disease and type 2 diabetes. Circulation, 2005;112(20): 3066-
72. 
431. Vari IS, Balkau B, Kettaneh A, Andre P, Tichet J, Fumeron F. Ferritin and transferrin are 
associated with metabolic syndrome abnormalities and their change over time in a 
general population: Data from an Epidemiological Study on the Insulin Resistance 
Syndrome (DESIR). Diabetes Care 2007, 30:1795–1801. 
432. Park SK, Ryoo JH, Kim MG, Shin JY: Association of serum ferritin and the development 
of metabolic syndrome in middle-aged Korean men: a 5-year follow-up study. 
Diabetes Care 2012, 35:2521–2526. 
433. Xiao X, Liu J, Luo B, Feng X, Su Y. [Relationship of dietary iron intake, body 
iron overload and the risk of metabolic syndrome]. Wei Sheng Yan Jiu 2011;40: 
32-35. 
434. Hamalainen P, Saltevo J, Kautiainen H, Mantyselka P, Vanhala M: Erythropoietin, ferritin, 
haptoglobin, hemoglobin and transferrin receptor in metabolic yndrome: a case 
control study. Cardiovasc Diabetol, 2012;11:116. doi: 10.1186/1475-2840-11-116. 
435. Choi KM, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS and Baik SH. 
Association among serum ferritin, alanine aminotransferase levels, and metabolic 
syndrome in Korean post- menopausal women. Metabolism, 2005;54: 1510-1514. 
436. Shi Z, Hu X, Yuan B, Hu G, Pan X, Holmboe-Ottesen G. Coexistence of anaemia and the 
metabolic syndrome in adults in Jiangsu, China. Asia Pac J lin Nutr 2008, 17:505–513. 
437. Ryu SY, Kim KS, Park J, Kang MG, Han MA. Serum ferritin and risk of the metabolic 




438. Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, 
Gabrielsen D, Adams TD, Hunt SC, Hopkins PN, Cefalu WT and McClain DA. 
Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest, 
2012;12: 3529-3540. 
439. Tang L. The relationship between serum ferritin and metabolic syndrome. 
Zhejiang Medical Journal, 2007;29: 1331-1333. 
440. Jin Y, He L, Chen Y, et al. Association between serum ferritin levels and 
metabolic syndrome: an updated meta-analysis. Int J Clin Exp Med, 2015;8(8): 
13317-22. 
441. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty 
liver disease. Dig Dis, 2010;28: 155-61. 
442. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global 
perspective. Semin Liver Dis, 2008;28: 339-50. 
443. McCullough AJ. Epidemiology of the metabolic syndrome in the USA. J 
Digestive Dis, 2011;12: 333-40. 
444. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin 
Gastroenterol, 2006;40: S5-10. 
445. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis 
in an urban population in the United States: impact of ethnicity. Hepatol, 2004;40: 
1387-95. 
446. Vernon G, baranova A, Younossi ZM. Systematic review: the epidemiology and 
natural history of non-alcoholic fatty liver disease and non-alcoholic 




447. Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Women’s 
Health, 2009;5(2): 191-203. 
448. Rodrigues M, Diniz M, Medeiros-Filho J, et al. Metabolic syndrome and risk 
factors for non-alcoholic fatty liver disease. Arq Gastroenterol, 2012;49(1): 8p. 
449. Sherif ZA, Saeed A, Ghavimi S, et al. Global epidemiology of non-alcoholic fatty 
liver disease and perspectives on US minority populations. Dig Dis Sci, 
2016;61(5): 21p. 
450. Mohan V. Farooq S, Deepa, M, et al. Prevalence of non-alcoholic fatty liver 
disease in urban south Indians in relation to different grades of glucose 
intolerance and metabolic syndrome. Diabetes Res Clin Pract, 2009;84: 84-91. 
451. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-
alcoholic fatty liver disease. J Gastroenterol, 2013;48(4): 434-41. 
452. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology 
and pathogenesis. Ann Rev Pathol Mech Dis, 2010;5: 145-71. 
453. Yeh, MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin 
Pathol, 2007;128: 837-47. 
454. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev 
Gastroenterol Hepatol, 2017;14: 397-411. 
455. Green A, Rumberger JM, Stuart CA, et al. Stimulation of lipolysis by tumor 
necrosis factor-alpha in 3T3-L1 adipocytes is glucose dependent: implications for 
long-term regulation of lipolysis. Diabetes, 2004;53(1): 74-81. 
456. Yang J, Park Y, Zhang H, et al. Feed-forward signaling of TNF-alpha and NF-kB 




dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol, 
2009;296(6): H1850-58. 
457. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty 
liver disease. Q J Med, 2010;103: 71-83. 
458. Carulli L, Lonardo A, Lombardini S, et al. Gender, fatty liver and GGT. Hepatol, 
2006;44(1): 278-9. 
459. Zhang H, Liu Y, Li Z, et al. Differential effects of estrogen/androgen on the 
prevention of nonalcoholic fatty liver disease in the male rat. J Lipid Res, 
2013;54(2): 345-57. 
460. Dongiovanni P, Fracanzani AL, Fargion L. Iron in fatty liver and in the metabolic 
syndrome: a promising therapeutic target. J Hepatol, 2011;55: 920-32. 
461. Jézéquel C, Lainé F, Laviolle B, Kiani A, Bardou-Jacquet E, et al. (2015) Both 
hepatic and body iron stores are increased in dysmetabolic iron overload 
syndrome: a case-control study. PLoS ONE 10(6): 1-4. 
462. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty 
liver disease. Hepatol, 1999;30: 847-50. 
463. Mitsuyoshi H, Yasui K, Harano Y, et al. Analysis of hepatic genes involved in the 
metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol 
Res, 2009;39: 366-73. 
464. Nelson JE, Wilson L, Brunt EM, et al. Relationship between pattern of hepatic 
iron deposition and histologic severity in nonalcoholic fatty liver disease. 




465. Shim JJ. Body iron, serum ferritin, and non-alcoholic fatty liver disease. Korean J 
Hepatol, 2012;18: 105-7. 
466. Nelson JE, Brunt EM, Kowdley KV. Lower serum hepcidin and greater 
parenchymal iron in non-alcoholic fatty liver disease patients with C282Y HFE 
mutations. Hepatology, 2012; 56: 1730-40. 
467. Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic 
iron overload. Gastroenterology, 1999;117: 1155-63. 
468. Jaruvongvanich V, Riangwiwat T, Sanguankeo A, et al. Outcome of phlebotomy 
for treating nonalcoholic fatty liver disease: a systematic review and meta-
analysis. Saudi J Gastroenterol, 2016;22(6): 407-14. 
469. Britton LJ, Subramaniam VN, Crawford DHG. Iron and non-alcoholic fatty liver 
disease. WJG, 2016;22(36): 8112-22. 
470. Otogawa K, Kinoshita K, Fujii H, et al. Erythrophagocytosis by liver 
macrophages (Kupffer cells) promotes oxidative stress, inflammation and fibrosis 
in a rabbit model of steatohepatitis. Am J Patho, 2007;170(3): 967-80. 
471. Ghamarchehreh ME, Jonaidi-Jafari N, Bigdeli M, et al. Iron status and metabolic 
syndrome in patients with non-alcoholic fatty liver disease. Middle east J Dig Dis, 
2016;8(1): 31-38. 
472. Barisani D, Pelucchi S, Mariani R, et al. Hepcidin and iron-related gene 





473. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy 
improves insulin resistance in patients with NAFLD and hyperferritinemia: 
evidence from a case control study. Am J Gastroenterol, 2007;102: 1251-58. 
474. Bonora E, Kiechl S, Johann W, et al. Prevalence of insulin resistance in metabolic 
disorders: the Bruneck study. Diabetes, 1998;47(10): 1643-49. 
475. Savage DB, Peterson KF, Shulman GI. Mechanisms of insulin resistance in 
humans and possible links with inflammation. Hypertension, 2005;45: 828-833. 
476. Peterson KF, Shulman GI. Etiology of insulin resistance. Am J Med, 2006:119(5 
Suppl 1): S10-S16. 
477. Duez H, Lewis GF (Eds). Contemporary endocrinology: type 2 diabetes mellitus: 
an evidence-based approach to practical management. Fat metabolism in insulin 
resistance and type 2 diabetes. Feinglos MN, Bethel MA (Eds): Humana Press, 
Totowa, NJ; 2008. 
478. Muoio DM, Koves TR, An J, et al (Eds). Contemporary endocrinology: type 2 
diabetes mellitus: an evidence-based approach to practical management. 
Metabolic mechanisms of muscle insulin resistance. Feinglos MN, Bethel MA 
(Eds): Humana Press, Totowa, NJ; 2008. 
479. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of 
glucose homeostasis and metabolic harmony. J Clin Invest, 2006;116(7): 1767-75. 
480. Carvalho E, Kotani K, Peroni OD, et al. Adipose-specific overexpression of 
GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 




481. Long SD, Pekala PH. Lipid mediators of insulin resistance: ceramide signaling 
down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J, 
1996;319(Pt 1): 179-84. 
482. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and 
causes the redistribution of intracellular transferrin receptors to the plasma 
membrane. J Biol Chem. 1986, 261:8708–8711. 
483. Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 
3T3-L1 adipocytes through an increase in the rate constant for receptor 
externalization. J Biol Chem. 1987, 262:8975–8980. 
484. Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance 
of glucose transport in adipocytes. Metab, 2006;55(8): 1042-5. 
485. Jiang X, Wang H, Shi W, et al. Hyperinsulinemia induces hepatic iron overload 
by increasing liver TFR1 via the PI3K/IRP2 pathway. J Mol Endocrinol, 
2014;53(3): 381-92. 
486. Clairmont KB, Czech MP. Insulin injection increases the levels of serum 
receptors for transferrin and insulin-like growth factor-II/mannone-6-phosphate in 
intact rats. Endocrinol, 1990;127(4): 1568-73. 
487. Sheokand N, Malhotra H, Kumar S, et al. Moonlighting cell-surface GAPDH 
recruits apotransferrin to effect iron egress from mammalian cells. J Cell Sci, 
2014;127: 4279-91. 
488. Boradia VM, Raje M, Raje CI. Protein moonlighting in iron metabolism: 
glyceride-3-phosphate dehydrogenase (GAPDH). Biochem Soc Trans, 




489. Zager RA. Parenteral iron treatement induces MCP-1 accumulation in plasma, 
normal kidneys and in experimental nephropathy. Kidney Int, 2005;68(4): 1533-
1542. 
490. Elsammak M, Refai W, Elsawaf A, et al. Elevated serum tumor necrosis factor 
alpha and ferritin may contribute to the insulin resistance found in HCV positive 
Egyptian patients. Curr Med Res Opin, 2005;21(4): 527-33. 
491. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma 
protein encoded by the obese gene. Science, 1995;269(5223): 543-6. 
492. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory 
protein to biomarker of the metabolic syndrome. J Intern Med, 2005;257(2): 167-
75. 
493. Gavrila A, Peng CK, Chan JL, et al. Diurnal and ultradian dynamics of serum 
adiponectin in healthy men: comparison with leptin, circulating soluble leptin 
receptor and cortisol patterns. J Clin Endocrinol Met, 2003;88(6): 2838-2843. 
494. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin 
resistance and obesity. Clin Nutr, 2004;23(5): 963-74. 
495. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin 
receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest, 
2006;116(7): 1784-1782. 
496. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase 
expression and plasma concentrations of adiponectin, an adipose-derived protein. 




497. Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth 
muscle cell growth. Br J Pharmacol, 2012;165(3): 643-58. 
498. Ku BJ, Kim SY, Lee TY, et al. Serum ferritin is inversely correlated with serum 
adiponectin level: population-based cross-sectional study. Dis Markers, 
2009;27(6): 303-10. 
499. Kusminski CM, Holland WL, Sun K, et al. MitoNEET, a key regulator of 
mitochondrial function and lipid homeostasis. Nat Med, 2012;18(10): 1539-49. 
500. Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome 
proliferator-activated receptor-gamma target genes related to lipid storage in vivo. 
Diabetes Care, 2004;27(7): 1660-67. 
501. Qian M, Eaton JW. Iron translocation by free fatty acids. Am J Patho, 
1991;139(6): 1425-34. 
502. Nalini S, Balasubramanian KA. Studies of iron binding by free fatty acids. 
Indian J Biochem Biophys, 1993;30: 224-28. 
503. Boiteau RM, Mende DR, Hawco et al. Siderophore-based microbial 
adaptations to iron scarcity across the eastern Pacific Ocean. PNAS, 
2016;113(50): 14237-14242. 
504. Simpson RJ, Peters TJ. Transport of Fe2+ across lipid bilayers: possible role of 
free fatty acids. Biochim Biophys Acta, 1987;898(2): 187-95. 
505. National Center for Health Statistics. Plan and operation of the Third National 




506. National Center for Health Statistics. National Health and Nutrition Examination 
Survey response rate data available from: 
https://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0304MF.pdf 
507. National Center for Health Statistics. National Health and Nutrition Examination 
Survey response rate data available from: 
https://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0506MF.pdf 
508. National Center for Health Statistics. National Health and Nutrition Examination 
Survey response rate data available from: 
https://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0708MF.pdf 
509. National Center for Health Statistics. National Health and Nutrition Examination 
Survey response rate data available from: 
https://www.cdc.gov/nchs/data/nhanes/response_rates_cps/RRT0910.pdf 
510. National Center for Health Statistics. National Health and Nutrition Examination 
Survey 2003-2004. Documentation, codebook, and frequencies. Laboratory 
component. Ferritin and transferrin receptor. Available from: 
http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l06tfr_c.pdf. 
511. Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in 
US preschool children and nonpregnant females of childbearing age: National 
Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr, 2009;89: 
1333-42. 
512. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative 




513. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 
412-9.  
514. Whitfield JB. Gamma glutamyl transferase. Critical Rev Clin Lab Sci, 
2001;38(4): 263-355. 
515. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The 
NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in 
patients with NAFLD. Hepatology, 2007; 45:846–854. 
516. Taylor KW, Hoffman K, Thayer KA, et al. Polyfluoroalkyl chemicals and 
menopause among women 20-65 years of age (NHANES). Environ Health 
Perspect, 2014;122(2): 145-50. DOI:10.1289/ehp.1306707 
517. Wittes, J. Sample size calculations for the randomized controlled trials.  
Epidemiologic Reviews, 2002;24(1): 39-53. 
518. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 
6(2):65-70, 1979. 









Figure 1: Flowchart of sample N’s. 
 
 Females aged 12 and older in NHANES from 2003-2010 
N = 14,895 
Females with probable hemochromatosis  
N = 304 
Females with self-reported Hepatitis C infection 
N = 328 
Females who self-reported being pregnant at the time of interview 
N = 695 
Females missing data for serum ferritin or serum transferrin receptor  
N = 6,107 




Table 1: Demographics of female participants: continuous NHANES 2003-2010 
(N = 7,461) 




12-21 3,200 (42.89) 
22-31 1,490 (19.97) 
32-41 1,504 (20.16) 
42-49 1,267 (16.98) 
 
Ethnicity 
White 3,182 (42.65) 
Black 1,846 (24.76) 




< High school diploma 3,952 (52.97) 
High school diploma / GED 986 (13.22) 
Some college 1,542 (20.43) 
College degree / post graduate degree 995 (13.34) 
Waist circumference Mean (sd) 89.33 (16.85) 
Body mass index 
< 18.5 403 (5.46) 
18.5 – 24.9 3,039 (41.21) 
25.0 – 29.9 1,761 (23.88) 
> 29.9 2,172 (29.45) 
Alcohol 
Consumption 
0 drinks/d 4,635 (62.14) 
1-3 drinks/d 2,259 (30.29) 
> 3 drinks/d 565 (7.57) 
Smoking Status 
0 cigarettes/d 6,138 (82.29) 
1-5 cigarettes/d 506 (6.78) 
> 5 cigarettes/d 815 (10.93) 


























Table 2: Variables associated with reproductive lifespan of female 
participants: continuous NHANES 2003-2010 (N = 7,461) 
Variable Value N (%) 
Age at menarche Mean (sd) 12.36 (1.61) 
Age at menarche 
category* 
< 12 y  1,813 (27.75) 
12 y  1,851 (28.33) 
> 12 y  2,870 (43.92) 
Oral Contraceptive 
Use* 
No 3,063 (46.89) 
Yes  3,469 (53.11) 
Parity* 
0 3,235 (49.51) 
1 655 (10.02) 
2-3 1,628 (24.92) 
> 3 1,016 (15.55) 
Age at menopause Mean (sd) 43.94 (4.80) 
Age at menopause 
category* 
< 40 y  61 (16.99) 
40-45 y 127 (35.28) 
> 45 y 171 (47.63) 










































Table 3: Biochemical parameters of female participants: continuous NHANES 2003-2010 





females, mean (sd) 
Hemoglobin 
(g/dL) 
13.44 (2.96) 13.42 (2.64) 13.88 (1.10) 
Hematrocrit (%) 39.39 (9.09) 39.30 (8.02) 40.64 (3.75) 
Serum Iron 
(μg/dL) 
77.42 (48.74) 77.72 (47.89) 79.61 (39.34) 
TIBC (μg/dL) 365.02 (102.28) 366.06 (104.61) 340.57 (43.57) 
TSAT (%) 21.84 (13.68) 21.80 (12.86) 23.33 (11.57) 
sTfR (mg/L) 3.59 (2.47) 3.60 (2.43) 3.27 (1.56) 
Ferritin (μg/L) 47.94 (47.47) 44.73 (45.93) 86.28 (50.75) 
Serum Insulin 
(uIU/mL) 
11.67 (13.61) 11.46 (13.44) 11.12 (5.66) 
Serum Glucose 
(mmol/L) 
5.27 (1.41) 5.25 (1.40) 5.52 (0.96) 
GGT (U/L) 18.92 (29.63) 18.01 (26.45) 28.88 (40.07) 
Platelets (1000 
cells/uL) 
284.75 (118.27) 283.07 (117.33) 287.15 (86.42) 
Albumin (g/dL) 4.21 (0.62) 4.21 (0.62) 4.20 (0.43) 
Triglycerides 
(mg/dL) 
106.87 (138.58) 104.82 (146.83) 139.63 (55.40) 
HDL cholesterol 
(mg/dL) 
57.62 (36.17) 57.53 (34.33) 57.82 (17.69) 
HbA1c (%) 5.28 (0.78) 5.25 (0.80) 5.53 (0.84) 
C-reactive protein 
(mg/dL) 
0.39 (0.96) 0.38 (0.98) 0.51 (0.54) 
Table 4: Predictor and Outcome Variables 
 
Variable 









females, mean (sd) or 
tertile/category  cutoff 
% 
FeCOOK mean (SD) 6.98 (4.82) 6.74 (4.87) 9.98 (3.34) 
 
FeCOOK 
White 7.27 (4.28) 7.02 (4.21) 10.03 (2.36) 
Hispanic 6.51 (6.81) 6.31 (6.25) 10.33 (1.68) 
Black 5.95 (4.24) 5.70 (5.33) 9.46 (2.49) 
 
HOMA-IR 
< 3 64.06% 65.14% 62.05% 
3 - 5 24.96% 24.25% 22.56% 
> 5 10.98% 10.61% 15.38% 
 
U.S.-FLI 
< 30 92.62% 92.94% 88.42% 
≥ 30 7.38% 7.06% 11.58% 
NFS ≤ 0.676 99.63% 99.70% 97.87% 
> 0.676 0.37% 0.30% 2.13% 
Metabolic 
Syndrome 
Absent 84.29% 85.31% 69.52% 
Present 15.71% 14.69% 30.48% 
T2DM Absent 96.66% 97.08% 91.78% 




Table 5: Common iron parameters with reference ranges 
Iron Parameter Lab Test / Calculation Typical Range of Values / 
Reference Range 
Hemoglobin (Hb) Colorimeter  Males: 14 - 18 g/dL 
Females: 12 - 16 g /dL  
Hematocrit (Hct) Automated cell counter: (Red Cell 
Number/MCV) or 
Indirect: (packed red cells/1000 ml of 
whole blood) 
Range: 0 - 100% 
Males: 40 - 54% 
Females: 36 - 48% 
Hepcidin Immunoassay Males: 0.6 – 23.3 nM 
Females: 0.5 – 23.2 nM 
 
Mean corpuscular volume 
(MCV) 
(Volume of packed red cells/1000 mL 
of whole blood) / (red cell count in 
millions/mL) 
80 – 100 fL 
Mean corpuscular hemoglobin 
(MCH) 
(Hb (g) / 1000 mL whole blood) / (red 
cell count in millions/mL) 
26 – 34 pg/cell 
Mean corpuscular hemoglobin 
concentration (MCHC) 
(Hb (g) / 1000 mL whole blood) / 
(Volume of packed red cells/1000 mL 
of whole blood) 
31 -37 g/dL 
RDW Whole Blood 11.5 – 14.5% 
Glycosylated Hb 
Whole Blood 
4 – 6% 
Serum Iron (μg/dL) 
Whole Blood 












Table 5 (continued): Common iron parameters with reference ranges 
Transferrin  
Whole Blood 
170 – 370 mg/dL 
TIBC (μg/dL) 
Whole Blood 
250 – 450 mcg/dL 
TSAT (%) Serum Iron*(100)/TIBC Range: 0-100% 
25 – 35% 
sTfR (mg/L) Immunoassay  5.6 ± 0.3 mcg/L 
Ferritin (μg/L) Immunoassay  Males: 20 – 300 ng/mL 
Females: 15 – 200 ng/mL 
FeCOOK (mg/kg) (−[log10⁡(𝑅 ∗ 1000/𝐹)
− 2.8229])
/0.1207 
Range: -20 – 20 
Mean = 5.5 ± 3.4 mg/kg 
sTfR:Ferritin Index sTfR/log(F) Range: 1 – 10 
Mean = 4.1 ± 1.7 
Log(sTfR)/Ferritin ratio log(sTfR)/F  Range: 1 – 10  













Table 6a: Iron-loading conditions (primary iron overload) 















HFE 6p21 Autosomal 
recessive 


















TFR2 7q22 Autosomal 
recessive 















































































Table 6b: Iron-loading conditions (ineffective erythropoiesis) 






Locus Mode of 
Inheritance 

















































Table 6c: Iron-loading conditions (chronic hemolytic anemias) 






















































Table 6d: Iron-loading conditions (hypoplastic anemias) 

























Heterogeneous   Low 
hepcidin 






   High 
hepcidin 
 Iron loading, 
anemia due to 
ineffective 
erythropoiesis 
Adapted from 178-181 
 
 
Table 6e: Iron-loading conditions (other iron loading conditions) 




































































Table 7: Comparison of non-invasive measure for hepatic steatosis  
NALFD estimate Individual Components Sensitivity Specificity AUC 
Biopsy Liver sample ref ref ref 
Abdominal Ultrasound 
(AUS) 




Ratio between median 
brightness level of the liver 
and cortex of the right 
kidney  
Cutoff ≥ 1.5 
(representing 5% 
fatty liver), 100% 
(vs biopsy) 
(Webb) 
Cutoff ≥ 1.5 
(representing 5% 




AST-to-platelet ratio index 
(APRI) 
Aspartate aminotransferase 
/ platelet count 
89% (Adler) 75% (Adler) 0.82 (Adler) 
 
AST-to-ALT ratio Aspartate 
aminotransferase, alanine 
aminotransferase ratio 
53% 100% N/A 
 
Original European Liver 
Fibrosis panel (OELF) / 
Enhanced Liver Panel (ELF) 
Age, hyaluronic acid, n-
terminal propeptide of type 
III collagen, tissue 
inhibitors of matrix 
metalloproteinase-1 
Cutoff > 0.375, 
89% (Rosenberg) 























Table 7 (con’t): Comparison of non-invasive measure for hepatic steatosis  
NALFD estimate Individual Components Sensitivity Specificity AUC 
Fatty Liver Index (FLI) triglycerides, body mass 
index, gamma glutamyl 
transferase 
Cutoff > 20, 62% 
vs LAP (yang) 
Cutoff > 20, 






Cutoff ≥ 60, 87% 
(Bedogni) 
Cutoff ≥ 60, 
86% (Bedogni) 
 
Cutoff > 30, 
72% (Huang) 
 





Cutoff > 30, 80% 
Huang  
 
Cutoff = 60, 62% 
(Koehler) 
FIB-4 index Platelet count, aspartate 
aminotransferase, alanine 
aminotransferase, age  
Cutoff = 1.3, 85% 
(McPherson) 
70% (Shah) 







FibroIndex Platelet count, aspartate 
aminotransferase, gamma 
glutamyl transferase 
78% 74% N/A 
 




hyaluronic acid, blood urea 
nitrogen 
Cutoff = 0.61, 
79% (Cales) 




Fibrospect II Hyaluronic acid, tissue 
inhibitors of matrix 
metalloproteinase-1, alpha-
2 macroglobulin 
83.5% 66.7% N/A 
 
FibroTest gamma-2 macroglobulin, 
apolipoprotein A1, gamma 
glutamyl transferase, total 
bilirubin  
Fibrosis cutoff 
score ≥ 2, 77% 
(Ratziu) 
Fibrosis cutoff 




Forns Age, platelet count, gamma 
glutamyl transferase, 
cholesterol level 






Table 7 (con’t): Comparison of non-invasive measure for hepatic steatosis  
NALFD estimate Individual Components Sensitivity Specificity AUC 











Cutoff = 31.6, 
66% (Chiang) 






PGA index Prothrombin index, gamma 
glutamyl transferase, 
apolipoprotein A1 
91% 81% N/A 
 
SHASTA index Hyaluronic acid, aspartate 
aminotransferase, albumin 
100% 52% N/A 
 
SimpleTest Age, hyperglycemia, body 
mass index, platelet count, 
albumin, AST/ALT ratio 
78% 58% N/A 
 
SteatoTest FibroTest + alanine 
aminotransferase, body 
mass index, glucose, 
triglycerides, cholesterol, 
gender, age, sex 
Cutoff = 0.30, 
90% (vs biopsy) 
Cutoff = 0.30, 
90% (Poynard) 
Cutoff = 0.30, 
54%, (vs biopsy) 














Table 8: The association between iron stores and type 2 diabetes mellitus 
Author(s) Year Country / 
Ethnicity 
Study design Case selection / 
Source 
population 
Control selection N 










2006 Egypt Case-control NA Normal healthy 
volunteers 
20 /10 48.5 (10.6) Female only Serum ferritin, 
sTfR 
Mean difference in 
ferritin concentration 









2010 Tehran, Iran Cross-
sectional 
Members of the 
Iranian diabetes 
society in Tehran 
Normal healthy 
volunteers 




 Serum ferritin Mean difference in 
ferritin concentration 










DM patients w/o 
retinopathy 
Patients free from 
T2DM and 
retiopathy 
51 / 40 T2DM w/ 
retinopathy: 58 (3); 
T2DM w/o 
retinopathy: 63 










Mean difference in 
ferritin concentration 






Elsammak 2005 Egypt Case- control T2DM patients NA 22 / 18 Cases: 52.5 (7.8); 







Serum ferritin Mean difference in 
ferritin concentration 






Ford 1999 U.S.A Cross-
sectional 
NHANES III NHANES III w/o 
T2DM 
924 / 7,861 Non-DM: 42.1 
(SE: 0.4); IFG: 56.6 
(SE:0.9); Newly dx 
DM: 59.4 (SE: 
1.0); previously dx 
DM: 58.9 (SE: 0.8) 
Non-DM: 49.1 
(SE: 0.7); Newly 
dx DM: 52.7 
(SE: 4.6); 
previously dx 






































Table 8 (con’t): The association between iron stores and type 2 diabetes mellitus 
Author(s) Year Country / 
Ethnicity 
Study design Case selection / 
Source 
population 







Iron Indices Comparison Effect size Matching / 
adjustment 
variables 
Ganesh 2012 India Case-control Attendees of the 
Endocrine Clinic 




30 / 30 Cases: 43.6 (9.5); 






Mean difference in 
ferritin concentration 











aged 40-69 yrs 
from Singapore 
gen pop 
Those free from 
T2DM in same 
sample 
population 
126 / 530 Range: 40-69 51.2 Serum ferritin Mean difference in 
ferritin concentration 



















NHANES III w/o 
T2DM 
244 / 6,015 T2DM: 46 non-
T2DM: 36 
Females only Serum ferritin Mean difference in 
ferritin concentration 














1,054 / 11,036 Males: NFG: 50.4 
(9.5); IFG: 52.2 
(8.3); T2DM: 55.3 
(8.6) 
Females: NFG: 
49.5 (8.9); IFG: 
53.3 (8.8); T2DM: 
58.1 (8.2) 





Lee 2011 South Korea Cross-
sectional 
KNHANES 2008 KNHANES 2008 
participants w/o/ 
T2DM 
313 / 5,998 Males: 43.3 (SE: 
0.45) 
Premenopausal 
Females: 36.9 (SE: 
0.33)  
Postmenopausal 



























Table 8 (con’t): The association between iron stores and type 2 diabetes mellitus 
Author(s) Year Country / 
Ethnicity 
Study design Case selection / 
Source 
population 







Iron Indices Comparison Effect size Matching / 
adjustment 
variables 
Luan 2008 China Cross-
sectional 
CHANES CHANES 147 / 2,850 Males: 47.2 
(14.6); Females: 
46.8 (14.4) 










100 / 2,722 Males: 47.2 
(14.6); Females: 
46.8 (14.4) 
















Serum ferritin Mean difference in 
ferritin 
concentration 












50 / 50 Cases: 39.1 
(2.88); controls: 
39 (3.10) 
56 Serum ferritin Mean difference in 
ferritin 
concentration 





Sun 2008 China Cross-
sectional 
Nutrition & 






















FPG < 6 mmol/L 
30 / 30 NA NA Serum ferritin Mean difference in 
ferritin 
concentration 




Adapted from 395, 396 
   
Table 8 (con’t): The association between iron stores and type 2 diabetes mellitus 




Case selection / 
Source 
population 







Iron Indices Comparison Effect size Matching / 
adjustment 
variables 


























ARIC Study ARIC Study 599 / 690 Cases: 53.3 SE: 
0.24) 















698 / 716 Cases: 56.5 (6.9); 
controls: 56.4 (6.9) 

















1995 & 2001 
220 / 5,292 Males: 48.1 (9.2); 
Females: 48.6 (9.2) 

















280 / 280 Cases: 50.4 (SE: 
0.6); controls: 50.2 
(SE: 0.6) 









Salmoaa 2010 Finland Cohort 
(Follow-up 







179 / 4,798 Males: 52.1 (9.7) 
Females: 53.7 
(10.5) 
























Table 9: The association between iron stores and metabolic syndrome 
Author(s) Year Country / 
Ethnicity 




Control selection N 





Iron Indices Comparison Effect size Matching / 
adjustment 
variables 
Lee 2014 Korea Cross-sectional   51 / 1,299   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 






Rajpathak 2009 U.S.A Case-control   280 / 280   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 
(cases vs controls) 
50.4 (0.6) 
ng/mL vs 50.2 
(0.6) ng/mL 
 
Lin 2010 China Cross-sectional   166 / 1,479   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 
(cases vs controls) 
102.4 (65.95) 





2012 U.S.A Cohort   38 / 87   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 
(cases vs controls) 
260 (23) 
ng/mL vs. 185 
(21) ng/mL 
 
Tang 2007 China Case-control   60 / 63   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 






Li 2006 China Case-control   60 / 60   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 






Xiao 2011 China Case-control   87 / 102   Serum ferritin Mean difference in 
ferritin 
concentration (SD) 























Table 9 (con’t): The association between iron stores and metabolic syndrome 
Author(s) Year Country / 
Ethnicity 
Study design Case selection / 
Source population 
Control selection N 





Iron Indices Comparison Effect size Matching / 
adjustment 
variables 
Iwanaga 2014 Japan Cohort   47 / 638   Serum ferritin Mean difference in 
ferritin concentration 
(SD) (cases vs 
controls) 
204.7 (140.9) ng/mL 
vs. 96.4 (91.9) ng/mL 
 
Jehn 2004 U.S.A Cross-sectional NHANES III NHANES III 5,949 48 52 Serum ferritin Quartiles (Q1 vs Q4) 
OR 







Bozzini 2005 Italy Cross-sectional Verona Heart 
Project 
Verona Heart Project 479 58 27 Serum ferritin OR 1.53 (1.27-1.84)  
Choi 2005 Korea Cross-sectional Welfare Centers of 
Seoul Metropolitan 
Welfare Centers of 
Seoul Metropolitan 






2006 Spain Cross-sectional Patients of the 
Endocrinology & 
Nutrition Service of 
Hospital 
Patients of the 
Endocrinology & 
Nutrition Service of 
Hospital 
598 38 66 Serum ferritin OR 2.03 (1.69-2.44)  






Shi 2008 China Cross-sectional CHANES 2002 CHANES 2002 2,816 Range: 40-49 54 Serum ferritin Quartiles (Q1 vs Q4) 
OR 
Males: 1.16 (0.73-
1.84); Females: 1.66 
(1.15-2.39) 
 
Sun 2008 China Cross-sectional Nutrition & Health 
of Aging Population 
in China Study 
participants w/ 
MetS 
Nutrition & Health of 
Aging Population in 
China Study 
participants w/ MetS 
3,165 58 56 Serum ferritin Quartiles (Q1 vs Q4) 
OR 
1.95 (1.48-2.57)  




1,444 58 62 Serum ferritin Quartiles (Q1 vs Q4) Males: 1.41 (0.74-
2.68); Females: 1.61 
(1.03-2.51) 
 
Kim 2011 Korea Cross-sectional Healthy volunteers Healthy volunteers 7,253 51 47 Serum ferritin OR Males: 1.58 (1.06-
2.36); Females: 1.07 
(0.71-1.62) 
 
Park 2012 Korea Cohort Check-up of men in 
Health Promotion 
Center 
Check-up of men in 
Health Promotion 
Center 
13,084 44 0 Serum ferritin OR 1.66 (1.38-2.00)  
Kang 2012 Korea Cross-sectional KNHANES IV KNHANES IV 7,346 48 56 Serum ferritin Quartiles (Q1 vs Q4) Males: 1.46 (1.08-
1.98); Females: 1.22 
(0.91-1.64) 
 
Hamalainen 2012 Finland Case-control Citizens invited to 
health check-up 
2004 
Citizens invited to 
health check-up 2004 
766 52 55 Serum ferritin OR Males: 1.59 (1.29-
1.95); Females: 1.71 
(1.40-2.09) 
 
Leiva 2013 Chile Cross-sectional Research program 
of Risk Factors for 
Cardiovascular 
Disease of Talca 
Research program of 
Risk Factors for 
Cardiovascular 
Disease of Talca 
155 57 69 Serum ferritin OR 3.36 (1.75-6.45)  
Chang 2013 Taiwan Cross-sectional NAHSIT 2005-
2008 
NAHSIT 2005-2008 2,654 55 57 Serum ferritin OR 1.72 (1.21-2.45)  
Li 2013 China Cross-sectional CHANES CHANES 8,441 51 53 Serum ferritin Quartiles (Q1 vs Q4) Males: 4.05 (3.19-
5.14); Females: 2.34 
(1.84-2.97) 
 

















Table 10: The association between iron stores and non-alcoholic fatty liver disease 
Author(s) Year Country / 
Ethnicity 















Comparison Effect size Matching / 
adjustment 
variables 
Valenti 2007 Italy Non-
randomized 
controlled 
3 liver units in 
northern Italy 
12 64 / 64 Phlebotomy group: 
Controls: 
17 Removing 
350cc of blood 
every 10-15 
days according 
to baseline Hb 
until ferritin 
concentration 
was < 80ng/mL 
in the presence 





1.73 (1.27-2.19)  
Valenti 2011 Italy Non-
randomized 
controlled 
3 Italian centers 
across an 18 
month period 
6-8 79 / 119 Phlebotomy group: 
Controls: 
16.7 Weekly or 
fortnightly 
removal of 






was < 80ng/mL 
in the presence 





1.14 (0.57-1.71)  
Valenti 2014 Italy Randomized 
controlled 
 24 21 / 17 Phlebotomy group: 
Controls: 
10.5 Removing 
350cc of blood 
every 10-15 
days according 
to baseline Hb 
until ferritin 
concentration 
was < 30ng/mL 






0.30 (-0.45-1.05)  
Adams 2016 Australia Randomized 
controlled 















0.20 (0.02-0.38)  
Perez-
Aguilar 







22 / 21   Any iron-
loading HFE 
mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients 
vs. controls 
0.67 (0.39-1.16)  







33 / 125   Any iron-
loading HFE 
mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients 
vs. controls 
0.96 (0.16-5.67)  







30 / 2,677   Any iron-
loading HFE 
mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients 
vs. controls 
2.29 (1.12-4.70) * 







125 / 221   Any iron-
loading HFE 
mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients 
vs. controls 
1.54 (1.09-2.20) * 







171 / 205   Any iron-
loading HFE 
mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients 
vs. controls 
1.03 (0.82-1.31)  









61 / 20   Any iron-
loading HFE 
mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients 
vs. controls 
0.95 (0.80-1.12)  





















































Table 10: The association between iron stores and non-alcoholic fatty liver disease 




Case selection / 
Source 
population 
Control selection N 





Iron Indices Comparison Effect size Matching / 
adjustment 
variables 







12 / 9   Any iron-loading 
HFE mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients vs. 
controls 
1.43 (0.71-2.88)  









41 / 257   Any iron-loading 
HFE mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients vs. 
controls 
1.52 (0.81-2.84)  





Blood donors 210 / 204   Any iron-loading 
HFE mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients vs. 
controls 
1.09 (0.89-1.34)  







86 / 75   Any iron-loading 
HFE mutation 
Odds (OR) of any 
HFE mutation in 
NAFLD patients vs. 
controls 
0.72 (0.54-0.95) * 
Table 10: The association between iron stores and non-alcoholic steatohepatitis 
Author(s) Year Country 
/ 
Ethnicity 










Iron Indices Comparison Effect size Matching / 
adjustment 
variables 






51 / 2465   Any iron-loading 
HFE mutation 
Odds (OR) of any HFE 
mutation in NASH 










57 / 348   Any iron-loading 
HFE mutation 
Odds (OR) of any HFE 
mutation in NASH 










42 / 127   Any iron-loading 
HFE mutation 
Odds (OR) of any HFE 
mutation in NASH 










594 / 184   Any iron-loading 
HFE mutation 
Odds (OR) of any HFE 
mutation in NASH 










29 / 20   Any iron-loading 
HFE mutation 
Odds (OR) of any HFE 
mutation in NASH 










272 / 430   Any iron-loading 
HFE mutation 
Odds (OR) of any HFE 
mutation in NASH 

















7 Family history of diabetes 
8 Physical activity 
9 Smoking 
10 Alcohol consumption 
11 Dietary factors 
12 Cholesterol 
13 Menopausal status 
14 Fasting status 
15 Blood glucose 
16 Waist circumference/central obesity 








25 Sedentary time 
26 Obesity 
27 Medication used to treat hypertension 
28 History of cardiovascular disease 
29 Geographic location 
30 Use of iron supplements 
31 Inflammatory factors (e.g., CRP) 
32 Examination session attended 
33 Fasting insulin concentration 
34 Study center 
35 Fasting glucose concentration 
36 Glycemic load 
37 Glycated hemoglobin 
38 sTfR 
39 Abnormal blood lipids 
40 Hemoglobin concentration 
41 General practice 
42 Recruitment date 
















Table 12: Odds of metabolic dysfunction (continuously-scaled predictors) 
 FeCOOK TSAT 










Adjusted OR Adjusted P-
value 
T2DM Basic Model 1.03 0.15 - - 0.97 0.08   
Age - - 1.01 0.43   0.97 0.08 
Ethnicity - - 1.05 0.05   0.97 0.17 
Education - - 1.03 0.16   0.98 0.08 
BMI - - 1.03 0.24   0.97 0.84 
Age at menarche - - 1.03 0.25   0.97 0.09 
OC use - - 1.02 0.40   0.97 0.09 
Parity - - 1.03 0.21   0.97 0.13 
Menopausal Status - - 1.00 0.94   0.97 0.08 
Alcohol Consumption - - 1.04 0.12   0.97 0.09 
Smoking History - - 1.03 0.17   0.97 0.07 
Physical Activity - - 1.03 0.16   0.97 0.08 
C-reactive protein - - 1.02 0.37   0.99 0.43 
Full model - - 1.02 0.53   1.00 0.91 
Metabolic 
Syndrome 
Basic Model 1.01 0.23 - - 0.97 <0.0001   
Age - - 1.00 0.92   0.96 <0.0001 
Ethnicity - - 1.01 0.13   0.96 <0.0001 
Education - - 1.01 0.35   0.96 <0.0001 
BMI - - 1.01 0.53   0.99 0.21 
Age at menarche - - 1.01 0.64   0.96 <0.0001 
OC use - - 1.00 0.86   0.96 <0.0001 
Parity - - 1.01 0.54   0.97 <0.0001 
Menopausal Status - - 0.99 0.36   0.96 <0.0001 
Alcohol Consumption - - 1.01 0.36   0.96 <0.0001 
Smoking History - - 1.01 0.31   0.96 <0.0001 
Physical Activity - - 1.01 0.24   0.96 <0.0001 
C-reactive protein - - 1.00 0.73   0.97 0.0003 





















Table 12 (continued): Odds of metabolic dysfunction (continuously-scaled predictors) 
 FeCOOK TSAT 










Adjusted OR Adjusted P-
value 
NALFD Basic Model 1.04 0.04 - - 0.96 <0.0001   
Age - - 1.02 0.11   0.96 <0.0001 
Ethnicity - - 1.04 0.02   0.96 <0.0001 
Education - - 1.04 0.04   0.96 <0.0001 
BMI - - 1.01 0.48   0.98 0.13 
Age at menarche - - 1.04 0.09   0.96 <0.0001 
OC use - - 1.03 0.11   0.96 <0.0001 
Parity - - 1.03 0.09   0.96 <0.0001 
Menopausal Status - - 1.03 0.21   0.96 <0.0001 
Alcohol Consumption - - 1.02 0.31   0.95 <0.0001 
Smoking History - - 1.02 0.35   0.95 <0.0001 
Physical Activity - - 1.02 0.31   0.95 <0.0001 
C-reactive protein - - 1.02 0.22   0.97 0.001 
Full model - - 1.00 0.99   0.99 0.26 
Insulin 
Resistance 
Basic Model 1.04 0.05 - - 0.97 0.01   
Age - - 1.04 0.04   0.98 0.03 
Ethnicity - - 1.05 0.01   0.98 0.06 
Education - - 1.04 0.02   0.98 0.02 
BMI - - 1.03 0.20   0.99 0.51 
Age at menarche - - 1.04 0.04   0.98 0.06 
OC use - - 1.04 0.03   0.97 0.05 
Parity - - 1.04 0.04   0.97 0.03 
Menopausal Status - - 1.04 0.07   0.97 0.04 
Alcohol Consumption - - 1.03 0.12   0.97 0.01 
Smoking History - - 1.03 0.17   0.97 0.01 
Physical Activity - - 1.03 0.22   0.96 0.002 
C-reactive protein - - 1.02 0.27   0.98 0.16 












Table 13: Odds of metabolic dysfunction: highest tertile versus lowest tertile 
 FeCOOK TSAT 
Outcome Categorization OR 95%CI Ptrend OR 95%CI Ptrend 
T2DM All females 1.30 0.90-1.89 0.17 0.48 0.26-0.86 0.01 
White 1.01 0.57-2.19 0.75 0.41 0.17-1.04 0.06 
Hispanic 1.52 0.87-2.64 0.14 0.70 0.30-1.66 0.42 
Black 2.52 1.39-4.57 0.002 0.74 0.23-2.40 0.61 
Metabolic 
Syndrome 
All females 1.14 0.94-1.39 0.18 0.47 0.31-0.71 0.0003 
White 1.08 0.82-1.41 0.61 0.44 0.25-0.77 0.004 
Hispanic 1.28 0.90-1.81 0.005 0.54 0.25-1.15 0.11 
Black 1.57 1.15-2.16 0.02 0.50 0.22-1.11 0.09 
NAFLD All females 1.35 1.00-1.81 0.05 0.41 0.28-0.61 <0.0001 
White 1.52 1.00-2.31 0.05 0.39 0.22-0.69 0.001 
Hispanic 1.10 0.69-1.75 0.69 0.40 0.17-0.90 0.02 
Black 1.62 0.88-3.01 0.12 0.69 0.29-1.64 0.40 
Insulin 
Resistance 
All females 1.46 1.03-2.06 0.03 0.50 0.28-0.90 0.02 
White 2.59 1.45-4.65 0.005 0.56 0.23-1.40 0.28 
Hispanic 1.04 0.60-1.78 0.58 0.48 0.17-1.34 0.19 
Black 1.25 0.80-1.96 0.47 0.74 0.30-1.83 0.77 
 
Table 14: Association between highest vs. lowest FeCOOK tertile, postmenopausal status and metabolic dysfunction 
Outcome OR 95%CI Ptrend 
T2DM 1.12 0.15-8.62 0.91 
Metabolic Syndrome 1.10 0.46-2.62 0.83 
NAFLD 1.76 0.41-7.46 0.44 
Insulin Resistance 2.24 0.30-16.58 0.43 
 
Table 15: Association between highest vs. lowest TSAT tertile, postmenopausal status and metabolic dysfunction 
Outcome OR 95%CI Ptrend 
T2DM 1.00 0.16-6.31 0.99 
Metabolic Syndrome 0.97 0.37-2.48 0.94 
NAFLD 2.93 0.39-22.12 0.30 
Insulin Resistance 1.64 0.18-15.39 0.66 










































































































































































































































































































































































































































































Mechanics of FeCOOK   So that the reader develops a more complete understanding 
of the mechanics of FeCOOK, the following section details how the index changes when 
1) serum transferrin receptor concentrations increase, holding serum ferritin 
concentrations constant, 2) serum transferrin receptor decrease, holding serum ferritin 
concentrations constant, 3) serum ferritin concentrations increase, holding serum 
transferrin receptor concentrations constant, 4) serum ferritin concentrations decrease, 
holding serum transferrin receptor concentrations constant, 5) serum transferrin receptor 
concentrations increase and serum ferritin concentrations decrease, 6) serum transferrin 
concentrations decrease and serum ferritin concentrations increase, 7) both increase and 
8) both decrease. For convenience, the index is given below: 







where R = serum transferrin receptor (mg/L) and F = serum ferritin (µg/L). As 
mentioned, serum transferrin receptor is primarily derived from developing red blood 
cells, reflects the magnitude of erythropoiesis and the body’s demand for iron and is 
relatively unaffected by inflammation. Ferritin is an intracellular protein whose primary 
function is iron storage.  
 As one can see from the simulations below, the index increases substantially 
when serum transferrin receptor concentrations decrease and serum ferritin 
concentrations are held constant or increase (simulations 2 and 6, respectively). 
Simulation 2 represents a scenario where there is a decreased requirement for iron in the 
presence of stable iron stores. Therefore, if serum ferritin concentrations do not change 




increases. Simulation 6 represents a scenario where there is a decreased requirement for 
iron coupled with an increase in iron stores, indicative of increased iron absorption with 
a concomitant increase in FeCOOK. The index increases more slowly when both analytes 
increase (simulation 7) and this represents a scenario of both an increased requirement 
for iron with an increase in iron storage. The opposite is true when serum transferrin 
receptor concentrations increase and serum ferritin concentrations are held constant or 
decrease (simulations 1 and 5, respectively). Simulation 1 represents a scenario of 
increasing iron deficiency with stable serum ferritin concentrations. Therefore, if serum 
ferritin concentrations do not change in the presence of increasing serum transferrin 
receptor concentrations, the index decreases. Simulation 5 represents a scenario of 
increasing iron deficiency coupled with decreased iron storage. This scenario might be 
best visualized within the context of continual blood donation. The index decreases 
more slowly when both analytes decrease (simulation 8), represented by a scenario 
where there is a decreased requirement for iron coupled with a decrease in iron stores. 
When serum transferrin receptor concentrations are held constant, the index increases 
with increasing serum ferritin concentrations (simulation 3) and decreases with 
decreasing serum ferritin concentrations (simulation 4). Given that serum transferrin 
receptor concentrations are only affected by the rate of erythropoiesis and cellular iron 
content and are unaffected by inflammation, simulation 3 represents a scenario where 
the behavior of the index can be examined under such conditions (i.e., increases in 
serum ferritin concentrations due to inflammation). As is evident, the index increases but 












1 50 12.60870 
1.5 50 11.14978 
2 50 10.11466 
2.5 50 9.31176 
3 50 8.65575 
3.5 50 8.10109 
4 50 7.62063 
4.5 50 7.19683 
5 50 6.81773 
 
 






5 50 6.81773 
4.5 50 7.19683 
4 50 7.62063 
3.5 50 8.10109 
3 50 8.65575 
2.5 50 9.31176 
2 50 10.11466 
1.5 50 11.14978 
1 50 12.60870 
 
 






3 50 8.65575 
3 55 8.99869 
3 60 9.31176 
3 65 9.59977 
3 70 9.86642 
3 75 10.11466 
3 80 10.34688 
3 85 10.56502 
3 90 10.77068 
 
 






3 90 10.77068 
3 85 10.56502 
3 80 10.34688 
3 75 10.11466 
3 70 9.86642 
3 65 9.59977 
3 60 9.31176 
3 55 8.99869 


















2.7 90 11.14978 
2.8 85 10.81326 
2.9 80 10.46886 
3.0 75 10.11466 
3.1 70 9.74844 
3.2 65 9.36755 
3.3 60 8.96883 
3.4 55 8.54833 
3.5 50 8.10109 
 
 






2.5 50 9.31176 
2.4 55 9.80159 
2.3 60 10.26780 
2.2 65 10.71575 
2.1 70 11.14978 
2.0 75 11.57358 
1.9 80 11.99036 
1.8 85 12.40304 
1.7 90 12.81436 
 
 






2.7 50 9.03485 
2.8 55 9.24693 
2.9 60 9.43375 
3.0 65 9.59977 
3.1 70 9.74844 
3.2 75 9.88245 
3.3 80 10.00394 
3.4 85 10.11466 
3.5 90 10.21603 
 
 






2.5 90 11.42670 
2.4 85 11.36792 
2.3 80 11.30292 
2.2 75 11.23064 
2.1 70 11.14978 
2.0 65 11.05869 
1.9 60 10.95524 
1.8 55 10.83670 








Transferrin saturation (TSAT) and Metabolic Dysfunction    The odds of T2DM 
decreased with increasing TSAT (OR = 0.97 95%CI: 0.95-1.00, P = 0.07 for each unit 
increase in TSAT. The effect was slightly amplified after adjusting for covariates. When 
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at 
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10) 
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of 
T2DM were 1) 0.97 (95%CI: 0.95-1.00, P = 0.08), 2) 0.98 (95%CI: 0.95-1.01, P  = 0.17), 
3) 0.97 (95%CI: 0.95-1.00, P  = 0.08), 4) 0.97 (95%CI: 0.96-1.03, P  = 0.84), 5) 0.97 
(95%CI: 0.94-1.01, P  = 0.09), 6) 0.97 (95%CI: 0.94-1.01, P  = 0.09), 7) 0.97 (95%CI: 
0.94-1.01, P  = 0.13), 8) 0.97 (95%CI: 0.93-1.00, P  = 0.08), 9) 0.97 (95%CI: 0.95-1.00, 
P  = 0.09), 10) 0.97 (95%CI: 0.95-1.00, P  = 0.07), 11) 0.97 (95%CI: 0.94-1.02, P  = 
0.08) and 12) 0.99 (95%CI: 0.96-1.05, P = 0.43) (Table x), respectively. In a full model 
which adjusted for all covariates, the odds of T2DM did not increase with increasing 
TSAT (OR = 1.00, 95%CI: 0.96-1.05, P = 0.91) (Table 12).  
When TSAT was categorized according to tertiles, the odds of T2DM among 
those in the highest tertile of TSAT compared to those in the lowest tertile were 0.48 
(95%CI: 0.26-0.86, P = 0.01). A similar pattern was observed after stratifying by 
ethnicity. Among white females, the odds of T2DM among those in the highest tertile of 
TSAT compared to those in the lowest tertile were 0.41 (95%CI: 0.17-1.04, P = 0.06). 
The odds of T2DM were higher among Hispanic and black females in the highest tertile 
of TSAT compared to those in the lowest tertile: OR = 0.70 (95%CI: 0.30-1.66, P = 0.42) 




The odds of metabolic syndrome decreased with increasing TSAT (OR = 0.97 
95%CI: 0.95-0.98, P < 0.0001 for each unit increase in TSAT. The effect was slightly 
amplified after adjusting for individual covariates in the full model. When independently 
adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at menarche, 6) OC use, 7) 
parity, 8) menopausal status, 9) alcohol consumption, 10) smoking history, 11) physical 
activity and 12) C-reactive protein (CRP), the odds of metabolic syndrome were 1) 0.96 
(95%CI: 0.95-0.98, P < 0.0001), 2) 0.96 (95%CI: 0.95-0.98, P < 0.0001), 3) 0.96 
(95%CI: 0.95-0.98, P < 0.0001), 4) 0.99 (95%CI: 0.97-1.01, P  = 0.21), 5) 0.96 (95%CI: 
0.95-0.98, P < 0.0001), 6) 0.96 (95%CI: 0.95-0.98, P < 0.0001), 7) 0.97 (95%CI: 0.95-
0.98, P  < 0.0001), 8) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 9) 0.96 (95%CI: 0.95-0.98, P 
< 0.0001), 10) 0.96 (95%CI: 0.95-0.98, P < 0.0001), 11) 0.96 (95%CI: 0.95-0.98, P < 
0.0001) and 12) 0.97 (95%CI: 0.98-0.99, P  = 0.0003) (Table 12), respectively. In a full 
model which adjusted for all covariates, the odds of metabolic syndrome slightly 
increased to 0.98 (95%CI: 0.96-1.01), which was no longer statistically significant (P = 
0.14) (Table 12).  
When TSAT was categorized according to tertiles, the odds of metabolic 
syndrome among those in the highest tertile of TSAT compared to those in the lowest 
tertile were 0.46 (95%CI: 0.30-0.70, P = 0.0003). A similar pattern was observed after 
stratifying by ethnicity. Among white females, the odds of metabolic syndrome among 
those in the highest tertile of TSAT compared to those in the lowest tertile were 0.43 
(95%CI: 0.25-0.76, P = 0.004). The odds of metabolic syndrome were higher among 




tertile: OR = 0.53 (95%CI: 0.25-1.13, P = 0.10) and OR = 0.49 (95%CI: 0.22-1.09, P = 
0.08), respectively.  
TSAT was inversely associated with U.S.-FLI. For each unit increase in U.S.-FLI, 
TSAT decreased 0.15% (P < 0.0001). Similarly, for each unit increase in TSAT, U.S.-FLI 
decreased 0.31 units (P < 0.0001). The odds of NAFLD decreased with increasing TSAT 
(OR = 0.96, 95%CI: 0.94-0.97, P < 0.0001 for each unit increase in TSAT. The effect was 
slightly amplified in the full model after adjusting for covariates. When independently 
adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at menarche, 6) OC use, 7) 
parity, 8) menopausal status, 9) alcohol consumption, 10) smoking history, 11) physical 
activity and 12) C-reactive protein (CRP), the odds of NAFLD were 1) 0.96 (95%CI: 
0.94-0.98, P < 0.0001), 2) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 3) 0.96 (95%CI: 0.94-
0.98, P < 0.0001), 4) 0.98 (95%CI: 0.96-1.01, P  = 0.13), 5) 0.96 (95%CI: 0.94-0.98, P  < 
0.0001), 6) 0.96 (95%CI: 0.94-0.98, P  < 0.0001), 7) 0.96 (95%CI: 0.94-0.98, P < 
0.0001), 8) 0.96 (95%CI: 0.94-0.98, P < 0.0001), 9) 0.95 (95%CI: 0.93-0.97, P  < 
0.0001), 10) 0.95 (95%CI: 0.93-0.97, P  < 0.0001), 11) 0.95 (95%CI: 0.93-0.97, P  < 
0.0001) and 12) 0.97 (95%CI: 0.96-0.99, P  = 0.001) (Table x), respectively. In a full 
model which adjusted for all covariates, no increased odds of NAFLD as a function of 
TSAT were observed (OR = 0.99, 95%CI: 0.96-1.01, P = 0.26) (Table 12). 
When TSAT was categorized according to tertiles, the odds of NAFLD decreased 
across increasing tertiles (Ptrend < 0.0001). Compared to those in the lowest tertile of 
TSAT the odds of NAFLD were 0.62 (95%CI: 0.39-0.97, P = 0.04) for those in the 
middle tertile of TSAT. Compared to those in the lowest tertile of TSAT, the odds of 




similar pattern was observed after stratifying by ethnicity. Among white females, the 
odds of NAFLD among those in the highest tertile of TSAT compared to those in the 
lowest tertile were 0.39 (95%CI: 0.22-0.69, P = 0.001). The odds of NAFLD were higher 
among Hispanic females in the highest tertile of TSAT compared to those in the lowest 
tertile: OR = 0.40 (95%CI: 0.17-0.90, P = 0.02). Compared to their white and Hispanic 
counterparts, the odds of NAFLD were higher among black females in the highest tertile 
of TSAT compared to those in the lowest tertile: OR = 0.69 (95%CI: 0.29-1.64, P = 
0.40). TSAT was also inversely associated with liver fibrosis (i.e., NFS). For each unit 
increase in NFS, TSAT decreased 0.56% (P = 0.01). Similarly, for each unit increase in 
TSAT, NFS decreased 0.01 units (P = 0.02).  
TSAT was inversely associated with insulin resistance. For each unit increase in 
HOMA-IR, TSAT decreased 0.60% (P = 0.002). Similarly, for each unit increase in 
TSAT, HOMA-IR decreased 0.04 units (P < 0.0001). The odds of insulin resistance 
decreased with increasing TSAT (OR = 0.97, 95%CI: 0.95-0.99, P = 0.01) for each unit 
increase in TSAT. The effect was slightly amplified after adjusting for covariates. When 
independently adjusting for 1) age, 2) ethnicity, 3) education, 4) BMI, 5) age at 
menarche, 6) OC use, 7) parity, 8) menopausal status, 9) alcohol consumption, 10) 
smoking history, 11) physical activity and 12) C-reactive protein (CRP), the odds of 
insulin resistance were 1) 0.97 (95%CI: 0.95-0.99, P = 0.01), 2) 0.98 (95%CI: 0.97-0.99, 
P  = 0.03), 3) 0.98 (95%CI: 0.96-1.00, P  = 0.06), 4) 0.98 (95%CI: 0.95-0.99, P  = 0.02), 
5) 0.99 (95%CI: 0.96-1.02, P  = 0.51), 6) 0.98 (95%CI: 0.95-1.00, P  = 0.06), 7) 0.97 
(95%CI: 0.95-1.00, P  = 0.05), 8) 0.97 (95%CI: 0.94-0.99, P  = 0.03), 9) 0.97 (95%CI: 




0.99, P  = 0.002) and 12) 0.98 (95%CI: 0.96-1.01, P  = 0.16) (Table x), respectively. In a 
full model which adjusted for all covariates, the odds of insulin resistance did not 
increase with increasing TSAT (OR = 1.00 95%CI: 0.97-1.04, P = 0.93) (Table 12). 
When TSAT was categorized according to tertiles, the odds of insulin resistance 
decreased across increasing tertiles (Ptrend = 0.06). Compared to those in the lowest tertile 
of TSAT the odds of insulin resistance were 0.75 (95%CI: 0.44-1.28, P = 0.29) for those 
in the middle tertile of TSAT. Compared to those in the lowest tertile of TSAT, the odds 
of insulin resistance were 0.50 (95%CI: 0.28-0.90, P = 0.02) among those in the highest 
tertile of TSAT. A similar pattern was observed after stratifying by ethnicity, especially 
among white females. Among white females, the odds of insulin resistance among those 
in the highest tertile of TSAT compared to those in the lowest tertile were 0.56 (95%CI: 
0.23-1.40, P = 0.28). The odds of insulin resistance were also higher among Hispanic and 
black females in the highest tertile of TSAT compared to those in the lowest tertile: OR = 

















Appendix 3: Power Calculations 
Insulin Resistance: 
proc power; 
 twosamplefreq test=pchi 
  relativerisk = 1.2 1.3 1.4 1.5 
   refproportion = 0.35 
   ntotal = 3149 
   sides = 2 
   alpha = 0.0125 
   power = . ; 
run; 
 
Non-alcoholic fatty liver disease: 
proc power; 
 twosamplefreq test=pchi 
  relativerisk = 1.2 1.3 1.4 1.5 
   refproportion = 0.291 
   ntotal = 3057 
   sides = 2 
   alpha = 0.0125 





 twosamplefreq test=pchi 
  relativerisk = 1.2 1.3 1.4 1.5 
   refproportion = 0.234 
   ntotal = 6511 
   sides = 2 
   alpha = 0.0125 
   power = . ; 
run; 
 
Type 2 diabetes mellitus: 
proc power; 
 twosamplefreq test=pchi 
  relativerisk = 1.2 1.3 1.4 1.5 
   refproportion = 0.11 
   ntotal = 6841 
   sides = 2 
   alpha = 0.0125 



































Type 2 diabetes 
mellitus 
11.2% 2003-2004 2468 1.2 0.40 
11.2% 2468 1.3 0.70 
11.2% 2468 1.4 0.90 
11.2% 2468 1.5 0.98 
11.2% 2005-2006 2682 1.2 0.42 
11.2% 2682 1.3 0.74 
11.2% 2682 1.4 0.93 
11.2% 2682 1.5 0.99 
11.2% 2007-2008 2109 1.2 0.35 
11.2% 2109 1.3 0.63 
11.2% 2109 1.4 0.86 
11.2% 2109 1.5 0.96 
11.2% 2009-2010 2512 1.2 0.40 
11.2% 2512 1.3 0.71 
11.2% 2512 1.4 0.91 
11.2% 2512 1.5 0.98 
11.2% 2003-2010 
(pooled) 
9771 1.2 0.92 
11.2% 9771 1.3 0.99 
11.2% 9771 1.4 > 0.99 
11.2% 9771 1.5 > 0.99 
 
*Total sample size refers to the number of females during each year who have complete  
data for the calculation for TotFe and Non-alcoholic fatty liver disease.  


































































11.2% 2468 1.3 0.70 
11.2% 2468 1.4 0.90 
11.2% 2468 1.5 0.98 
11.2% 2005-2006 2682 1.2 0.42 
11.2% 2682 1.3 0.74 
11.2% 2682 1.4 0.93 
11.2% 2682 1.5 0.99 
11.2% 2007-2008 2109 1.2 0.35 
11.2% 2109 1.3 0.63 
11.2% 2109 1.4 0.86 
11.2% 2109 1.5 0.96 
11.2% 2009-2010 2512 1.2 0.40 
11.2% 2512 1.3 0.71 
11.2% 2512 1.4 0.91 
11.2% 2512 1.5 0.98 
11.2% 2003-2010 
(pooled) 
9771 1.2 0.92 
11.2% 9771 1.3 0.99 
11.2% 9771 1.4 > 0.99 
11.2% 9771 1.5 > 0.99 
 
*Total sample size refers to the number of females during each year who have complete  
data for the calculation for TotFe and Non-alcoholic fatty liver disease.  























































fatty liver disease 


























11.2% 2468 1.3 0.70 
11.2% 2468 1.4 0.90 
11.2% 2468 1.5 0.98 
11.2% 2005-2006 2682 1.2 0.42 
11.2% 2682 1.3 0.74 
11.2% 2682 1.4 0.93 
11.2% 2682 1.5 0.99 
11.2% 2007-2008 2109 1.2 0.35 
11.2% 2109 1.3 0.63 
11.2% 2109 1.4 0.86 
11.2% 2109 1.5 0.96 
11.2% 2009-2010 2512 1.2 0.40 
11.2% 2512 1.3 0.71 
11.2% 2512 1.4 0.91 
11.2% 2512 1.5 0.98 
11.2% 2003-2010 
(pooled) 
9771 1.2 0.92 
11.2% 9771 1.3 0.99 
11.2% 9771 1.4 > 0.99 
11.2% 9771 1.5 > 0.99 
 
*Total sample size refers to the number of females during each year who have complete  
data for the calculation for TotFe and Non-alcoholic fatty liver disease.  











































































11.2% 2468 1.3 0.70 
11.2% 2468 1.4 0.90 
11.2% 2468 1.5 0.98 
11.2% 2005-2006 2682 1.2 0.42 
11.2% 2682 1.3 0.74 
11.2% 2682 1.4 0.93 
11.2% 2682 1.5 0.99 
11.2% 2007-2008 2109 1.2 0.35 
11.2% 2109 1.3 0.63 
11.2% 2109 1.4 0.86 
11.2% 2109 1.5 0.96 
11.2% 2009-2010 2512 1.2 0.40 
11.2% 2512 1.3 0.71 
11.2% 2512 1.4 0.91 
11.2% 2512 1.5 0.98 
11.2% 2003-2010 
(pooled) 
9771 1.2 0.92 
11.2% 9771 1.3 0.99 
11.2% 9771 1.4 > 0.99 
11.2% 9771 1.5 > 0.99 
 
*Total sample size refers to the number of females during each year who have complete  
data for the calculation for TotFe and Non-alcoholic fatty liver disease.  
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My skill set is most effectively applied to solving problems with research, mathematics, 
epidemiology, biostatistics, data management (e.g., data warehousing, relational databases, 
data cleaning), data analysis (e.g., parametric modeling, nonparametric modeling, performance 
metrics, business intelligence), simulations (e.g., algorithm optimization, risk analysis, 
sensitivity analysis, predictive modeling).  
 
I implement the aforementioned skill set using SAS, R, PL/SQL Developer, SQL Server, 









Research and Clinical Interests 
 
Psychiatric Pharmacogenomics, Cancer Epidemiology, Genetic Epidemiology, Aging 
Immunology, Tumor Immunology, Childhood Cancer, Maternal & Child Health. 
 
 
Professional Employment Experience 
 
 
2016-present  Analytics Consultant     Humana, Inc. 
 
Work with team to maintain current version of a dynamic claims-based provider attribution 
algorithm which incorporates member and provider attributes such as geographical distance, 
provider specialty and a variety of proprietary business rules in order to establish value-based 
member-provider (PCP) assignments.  
 
Developed and implemented a method to examine the financial impact (i.e., claims spend, 
premiums spend, MER) of a provider attribution algorithm among members whose PCP was 
determined by self-selection, Humana assignment (i.e., proprietary business rules), claims-
based assignment. 
 
Worked with team to complete a Six-Sigma Green Belt project which examined root causes of 
inaccurate member-provider assignments. Deliverable to leadership included recommending 
people, processes and technology to improve member/provider experience with business 
impacts being accurate panel lists and related STARS quality data & rewards and improved 
relationships/trust with participating PCPs. 
 
Developed and maintain a fuzzy matching algorithm using SAS functions SPEDIS, 
SOUNDEX, CONTAINS, COMPARE, COMPGED, PRXPARSE, PRXMATCH to evaluate 
the concordance between member-PCP relationships across two databases. Automated said 
project with Microsoft Access.  
 
Developing a prescriber attribution model which quantifies the effect of incorporating 
pharmacy claims into provider attribution models which do not utilize said data. Developed 
conditional logic which allows members to be attributed to a prescribing provider when no 
other claims (e.g., AWV, E&M) are available.  
 
Developed a novel metric for use in the calculation of continuity of care among member-
provider networks. The equation takes into account within-provider prescribing behavior that 
can lead to drug-drug interactions as well as between-provider prescribing behavior that can 
lead to additional drug-drug interactions. 
 
Developed an annotated training manual for future Attribution Analytics associates. 
 
Developing a PCP Treating model using graph theory and social network analysis and an 








2012–2016  Biostatistician      Assurex Health, 
Inc. 
    
Using a priori biological knowledge and preselected SNPs within a finite set of xenobiotic 
metabolizing and transport genes, assist in the development of clinical decision support 
algorithms which classify and predict pharmacokinetic and pharmacodynamic response to a 
panel of commonly prescribed psychotropic and analgesic medications by reducing the 
dimensionality inherent to permutations and combinations of drug-drug, drug-gene, and gene-
gene interactions. 
 
Conduct cross-validation analyses of results obtained from previous in-house clinical trials. 
Head of using a systematic and methodological approach to data imputation in order to 
account for the differential effect of subject (i.e., treated vs control) attrition in the above 
mentioned clinical trials. 
 
Following testing for clinical, methodological, and statistical heterogeneity, merge data from 
in-house clinical trials of similar design to derive pooled effect sizes, which in turn are used to 
inform sample size calculation for future trials. 
 
Conducted a current (as of Dec 2012) meta-analysis of the published literature reporting upon 
the effect of the -759C/T HTR2C transition on antipsychotic-induced weight-gain (AIWG), 
stratified by drug-experienced versus drug-naive subjects. Random-effects models were 
employed to account for heterogeneity among study designs. Publication bias was examined 
via funnel plots and Egger’s regression. 
 
Lead biostatistician of a recently launched large-scale (projected N = 1350), treatment-
resistant depression (TRD), randomized, controlled trial examining the clinical utility and 
clinical validity of a multigenic combinatorial phenotype method for selecting genetically-
concordant antidepressant medications. 
 
Executed sensitivity analyses for TRD RCT solving for sample size, alpha, and power in order 
to provide study sponsor with information to guide strategic decision making with respect to 
overall study recruitment. 
 
Using the CRF implemented in the above TRD RCT as guidance, created a data schema to 
standardize and accommodate all previous/ongoing clinical trial data. Developed a clinical 
database/data warehouse thereafter using MySQL to store standardized data. 
 
Co-developed a novel data reduction method which facilitates pairwise comparisons across 
single enzyme phenotypes and a composite (5 enzyme) phenotype. 
 
Head of creation and management of clinical trials dossier. 
 
Co-developed a methodology to evaluate the performance of several versions of the same 
clinical decision support algorithm via simulation. Head of automation and statistical analyses 
of simulations using SAS & R. 
 
Co-developed the methodology to calculate company-wide sales metrics based upon physician 






Co-developed the methodology to calculate 13 KPIs for the Medical Affairs/Clinical 
Development department within the company. Independently created a SAS program to 




2010-present   Assistant Professor  Jefferson Community & 
Technical College 
 
Full-time professor of three psychology courses at the Carrollton, KY extension campus.  
 
Courses taught: PSY110 (General Psychology), PSY223 (Developmental Psychology), 
PSY230 (Psychological Aspects of Aging, Dying, Death, & Bereavement. 
 
Direct undergraduate students in the stepwise process of curating academic literature from 
various databases in order to construct annotated bibliographies, which in turn are employed in 
the development of a term paper of publishable quality; assist students in the interpretation of 
academic literature; develop and deploy psychology courses on Blackboard; deliver fifteen 






2014: Project Manager, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Frank D. Groves, M.D., M.P.H. 
 
Conducted a secondary analysis of a multistage, nationally-representative probabilistic 
sample of NHANES I/NHEFS linked databases examining the role of hematological 
parameters on subsequent development of cardiovascular disease and cancer. Kaplan-
Meier curves were constructed to estimate differential survival among sample 
population, stratified by each hematological parameter. Cox proportional hazards 
regression analyses were employed derive hazard ratios associated with each 




2013: Project Manager, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Kira Taylor, Ph.D., M.S. 
 
Completed and submitted manuscript proposal for a candidate gene study examining 
genetic variation in the PI3k/Akt/mTOR pathway and subsequent development of 
pathological left ventricular hypertrophy in Jackson Heart Study population. Bayesian 
network analysis (BNA) was employed using R software to curate a concise set of 
genes within the signaling pathway. Validity and robustness of BNA was ascertained 
using likelihood ratio tests and bootstrapping for cross-validation. Multi-factor 




selected genes for statistical modeling to reduce the effect of multiple testing. Principal 
components analysis was employed to reduce multicollinearity among covariates in 
final logistic regression model. 
 
 
2013: Project Manager, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Elizabeth O’Brien, Ph.D. 
 
Conducted an exploratory simulation to model the dependency of genetic expression 
on genetic variants within PI3K/Akt/mTOR signaling pathway to augment the above 
candidate gene study. Using a priori biological knowledge, dynamic Bayesian network 
analysis was employed using R and Markov chain Monte Carlo and Python software 
to account for time-varying probabilistic modeling of RNA expression. Normalized 
mutual information (MI) between genetic variants and gene expression was calculated 
to derive statistical models with greatest maximum likelihood. Chi-square tests were 
then applied to test statistical significance of the final set of MIs.  
 
 
2012: Project Collaborator, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Rudolph Parrish, Ph.D. 
  
Collaborated on secondary data analysis to explore age-period and site-related effects of air 
pollution and passive smoking on the development of wheezing in two cohorts of children. T-
tests were employed to quantify differential demographic characteristics with continuous 
outcomes and chi-squared tests were employed to examine differential demographic 
characteristics with categorical outcomes. Generalized estimating equations were employed to 
model categorical time-dependent repeated measures and to test for the effect of site on 
symptom development. QIC criterion was used to evaluate model selection. 
 
 
2012: Project Manager, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Frank D. Groves, M.D., M.P.H. 
 
Employed MedlineR (a library of literature mining alogorithms in R), PubMatrix, and Bitola 
to mine academic databases to curate a comprehensive literature on tumor immunology. 
Methodological algorithms were developed and articles were scored and sorted by scientific 
strength using SAS Enterprise Miner. A formal literature review was produced to update the 












2011: Project Collaborator, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: John Myers, Ph.D. 
 
Evaluated the performance of two novel bioassays for the detection of bovine paratuberculosis 
by employing ROC/AUC analysis. Sensitivity and specificity for each test were calculated, 
followed by the statistical comparison of each AUC. Estimates and standard errors from each 
test were utilized to derive a difference score. Difference scores and standard error of the 
combined tests were then used to calculate z-scores for each respective test.  Z-scores were 
used to obtain p-values to test the null hypothesis that the tests exhibited similar performance. 
 
 
2011: Project Manager, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Frank D. Groves, M.D., M.P.H.,  
  
Employed MedlineR, PubMatrix, Bitola, and CoPub to mine academic databases to curate a 
comprehensive literature focused on the association between iron deficiency/iron overload and 
subsequent development of cancer. Using Python, natural language processing was further 
applied to published abstracts to extract novel associations between the explanatory variables 
and outcome. Methodological algorithms were developed and articles were scored and sorted 
by scientific strength using SAS Enterprise Miner. A formal literature review was then 
produced to update the field on emerging concepts and techniques.  
 
 
2011: Project Manager, School of Public Health and Information Sciences, Department of 
Epidemiology and Population Health, University of Louisville. 
Supervisor: Susan Muldoon, Ph.D. 
  
Following a comprehensive Medline literature review, designed and conducted a meta-
analysis using SAS software to examine the association between dietary iron excess and 
subsequent development of Alzheimer’s Disease. A weighting variable was created to account 
for strength of study methodology and statistical analysis. Studies were scored and sorted by 
employing SAS Enterprise Miner. Effect estimates were derived by applying additivity of chi-
squared statistics, creating a composite chi-squared test statistic for all studies using study as 
the effect. Covariates were then added to the model.  
 
 
2010-2011: Project Manager, School of Public Health and Information Sciences, Department 
of Epidemiology and Population Health, University of Louisville. 
Supervisor: Carlton Hornung, Ph.D. 
 
Following a comprehensive Medline literature review, designed and conducted a meta-
analysis using SAS examining the association between maternal NIDDM and congenital heart 
defects in neonates. A weighting variable was created to account for strength of study 
methodology and statistical analysis. Studies were scored and sorted by employing SAS 
Enterprise Miner. Effect estimates were derived by applying additivity of chi-squared 
statistics, creating a composite chi-squared test statistic for all studies using study as the effect. 







2009-2010: Project Manager, Health Behavior Change Research Program, Department of 
Psychological and Brain Sciences, University of Louisville. 
Supervisor: Barbara A. Stetson, Ph.D.  
 
Secondary data analysis of 65 adults with Type 1 diabetes examining personal history of 
hypoglycemia and hypoglycemia-associated cognitions and their associations with physical 
activity. ANOVA tests were employed to examine the association between participant 
questionnaire responses and outcome. Self-reported scores on the Exercise Benefits/Barriers 
Scale (EBBS) were associated with the Stanford Usual Activity Questionnaire (SUAQ) [R2 = 
0.87, F = 3.99, df = 1,42 p = 0.042]. Entry of a 2nd block with the item “disliking sensations of 
physical activity” yielded no significant change in R2. Entry of a 2nd block item “difficulty 
distinguishing sensations of physical activity from low blood glucose” significantly increased 
R2 for SUAQ vigorous activity (p=0.049) and marginally increased R2 for SUAQ moderate 
activity (p=0.052). Noteworthy in this study was that less than 1/3 of all participants reported 
receiving physical activity instructions from their health care provider. 
 
 
2009-2010: Research Coordinator and Project Manager for multi-site study examining 
psychological predictors for exercise initiation among adults with Type 2 diabetes following a 
diabetes self-management education program. 
Supervisor: Jason Bonner, Ph.D. 
  
General Role: In-field data collection of survey data, participant recruitment, database and 
supplies management, participant tracking, collaboration on statistical analyses, and expediting 
data summaries to lead investigator.  
 
Statistical role: employing ANCOVA to determine if the means of each of the outcome 
variables in the study were equal across levels of salient predictor variables, controlling for 
other covariates. Employing hierarchical cluster analysis to the Health Action Process 





2012 Statistical consultant 
 
Assisted in an exploratory factor analysis of a 26-item quality of life survey for a population of 
adults with type 2 diabetes. Factors were extracted using principal components analysis with 
varimax rotation and a scree plot was developed. KMO test was employed to verify sampling 
adequacy (KMO = .93). Three questionnaire components emerged which had eigenvalues 
above Kaiser’s criterion of 1 and in combination explained 55.46% of the variance. 
 











2011 Statistical consultant  
 
Co-developed project methodology and headed statistical testing of a secondary data analysis 
examining the association between genetic variation in BRCA1/BRCA2 and response to 
letrozole in cohort of patients with ovarian cancer. This gene-drug interaction project tested 
the hypothesis that early-stage ovarian cancer patients with BRCA1/BRCA2 mutations would 
be more responsive to therapy. T-tests were employed to quantify differential demographic 
characteristics with continuous outcomes and chi-squared tests were employed to examine 
differential demographic characteristics with categorical outcomes. MANOVA was employed 
to model differences in treatment response and stage of ovarian cancer as a function of 
BRCA1/BRCA2 carrier status (i.e., homozygous, carrier, null). MANOVA was followed with 
discriminant function analysis to obtain the relative contribution of genetic variation to 
treatment response and stage of cancer. 
 





2015: Altar CA, Carhart JM, Allen JD, Hall-Flavin D, Winner JG, Dechairo BM. Clinical 
Utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from 
three clinical studies. Mol Neuropsychiat, 2015 
 
2015: Winner JG, Carhart JM, Altar CA, Goldfarb S Lavezzari G, Parsons KK, Marshak 
AG, Garavaglia A, Dechario BM. Combinatorial pharmacogenomic guidance for psychiatric 
medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res 
Opin,  
 
2015: Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, DeChairo BM, Winner JG. Clinical 
validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare 
utilizations better than single gene phenotypes. The Pharmacogenomics Journal, 2015.  
 
 
2013: Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, 
Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomics testing to 
support the treatment of major depressive disorder in a psychiatric outpatient setting. 
Pharmacogenetics & Genomics, 2013;23(10): 535-548. 
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testing for major depressive disorder. Discovery Medicine, 2013;16(89): 219-227. 
 
2011: Stetson, B., Bonner, J. Carhart, J. (2011). Psychological predictors of self-reported 
physical activity initiation in type 2 diabetes patients following diabetes self-management 











2013: Winner, J., Carhart, JM., Allen, J., Dechario, B. Psychiatric pharmacogenomic 
decision support: metal analysis of prospective studies shows improved antidepressant 
efficacy and predicted outcomes. CINP: Pharmacogenomics and Personalized Medicine in 
Psychiatry. 
 
2013: Mrazek, D., Altar, CA., Allen, J., Carhart, JM. Combinatorial pharmacogenomics 
testing improves prediction of antidepressant responses and health utilizations compared to 
single gene testing. American Psychiatric Association. 
 
2013: Hall-Flavin, D., Winner, J., Allen, J., Carhart, JM. Translational pharmacogenomics: 
physician use and satisfaction with an integrated, multi-gene psychiatric pharmacogenomics 
test and interpretive report. American Psychiatric Assocation. 
 
2011: Carhart, J., Stetson, B., Mokshagundam S. (April, 2011). Hypoglycemia Experience 
and Barrier Associations with Physical Activity in Type 1 Diabetes. Rapid Communication 









Volunteer and Community Service Experiences 
 
 
2016   Little Loomhouse’s Friendly Fenley Cemetery Cleanup 
Cleaned above cemetery of detritus with fellow members of 
Humana’s Clinical Analytics Attribution team  
 
2011-present  Carroll County School System  Volunteer/Worker 
Designed and conducted physics demonstrations for grades K-3 for 
outdoor classroom 
 
2007-2009  American Cancer Society Volunteer/Worker 
Co-organized relay for life fundraiser within a rural community 
setting 
 
2008-2009  American Diabetes Association  Volunteer/Worker 
Co-organized fund raising bicycle ride within a rural community 
setting 
  
2008   Kentucky Humane Society  Volunteer/Worker 
    Conducted measures to curb feral cat population expansion 
 
2005   Habitat for Humanity   Volunteer/Worker 
Participated in a home rebuild post-flooding within a rural 
community 
